Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
NF - kappa B is a Entity, I kappa B alpha is a Protein, phosphatase 2A - sensitive sites is a Entity, NF - kappa B is a Entity, I kappa B alpha is a Protein, I kappa B alpha is a Protein, I kappa B alpha is a Protein, NF - kappa B heterodimer is a Entity, I kappa B alpha is a Protein, tumor necrosis factor alpha is a Protein, TNF - alpha is a Protein, I kappa B alpha is a Protein, TNF - alpha is a Protein, I kappa B alpha is a Protein, NF - kappa B is a Entity, I kappa B alpha is a Protein, TNF - alpha is a Protein, I kappa B alpha is a Protein, I kappa B alpha is a Protein, I kappa B alpha is a Protein, TNF - alpha is a Protein, I kappa B alpha is a Protein, proteasome is a Entity
780_task1
Sentence: Activation of NF-kappa B by phosphatase inhibitors involves the phosphorylation of I kappa B alpha at phosphatase 2A-sensitive sites. Activation of NF-kappa B by various cellular stimuli involves the phosphorylation and subsequent degradation of its inhibitor, I kappa B alpha, although the underlying mechanism remains unclear. In the present study, the role of serine/threonine phosphatases in the regulation of I kappa B alpha phosphorylation was investigated. Our studies demonstrate that incubation of human T cells with low concentrations (approximately 1-5 nM) of calyculin A or okadaic acid, potent inhibitors of protein phosphatase type 1 (PP-1) and type 2A (PP-2A), induces the phosphorylation of I kappa B alpha even in the absence of any cellular stimulus. This action of the phosphatase inhibitors, which is associated with the activation of the RelA.p50 NF-kappa B heterodimer, is not affected by agents that block the induction of I kappa B alpha phosphorylation by tumor necrosis factor alpha (TNF-alpha). Furthermore, the phosphorylated I kappa B alpha from calyculin A-treated cells, but not that from TNF-alpha-stimulated cells, is sensitive to PP-2A in vitro, suggesting the existence of fundamental differences in the phosphorylation of I kappa B alpha induced by the two different NF-kappa B inducers. However, induction of I kappa B alpha phosphorylation by both TNF-alpha and the phosphatase inhibitors is associated with the subsequent degradation of I kappa B alpha. We further demonstrate that TNF-alpha- and calyculin A-induced I kappa B alpha degradation exhibits similar but not identical sensitivities to a proteasome inhibitor. Together, these results suggest that phosphorylation of I kappa B alpha, mediated through both the TNF-alpha-inducible and the PP-2A-opposing kinases, may serve to target I kappa B alpha for proteasome-mediated degradation. Instructions: please typing these entity words according to sentence: NF - kappa B, I kappa B alpha, phosphatase 2A - sensitive sites, NF - kappa B, I kappa B alpha, I kappa B alpha, I kappa B alpha, NF - kappa B heterodimer, I kappa B alpha, tumor necrosis factor alpha, TNF - alpha, I kappa B alpha, TNF - alpha, I kappa B alpha, NF - kappa B, I kappa B alpha, TNF - alpha, I kappa B alpha, I kappa B alpha, I kappa B alpha, TNF - alpha, I kappa B alpha, proteasome Options: Entity, Protein
[ "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Entity", "O", "O", "O", "O", "O" ]
Activation of NF-kappa B by phosphatase inhibitors involves the phosphorylation of I kappa B alpha at phosphatase 2A-sensitive sites. Activation of NF-kappa B by various cellular stimuli involves the phosphorylation and subsequent degradation of its inhibitor, I kappa B alpha, although the underlying mechanism remains unclear. In the present study, the role of serine/threonine phosphatases in the regulation of I kappa B alpha phosphorylation was investigated. Our studies demonstrate that incubation of human T cells with low concentrations (approximately 1-5 nM) of calyculin A or okadaic acid, potent inhibitors of protein phosphatase type 1 (PP-1) and type 2A (PP-2A), induces the phosphorylation of I kappa B alpha even in the absence of any cellular stimulus. This action of the phosphatase inhibitors, which is associated with the activation of the RelA.p50 NF-kappa B heterodimer, is not affected by agents that block the induction of I kappa B alpha phosphorylation by tumor necrosis factor alpha (TNF-alpha). Furthermore, the phosphorylated I kappa B alpha from calyculin A-treated cells, but not that from TNF-alpha-stimulated cells, is sensitive to PP-2A in vitro, suggesting the existence of fundamental differences in the phosphorylation of I kappa B alpha induced by the two different NF-kappa B inducers. However, induction of I kappa B alpha phosphorylation by both TNF-alpha and the phosphatase inhibitors is associated with the subsequent degradation of I kappa B alpha. We further demonstrate that TNF-alpha- and calyculin A-induced I kappa B alpha degradation exhibits similar but not identical sensitivities to a proteasome inhibitor. Together, these results suggest that phosphorylation of I kappa B alpha, mediated through both the TNF-alpha-inducible and the PP-2A-opposing kinases, may serve to target I kappa B alpha for proteasome-mediated degradation.
[ "Activation", "of", "NF", "-", "kappa", "B", "by", "phosphatase", "inhibitors", "involves", "the", "phosphorylation", "of", "I", "kappa", "B", "alpha", "at", "phosphatase", "2A", "-", "sensitive", "sites", ".", "\n", "Activation", "of", "NF", "-", "kappa", "B", "by", "various", "cellular", "stimuli", "involves", "the", "phosphorylation", "and", "subsequent", "degradation", "of", "its", "inhibitor", ",", "I", "kappa", "B", "alpha", ",", "although", "the", "underlying", "mechanism", "remains", "unclear", ".", "In", "the", "present", "study", ",", "the", "role", "of", "serine", "/", "threonine", "phosphatases", "in", "the", "regulation", "of", "I", "kappa", "B", "alpha", "phosphorylation", "was", "investigated", ".", "Our", "studies", "demonstrate", "that", "incubation", "of", "human", "T", "cells", "with", "low", "concentrations", "(", "approximately", "1", "-", "5", "nM", ")", "of", "calyculin", "A", "or", "okadaic", "acid", ",", "potent", "inhibitors", "of", "protein", "phosphatase", "type", "1", "(", "PP-1", ")", "and", "type", "2A", "(", "PP-2A", ")", ",", "induces", "the", "phosphorylation", "of", "I", "kappa", "B", "alpha", "even", "in", "the", "absence", "of", "any", "cellular", "stimulus", ".", "This", "action", "of", "the", "phosphatase", "inhibitors", ",", "which", "is", "associated", "with", "the", "activation", "of", "the", "RelA.p50", "NF", "-", "kappa", "B", "heterodimer", ",", "is", "not", "affected", "by", "agents", "that", "block", "the", "induction", "of", "I", "kappa", "B", "alpha", "phosphorylation", "by", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha", ")", ".", "Furthermore", ",", "the", "phosphorylated", "I", "kappa", "B", "alpha", "from", "calyculin", "A", "-", "treated", "cells", ",", "but", "not", "that", "from", "TNF", "-", "alpha", "-", "stimulated", "cells", ",", "is", "sensitive", "to", "PP-2A", "in", "vitro", ",", "suggesting", "the", "existence", "of", "fundamental", "differences", "in", "the", "phosphorylation", "of", "I", "kappa", "B", "alpha", "induced", "by", "the", "two", "different", "NF", "-", "kappa", "B", "inducers", ".", "However", ",", "induction", "of", "I", "kappa", "B", "alpha", "phosphorylation", "by", "both", "TNF", "-", "alpha", "and", "the", "phosphatase", "inhibitors", "is", "associated", "with", "the", "subsequent", "degradation", "of", "I", "kappa", "B", "alpha", ".", "We", "further", "demonstrate", "that", "TNF", "-", "alpha-", "and", "calyculin", "A", "-", "induced", "I", "kappa", "B", "alpha", "degradation", "exhibits", "similar", "but", "not", "identical", "sensitivities", "to", "a", "proteasome", "inhibitor", ".", "Together", ",", "these", "results", "suggest", "that", "phosphorylation", "of", "I", "kappa", "B", "alpha", ",", "mediated", "through", "both", "the", "TNF", "-", "alpha", "-", "inducible", "and", "the", "PP-2A", "-", "opposing", "kinases", ",", "may", "serve", "to", "target", "I", "kappa", "B", "alpha", "for", "proteasome", "-", "mediated", "degradation", ".", "\n" ]
[ "Entity", "Protein" ]
NF - kappa B, I kappa B alpha, phosphatase 2A - sensitive sites, NF - kappa B, I kappa B alpha, I kappa B alpha, I kappa B alpha, NF - kappa B heterodimer, I kappa B alpha, tumor necrosis factor alpha, TNF - alpha, I kappa B alpha, TNF - alpha, I kappa B alpha, NF - kappa B, I kappa B alpha, TNF - alpha, I kappa B alpha, I kappa B alpha, I kappa B alpha, TNF - alpha, I kappa B alpha, proteasome
780_task2
Sentence: Activation of NF-kappa B by phosphatase inhibitors involves the phosphorylation of I kappa B alpha at phosphatase 2A-sensitive sites. Activation of NF-kappa B by various cellular stimuli involves the phosphorylation and subsequent degradation of its inhibitor, I kappa B alpha, although the underlying mechanism remains unclear. In the present study, the role of serine/threonine phosphatases in the regulation of I kappa B alpha phosphorylation was investigated. Our studies demonstrate that incubation of human T cells with low concentrations (approximately 1-5 nM) of calyculin A or okadaic acid, potent inhibitors of protein phosphatase type 1 (PP-1) and type 2A (PP-2A), induces the phosphorylation of I kappa B alpha even in the absence of any cellular stimulus. This action of the phosphatase inhibitors, which is associated with the activation of the RelA.p50 NF-kappa B heterodimer, is not affected by agents that block the induction of I kappa B alpha phosphorylation by tumor necrosis factor alpha (TNF-alpha). Furthermore, the phosphorylated I kappa B alpha from calyculin A-treated cells, but not that from TNF-alpha-stimulated cells, is sensitive to PP-2A in vitro, suggesting the existence of fundamental differences in the phosphorylation of I kappa B alpha induced by the two different NF-kappa B inducers. However, induction of I kappa B alpha phosphorylation by both TNF-alpha and the phosphatase inhibitors is associated with the subsequent degradation of I kappa B alpha. We further demonstrate that TNF-alpha- and calyculin A-induced I kappa B alpha degradation exhibits similar but not identical sensitivities to a proteasome inhibitor. Together, these results suggest that phosphorylation of I kappa B alpha, mediated through both the TNF-alpha-inducible and the PP-2A-opposing kinases, may serve to target I kappa B alpha for proteasome-mediated degradation. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Entity", "O", "O", "O", "O", "O" ]
Activation of NF-kappa B by phosphatase inhibitors involves the phosphorylation of I kappa B alpha at phosphatase 2A-sensitive sites. Activation of NF-kappa B by various cellular stimuli involves the phosphorylation and subsequent degradation of its inhibitor, I kappa B alpha, although the underlying mechanism remains unclear. In the present study, the role of serine/threonine phosphatases in the regulation of I kappa B alpha phosphorylation was investigated. Our studies demonstrate that incubation of human T cells with low concentrations (approximately 1-5 nM) of calyculin A or okadaic acid, potent inhibitors of protein phosphatase type 1 (PP-1) and type 2A (PP-2A), induces the phosphorylation of I kappa B alpha even in the absence of any cellular stimulus. This action of the phosphatase inhibitors, which is associated with the activation of the RelA.p50 NF-kappa B heterodimer, is not affected by agents that block the induction of I kappa B alpha phosphorylation by tumor necrosis factor alpha (TNF-alpha). Furthermore, the phosphorylated I kappa B alpha from calyculin A-treated cells, but not that from TNF-alpha-stimulated cells, is sensitive to PP-2A in vitro, suggesting the existence of fundamental differences in the phosphorylation of I kappa B alpha induced by the two different NF-kappa B inducers. However, induction of I kappa B alpha phosphorylation by both TNF-alpha and the phosphatase inhibitors is associated with the subsequent degradation of I kappa B alpha. We further demonstrate that TNF-alpha- and calyculin A-induced I kappa B alpha degradation exhibits similar but not identical sensitivities to a proteasome inhibitor. Together, these results suggest that phosphorylation of I kappa B alpha, mediated through both the TNF-alpha-inducible and the PP-2A-opposing kinases, may serve to target I kappa B alpha for proteasome-mediated degradation.
[ "Activation", "of", "NF", "-", "kappa", "B", "by", "phosphatase", "inhibitors", "involves", "the", "phosphorylation", "of", "I", "kappa", "B", "alpha", "at", "phosphatase", "2A", "-", "sensitive", "sites", ".", "\n", "Activation", "of", "NF", "-", "kappa", "B", "by", "various", "cellular", "stimuli", "involves", "the", "phosphorylation", "and", "subsequent", "degradation", "of", "its", "inhibitor", ",", "I", "kappa", "B", "alpha", ",", "although", "the", "underlying", "mechanism", "remains", "unclear", ".", "In", "the", "present", "study", ",", "the", "role", "of", "serine", "/", "threonine", "phosphatases", "in", "the", "regulation", "of", "I", "kappa", "B", "alpha", "phosphorylation", "was", "investigated", ".", "Our", "studies", "demonstrate", "that", "incubation", "of", "human", "T", "cells", "with", "low", "concentrations", "(", "approximately", "1", "-", "5", "nM", ")", "of", "calyculin", "A", "or", "okadaic", "acid", ",", "potent", "inhibitors", "of", "protein", "phosphatase", "type", "1", "(", "PP-1", ")", "and", "type", "2A", "(", "PP-2A", ")", ",", "induces", "the", "phosphorylation", "of", "I", "kappa", "B", "alpha", "even", "in", "the", "absence", "of", "any", "cellular", "stimulus", ".", "This", "action", "of", "the", "phosphatase", "inhibitors", ",", "which", "is", "associated", "with", "the", "activation", "of", "the", "RelA.p50", "NF", "-", "kappa", "B", "heterodimer", ",", "is", "not", "affected", "by", "agents", "that", "block", "the", "induction", "of", "I", "kappa", "B", "alpha", "phosphorylation", "by", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha", ")", ".", "Furthermore", ",", "the", "phosphorylated", "I", "kappa", "B", "alpha", "from", "calyculin", "A", "-", "treated", "cells", ",", "but", "not", "that", "from", "TNF", "-", "alpha", "-", "stimulated", "cells", ",", "is", "sensitive", "to", "PP-2A", "in", "vitro", ",", "suggesting", "the", "existence", "of", "fundamental", "differences", "in", "the", "phosphorylation", "of", "I", "kappa", "B", "alpha", "induced", "by", "the", "two", "different", "NF", "-", "kappa", "B", "inducers", ".", "However", ",", "induction", "of", "I", "kappa", "B", "alpha", "phosphorylation", "by", "both", "TNF", "-", "alpha", "and", "the", "phosphatase", "inhibitors", "is", "associated", "with", "the", "subsequent", "degradation", "of", "I", "kappa", "B", "alpha", ".", "We", "further", "demonstrate", "that", "TNF", "-", "alpha-", "and", "calyculin", "A", "-", "induced", "I", "kappa", "B", "alpha", "degradation", "exhibits", "similar", "but", "not", "identical", "sensitivities", "to", "a", "proteasome", "inhibitor", ".", "Together", ",", "these", "results", "suggest", "that", "phosphorylation", "of", "I", "kappa", "B", "alpha", ",", "mediated", "through", "both", "the", "TNF", "-", "alpha", "-", "inducible", "and", "the", "PP-2A", "-", "opposing", "kinases", ",", "may", "serve", "to", "target", "I", "kappa", "B", "alpha", "for", "proteasome", "-", "mediated", "degradation", ".", "\n" ]
[ "Entity", "Protein" ]
patients is an umlsterm, atopic eczema is an umlsterm, patients is an umlsterm, skin is an umlsterm, treatment is an umlsterm, IgE is an umlsterm, treatment is an umlsterm, treatment is an umlsterm, atopic eczema is an umlsterm
DerHautarzt.70480645.eng.abstr_task0
Sentence: Of 46 patients with severe atopic eczema treated with UVA-1, 14 were evaluated as non-responders and 32 as responders . Responding patients significantly had ( p 0.05 ) more severe skin involvement before onset of treatment ( clinical severity score SCORAD 62.7 +/- 12.4 points ) compared to non-responders ( 53.0 +/- 10.6 points ) . Serum levels of total IgE , ECP and sIL2R before treatment did not show any significant differences between the two groups . The data confirm the efficacy of UVA-1 treatment in severe cases of atopic eczema . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Of 46 patients with severe atopic eczema treated with UVA-1, 14 were evaluated as non-responders and 32 as responders . Responding patients significantly had ( p 0.05 ) more severe skin involvement before onset of treatment ( clinical severity score SCORAD 62.7 +/- 12.4 points ) compared to non-responders ( 53.0 +/- 10.6 points ) . Serum levels of total IgE , ECP and sIL2R before treatment did not show any significant differences between the two groups . The data confirm the efficacy of UVA-1 treatment in severe cases of atopic eczema .
[ "Of", "46", "patients", "with", "severe", "atopic", "eczema", "treated", "with", "UVA-1", ",", "14", "were", "evaluated", "as", "non", "-", "responders", "and", "32", "as", "responders", ".", "Responding", "patients", "significantly", "had", "(", "p", "0.05", ")", "more", "severe", "skin", "involvement", "before", "onset", "of", "treatment", "(", "clinical", "severity", "score", "SCORAD", "62.7", "+", "/-", "12.4", "points", ")", "compared", "to", "non", "-", "responders", "(", "53.0", "+", "/-", "10.6", "points", ")", ".", "Serum", "levels", "of", "total", "IgE", ",", "ECP", "and", "sIL2R", "before", "treatment", "did", "not", "show", "any", "significant", "differences", "between", "the", "two", "groups", ".", "The", "data", "confirm", "the", "efficacy", "of", "UVA-1", "treatment", "in", "severe", "cases", "of", "atopic", "eczema", "." ]
[ "umlsterm" ]
patients is an umlsterm, atopic eczema is an umlsterm, patients is an umlsterm, skin is an umlsterm, treatment is an umlsterm, IgE is an umlsterm, treatment is an umlsterm, treatment is an umlsterm, atopic eczema is an umlsterm
DerHautarzt.70480645.eng.abstr_task1
Sentence: Of 46 patients with severe atopic eczema treated with UVA-1, 14 were evaluated as non-responders and 32 as responders . Responding patients significantly had ( p 0.05 ) more severe skin involvement before onset of treatment ( clinical severity score SCORAD 62.7 +/- 12.4 points ) compared to non-responders ( 53.0 +/- 10.6 points ) . Serum levels of total IgE , ECP and sIL2R before treatment did not show any significant differences between the two groups . The data confirm the efficacy of UVA-1 treatment in severe cases of atopic eczema . Instructions: please typing these entity words according to sentence: patients, atopic eczema, patients, skin, treatment, IgE, treatment, treatment, atopic eczema Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Of 46 patients with severe atopic eczema treated with UVA-1, 14 were evaluated as non-responders and 32 as responders . Responding patients significantly had ( p 0.05 ) more severe skin involvement before onset of treatment ( clinical severity score SCORAD 62.7 +/- 12.4 points ) compared to non-responders ( 53.0 +/- 10.6 points ) . Serum levels of total IgE , ECP and sIL2R before treatment did not show any significant differences between the two groups . The data confirm the efficacy of UVA-1 treatment in severe cases of atopic eczema .
[ "Of", "46", "patients", "with", "severe", "atopic", "eczema", "treated", "with", "UVA-1", ",", "14", "were", "evaluated", "as", "non", "-", "responders", "and", "32", "as", "responders", ".", "Responding", "patients", "significantly", "had", "(", "p", "0.05", ")", "more", "severe", "skin", "involvement", "before", "onset", "of", "treatment", "(", "clinical", "severity", "score", "SCORAD", "62.7", "+", "/-", "12.4", "points", ")", "compared", "to", "non", "-", "responders", "(", "53.0", "+", "/-", "10.6", "points", ")", ".", "Serum", "levels", "of", "total", "IgE", ",", "ECP", "and", "sIL2R", "before", "treatment", "did", "not", "show", "any", "significant", "differences", "between", "the", "two", "groups", ".", "The", "data", "confirm", "the", "efficacy", "of", "UVA-1", "treatment", "in", "severe", "cases", "of", "atopic", "eczema", "." ]
[ "umlsterm" ]
patients, atopic eczema, patients, skin, treatment, IgE, treatment, treatment, atopic eczema
DerHautarzt.70480645.eng.abstr_task2
Sentence: Of 46 patients with severe atopic eczema treated with UVA-1, 14 were evaluated as non-responders and 32 as responders . Responding patients significantly had ( p 0.05 ) more severe skin involvement before onset of treatment ( clinical severity score SCORAD 62.7 +/- 12.4 points ) compared to non-responders ( 53.0 +/- 10.6 points ) . Serum levels of total IgE , ECP and sIL2R before treatment did not show any significant differences between the two groups . The data confirm the efficacy of UVA-1 treatment in severe cases of atopic eczema . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Of 46 patients with severe atopic eczema treated with UVA-1, 14 were evaluated as non-responders and 32 as responders . Responding patients significantly had ( p 0.05 ) more severe skin involvement before onset of treatment ( clinical severity score SCORAD 62.7 +/- 12.4 points ) compared to non-responders ( 53.0 +/- 10.6 points ) . Serum levels of total IgE , ECP and sIL2R before treatment did not show any significant differences between the two groups . The data confirm the efficacy of UVA-1 treatment in severe cases of atopic eczema .
[ "Of", "46", "patients", "with", "severe", "atopic", "eczema", "treated", "with", "UVA-1", ",", "14", "were", "evaluated", "as", "non", "-", "responders", "and", "32", "as", "responders", ".", "Responding", "patients", "significantly", "had", "(", "p", "0.05", ")", "more", "severe", "skin", "involvement", "before", "onset", "of", "treatment", "(", "clinical", "severity", "score", "SCORAD", "62.7", "+", "/-", "12.4", "points", ")", "compared", "to", "non", "-", "responders", "(", "53.0", "+", "/-", "10.6", "points", ")", ".", "Serum", "levels", "of", "total", "IgE", ",", "ECP", "and", "sIL2R", "before", "treatment", "did", "not", "show", "any", "significant", "differences", "between", "the", "two", "groups", ".", "The", "data", "confirm", "the", "efficacy", "of", "UVA-1", "treatment", "in", "severe", "cases", "of", "atopic", "eczema", "." ]
[ "umlsterm" ]
Clostridium perfringens is an umlsterm, Mediastinitis is an umlsterm, Diagnose is an umlsterm, Oesophagektomie is an umlsterm, Fistel is an umlsterm, Gastrostomie is an umlsterm, Lavage is an umlsterm, Erbrechen is an umlsterm, Erbrechen is an umlsterm, Schmerz is an umlsterm, Hautemphysem is an umlsterm, Diagnose is an umlsterm
DerChirurg.70680929.ger.abstr_task0
Sentence: Zusammenfassung . Sowohl das Auftreten einer durch Clostridium perfringens hervorgerufenen Mediastinitis als auch einer spontanen Oesophagusruptur stellt eine Diagnose dar , die mit einer hohen Letalitaet einhergeht . Die Kombination beider Krankheitsbilder fuehrte bei einer 38 jaehrigen Patientin zu einem septischen Multiorganversagen , das mittels Oesophagektomie mit kollarer Fistel , Gastrostomie und postoperativer Lavage durch ein Laparostoma erfolgreich behandelt wurde . Das anamnestische Fehlen des Leitsymptoms Erbrechen und das erst spaet ausgebildete Vollbild der Symptomentrias ( Erbrechen , heftigster epigastrischer Schmerz und Hautemphysem ) hatte zu einer verzoegerten Diagnose gefuehrt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Sowohl das Auftreten einer durch Clostridium perfringens hervorgerufenen Mediastinitis als auch einer spontanen Oesophagusruptur stellt eine Diagnose dar , die mit einer hohen Letalitaet einhergeht . Die Kombination beider Krankheitsbilder fuehrte bei einer 38 jaehrigen Patientin zu einem septischen Multiorganversagen , das mittels Oesophagektomie mit kollarer Fistel , Gastrostomie und postoperativer Lavage durch ein Laparostoma erfolgreich behandelt wurde . Das anamnestische Fehlen des Leitsymptoms Erbrechen und das erst spaet ausgebildete Vollbild der Symptomentrias ( Erbrechen , heftigster epigastrischer Schmerz und Hautemphysem ) hatte zu einer verzoegerten Diagnose gefuehrt .
[ "Zusammenfassung", ".", "Sowohl", "das", "Auftreten", "einer", "durch", "Clostridium", "perfringens", "hervorgerufenen", "Mediastinitis", "als", "auch", "einer", "spontanen", "Oesophagusruptur", "stellt", "eine", "Diagnose", "dar", ",", "die", "mit", "einer", "hohen", "Letalitaet", "einhergeht", ".", "Die", "Kombination", "beider", "Krankheitsbilder", "fuehrte", "bei", "einer", "38", "jaehrigen", "Patientin", "zu", "einem", "septischen", "Multiorganversagen", ",", "das", "mittels", "Oesophagektomie", "mit", "kollarer", "Fistel", ",", "Gastrostomie", "und", "postoperativer", "Lavage", "durch", "ein", "Laparostoma", "erfolgreich", "behandelt", "wurde", ".", "Das", "anamnestische", "Fehlen", "des", "Leitsymptoms", "Erbrechen", "und", "das", "erst", "spaet", "ausgebildete", "Vollbild", "der", "Symptomentrias", "(", "Erbrechen", ",", "heftigster", "epigastrischer", "Schmerz", "und", "Hautemphysem", ")", "hatte", "zu", "einer", "verzoegerten", "Diagnose", "gefuehrt", "." ]
[ "umlsterm" ]
Clostridium perfringens is an umlsterm, Mediastinitis is an umlsterm, Diagnose is an umlsterm, Oesophagektomie is an umlsterm, Fistel is an umlsterm, Gastrostomie is an umlsterm, Lavage is an umlsterm, Erbrechen is an umlsterm, Erbrechen is an umlsterm, Schmerz is an umlsterm, Hautemphysem is an umlsterm, Diagnose is an umlsterm
DerChirurg.70680929.ger.abstr_task1
Sentence: Zusammenfassung . Sowohl das Auftreten einer durch Clostridium perfringens hervorgerufenen Mediastinitis als auch einer spontanen Oesophagusruptur stellt eine Diagnose dar , die mit einer hohen Letalitaet einhergeht . Die Kombination beider Krankheitsbilder fuehrte bei einer 38 jaehrigen Patientin zu einem septischen Multiorganversagen , das mittels Oesophagektomie mit kollarer Fistel , Gastrostomie und postoperativer Lavage durch ein Laparostoma erfolgreich behandelt wurde . Das anamnestische Fehlen des Leitsymptoms Erbrechen und das erst spaet ausgebildete Vollbild der Symptomentrias ( Erbrechen , heftigster epigastrischer Schmerz und Hautemphysem ) hatte zu einer verzoegerten Diagnose gefuehrt . Instructions: please typing these entity words according to sentence: Clostridium perfringens, Mediastinitis, Diagnose, Oesophagektomie, Fistel, Gastrostomie, Lavage, Erbrechen, Erbrechen, Schmerz, Hautemphysem, Diagnose Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Sowohl das Auftreten einer durch Clostridium perfringens hervorgerufenen Mediastinitis als auch einer spontanen Oesophagusruptur stellt eine Diagnose dar , die mit einer hohen Letalitaet einhergeht . Die Kombination beider Krankheitsbilder fuehrte bei einer 38 jaehrigen Patientin zu einem septischen Multiorganversagen , das mittels Oesophagektomie mit kollarer Fistel , Gastrostomie und postoperativer Lavage durch ein Laparostoma erfolgreich behandelt wurde . Das anamnestische Fehlen des Leitsymptoms Erbrechen und das erst spaet ausgebildete Vollbild der Symptomentrias ( Erbrechen , heftigster epigastrischer Schmerz und Hautemphysem ) hatte zu einer verzoegerten Diagnose gefuehrt .
[ "Zusammenfassung", ".", "Sowohl", "das", "Auftreten", "einer", "durch", "Clostridium", "perfringens", "hervorgerufenen", "Mediastinitis", "als", "auch", "einer", "spontanen", "Oesophagusruptur", "stellt", "eine", "Diagnose", "dar", ",", "die", "mit", "einer", "hohen", "Letalitaet", "einhergeht", ".", "Die", "Kombination", "beider", "Krankheitsbilder", "fuehrte", "bei", "einer", "38", "jaehrigen", "Patientin", "zu", "einem", "septischen", "Multiorganversagen", ",", "das", "mittels", "Oesophagektomie", "mit", "kollarer", "Fistel", ",", "Gastrostomie", "und", "postoperativer", "Lavage", "durch", "ein", "Laparostoma", "erfolgreich", "behandelt", "wurde", ".", "Das", "anamnestische", "Fehlen", "des", "Leitsymptoms", "Erbrechen", "und", "das", "erst", "spaet", "ausgebildete", "Vollbild", "der", "Symptomentrias", "(", "Erbrechen", ",", "heftigster", "epigastrischer", "Schmerz", "und", "Hautemphysem", ")", "hatte", "zu", "einer", "verzoegerten", "Diagnose", "gefuehrt", "." ]
[ "umlsterm" ]
Clostridium perfringens, Mediastinitis, Diagnose, Oesophagektomie, Fistel, Gastrostomie, Lavage, Erbrechen, Erbrechen, Schmerz, Hautemphysem, Diagnose
DerChirurg.70680929.ger.abstr_task2
Sentence: Zusammenfassung . Sowohl das Auftreten einer durch Clostridium perfringens hervorgerufenen Mediastinitis als auch einer spontanen Oesophagusruptur stellt eine Diagnose dar , die mit einer hohen Letalitaet einhergeht . Die Kombination beider Krankheitsbilder fuehrte bei einer 38 jaehrigen Patientin zu einem septischen Multiorganversagen , das mittels Oesophagektomie mit kollarer Fistel , Gastrostomie und postoperativer Lavage durch ein Laparostoma erfolgreich behandelt wurde . Das anamnestische Fehlen des Leitsymptoms Erbrechen und das erst spaet ausgebildete Vollbild der Symptomentrias ( Erbrechen , heftigster epigastrischer Schmerz und Hautemphysem ) hatte zu einer verzoegerten Diagnose gefuehrt . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Sowohl das Auftreten einer durch Clostridium perfringens hervorgerufenen Mediastinitis als auch einer spontanen Oesophagusruptur stellt eine Diagnose dar , die mit einer hohen Letalitaet einhergeht . Die Kombination beider Krankheitsbilder fuehrte bei einer 38 jaehrigen Patientin zu einem septischen Multiorganversagen , das mittels Oesophagektomie mit kollarer Fistel , Gastrostomie und postoperativer Lavage durch ein Laparostoma erfolgreich behandelt wurde . Das anamnestische Fehlen des Leitsymptoms Erbrechen und das erst spaet ausgebildete Vollbild der Symptomentrias ( Erbrechen , heftigster epigastrischer Schmerz und Hautemphysem ) hatte zu einer verzoegerten Diagnose gefuehrt .
[ "Zusammenfassung", ".", "Sowohl", "das", "Auftreten", "einer", "durch", "Clostridium", "perfringens", "hervorgerufenen", "Mediastinitis", "als", "auch", "einer", "spontanen", "Oesophagusruptur", "stellt", "eine", "Diagnose", "dar", ",", "die", "mit", "einer", "hohen", "Letalitaet", "einhergeht", ".", "Die", "Kombination", "beider", "Krankheitsbilder", "fuehrte", "bei", "einer", "38", "jaehrigen", "Patientin", "zu", "einem", "septischen", "Multiorganversagen", ",", "das", "mittels", "Oesophagektomie", "mit", "kollarer", "Fistel", ",", "Gastrostomie", "und", "postoperativer", "Lavage", "durch", "ein", "Laparostoma", "erfolgreich", "behandelt", "wurde", ".", "Das", "anamnestische", "Fehlen", "des", "Leitsymptoms", "Erbrechen", "und", "das", "erst", "spaet", "ausgebildete", "Vollbild", "der", "Symptomentrias", "(", "Erbrechen", ",", "heftigster", "epigastrischer", "Schmerz", "und", "Hautemphysem", ")", "hatte", "zu", "einer", "verzoegerten", "Diagnose", "gefuehrt", "." ]
[ "umlsterm" ]
Glucocorticoid receptor is a protein, streptozotocin is a compound
DS.d1111_task0
Sentence: Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]
Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice.
[ "Glucocorticoid", "receptor", "blockade", "normalizes", "hippocampal", "alterations", "and", "cognitive", "impairment", "in", "streptozotocin", "-", "induced", "type", "1", "diabetes", "mice", "." ]
[ "protein", "compound" ]
Glucocorticoid receptor is a protein, streptozotocin is a compound
DS.d1111_task1
Sentence: Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice. Instructions: please typing these entity words according to sentence: Glucocorticoid receptor, streptozotocin Options: compound, protein
[ "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]
Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice.
[ "Glucocorticoid", "receptor", "blockade", "normalizes", "hippocampal", "alterations", "and", "cognitive", "impairment", "in", "streptozotocin", "-", "induced", "type", "1", "diabetes", "mice", "." ]
[ "protein", "compound" ]
Glucocorticoid receptor, streptozotocin
DS.d1111_task2
Sentence: Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice. Instructions: please extract entity words from the input sentence
[ "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]
Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice.
[ "Glucocorticoid", "receptor", "blockade", "normalizes", "hippocampal", "alterations", "and", "cognitive", "impairment", "in", "streptozotocin", "-", "induced", "type", "1", "diabetes", "mice", "." ]
[ "protein", "compound" ]
tricyclic bispyran sulfone is a CHEMICAL, γ - secretase is a GENE-N, sulfone is a CHEMICAL, SCH 900229 is a CHEMICAL, γ - secretase is a GENE-N, 4-CF(3 ) is a CHEMICAL, 4-Br is a CHEMICAL, arylsulfone is a CHEMICAL, sulfone is a CHEMICAL
23761_task0
Sentence: Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors. An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (SCH 900229), a potent, PS1-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease. Specifically, 4-CF(3) and 4-Br substituted arylsulfone analogs, (-)-1b and (-)-1c, are equipotent to compound (-)-1a. On the right hand side chain, linker size and terminal substituents of the pendant sulfone group are also investigated. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]
Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors. An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (SCH 900229), a potent, PS1-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease. Specifically, 4-CF(3) and 4-Br substituted arylsulfone analogs, (-)-1b and (-)-1c, are equipotent to compound (-)-1a. On the right hand side chain, linker size and terminal substituents of the pendant sulfone group are also investigated.
[ "Structure", "activity", "relationship", "studies", "of", "tricyclic", "bispyran", "sulfone", "γ", "-", "secretase", "inhibitors", ".", "\n", "An", "investigation", "is", "detailed", "of", "the", "structure", "activity", "relationships", "(", "SAR", ")", "of", "two", "sulfone", "side", "chains", "of", "compound", "(", "-)-1a", "(", "SCH", "900229", ")", ",", "a", "potent", ",", "PS1-selective", "γ", "-", "secretase", "inhibitor", "and", "clinical", "candidate", "for", "the", "treatment", "of", "Alzheimer", "'s", "disease", ".", "Specifically", ",", "4-CF(3", ")", "and", "4-Br", "substituted", "arylsulfone", "analogs", ",", "(", "-)-1b", "and", "(", "-)-1c", ",", "are", "equipotent", "to", "compound", "(", "-)-1a", ".", "On", "the", "right", "hand", "side", "chain", ",", "linker", "size", "and", "terminal", "substituents", "of", "the", "pendant", "sulfone", "group", "are", "also", "investigated", "." ]
[ "CHEMICAL", "GENE-N", "GENE-Y" ]
tricyclic bispyran sulfone is a CHEMICAL, γ - secretase is a GENE-N, sulfone is a CHEMICAL, SCH 900229 is a CHEMICAL, γ - secretase is a GENE-N, 4-CF(3 ) is a CHEMICAL, 4-Br is a CHEMICAL, arylsulfone is a CHEMICAL, sulfone is a CHEMICAL
23761_task1
Sentence: Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors. An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (SCH 900229), a potent, PS1-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease. Specifically, 4-CF(3) and 4-Br substituted arylsulfone analogs, (-)-1b and (-)-1c, are equipotent to compound (-)-1a. On the right hand side chain, linker size and terminal substituents of the pendant sulfone group are also investigated. Instructions: please typing these entity words according to sentence: tricyclic bispyran sulfone, γ - secretase, sulfone, SCH 900229, γ - secretase, 4-CF(3 ), 4-Br, arylsulfone, sulfone Options: GENE-N, CHEMICAL
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]
Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors. An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (SCH 900229), a potent, PS1-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease. Specifically, 4-CF(3) and 4-Br substituted arylsulfone analogs, (-)-1b and (-)-1c, are equipotent to compound (-)-1a. On the right hand side chain, linker size and terminal substituents of the pendant sulfone group are also investigated.
[ "Structure", "activity", "relationship", "studies", "of", "tricyclic", "bispyran", "sulfone", "γ", "-", "secretase", "inhibitors", ".", "\n", "An", "investigation", "is", "detailed", "of", "the", "structure", "activity", "relationships", "(", "SAR", ")", "of", "two", "sulfone", "side", "chains", "of", "compound", "(", "-)-1a", "(", "SCH", "900229", ")", ",", "a", "potent", ",", "PS1-selective", "γ", "-", "secretase", "inhibitor", "and", "clinical", "candidate", "for", "the", "treatment", "of", "Alzheimer", "'s", "disease", ".", "Specifically", ",", "4-CF(3", ")", "and", "4-Br", "substituted", "arylsulfone", "analogs", ",", "(", "-)-1b", "and", "(", "-)-1c", ",", "are", "equipotent", "to", "compound", "(", "-)-1a", ".", "On", "the", "right", "hand", "side", "chain", ",", "linker", "size", "and", "terminal", "substituents", "of", "the", "pendant", "sulfone", "group", "are", "also", "investigated", "." ]
[ "CHEMICAL", "GENE-N", "GENE-Y" ]
tricyclic bispyran sulfone, γ - secretase, sulfone, SCH 900229, γ - secretase, 4-CF(3 ), 4-Br, arylsulfone, sulfone
23761_task2
Sentence: Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors. An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (SCH 900229), a potent, PS1-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease. Specifically, 4-CF(3) and 4-Br substituted arylsulfone analogs, (-)-1b and (-)-1c, are equipotent to compound (-)-1a. On the right hand side chain, linker size and terminal substituents of the pendant sulfone group are also investigated. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]
Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors. An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (SCH 900229), a potent, PS1-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease. Specifically, 4-CF(3) and 4-Br substituted arylsulfone analogs, (-)-1b and (-)-1c, are equipotent to compound (-)-1a. On the right hand side chain, linker size and terminal substituents of the pendant sulfone group are also investigated.
[ "Structure", "activity", "relationship", "studies", "of", "tricyclic", "bispyran", "sulfone", "γ", "-", "secretase", "inhibitors", ".", "\n", "An", "investigation", "is", "detailed", "of", "the", "structure", "activity", "relationships", "(", "SAR", ")", "of", "two", "sulfone", "side", "chains", "of", "compound", "(", "-)-1a", "(", "SCH", "900229", ")", ",", "a", "potent", ",", "PS1-selective", "γ", "-", "secretase", "inhibitor", "and", "clinical", "candidate", "for", "the", "treatment", "of", "Alzheimer", "'s", "disease", ".", "Specifically", ",", "4-CF(3", ")", "and", "4-Br", "substituted", "arylsulfone", "analogs", ",", "(", "-)-1b", "and", "(", "-)-1c", ",", "are", "equipotent", "to", "compound", "(", "-)-1a", ".", "On", "the", "right", "hand", "side", "chain", ",", "linker", "size", "and", "terminal", "substituents", "of", "the", "pendant", "sulfone", "group", "are", "also", "investigated", "." ]
[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Endothel is an umlsterm, Endothel is an umlsterm, Transplantation is an umlsterm, Transplantation is an umlsterm, Endothelzellen is an umlsterm
DerOpthalmologe.90960555.ger.abstr_task0
Sentence: Hintergrund : Das humane korneale Endothel ist in vivo nur eingeschraenkt teilungsfaehig und geschaedigtes Endothel kann bisher nur durch die Transplantation einer Spenderhornhaut ersetzt werden . Die Transplantation von isolierten und in-vitro-kultivierten Endothelzellen koennte zukuenftig eine therapeutische Alternative darstellen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Hintergrund : Das humane korneale Endothel ist in vivo nur eingeschraenkt teilungsfaehig und geschaedigtes Endothel kann bisher nur durch die Transplantation einer Spenderhornhaut ersetzt werden . Die Transplantation von isolierten und in-vitro-kultivierten Endothelzellen koennte zukuenftig eine therapeutische Alternative darstellen .
[ "Hintergrund", ":", "Das", "humane", "korneale", "Endothel", "ist", "in", "vivo", "nur", "eingeschraenkt", "teilungsfaehig", "und", "geschaedigtes", "Endothel", "kann", "bisher", "nur", "durch", "die", "Transplantation", "einer", "Spenderhornhaut", "ersetzt", "werden", ".", "Die", "Transplantation", "von", "isolierten", "und", "in", "-", "vitro", "-", "kultivierten", "Endothelzellen", "koennte", "zukuenftig", "eine", "therapeutische", "Alternative", "darstellen", "." ]
[ "umlsterm" ]
Endothel is an umlsterm, Endothel is an umlsterm, Transplantation is an umlsterm, Transplantation is an umlsterm, Endothelzellen is an umlsterm
DerOpthalmologe.90960555.ger.abstr_task1
Sentence: Hintergrund : Das humane korneale Endothel ist in vivo nur eingeschraenkt teilungsfaehig und geschaedigtes Endothel kann bisher nur durch die Transplantation einer Spenderhornhaut ersetzt werden . Die Transplantation von isolierten und in-vitro-kultivierten Endothelzellen koennte zukuenftig eine therapeutische Alternative darstellen . Instructions: please typing these entity words according to sentence: Endothel, Endothel, Transplantation, Transplantation, Endothelzellen Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Hintergrund : Das humane korneale Endothel ist in vivo nur eingeschraenkt teilungsfaehig und geschaedigtes Endothel kann bisher nur durch die Transplantation einer Spenderhornhaut ersetzt werden . Die Transplantation von isolierten und in-vitro-kultivierten Endothelzellen koennte zukuenftig eine therapeutische Alternative darstellen .
[ "Hintergrund", ":", "Das", "humane", "korneale", "Endothel", "ist", "in", "vivo", "nur", "eingeschraenkt", "teilungsfaehig", "und", "geschaedigtes", "Endothel", "kann", "bisher", "nur", "durch", "die", "Transplantation", "einer", "Spenderhornhaut", "ersetzt", "werden", ".", "Die", "Transplantation", "von", "isolierten", "und", "in", "-", "vitro", "-", "kultivierten", "Endothelzellen", "koennte", "zukuenftig", "eine", "therapeutische", "Alternative", "darstellen", "." ]
[ "umlsterm" ]
Endothel, Endothel, Transplantation, Transplantation, Endothelzellen
DerOpthalmologe.90960555.ger.abstr_task2
Sentence: Hintergrund : Das humane korneale Endothel ist in vivo nur eingeschraenkt teilungsfaehig und geschaedigtes Endothel kann bisher nur durch die Transplantation einer Spenderhornhaut ersetzt werden . Die Transplantation von isolierten und in-vitro-kultivierten Endothelzellen koennte zukuenftig eine therapeutische Alternative darstellen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Hintergrund : Das humane korneale Endothel ist in vivo nur eingeschraenkt teilungsfaehig und geschaedigtes Endothel kann bisher nur durch die Transplantation einer Spenderhornhaut ersetzt werden . Die Transplantation von isolierten und in-vitro-kultivierten Endothelzellen koennte zukuenftig eine therapeutische Alternative darstellen .
[ "Hintergrund", ":", "Das", "humane", "korneale", "Endothel", "ist", "in", "vivo", "nur", "eingeschraenkt", "teilungsfaehig", "und", "geschaedigtes", "Endothel", "kann", "bisher", "nur", "durch", "die", "Transplantation", "einer", "Spenderhornhaut", "ersetzt", "werden", ".", "Die", "Transplantation", "von", "isolierten", "und", "in", "-", "vitro", "-", "kultivierten", "Endothelzellen", "koennte", "zukuenftig", "eine", "therapeutische", "Alternative", "darstellen", "." ]
[ "umlsterm" ]
muscle relaxant analgesic combination is a Intervention_Pharmacological, acute lumbago is a Participant_Condition
14065_task0
Sentence: A controlled clinical trial of a muscle relaxant analgesic combination in the treatment of acute lumbago . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition
[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O" ]
A controlled clinical trial of a muscle relaxant analgesic combination in the treatment of acute lumbago .
[ "A", "controlled", "clinical", "trial", "of", "a", "muscle", "relaxant", "analgesic", "combination", "in", "the", "treatment", "of", "acute", "lumbago", "." ]
[ "Intervention_Pharmacological", "Participant_Condition" ]
muscle relaxant analgesic combination is a Intervention_Pharmacological, acute lumbago is a Participant_Condition
14065_task1
Sentence: A controlled clinical trial of a muscle relaxant analgesic combination in the treatment of acute lumbago . Instructions: please typing these entity words according to sentence: muscle relaxant analgesic combination, acute lumbago Options: Intervention_Pharmacological, Participant_Condition
[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O" ]
A controlled clinical trial of a muscle relaxant analgesic combination in the treatment of acute lumbago .
[ "A", "controlled", "clinical", "trial", "of", "a", "muscle", "relaxant", "analgesic", "combination", "in", "the", "treatment", "of", "acute", "lumbago", "." ]
[ "Intervention_Pharmacological", "Participant_Condition" ]
muscle relaxant analgesic combination, acute lumbago
14065_task2
Sentence: A controlled clinical trial of a muscle relaxant analgesic combination in the treatment of acute lumbago . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O" ]
A controlled clinical trial of a muscle relaxant analgesic combination in the treatment of acute lumbago .
[ "A", "controlled", "clinical", "trial", "of", "a", "muscle", "relaxant", "analgesic", "combination", "in", "the", "treatment", "of", "acute", "lumbago", "." ]
[ "Intervention_Pharmacological", "Participant_Condition" ]
animal experiments is an umlsterm, prostheses is an umlsterm, diclofenac is an umlsterm, objective is an umlsterm, direct is an umlsterm, diclofenac is an umlsterm, times is an umlsterm, bone is an umlsterm, cells is an umlsterm, progenitor cells is an umlsterm, prostheses is an umlsterm, Methods is an umlsterm, human is an umlsterm, in vitro is an umlsterm, osteoblasts is an umlsterm, bone marrow cells is an umlsterm, medications is an umlsterm, diclofenac is an umlsterm, metabolism is an umlsterm, cell lines is an umlsterm, plasma is an umlsterm, concentration is an umlsterm, tablet is an umlsterm, Voltaren is an umlsterm, diclofenac is an umlsterm, concentrations is an umlsterm, values is an umlsterm, control group is an umlsterm, diclofenac is an umlsterm, drug effect is an umlsterm, osteoblasts is an umlsterm, progenitor cells is an umlsterm, in vitro is an umlsterm, bone marrow cells is an umlsterm, cells is an umlsterm, diclofenac is an umlsterm, concentration is an umlsterm, Osteoblasts is an umlsterm, concentration is an umlsterm, DNA is an umlsterm, bone marrow cells is an umlsterm, osteoblasts is an umlsterm, contrast is an umlsterm, collagen is an umlsterm, osteoblasts is an umlsterm, cells is an umlsterm, osteocalcin is an umlsterm, osteoblasts is an umlsterm, alkaline phosphatase is an umlsterm, bone marrow cells is an umlsterm, osteoblasts is an umlsterm, prosthesis is an umlsterm, diclofenac is an umlsterm, bone is an umlsterm, metabolism is an umlsterm, osteocalcin is an umlsterm, Osteocalcin is an umlsterm, collagen is an umlsterm
ZfuerRheumatologie.90580013.eng.abstr_task0
Sentence: Introduction : Results of animal experiments have demonstrated that the osseous integration of non-cemented prostheses can , at the very least temporarily , be impaired by the application of non-steroidal antiphlogistic agents ( such as diclofenac ) . It is the objective of this study to examine whether there is a direct influence of diclofenac used in usual clinical dosages ( 3 times 50 mg daily ) on bone cells and their progenitor cells which would explain the observed slow integration of the prostheses . Methods : To investigate this , cultivated human in vitro osteoblasts and stromal bone marrow cells were incubated with increasing doses of the medications . Our study focused on the effect of diclofenac application on proliferation and functional metabolism in both cell lines . The measurable maximal plasma concentration 2h after the application of one tablet Voltaren 50 reached 1.6µg/ml. This correlated with diclofenac concentrations between 1 and 10 ml found in our experiments . The detected values were correlated to the control group ( 0 µg/ml diclofenac ) . Results : The drug effect upon osteoblasts was higher than on progenitor cells . The proliferation of in vitro stromal bone marrow cells , compared to untreated cells , was found to be decreased . We observed a decrease to 82% at a diclofenac concentration of 1 µg/ml, Osteoblasts exhibited a decrease to 97,5% at the same concentration . The DNA synthesis increased to 118% in stromal bone marrow cells , in osteoblasts to 144% . In contrast , we detected a neglectible decrease to 92% in the collagen synthesis of osteoblasts compared to untreated cells . The synthesis of osteocalcin by osteoblasts increased to 119% . The alkaline phosphatase activity was found to be decreased to 88% in stromal bone marrow cells and increased in osteoblasts to 111% . Conclusion : Temporary inhibiting effects on osseous integration in non-cemented prosthesis by diclofenac could be caused by a disturbance in the anabolic bone metabolism , exhibited by an increase of osteoblastic osteocalcin expression . Osteocalcin as a known negative regulator of the osteoneogenesis is most likely inhibiting the collagen matrix deposition . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Introduction : Results of animal experiments have demonstrated that the osseous integration of non-cemented prostheses can , at the very least temporarily , be impaired by the application of non-steroidal antiphlogistic agents ( such as diclofenac ) . It is the objective of this study to examine whether there is a direct influence of diclofenac used in usual clinical dosages ( 3 times 50 mg daily ) on bone cells and their progenitor cells which would explain the observed slow integration of the prostheses . Methods : To investigate this , cultivated human in vitro osteoblasts and stromal bone marrow cells were incubated with increasing doses of the medications . Our study focused on the effect of diclofenac application on proliferation and functional metabolism in both cell lines . The measurable maximal plasma concentration 2h after the application of one tablet Voltaren 50 reached 1.6µg/ml. This correlated with diclofenac concentrations between 1 and 10 ml found in our experiments . The detected values were correlated to the control group ( 0 µg/ml diclofenac ) . Results : The drug effect upon osteoblasts was higher than on progenitor cells . The proliferation of in vitro stromal bone marrow cells , compared to untreated cells , was found to be decreased . We observed a decrease to 82% at a diclofenac concentration of 1 µg/ml, Osteoblasts exhibited a decrease to 97,5% at the same concentration . The DNA synthesis increased to 118% in stromal bone marrow cells , in osteoblasts to 144% . In contrast , we detected a neglectible decrease to 92% in the collagen synthesis of osteoblasts compared to untreated cells . The synthesis of osteocalcin by osteoblasts increased to 119% . The alkaline phosphatase activity was found to be decreased to 88% in stromal bone marrow cells and increased in osteoblasts to 111% . Conclusion : Temporary inhibiting effects on osseous integration in non-cemented prosthesis by diclofenac could be caused by a disturbance in the anabolic bone metabolism , exhibited by an increase of osteoblastic osteocalcin expression . Osteocalcin as a known negative regulator of the osteoneogenesis is most likely inhibiting the collagen matrix deposition .
[ "Introduction", ":", "Results", "of", "animal", "experiments", "have", "demonstrated", "that", "the", "osseous", "integration", "of", "non", "-", "cemented", "prostheses", "can", ",", "at", "the", "very", "least", "temporarily", ",", "be", "impaired", "by", "the", "application", "of", "non", "-", "steroidal", "antiphlogistic", "agents", "(", "such", "as", "diclofenac", ")", ".", "It", "is", "the", "objective", "of", "this", "study", "to", "examine", "whether", "there", "is", "a", "direct", "influence", "of", "diclofenac", "used", "in", "usual", "clinical", "dosages", "(", "3", "times", "50", "mg", "daily", ")", "on", "bone", "cells", "and", "their", "progenitor", "cells", "which", "would", "explain", "the", "observed", "slow", "integration", "of", "the", "prostheses", ".", "Methods", ":", "To", "investigate", "this", ",", "cultivated", "human", "in", "vitro", "osteoblasts", "and", "stromal", "bone", "marrow", "cells", "were", "incubated", "with", "increasing", "doses", "of", "the", "medications", ".", "Our", "study", "focused", "on", "the", "effect", "of", "diclofenac", "application", "on", "proliferation", "and", "functional", "metabolism", "in", "both", "cell", "lines", ".", "The", "measurable", "maximal", "plasma", "concentration", "2h", "after", "the", "application", "of", "one", "tablet", "Voltaren", "50", "reached", "1.6µg", "/", "ml", ".", "This", "correlated", "with", "diclofenac", "concentrations", "between", "1", "and", "10", "ml", "found", "in", "our", "experiments", ".", "The", "detected", "values", "were", "correlated", "to", "the", "control", "group", "(", "0", "µg", "/", "ml", "diclofenac", ")", ".", "Results", ":", "The", "drug", "effect", "upon", "osteoblasts", "was", "higher", "than", "on", "progenitor", "cells", ".", "The", "proliferation", "of", "in", "vitro", "stromal", "bone", "marrow", "cells", ",", "compared", "to", "untreated", "cells", ",", "was", "found", "to", "be", "decreased", ".", "We", "observed", "a", "decrease", "to", "82", "%", "at", "a", "diclofenac", "concentration", "of", "1", "µg", "/", "ml", ",", "Osteoblasts", "exhibited", "a", "decrease", "to", "97,5", "%", "at", "the", "same", "concentration", ".", "The", "DNA", "synthesis", "increased", "to", "118", "%", "in", "stromal", "bone", "marrow", "cells", ",", "in", "osteoblasts", "to", "144", "%", ".", "In", "contrast", ",", "we", "detected", "a", "neglectible", "decrease", "to", "92", "%", "in", "the", "collagen", "synthesis", "of", "osteoblasts", "compared", "to", "untreated", "cells", ".", "The", "synthesis", "of", "osteocalcin", "by", "osteoblasts", "increased", "to", "119", "%", ".", "The", "alkaline", "phosphatase", "activity", "was", "found", "to", "be", "decreased", "to", "88", "%", "in", "stromal", "bone", "marrow", "cells", "and", "increased", "in", "osteoblasts", "to", "111", "%", ".", "Conclusion", ":", "Temporary", "inhibiting", "effects", "on", "osseous", "integration", "in", "non", "-", "cemented", "prosthesis", "by", "diclofenac", "could", "be", "caused", "by", "a", "disturbance", "in", "the", "anabolic", "bone", "metabolism", ",", "exhibited", "by", "an", "increase", "of", "osteoblastic", "osteocalcin", "expression", ".", "Osteocalcin", "as", "a", "known", "negative", "regulator", "of", "the", "osteoneogenesis", "is", "most", "likely", "inhibiting", "the", "collagen", "matrix", "deposition", "." ]
[ "umlsterm" ]
animal experiments is an umlsterm, prostheses is an umlsterm, diclofenac is an umlsterm, objective is an umlsterm, direct is an umlsterm, diclofenac is an umlsterm, times is an umlsterm, bone is an umlsterm, cells is an umlsterm, progenitor cells is an umlsterm, prostheses is an umlsterm, Methods is an umlsterm, human is an umlsterm, in vitro is an umlsterm, osteoblasts is an umlsterm, bone marrow cells is an umlsterm, medications is an umlsterm, diclofenac is an umlsterm, metabolism is an umlsterm, cell lines is an umlsterm, plasma is an umlsterm, concentration is an umlsterm, tablet is an umlsterm, Voltaren is an umlsterm, diclofenac is an umlsterm, concentrations is an umlsterm, values is an umlsterm, control group is an umlsterm, diclofenac is an umlsterm, drug effect is an umlsterm, osteoblasts is an umlsterm, progenitor cells is an umlsterm, in vitro is an umlsterm, bone marrow cells is an umlsterm, cells is an umlsterm, diclofenac is an umlsterm, concentration is an umlsterm, Osteoblasts is an umlsterm, concentration is an umlsterm, DNA is an umlsterm, bone marrow cells is an umlsterm, osteoblasts is an umlsterm, contrast is an umlsterm, collagen is an umlsterm, osteoblasts is an umlsterm, cells is an umlsterm, osteocalcin is an umlsterm, osteoblasts is an umlsterm, alkaline phosphatase is an umlsterm, bone marrow cells is an umlsterm, osteoblasts is an umlsterm, prosthesis is an umlsterm, diclofenac is an umlsterm, bone is an umlsterm, metabolism is an umlsterm, osteocalcin is an umlsterm, Osteocalcin is an umlsterm, collagen is an umlsterm
ZfuerRheumatologie.90580013.eng.abstr_task1
Sentence: Introduction : Results of animal experiments have demonstrated that the osseous integration of non-cemented prostheses can , at the very least temporarily , be impaired by the application of non-steroidal antiphlogistic agents ( such as diclofenac ) . It is the objective of this study to examine whether there is a direct influence of diclofenac used in usual clinical dosages ( 3 times 50 mg daily ) on bone cells and their progenitor cells which would explain the observed slow integration of the prostheses . Methods : To investigate this , cultivated human in vitro osteoblasts and stromal bone marrow cells were incubated with increasing doses of the medications . Our study focused on the effect of diclofenac application on proliferation and functional metabolism in both cell lines . The measurable maximal plasma concentration 2h after the application of one tablet Voltaren 50 reached 1.6µg/ml. This correlated with diclofenac concentrations between 1 and 10 ml found in our experiments . The detected values were correlated to the control group ( 0 µg/ml diclofenac ) . Results : The drug effect upon osteoblasts was higher than on progenitor cells . The proliferation of in vitro stromal bone marrow cells , compared to untreated cells , was found to be decreased . We observed a decrease to 82% at a diclofenac concentration of 1 µg/ml, Osteoblasts exhibited a decrease to 97,5% at the same concentration . The DNA synthesis increased to 118% in stromal bone marrow cells , in osteoblasts to 144% . In contrast , we detected a neglectible decrease to 92% in the collagen synthesis of osteoblasts compared to untreated cells . The synthesis of osteocalcin by osteoblasts increased to 119% . The alkaline phosphatase activity was found to be decreased to 88% in stromal bone marrow cells and increased in osteoblasts to 111% . Conclusion : Temporary inhibiting effects on osseous integration in non-cemented prosthesis by diclofenac could be caused by a disturbance in the anabolic bone metabolism , exhibited by an increase of osteoblastic osteocalcin expression . Osteocalcin as a known negative regulator of the osteoneogenesis is most likely inhibiting the collagen matrix deposition . Instructions: please typing these entity words according to sentence: animal experiments, prostheses, diclofenac, objective, direct, diclofenac, times, bone, cells, progenitor cells, prostheses, Methods, human, in vitro, osteoblasts, bone marrow cells, medications, diclofenac, metabolism, cell lines, plasma, concentration, tablet, Voltaren, diclofenac, concentrations, values, control group, diclofenac, drug effect, osteoblasts, progenitor cells, in vitro, bone marrow cells, cells, diclofenac, concentration, Osteoblasts, concentration, DNA, bone marrow cells, osteoblasts, contrast, collagen, osteoblasts, cells, osteocalcin, osteoblasts, alkaline phosphatase, bone marrow cells, osteoblasts, prosthesis, diclofenac, bone, metabolism, osteocalcin, Osteocalcin, collagen Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Introduction : Results of animal experiments have demonstrated that the osseous integration of non-cemented prostheses can , at the very least temporarily , be impaired by the application of non-steroidal antiphlogistic agents ( such as diclofenac ) . It is the objective of this study to examine whether there is a direct influence of diclofenac used in usual clinical dosages ( 3 times 50 mg daily ) on bone cells and their progenitor cells which would explain the observed slow integration of the prostheses . Methods : To investigate this , cultivated human in vitro osteoblasts and stromal bone marrow cells were incubated with increasing doses of the medications . Our study focused on the effect of diclofenac application on proliferation and functional metabolism in both cell lines . The measurable maximal plasma concentration 2h after the application of one tablet Voltaren 50 reached 1.6µg/ml. This correlated with diclofenac concentrations between 1 and 10 ml found in our experiments . The detected values were correlated to the control group ( 0 µg/ml diclofenac ) . Results : The drug effect upon osteoblasts was higher than on progenitor cells . The proliferation of in vitro stromal bone marrow cells , compared to untreated cells , was found to be decreased . We observed a decrease to 82% at a diclofenac concentration of 1 µg/ml, Osteoblasts exhibited a decrease to 97,5% at the same concentration . The DNA synthesis increased to 118% in stromal bone marrow cells , in osteoblasts to 144% . In contrast , we detected a neglectible decrease to 92% in the collagen synthesis of osteoblasts compared to untreated cells . The synthesis of osteocalcin by osteoblasts increased to 119% . The alkaline phosphatase activity was found to be decreased to 88% in stromal bone marrow cells and increased in osteoblasts to 111% . Conclusion : Temporary inhibiting effects on osseous integration in non-cemented prosthesis by diclofenac could be caused by a disturbance in the anabolic bone metabolism , exhibited by an increase of osteoblastic osteocalcin expression . Osteocalcin as a known negative regulator of the osteoneogenesis is most likely inhibiting the collagen matrix deposition .
[ "Introduction", ":", "Results", "of", "animal", "experiments", "have", "demonstrated", "that", "the", "osseous", "integration", "of", "non", "-", "cemented", "prostheses", "can", ",", "at", "the", "very", "least", "temporarily", ",", "be", "impaired", "by", "the", "application", "of", "non", "-", "steroidal", "antiphlogistic", "agents", "(", "such", "as", "diclofenac", ")", ".", "It", "is", "the", "objective", "of", "this", "study", "to", "examine", "whether", "there", "is", "a", "direct", "influence", "of", "diclofenac", "used", "in", "usual", "clinical", "dosages", "(", "3", "times", "50", "mg", "daily", ")", "on", "bone", "cells", "and", "their", "progenitor", "cells", "which", "would", "explain", "the", "observed", "slow", "integration", "of", "the", "prostheses", ".", "Methods", ":", "To", "investigate", "this", ",", "cultivated", "human", "in", "vitro", "osteoblasts", "and", "stromal", "bone", "marrow", "cells", "were", "incubated", "with", "increasing", "doses", "of", "the", "medications", ".", "Our", "study", "focused", "on", "the", "effect", "of", "diclofenac", "application", "on", "proliferation", "and", "functional", "metabolism", "in", "both", "cell", "lines", ".", "The", "measurable", "maximal", "plasma", "concentration", "2h", "after", "the", "application", "of", "one", "tablet", "Voltaren", "50", "reached", "1.6µg", "/", "ml", ".", "This", "correlated", "with", "diclofenac", "concentrations", "between", "1", "and", "10", "ml", "found", "in", "our", "experiments", ".", "The", "detected", "values", "were", "correlated", "to", "the", "control", "group", "(", "0", "µg", "/", "ml", "diclofenac", ")", ".", "Results", ":", "The", "drug", "effect", "upon", "osteoblasts", "was", "higher", "than", "on", "progenitor", "cells", ".", "The", "proliferation", "of", "in", "vitro", "stromal", "bone", "marrow", "cells", ",", "compared", "to", "untreated", "cells", ",", "was", "found", "to", "be", "decreased", ".", "We", "observed", "a", "decrease", "to", "82", "%", "at", "a", "diclofenac", "concentration", "of", "1", "µg", "/", "ml", ",", "Osteoblasts", "exhibited", "a", "decrease", "to", "97,5", "%", "at", "the", "same", "concentration", ".", "The", "DNA", "synthesis", "increased", "to", "118", "%", "in", "stromal", "bone", "marrow", "cells", ",", "in", "osteoblasts", "to", "144", "%", ".", "In", "contrast", ",", "we", "detected", "a", "neglectible", "decrease", "to", "92", "%", "in", "the", "collagen", "synthesis", "of", "osteoblasts", "compared", "to", "untreated", "cells", ".", "The", "synthesis", "of", "osteocalcin", "by", "osteoblasts", "increased", "to", "119", "%", ".", "The", "alkaline", "phosphatase", "activity", "was", "found", "to", "be", "decreased", "to", "88", "%", "in", "stromal", "bone", "marrow", "cells", "and", "increased", "in", "osteoblasts", "to", "111", "%", ".", "Conclusion", ":", "Temporary", "inhibiting", "effects", "on", "osseous", "integration", "in", "non", "-", "cemented", "prosthesis", "by", "diclofenac", "could", "be", "caused", "by", "a", "disturbance", "in", "the", "anabolic", "bone", "metabolism", ",", "exhibited", "by", "an", "increase", "of", "osteoblastic", "osteocalcin", "expression", ".", "Osteocalcin", "as", "a", "known", "negative", "regulator", "of", "the", "osteoneogenesis", "is", "most", "likely", "inhibiting", "the", "collagen", "matrix", "deposition", "." ]
[ "umlsterm" ]
animal experiments, prostheses, diclofenac, objective, direct, diclofenac, times, bone, cells, progenitor cells, prostheses, Methods, human, in vitro, osteoblasts, bone marrow cells, medications, diclofenac, metabolism, cell lines, plasma, concentration, tablet, Voltaren, diclofenac, concentrations, values, control group, diclofenac, drug effect, osteoblasts, progenitor cells, in vitro, bone marrow cells, cells, diclofenac, concentration, Osteoblasts, concentration, DNA, bone marrow cells, osteoblasts, contrast, collagen, osteoblasts, cells, osteocalcin, osteoblasts, alkaline phosphatase, bone marrow cells, osteoblasts, prosthesis, diclofenac, bone, metabolism, osteocalcin, Osteocalcin, collagen
ZfuerRheumatologie.90580013.eng.abstr_task2
Sentence: Introduction : Results of animal experiments have demonstrated that the osseous integration of non-cemented prostheses can , at the very least temporarily , be impaired by the application of non-steroidal antiphlogistic agents ( such as diclofenac ) . It is the objective of this study to examine whether there is a direct influence of diclofenac used in usual clinical dosages ( 3 times 50 mg daily ) on bone cells and their progenitor cells which would explain the observed slow integration of the prostheses . Methods : To investigate this , cultivated human in vitro osteoblasts and stromal bone marrow cells were incubated with increasing doses of the medications . Our study focused on the effect of diclofenac application on proliferation and functional metabolism in both cell lines . The measurable maximal plasma concentration 2h after the application of one tablet Voltaren 50 reached 1.6µg/ml. This correlated with diclofenac concentrations between 1 and 10 ml found in our experiments . The detected values were correlated to the control group ( 0 µg/ml diclofenac ) . Results : The drug effect upon osteoblasts was higher than on progenitor cells . The proliferation of in vitro stromal bone marrow cells , compared to untreated cells , was found to be decreased . We observed a decrease to 82% at a diclofenac concentration of 1 µg/ml, Osteoblasts exhibited a decrease to 97,5% at the same concentration . The DNA synthesis increased to 118% in stromal bone marrow cells , in osteoblasts to 144% . In contrast , we detected a neglectible decrease to 92% in the collagen synthesis of osteoblasts compared to untreated cells . The synthesis of osteocalcin by osteoblasts increased to 119% . The alkaline phosphatase activity was found to be decreased to 88% in stromal bone marrow cells and increased in osteoblasts to 111% . Conclusion : Temporary inhibiting effects on osseous integration in non-cemented prosthesis by diclofenac could be caused by a disturbance in the anabolic bone metabolism , exhibited by an increase of osteoblastic osteocalcin expression . Osteocalcin as a known negative regulator of the osteoneogenesis is most likely inhibiting the collagen matrix deposition . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Introduction : Results of animal experiments have demonstrated that the osseous integration of non-cemented prostheses can , at the very least temporarily , be impaired by the application of non-steroidal antiphlogistic agents ( such as diclofenac ) . It is the objective of this study to examine whether there is a direct influence of diclofenac used in usual clinical dosages ( 3 times 50 mg daily ) on bone cells and their progenitor cells which would explain the observed slow integration of the prostheses . Methods : To investigate this , cultivated human in vitro osteoblasts and stromal bone marrow cells were incubated with increasing doses of the medications . Our study focused on the effect of diclofenac application on proliferation and functional metabolism in both cell lines . The measurable maximal plasma concentration 2h after the application of one tablet Voltaren 50 reached 1.6µg/ml. This correlated with diclofenac concentrations between 1 and 10 ml found in our experiments . The detected values were correlated to the control group ( 0 µg/ml diclofenac ) . Results : The drug effect upon osteoblasts was higher than on progenitor cells . The proliferation of in vitro stromal bone marrow cells , compared to untreated cells , was found to be decreased . We observed a decrease to 82% at a diclofenac concentration of 1 µg/ml, Osteoblasts exhibited a decrease to 97,5% at the same concentration . The DNA synthesis increased to 118% in stromal bone marrow cells , in osteoblasts to 144% . In contrast , we detected a neglectible decrease to 92% in the collagen synthesis of osteoblasts compared to untreated cells . The synthesis of osteocalcin by osteoblasts increased to 119% . The alkaline phosphatase activity was found to be decreased to 88% in stromal bone marrow cells and increased in osteoblasts to 111% . Conclusion : Temporary inhibiting effects on osseous integration in non-cemented prosthesis by diclofenac could be caused by a disturbance in the anabolic bone metabolism , exhibited by an increase of osteoblastic osteocalcin expression . Osteocalcin as a known negative regulator of the osteoneogenesis is most likely inhibiting the collagen matrix deposition .
[ "Introduction", ":", "Results", "of", "animal", "experiments", "have", "demonstrated", "that", "the", "osseous", "integration", "of", "non", "-", "cemented", "prostheses", "can", ",", "at", "the", "very", "least", "temporarily", ",", "be", "impaired", "by", "the", "application", "of", "non", "-", "steroidal", "antiphlogistic", "agents", "(", "such", "as", "diclofenac", ")", ".", "It", "is", "the", "objective", "of", "this", "study", "to", "examine", "whether", "there", "is", "a", "direct", "influence", "of", "diclofenac", "used", "in", "usual", "clinical", "dosages", "(", "3", "times", "50", "mg", "daily", ")", "on", "bone", "cells", "and", "their", "progenitor", "cells", "which", "would", "explain", "the", "observed", "slow", "integration", "of", "the", "prostheses", ".", "Methods", ":", "To", "investigate", "this", ",", "cultivated", "human", "in", "vitro", "osteoblasts", "and", "stromal", "bone", "marrow", "cells", "were", "incubated", "with", "increasing", "doses", "of", "the", "medications", ".", "Our", "study", "focused", "on", "the", "effect", "of", "diclofenac", "application", "on", "proliferation", "and", "functional", "metabolism", "in", "both", "cell", "lines", ".", "The", "measurable", "maximal", "plasma", "concentration", "2h", "after", "the", "application", "of", "one", "tablet", "Voltaren", "50", "reached", "1.6µg", "/", "ml", ".", "This", "correlated", "with", "diclofenac", "concentrations", "between", "1", "and", "10", "ml", "found", "in", "our", "experiments", ".", "The", "detected", "values", "were", "correlated", "to", "the", "control", "group", "(", "0", "µg", "/", "ml", "diclofenac", ")", ".", "Results", ":", "The", "drug", "effect", "upon", "osteoblasts", "was", "higher", "than", "on", "progenitor", "cells", ".", "The", "proliferation", "of", "in", "vitro", "stromal", "bone", "marrow", "cells", ",", "compared", "to", "untreated", "cells", ",", "was", "found", "to", "be", "decreased", ".", "We", "observed", "a", "decrease", "to", "82", "%", "at", "a", "diclofenac", "concentration", "of", "1", "µg", "/", "ml", ",", "Osteoblasts", "exhibited", "a", "decrease", "to", "97,5", "%", "at", "the", "same", "concentration", ".", "The", "DNA", "synthesis", "increased", "to", "118", "%", "in", "stromal", "bone", "marrow", "cells", ",", "in", "osteoblasts", "to", "144", "%", ".", "In", "contrast", ",", "we", "detected", "a", "neglectible", "decrease", "to", "92", "%", "in", "the", "collagen", "synthesis", "of", "osteoblasts", "compared", "to", "untreated", "cells", ".", "The", "synthesis", "of", "osteocalcin", "by", "osteoblasts", "increased", "to", "119", "%", ".", "The", "alkaline", "phosphatase", "activity", "was", "found", "to", "be", "decreased", "to", "88", "%", "in", "stromal", "bone", "marrow", "cells", "and", "increased", "in", "osteoblasts", "to", "111", "%", ".", "Conclusion", ":", "Temporary", "inhibiting", "effects", "on", "osseous", "integration", "in", "non", "-", "cemented", "prosthesis", "by", "diclofenac", "could", "be", "caused", "by", "a", "disturbance", "in", "the", "anabolic", "bone", "metabolism", ",", "exhibited", "by", "an", "increase", "of", "osteoblastic", "osteocalcin", "expression", ".", "Osteocalcin", "as", "a", "known", "negative", "regulator", "of", "the", "osteoneogenesis", "is", "most", "likely", "inhibiting", "the", "collagen", "matrix", "deposition", "." ]
[ "umlsterm" ]
Schisandrin B is a CHEMICAL, menadione is a CHEMICAL, DT - diaphorase is a GENE-Y
10939639_task0
Sentence: Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O" ]
Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity.
[ "Schisandrin", "B", "protects", "against", "menadione", "-", "induced", "hepatotoxicity", "by", "enhancing", "DT", "-", "diaphorase", "activity", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Schisandrin B is a CHEMICAL, menadione is a CHEMICAL, DT - diaphorase is a GENE-Y
10939639_task1
Sentence: Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Instructions: please typing these entity words according to sentence: Schisandrin B, menadione, DT - diaphorase Options: GENE-Y, CHEMICAL
[ "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O" ]
Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity.
[ "Schisandrin", "B", "protects", "against", "menadione", "-", "induced", "hepatotoxicity", "by", "enhancing", "DT", "-", "diaphorase", "activity", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Schisandrin B, menadione, DT - diaphorase
10939639_task2
Sentence: Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Instructions: please extract entity words from the input sentence
[ "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O" ]
Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity.
[ "Schisandrin", "B", "protects", "against", "menadione", "-", "induced", "hepatotoxicity", "by", "enhancing", "DT", "-", "diaphorase", "activity", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Blutung is an umlsterm, Schutzreflexe is an umlsterm, Lunge is an umlsterm, Pneumothorax is an umlsterm, Pleuradrainage is an umlsterm
IntensiveMedizin.80350711.ger.abstr_task0
Sentence: Wir berichten ueber eine 56jaehrige Patientin mit einer grossen intrazerebralen Blutung links parietal . Die Patientin ist soporoes ; die Schutzreflexe sind abgeschwaecht . Beim Versuch , eine Magensonde zu legen , kommt es zur Fehlplazierung in die Lunge mit Pneumothorax rechts , der problemlos mit einer Pleuradrainage behandelt werden kann . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Wir berichten ueber eine 56jaehrige Patientin mit einer grossen intrazerebralen Blutung links parietal . Die Patientin ist soporoes ; die Schutzreflexe sind abgeschwaecht . Beim Versuch , eine Magensonde zu legen , kommt es zur Fehlplazierung in die Lunge mit Pneumothorax rechts , der problemlos mit einer Pleuradrainage behandelt werden kann .
[ "Wir", "berichten", "ueber", "eine", "56jaehrige", "Patientin", "mit", "einer", "grossen", "intrazerebralen", "Blutung", "links", "parietal", ".", "Die", "Patientin", "ist", "soporoes", ";", "die", "Schutzreflexe", "sind", "abgeschwaecht", ".", "Beim", "Versuch", ",", "eine", "Magensonde", "zu", "legen", ",", "kommt", "es", "zur", "Fehlplazierung", "in", "die", "Lunge", "mit", "Pneumothorax", "rechts", ",", "der", "problemlos", "mit", "einer", "Pleuradrainage", "behandelt", "werden", "kann", "." ]
[ "umlsterm" ]
Blutung is an umlsterm, Schutzreflexe is an umlsterm, Lunge is an umlsterm, Pneumothorax is an umlsterm, Pleuradrainage is an umlsterm
IntensiveMedizin.80350711.ger.abstr_task1
Sentence: Wir berichten ueber eine 56jaehrige Patientin mit einer grossen intrazerebralen Blutung links parietal . Die Patientin ist soporoes ; die Schutzreflexe sind abgeschwaecht . Beim Versuch , eine Magensonde zu legen , kommt es zur Fehlplazierung in die Lunge mit Pneumothorax rechts , der problemlos mit einer Pleuradrainage behandelt werden kann . Instructions: please typing these entity words according to sentence: Blutung, Schutzreflexe, Lunge, Pneumothorax, Pleuradrainage Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Wir berichten ueber eine 56jaehrige Patientin mit einer grossen intrazerebralen Blutung links parietal . Die Patientin ist soporoes ; die Schutzreflexe sind abgeschwaecht . Beim Versuch , eine Magensonde zu legen , kommt es zur Fehlplazierung in die Lunge mit Pneumothorax rechts , der problemlos mit einer Pleuradrainage behandelt werden kann .
[ "Wir", "berichten", "ueber", "eine", "56jaehrige", "Patientin", "mit", "einer", "grossen", "intrazerebralen", "Blutung", "links", "parietal", ".", "Die", "Patientin", "ist", "soporoes", ";", "die", "Schutzreflexe", "sind", "abgeschwaecht", ".", "Beim", "Versuch", ",", "eine", "Magensonde", "zu", "legen", ",", "kommt", "es", "zur", "Fehlplazierung", "in", "die", "Lunge", "mit", "Pneumothorax", "rechts", ",", "der", "problemlos", "mit", "einer", "Pleuradrainage", "behandelt", "werden", "kann", "." ]
[ "umlsterm" ]
Blutung, Schutzreflexe, Lunge, Pneumothorax, Pleuradrainage
IntensiveMedizin.80350711.ger.abstr_task2
Sentence: Wir berichten ueber eine 56jaehrige Patientin mit einer grossen intrazerebralen Blutung links parietal . Die Patientin ist soporoes ; die Schutzreflexe sind abgeschwaecht . Beim Versuch , eine Magensonde zu legen , kommt es zur Fehlplazierung in die Lunge mit Pneumothorax rechts , der problemlos mit einer Pleuradrainage behandelt werden kann . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Wir berichten ueber eine 56jaehrige Patientin mit einer grossen intrazerebralen Blutung links parietal . Die Patientin ist soporoes ; die Schutzreflexe sind abgeschwaecht . Beim Versuch , eine Magensonde zu legen , kommt es zur Fehlplazierung in die Lunge mit Pneumothorax rechts , der problemlos mit einer Pleuradrainage behandelt werden kann .
[ "Wir", "berichten", "ueber", "eine", "56jaehrige", "Patientin", "mit", "einer", "grossen", "intrazerebralen", "Blutung", "links", "parietal", ".", "Die", "Patientin", "ist", "soporoes", ";", "die", "Schutzreflexe", "sind", "abgeschwaecht", ".", "Beim", "Versuch", ",", "eine", "Magensonde", "zu", "legen", ",", "kommt", "es", "zur", "Fehlplazierung", "in", "die", "Lunge", "mit", "Pneumothorax", "rechts", ",", "der", "problemlos", "mit", "einer", "Pleuradrainage", "behandelt", "werden", "kann", "." ]
[ "umlsterm" ]
Tumorvernichtung is an umlsterm, Strahlentherapie is an umlsterm, Literaturzusammenstellung is an umlsterm, Zeitfaktors is an umlsterm, Zeitfaktors is an umlsterm, Therapie is an umlsterm, Tumorzellen is an umlsterm, Fraktionierung is an umlsterm, Therapiepausen is an umlsterm, Experimentaltumoren is an umlsterm, Zeitfaktors is an umlsterm, Strahlentherapie is an umlsterm, Chemotherapie is an umlsterm, Experimentaltumoren is an umlsterm, Tumorzellen is an umlsterm, Tumorzellen is an umlsterm, Tumorgefaessnetzes is an umlsterm, Tumorhypoxie is an umlsterm, Zeitfaktor is an umlsterm
Strahlentherapie+Onkologie.01760443.ger.abstr_task0
Sentence: Eine Reihe experimenteller und prospektiv randomisierter Studien zeigt , dass die Chance der lokalen Tumorvernichtung mit zunehmender Gesamtbehandlungszeit einer fraktionierten Strahlentherapie vermindert werden kann . In einer Literaturzusammenstellung werden moegliche Mechanismen dieses Zeitfaktors diskutiert . Die Mechanismen des Zeitfaktors in der onkologischen Therapie sind komplex und derzeit nicht vollstaendig geklaert . Die schnelle Proliferation klonogener Tumorzellen waehrend kontinuierlicher Fraktionierung und in Therapiepausen konnte in Experimentaltumoren als eine wesentliche Ursache des Zeitfaktors fuer die Strahlentherapie ermittelt werden . Auch durch eine Chemotherapie kann die Repopulierung von Experimentaltumoren durch klonogene Tumorzellen stimuliert werden . Neben der Repopulierung durch klonogene Tumorzellen koennen weitere Faktoren , z . B. eine zunehmende Schaedigung des Tumorgefaessnetzes mit konsekutiver Zunahme der Tumorhypoxie , zum Zeitfaktor beitragen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Eine Reihe experimenteller und prospektiv randomisierter Studien zeigt , dass die Chance der lokalen Tumorvernichtung mit zunehmender Gesamtbehandlungszeit einer fraktionierten Strahlentherapie vermindert werden kann . In einer Literaturzusammenstellung werden moegliche Mechanismen dieses Zeitfaktors diskutiert . Die Mechanismen des Zeitfaktors in der onkologischen Therapie sind komplex und derzeit nicht vollstaendig geklaert . Die schnelle Proliferation klonogener Tumorzellen waehrend kontinuierlicher Fraktionierung und in Therapiepausen konnte in Experimentaltumoren als eine wesentliche Ursache des Zeitfaktors fuer die Strahlentherapie ermittelt werden . Auch durch eine Chemotherapie kann die Repopulierung von Experimentaltumoren durch klonogene Tumorzellen stimuliert werden . Neben der Repopulierung durch klonogene Tumorzellen koennen weitere Faktoren , z . B. eine zunehmende Schaedigung des Tumorgefaessnetzes mit konsekutiver Zunahme der Tumorhypoxie , zum Zeitfaktor beitragen .
[ "Eine", "Reihe", "experimenteller", "und", "prospektiv", "randomisierter", "Studien", "zeigt", ",", "dass", "die", "Chance", "der", "lokalen", "Tumorvernichtung", "mit", "zunehmender", "Gesamtbehandlungszeit", "einer", "fraktionierten", "Strahlentherapie", "vermindert", "werden", "kann", ".", "In", "einer", "Literaturzusammenstellung", "werden", "moegliche", "Mechanismen", "dieses", "Zeitfaktors", "diskutiert", ".", "Die", "Mechanismen", "des", "Zeitfaktors", "in", "der", "onkologischen", "Therapie", "sind", "komplex", "und", "derzeit", "nicht", "vollstaendig", "geklaert", ".", "Die", "schnelle", "Proliferation", "klonogener", "Tumorzellen", "waehrend", "kontinuierlicher", "Fraktionierung", "und", "in", "Therapiepausen", "konnte", "in", "Experimentaltumoren", "als", "eine", "wesentliche", "Ursache", "des", "Zeitfaktors", "fuer", "die", "Strahlentherapie", "ermittelt", "werden", ".", "Auch", "durch", "eine", "Chemotherapie", "kann", "die", "Repopulierung", "von", "Experimentaltumoren", "durch", "klonogene", "Tumorzellen", "stimuliert", "werden", ".", "Neben", "der", "Repopulierung", "durch", "klonogene", "Tumorzellen", "koennen", "weitere", "Faktoren", ",", "z", ".", "B.", "eine", "zunehmende", "Schaedigung", "des", "Tumorgefaessnetzes", "mit", "konsekutiver", "Zunahme", "der", "Tumorhypoxie", ",", "zum", "Zeitfaktor", "beitragen", "." ]
[ "umlsterm" ]
Tumorvernichtung is an umlsterm, Strahlentherapie is an umlsterm, Literaturzusammenstellung is an umlsterm, Zeitfaktors is an umlsterm, Zeitfaktors is an umlsterm, Therapie is an umlsterm, Tumorzellen is an umlsterm, Fraktionierung is an umlsterm, Therapiepausen is an umlsterm, Experimentaltumoren is an umlsterm, Zeitfaktors is an umlsterm, Strahlentherapie is an umlsterm, Chemotherapie is an umlsterm, Experimentaltumoren is an umlsterm, Tumorzellen is an umlsterm, Tumorzellen is an umlsterm, Tumorgefaessnetzes is an umlsterm, Tumorhypoxie is an umlsterm, Zeitfaktor is an umlsterm
Strahlentherapie+Onkologie.01760443.ger.abstr_task1
Sentence: Eine Reihe experimenteller und prospektiv randomisierter Studien zeigt , dass die Chance der lokalen Tumorvernichtung mit zunehmender Gesamtbehandlungszeit einer fraktionierten Strahlentherapie vermindert werden kann . In einer Literaturzusammenstellung werden moegliche Mechanismen dieses Zeitfaktors diskutiert . Die Mechanismen des Zeitfaktors in der onkologischen Therapie sind komplex und derzeit nicht vollstaendig geklaert . Die schnelle Proliferation klonogener Tumorzellen waehrend kontinuierlicher Fraktionierung und in Therapiepausen konnte in Experimentaltumoren als eine wesentliche Ursache des Zeitfaktors fuer die Strahlentherapie ermittelt werden . Auch durch eine Chemotherapie kann die Repopulierung von Experimentaltumoren durch klonogene Tumorzellen stimuliert werden . Neben der Repopulierung durch klonogene Tumorzellen koennen weitere Faktoren , z . B. eine zunehmende Schaedigung des Tumorgefaessnetzes mit konsekutiver Zunahme der Tumorhypoxie , zum Zeitfaktor beitragen . Instructions: please typing these entity words according to sentence: Tumorvernichtung, Strahlentherapie, Literaturzusammenstellung, Zeitfaktors, Zeitfaktors, Therapie, Tumorzellen, Fraktionierung, Therapiepausen, Experimentaltumoren, Zeitfaktors, Strahlentherapie, Chemotherapie, Experimentaltumoren, Tumorzellen, Tumorzellen, Tumorgefaessnetzes, Tumorhypoxie, Zeitfaktor Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Eine Reihe experimenteller und prospektiv randomisierter Studien zeigt , dass die Chance der lokalen Tumorvernichtung mit zunehmender Gesamtbehandlungszeit einer fraktionierten Strahlentherapie vermindert werden kann . In einer Literaturzusammenstellung werden moegliche Mechanismen dieses Zeitfaktors diskutiert . Die Mechanismen des Zeitfaktors in der onkologischen Therapie sind komplex und derzeit nicht vollstaendig geklaert . Die schnelle Proliferation klonogener Tumorzellen waehrend kontinuierlicher Fraktionierung und in Therapiepausen konnte in Experimentaltumoren als eine wesentliche Ursache des Zeitfaktors fuer die Strahlentherapie ermittelt werden . Auch durch eine Chemotherapie kann die Repopulierung von Experimentaltumoren durch klonogene Tumorzellen stimuliert werden . Neben der Repopulierung durch klonogene Tumorzellen koennen weitere Faktoren , z . B. eine zunehmende Schaedigung des Tumorgefaessnetzes mit konsekutiver Zunahme der Tumorhypoxie , zum Zeitfaktor beitragen .
[ "Eine", "Reihe", "experimenteller", "und", "prospektiv", "randomisierter", "Studien", "zeigt", ",", "dass", "die", "Chance", "der", "lokalen", "Tumorvernichtung", "mit", "zunehmender", "Gesamtbehandlungszeit", "einer", "fraktionierten", "Strahlentherapie", "vermindert", "werden", "kann", ".", "In", "einer", "Literaturzusammenstellung", "werden", "moegliche", "Mechanismen", "dieses", "Zeitfaktors", "diskutiert", ".", "Die", "Mechanismen", "des", "Zeitfaktors", "in", "der", "onkologischen", "Therapie", "sind", "komplex", "und", "derzeit", "nicht", "vollstaendig", "geklaert", ".", "Die", "schnelle", "Proliferation", "klonogener", "Tumorzellen", "waehrend", "kontinuierlicher", "Fraktionierung", "und", "in", "Therapiepausen", "konnte", "in", "Experimentaltumoren", "als", "eine", "wesentliche", "Ursache", "des", "Zeitfaktors", "fuer", "die", "Strahlentherapie", "ermittelt", "werden", ".", "Auch", "durch", "eine", "Chemotherapie", "kann", "die", "Repopulierung", "von", "Experimentaltumoren", "durch", "klonogene", "Tumorzellen", "stimuliert", "werden", ".", "Neben", "der", "Repopulierung", "durch", "klonogene", "Tumorzellen", "koennen", "weitere", "Faktoren", ",", "z", ".", "B.", "eine", "zunehmende", "Schaedigung", "des", "Tumorgefaessnetzes", "mit", "konsekutiver", "Zunahme", "der", "Tumorhypoxie", ",", "zum", "Zeitfaktor", "beitragen", "." ]
[ "umlsterm" ]
Tumorvernichtung, Strahlentherapie, Literaturzusammenstellung, Zeitfaktors, Zeitfaktors, Therapie, Tumorzellen, Fraktionierung, Therapiepausen, Experimentaltumoren, Zeitfaktors, Strahlentherapie, Chemotherapie, Experimentaltumoren, Tumorzellen, Tumorzellen, Tumorgefaessnetzes, Tumorhypoxie, Zeitfaktor
Strahlentherapie+Onkologie.01760443.ger.abstr_task2
Sentence: Eine Reihe experimenteller und prospektiv randomisierter Studien zeigt , dass die Chance der lokalen Tumorvernichtung mit zunehmender Gesamtbehandlungszeit einer fraktionierten Strahlentherapie vermindert werden kann . In einer Literaturzusammenstellung werden moegliche Mechanismen dieses Zeitfaktors diskutiert . Die Mechanismen des Zeitfaktors in der onkologischen Therapie sind komplex und derzeit nicht vollstaendig geklaert . Die schnelle Proliferation klonogener Tumorzellen waehrend kontinuierlicher Fraktionierung und in Therapiepausen konnte in Experimentaltumoren als eine wesentliche Ursache des Zeitfaktors fuer die Strahlentherapie ermittelt werden . Auch durch eine Chemotherapie kann die Repopulierung von Experimentaltumoren durch klonogene Tumorzellen stimuliert werden . Neben der Repopulierung durch klonogene Tumorzellen koennen weitere Faktoren , z . B. eine zunehmende Schaedigung des Tumorgefaessnetzes mit konsekutiver Zunahme der Tumorhypoxie , zum Zeitfaktor beitragen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Eine Reihe experimenteller und prospektiv randomisierter Studien zeigt , dass die Chance der lokalen Tumorvernichtung mit zunehmender Gesamtbehandlungszeit einer fraktionierten Strahlentherapie vermindert werden kann . In einer Literaturzusammenstellung werden moegliche Mechanismen dieses Zeitfaktors diskutiert . Die Mechanismen des Zeitfaktors in der onkologischen Therapie sind komplex und derzeit nicht vollstaendig geklaert . Die schnelle Proliferation klonogener Tumorzellen waehrend kontinuierlicher Fraktionierung und in Therapiepausen konnte in Experimentaltumoren als eine wesentliche Ursache des Zeitfaktors fuer die Strahlentherapie ermittelt werden . Auch durch eine Chemotherapie kann die Repopulierung von Experimentaltumoren durch klonogene Tumorzellen stimuliert werden . Neben der Repopulierung durch klonogene Tumorzellen koennen weitere Faktoren , z . B. eine zunehmende Schaedigung des Tumorgefaessnetzes mit konsekutiver Zunahme der Tumorhypoxie , zum Zeitfaktor beitragen .
[ "Eine", "Reihe", "experimenteller", "und", "prospektiv", "randomisierter", "Studien", "zeigt", ",", "dass", "die", "Chance", "der", "lokalen", "Tumorvernichtung", "mit", "zunehmender", "Gesamtbehandlungszeit", "einer", "fraktionierten", "Strahlentherapie", "vermindert", "werden", "kann", ".", "In", "einer", "Literaturzusammenstellung", "werden", "moegliche", "Mechanismen", "dieses", "Zeitfaktors", "diskutiert", ".", "Die", "Mechanismen", "des", "Zeitfaktors", "in", "der", "onkologischen", "Therapie", "sind", "komplex", "und", "derzeit", "nicht", "vollstaendig", "geklaert", ".", "Die", "schnelle", "Proliferation", "klonogener", "Tumorzellen", "waehrend", "kontinuierlicher", "Fraktionierung", "und", "in", "Therapiepausen", "konnte", "in", "Experimentaltumoren", "als", "eine", "wesentliche", "Ursache", "des", "Zeitfaktors", "fuer", "die", "Strahlentherapie", "ermittelt", "werden", ".", "Auch", "durch", "eine", "Chemotherapie", "kann", "die", "Repopulierung", "von", "Experimentaltumoren", "durch", "klonogene", "Tumorzellen", "stimuliert", "werden", ".", "Neben", "der", "Repopulierung", "durch", "klonogene", "Tumorzellen", "koennen", "weitere", "Faktoren", ",", "z", ".", "B.", "eine", "zunehmende", "Schaedigung", "des", "Tumorgefaessnetzes", "mit", "konsekutiver", "Zunahme", "der", "Tumorhypoxie", ",", "zum", "Zeitfaktor", "beitragen", "." ]
[ "umlsterm" ]
prevalence is an umlsterm, population is an umlsterm, adult is an umlsterm, rheumatology is an umlsterm, depression is an umlsterm, history is an umlsterm, depression is an umlsterm, population is an umlsterm, questionnaire is an umlsterm, patients is an umlsterm, patients is an umlsterm, depression is an umlsterm, patients is an umlsterm, history is an umlsterm, depression is an umlsterm, history is an umlsterm, depression is an umlsterm
ZfuerRheumatologie.8057s094.eng.abstr_task0
Sentence: The prevalence of FM in the general population is estimated at 2% . FM is among the three most common diagnoses in ambulatory adult rheumatology practice . To study the degree of depression , the familial history of depression and FM , as well as the psychological distress in our FM population , we mailed a standardized questionnaire to 304 FM patients . The response rate was 33% . We found BDI scores higher than 21 in 27% of the patients indicating clinical relevant depression . The patients had high levels of global distress measured with the SCL-90-R as well as elevated scores in the subscales . Twenty three percent had a familial history of depression , 46% a familial history of FM , and 46% had been diagnosed with depression in the past . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
The prevalence of FM in the general population is estimated at 2% . FM is among the three most common diagnoses in ambulatory adult rheumatology practice . To study the degree of depression , the familial history of depression and FM , as well as the psychological distress in our FM population , we mailed a standardized questionnaire to 304 FM patients . The response rate was 33% . We found BDI scores higher than 21 in 27% of the patients indicating clinical relevant depression . The patients had high levels of global distress measured with the SCL-90-R as well as elevated scores in the subscales . Twenty three percent had a familial history of depression , 46% a familial history of FM , and 46% had been diagnosed with depression in the past .
[ "The", "prevalence", "of", "FM", "in", "the", "general", "population", "is", "estimated", "at", "2", "%", ".", "FM", "is", "among", "the", "three", "most", "common", "diagnoses", "in", "ambulatory", "adult", "rheumatology", "practice", ".", "To", "study", "the", "degree", "of", "depression", ",", "the", "familial", "history", "of", "depression", "and", "FM", ",", "as", "well", "as", "the", "psychological", "distress", "in", "our", "FM", "population", ",", "we", "mailed", "a", "standardized", "questionnaire", "to", "304", "FM", "patients", ".", "The", "response", "rate", "was", "33", "%", ".", "We", "found", "BDI", "scores", "higher", "than", "21", "in", "27", "%", "of", "the", "patients", "indicating", "clinical", "relevant", "depression", ".", "The", "patients", "had", "high", "levels", "of", "global", "distress", "measured", "with", "the", "SCL-90-R", "as", "well", "as", "elevated", "scores", "in", "the", "subscales", ".", "Twenty", "three", "percent", "had", "a", "familial", "history", "of", "depression", ",", "46", "%", "a", "familial", "history", "of", "FM", ",", "and", "46", "%", "had", "been", "diagnosed", "with", "depression", "in", "the", "past", "." ]
[ "umlsterm" ]
prevalence is an umlsterm, population is an umlsterm, adult is an umlsterm, rheumatology is an umlsterm, depression is an umlsterm, history is an umlsterm, depression is an umlsterm, population is an umlsterm, questionnaire is an umlsterm, patients is an umlsterm, patients is an umlsterm, depression is an umlsterm, patients is an umlsterm, history is an umlsterm, depression is an umlsterm, history is an umlsterm, depression is an umlsterm
ZfuerRheumatologie.8057s094.eng.abstr_task1
Sentence: The prevalence of FM in the general population is estimated at 2% . FM is among the three most common diagnoses in ambulatory adult rheumatology practice . To study the degree of depression , the familial history of depression and FM , as well as the psychological distress in our FM population , we mailed a standardized questionnaire to 304 FM patients . The response rate was 33% . We found BDI scores higher than 21 in 27% of the patients indicating clinical relevant depression . The patients had high levels of global distress measured with the SCL-90-R as well as elevated scores in the subscales . Twenty three percent had a familial history of depression , 46% a familial history of FM , and 46% had been diagnosed with depression in the past . Instructions: please typing these entity words according to sentence: prevalence, population, adult, rheumatology, depression, history, depression, population, questionnaire, patients, patients, depression, patients, history, depression, history, depression Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
The prevalence of FM in the general population is estimated at 2% . FM is among the three most common diagnoses in ambulatory adult rheumatology practice . To study the degree of depression , the familial history of depression and FM , as well as the psychological distress in our FM population , we mailed a standardized questionnaire to 304 FM patients . The response rate was 33% . We found BDI scores higher than 21 in 27% of the patients indicating clinical relevant depression . The patients had high levels of global distress measured with the SCL-90-R as well as elevated scores in the subscales . Twenty three percent had a familial history of depression , 46% a familial history of FM , and 46% had been diagnosed with depression in the past .
[ "The", "prevalence", "of", "FM", "in", "the", "general", "population", "is", "estimated", "at", "2", "%", ".", "FM", "is", "among", "the", "three", "most", "common", "diagnoses", "in", "ambulatory", "adult", "rheumatology", "practice", ".", "To", "study", "the", "degree", "of", "depression", ",", "the", "familial", "history", "of", "depression", "and", "FM", ",", "as", "well", "as", "the", "psychological", "distress", "in", "our", "FM", "population", ",", "we", "mailed", "a", "standardized", "questionnaire", "to", "304", "FM", "patients", ".", "The", "response", "rate", "was", "33", "%", ".", "We", "found", "BDI", "scores", "higher", "than", "21", "in", "27", "%", "of", "the", "patients", "indicating", "clinical", "relevant", "depression", ".", "The", "patients", "had", "high", "levels", "of", "global", "distress", "measured", "with", "the", "SCL-90-R", "as", "well", "as", "elevated", "scores", "in", "the", "subscales", ".", "Twenty", "three", "percent", "had", "a", "familial", "history", "of", "depression", ",", "46", "%", "a", "familial", "history", "of", "FM", ",", "and", "46", "%", "had", "been", "diagnosed", "with", "depression", "in", "the", "past", "." ]
[ "umlsterm" ]
prevalence, population, adult, rheumatology, depression, history, depression, population, questionnaire, patients, patients, depression, patients, history, depression, history, depression
ZfuerRheumatologie.8057s094.eng.abstr_task2
Sentence: The prevalence of FM in the general population is estimated at 2% . FM is among the three most common diagnoses in ambulatory adult rheumatology practice . To study the degree of depression , the familial history of depression and FM , as well as the psychological distress in our FM population , we mailed a standardized questionnaire to 304 FM patients . The response rate was 33% . We found BDI scores higher than 21 in 27% of the patients indicating clinical relevant depression . The patients had high levels of global distress measured with the SCL-90-R as well as elevated scores in the subscales . Twenty three percent had a familial history of depression , 46% a familial history of FM , and 46% had been diagnosed with depression in the past . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
The prevalence of FM in the general population is estimated at 2% . FM is among the three most common diagnoses in ambulatory adult rheumatology practice . To study the degree of depression , the familial history of depression and FM , as well as the psychological distress in our FM population , we mailed a standardized questionnaire to 304 FM patients . The response rate was 33% . We found BDI scores higher than 21 in 27% of the patients indicating clinical relevant depression . The patients had high levels of global distress measured with the SCL-90-R as well as elevated scores in the subscales . Twenty three percent had a familial history of depression , 46% a familial history of FM , and 46% had been diagnosed with depression in the past .
[ "The", "prevalence", "of", "FM", "in", "the", "general", "population", "is", "estimated", "at", "2", "%", ".", "FM", "is", "among", "the", "three", "most", "common", "diagnoses", "in", "ambulatory", "adult", "rheumatology", "practice", ".", "To", "study", "the", "degree", "of", "depression", ",", "the", "familial", "history", "of", "depression", "and", "FM", ",", "as", "well", "as", "the", "psychological", "distress", "in", "our", "FM", "population", ",", "we", "mailed", "a", "standardized", "questionnaire", "to", "304", "FM", "patients", ".", "The", "response", "rate", "was", "33", "%", ".", "We", "found", "BDI", "scores", "higher", "than", "21", "in", "27", "%", "of", "the", "patients", "indicating", "clinical", "relevant", "depression", ".", "The", "patients", "had", "high", "levels", "of", "global", "distress", "measured", "with", "the", "SCL-90-R", "as", "well", "as", "elevated", "scores", "in", "the", "subscales", ".", "Twenty", "three", "percent", "had", "a", "familial", "history", "of", "depression", ",", "46", "%", "a", "familial", "history", "of", "FM", ",", "and", "46", "%", "had", "been", "diagnosed", "with", "depression", "in", "the", "past", "." ]
[ "umlsterm" ]
Epstein - Barr virus nuclear antigen 2 is a Protein, EBNA-2 is a Protein, Epstein - Barr virus ( EBV ) nuclear antigen 2 is a Protein, EBNA-2 is a Protein, EBNA-2 is a Protein, CD23 is a Protein, c - fgr is a Protein, latent membrane protein 1 is a Protein, LMP1 is a Protein, terminal protein 1 is a Protein, TP1 is a Protein, TP1 is a Protein, promoter is a Entity, BamHI C is a Protein, promoter is a Entity, EBNA-2 is a Protein, EBNA-2 is a Protein, LMP is a Protein, cis - acting elements is a Entity, LMP is a Protein, EBNA-2 is a Protein, EBNA-2 is a Protein, LMP is a Protein, promoter is a Entity, LMP is a Protein, LMP is a Protein, promoter is a Entity, EBNA-2 is a Protein, EBNA-2A is a Protein, TP1 is a Protein, promoter is a Entity, LMP is a Protein, promoter is a Entity, LMP is a Protein, promoter is a Entity
472_task0
Sentence: DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay.
[ "DNA", "-", "binding", "studies", "of", "the", "Epstein", "-", "Barr", "virus", "nuclear", "antigen", "2", "(", "EBNA-2", "):", "evidence", "for", "complex", "formation", "by", "latent", "membrane", "protein", "gene", "promoter", "-", "binding", "proteins", "in", "EBNA-2-positive", "cell", "lines", ".", "\n", "The", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "nuclear", "antigen", "2", "(", "EBNA-2", ")", "protein", "is", "essential", "for", "the", "immortalization", "of", "human", "primary", "B", "cells", "by", "EBV", ".", "EBNA-2", "trans", "-", "activates", "cellular", "and", "viral", "genes", "like", "CD23", ",", "c", "-", "fgr", ",", "latent", "membrane", "protein", "1", "(", "LMP1", ")", "and", "terminal", "protein", "1", "(", "TP1", ")", ".", "Trans", "-", "activation", "of", "the", "TP1", "promoter", "and", "of", "the", "BamHI", "C", "promoter", "has", "already", "been", "investigated", "in", "detail", "and", "appears", "to", "be", "mediated", "via", "protein", "-", "protein", "interactions", "and", "not", "by", "direct", "binding", "of", "EBNA-2", "type", "A", "(", "of", "EBV", "type", "1", ")", "to", "the", "DNA", ".", "EBNA-2", "is", "able", "to", "trans", "-", "activate", "the", "expression", "of", "the", "LMP", "gene", "in", "several", "cell", "lines", ".", "Various", "reports", "have", "delineated", "the", "cis", "-", "acting", "elements", "of", "the", "LMP", "promoter", "through", "which", "EBNA-2", "mediates", "trans", "-", "activation", ".", "To", "determine", "whether", "EBNA-2", "also", "trans", "-", "activates", "the", "LMP", "promoter", "by", "protein", "-", "protein", "interactions", ",", "we", "performed", "a", "series", "of", "gel", "retardation", "assays", "and", "competition", "experiments", "with", "LMP", "promoter", "fragments", "of", "different", "sizes", ".", "We", "determined", "that", "the", "protein", "-", "binding", "region", "on", "the", "LMP", "promoter", "was", "within", "a", "42", "bp", "fragment", "encompassing", "nucleotides", "-135", "to", "-176", "relative", "to", "the", "LMP", "transcriptional", "start", "site", ".", "None", "of", "the", "DNA", "fragments", "investigated", "indicated", "interaction", "of", "EBNA-2", "with", "the", "DNA", "via", "protein", "-", "protein", "interactions", ".", "No", "significant", "differences", "between", "EBNA-2-positive", "and", "EBNA-2-negative", "nuclear", "extracts", "could", "be", "seen", "in", "the", "gel", "retardation", "assay", "under", "conditions", "that", "clearly", "showed", "binding", "of", "EBNA-2A", "to", "the", "TP1", "promoter", ".", "However", ",", "analysis", "of", "sucrose", "gradient", "fractions", "in", "the", "gel", "retardation", "assay", "provided", "evidence", "that", "the", "LMP", "promoter", "-", "binding", "proteins", "form", "a", "complex", "of", "higher", "M(r", ")", "in", "EBNA-2-positive", "cell", "extracts", ".", "These", "complexes", "were", "destroyed", "by", "detergent", ".", "We", "deduce", "from", "these", "results", "that", "EBNA-2-positive", "cells", "might", "indeed", "contain", "specific", "complexes", "bound", "to", "the", "LMP", "promoter", "which", "are", ",", "however", ",", "too", "labile", "to", "be", "detected", "in", "a", "standard", "gel", "retardation", "assay", "." ]
[ "Protein", "Entity" ]
Epstein - Barr virus nuclear antigen 2 is a Protein, EBNA-2 is a Protein, Epstein - Barr virus ( EBV ) nuclear antigen 2 is a Protein, EBNA-2 is a Protein, EBNA-2 is a Protein, CD23 is a Protein, c - fgr is a Protein, latent membrane protein 1 is a Protein, LMP1 is a Protein, terminal protein 1 is a Protein, TP1 is a Protein, TP1 is a Protein, promoter is a Entity, BamHI C is a Protein, promoter is a Entity, EBNA-2 is a Protein, EBNA-2 is a Protein, LMP is a Protein, cis - acting elements is a Entity, LMP is a Protein, EBNA-2 is a Protein, EBNA-2 is a Protein, LMP is a Protein, promoter is a Entity, LMP is a Protein, LMP is a Protein, promoter is a Entity, EBNA-2 is a Protein, EBNA-2A is a Protein, TP1 is a Protein, promoter is a Entity, LMP is a Protein, promoter is a Entity, LMP is a Protein, promoter is a Entity
472_task1
Sentence: DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay. Instructions: please typing these entity words according to sentence: Epstein - Barr virus nuclear antigen 2, EBNA-2, Epstein - Barr virus ( EBV ) nuclear antigen 2, EBNA-2, EBNA-2, CD23, c - fgr, latent membrane protein 1, LMP1, terminal protein 1, TP1, TP1, promoter, BamHI C, promoter, EBNA-2, EBNA-2, LMP, cis - acting elements, LMP, EBNA-2, EBNA-2, LMP, promoter, LMP, LMP, promoter, EBNA-2, EBNA-2A, TP1, promoter, LMP, promoter, LMP, promoter Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay.
[ "DNA", "-", "binding", "studies", "of", "the", "Epstein", "-", "Barr", "virus", "nuclear", "antigen", "2", "(", "EBNA-2", "):", "evidence", "for", "complex", "formation", "by", "latent", "membrane", "protein", "gene", "promoter", "-", "binding", "proteins", "in", "EBNA-2-positive", "cell", "lines", ".", "\n", "The", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "nuclear", "antigen", "2", "(", "EBNA-2", ")", "protein", "is", "essential", "for", "the", "immortalization", "of", "human", "primary", "B", "cells", "by", "EBV", ".", "EBNA-2", "trans", "-", "activates", "cellular", "and", "viral", "genes", "like", "CD23", ",", "c", "-", "fgr", ",", "latent", "membrane", "protein", "1", "(", "LMP1", ")", "and", "terminal", "protein", "1", "(", "TP1", ")", ".", "Trans", "-", "activation", "of", "the", "TP1", "promoter", "and", "of", "the", "BamHI", "C", "promoter", "has", "already", "been", "investigated", "in", "detail", "and", "appears", "to", "be", "mediated", "via", "protein", "-", "protein", "interactions", "and", "not", "by", "direct", "binding", "of", "EBNA-2", "type", "A", "(", "of", "EBV", "type", "1", ")", "to", "the", "DNA", ".", "EBNA-2", "is", "able", "to", "trans", "-", "activate", "the", "expression", "of", "the", "LMP", "gene", "in", "several", "cell", "lines", ".", "Various", "reports", "have", "delineated", "the", "cis", "-", "acting", "elements", "of", "the", "LMP", "promoter", "through", "which", "EBNA-2", "mediates", "trans", "-", "activation", ".", "To", "determine", "whether", "EBNA-2", "also", "trans", "-", "activates", "the", "LMP", "promoter", "by", "protein", "-", "protein", "interactions", ",", "we", "performed", "a", "series", "of", "gel", "retardation", "assays", "and", "competition", "experiments", "with", "LMP", "promoter", "fragments", "of", "different", "sizes", ".", "We", "determined", "that", "the", "protein", "-", "binding", "region", "on", "the", "LMP", "promoter", "was", "within", "a", "42", "bp", "fragment", "encompassing", "nucleotides", "-135", "to", "-176", "relative", "to", "the", "LMP", "transcriptional", "start", "site", ".", "None", "of", "the", "DNA", "fragments", "investigated", "indicated", "interaction", "of", "EBNA-2", "with", "the", "DNA", "via", "protein", "-", "protein", "interactions", ".", "No", "significant", "differences", "between", "EBNA-2-positive", "and", "EBNA-2-negative", "nuclear", "extracts", "could", "be", "seen", "in", "the", "gel", "retardation", "assay", "under", "conditions", "that", "clearly", "showed", "binding", "of", "EBNA-2A", "to", "the", "TP1", "promoter", ".", "However", ",", "analysis", "of", "sucrose", "gradient", "fractions", "in", "the", "gel", "retardation", "assay", "provided", "evidence", "that", "the", "LMP", "promoter", "-", "binding", "proteins", "form", "a", "complex", "of", "higher", "M(r", ")", "in", "EBNA-2-positive", "cell", "extracts", ".", "These", "complexes", "were", "destroyed", "by", "detergent", ".", "We", "deduce", "from", "these", "results", "that", "EBNA-2-positive", "cells", "might", "indeed", "contain", "specific", "complexes", "bound", "to", "the", "LMP", "promoter", "which", "are", ",", "however", ",", "too", "labile", "to", "be", "detected", "in", "a", "standard", "gel", "retardation", "assay", "." ]
[ "Protein", "Entity" ]
Epstein - Barr virus nuclear antigen 2, EBNA-2, Epstein - Barr virus ( EBV ) nuclear antigen 2, EBNA-2, EBNA-2, CD23, c - fgr, latent membrane protein 1, LMP1, terminal protein 1, TP1, TP1, promoter, BamHI C, promoter, EBNA-2, EBNA-2, LMP, cis - acting elements, LMP, EBNA-2, EBNA-2, LMP, promoter, LMP, LMP, promoter, EBNA-2, EBNA-2A, TP1, promoter, LMP, promoter, LMP, promoter
472_task2
Sentence: DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines. The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) protein is essential for the immortalization of human primary B cells by EBV. EBNA-2 trans-activates cellular and viral genes like CD23, c-fgr, latent membrane protein 1 (LMP1) and terminal protein 1 (TP1). Trans-activation of the TP1 promoter and of the BamHI C promoter has already been investigated in detail and appears to be mediated via protein-protein interactions and not by direct binding of EBNA-2 type A (of EBV type 1) to the DNA. EBNA-2 is able to trans-activate the expression of the LMP gene in several cell lines. Various reports have delineated the cis-acting elements of the LMP promoter through which EBNA-2 mediates trans-activation. To determine whether EBNA-2 also trans-activates the LMP promoter by protein-protein interactions, we performed a series of gel retardation assays and competition experiments with LMP promoter fragments of different sizes. We determined that the protein-binding region on the LMP promoter was within a 42 bp fragment encompassing nucleotides -135 to -176 relative to the LMP transcriptional start site. None of the DNA fragments investigated indicated interaction of EBNA-2 with the DNA via protein-protein interactions. No significant differences between EBNA-2-positive and EBNA-2-negative nuclear extracts could be seen in the gel retardation assay under conditions that clearly showed binding of EBNA-2A to the TP1 promoter. However, analysis of sucrose gradient fractions in the gel retardation assay provided evidence that the LMP promoter-binding proteins form a complex of higher M(r) in EBNA-2-positive cell extracts. These complexes were destroyed by detergent. We deduce from these results that EBNA-2-positive cells might indeed contain specific complexes bound to the LMP promoter which are, however, too labile to be detected in a standard gel retardation assay.
[ "DNA", "-", "binding", "studies", "of", "the", "Epstein", "-", "Barr", "virus", "nuclear", "antigen", "2", "(", "EBNA-2", "):", "evidence", "for", "complex", "formation", "by", "latent", "membrane", "protein", "gene", "promoter", "-", "binding", "proteins", "in", "EBNA-2-positive", "cell", "lines", ".", "\n", "The", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "nuclear", "antigen", "2", "(", "EBNA-2", ")", "protein", "is", "essential", "for", "the", "immortalization", "of", "human", "primary", "B", "cells", "by", "EBV", ".", "EBNA-2", "trans", "-", "activates", "cellular", "and", "viral", "genes", "like", "CD23", ",", "c", "-", "fgr", ",", "latent", "membrane", "protein", "1", "(", "LMP1", ")", "and", "terminal", "protein", "1", "(", "TP1", ")", ".", "Trans", "-", "activation", "of", "the", "TP1", "promoter", "and", "of", "the", "BamHI", "C", "promoter", "has", "already", "been", "investigated", "in", "detail", "and", "appears", "to", "be", "mediated", "via", "protein", "-", "protein", "interactions", "and", "not", "by", "direct", "binding", "of", "EBNA-2", "type", "A", "(", "of", "EBV", "type", "1", ")", "to", "the", "DNA", ".", "EBNA-2", "is", "able", "to", "trans", "-", "activate", "the", "expression", "of", "the", "LMP", "gene", "in", "several", "cell", "lines", ".", "Various", "reports", "have", "delineated", "the", "cis", "-", "acting", "elements", "of", "the", "LMP", "promoter", "through", "which", "EBNA-2", "mediates", "trans", "-", "activation", ".", "To", "determine", "whether", "EBNA-2", "also", "trans", "-", "activates", "the", "LMP", "promoter", "by", "protein", "-", "protein", "interactions", ",", "we", "performed", "a", "series", "of", "gel", "retardation", "assays", "and", "competition", "experiments", "with", "LMP", "promoter", "fragments", "of", "different", "sizes", ".", "We", "determined", "that", "the", "protein", "-", "binding", "region", "on", "the", "LMP", "promoter", "was", "within", "a", "42", "bp", "fragment", "encompassing", "nucleotides", "-135", "to", "-176", "relative", "to", "the", "LMP", "transcriptional", "start", "site", ".", "None", "of", "the", "DNA", "fragments", "investigated", "indicated", "interaction", "of", "EBNA-2", "with", "the", "DNA", "via", "protein", "-", "protein", "interactions", ".", "No", "significant", "differences", "between", "EBNA-2-positive", "and", "EBNA-2-negative", "nuclear", "extracts", "could", "be", "seen", "in", "the", "gel", "retardation", "assay", "under", "conditions", "that", "clearly", "showed", "binding", "of", "EBNA-2A", "to", "the", "TP1", "promoter", ".", "However", ",", "analysis", "of", "sucrose", "gradient", "fractions", "in", "the", "gel", "retardation", "assay", "provided", "evidence", "that", "the", "LMP", "promoter", "-", "binding", "proteins", "form", "a", "complex", "of", "higher", "M(r", ")", "in", "EBNA-2-positive", "cell", "extracts", ".", "These", "complexes", "were", "destroyed", "by", "detergent", ".", "We", "deduce", "from", "these", "results", "that", "EBNA-2-positive", "cells", "might", "indeed", "contain", "specific", "complexes", "bound", "to", "the", "LMP", "promoter", "which", "are", ",", "however", ",", "too", "labile", "to", "be", "detected", "in", "a", "standard", "gel", "retardation", "assay", "." ]
[ "Protein", "Entity" ]
cathepsin D is a Protein, cathepsin D is a Protein, asparagine residues 70 is a Entity, 192 is a Entity, cathepsin D is a Protein, cathepsin D is a Protein, Cathepsin D is a Protein, cathepsin D is a Protein
228_task0
Sentence: Amino acid sequence of porcine spleen cathepsin D. The amino acid sequence of porcine spleen cathepsin D heavy chain has been determined and, hence, the complete structure of this enzyme is now known. The sequence of heavy chain was constructed by aligning the structures of peptides generated by cyanogen bromide, trypsin, and endo-proteinase Lys C cleavages. The structure of the light chain has been published previously. The cathepsin D molecule contains 339 amino acid residues in two polypeptide chains: a 97-residue light chain and a 242-residue heavy chain, with a combined Mr of 36,779 (without carbohydrate). There are two carbohydrate units linked to asparagine residues 70 and 192. The disulfide bond arrangement in cathepsin D is probably similar to that of pepsin, because the positions of six half-cystine residues are conserved. The active site aspartyl residues, corresponding to aspartic acid-32 and -215 of pepsin, are located at residues 33 and 224 in the cathepsin D molecule. The amino acid sequence around these aspartyl residues is strongly conserved. Cathepsin D shows a strong homology with other acid proteases. When the sequence of cathepsin D, renin, and pepsin are aligned, 32.7% of the residues are identical. The homology is observed throughout the length of the molecules, indicating that three-dimensional structures of all three molecules are similar. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Amino acid sequence of porcine spleen cathepsin D. The amino acid sequence of porcine spleen cathepsin D heavy chain has been determined and, hence, the complete structure of this enzyme is now known. The sequence of heavy chain was constructed by aligning the structures of peptides generated by cyanogen bromide, trypsin, and endo-proteinase Lys C cleavages. The structure of the light chain has been published previously. The cathepsin D molecule contains 339 amino acid residues in two polypeptide chains: a 97-residue light chain and a 242-residue heavy chain, with a combined Mr of 36,779 (without carbohydrate). There are two carbohydrate units linked to asparagine residues 70 and 192. The disulfide bond arrangement in cathepsin D is probably similar to that of pepsin, because the positions of six half-cystine residues are conserved. The active site aspartyl residues, corresponding to aspartic acid-32 and -215 of pepsin, are located at residues 33 and 224 in the cathepsin D molecule. The amino acid sequence around these aspartyl residues is strongly conserved. Cathepsin D shows a strong homology with other acid proteases. When the sequence of cathepsin D, renin, and pepsin are aligned, 32.7% of the residues are identical. The homology is observed throughout the length of the molecules, indicating that three-dimensional structures of all three molecules are similar.
[ "Amino", "acid", "sequence", "of", "porcine", "spleen", "cathepsin", "D.", "\n", "The", "amino", "acid", "sequence", "of", "porcine", "spleen", "cathepsin", "D", "heavy", "chain", "has", "been", "determined", "and", ",", "hence", ",", "the", "complete", "structure", "of", "this", "enzyme", "is", "now", "known", ".", "The", "sequence", "of", "heavy", "chain", "was", "constructed", "by", "aligning", "the", "structures", "of", "peptides", "generated", "by", "cyanogen", "bromide", ",", "trypsin", ",", "and", "endo", "-", "proteinase", "Lys", "C", "cleavages", ".", "The", "structure", "of", "the", "light", "chain", "has", "been", "published", "previously", ".", "The", "cathepsin", "D", "molecule", "contains", "339", "amino", "acid", "residues", "in", "two", "polypeptide", "chains", ":", "a", "97-residue", "light", "chain", "and", "a", "242-residue", "heavy", "chain", ",", "with", "a", "combined", "Mr", "of", "36,779", "(", "without", "carbohydrate", ")", ".", "There", "are", "two", "carbohydrate", "units", "linked", "to", "asparagine", "residues", "70", "and", "192", ".", "The", "disulfide", "bond", "arrangement", "in", "cathepsin", "D", "is", "probably", "similar", "to", "that", "of", "pepsin", ",", "because", "the", "positions", "of", "six", "half", "-", "cystine", "residues", "are", "conserved", ".", "The", "active", "site", "aspartyl", "residues", ",", "corresponding", "to", "aspartic", "acid-32", "and", "-215", "of", "pepsin", ",", "are", "located", "at", "residues", "33", "and", "224", "in", "the", "cathepsin", "D", "molecule", ".", "The", "amino", "acid", "sequence", "around", "these", "aspartyl", "residues", "is", "strongly", "conserved", ".", "Cathepsin", "D", "shows", "a", "strong", "homology", "with", "other", "acid", "proteases", ".", "When", "the", "sequence", "of", "cathepsin", "D", ",", "renin", ",", "and", "pepsin", "are", "aligned", ",", "32.7", "%", "of", "the", "residues", "are", "identical", ".", "The", "homology", "is", "observed", "throughout", "the", "length", "of", "the", "molecules", ",", "indicating", "that", "three", "-", "dimensional", "structures", "of", "all", "three", "molecules", "are", "similar", "." ]
[ "Entity", "Protein" ]
cathepsin D is a Protein, cathepsin D is a Protein, asparagine residues 70 is a Entity, 192 is a Entity, cathepsin D is a Protein, cathepsin D is a Protein, Cathepsin D is a Protein, cathepsin D is a Protein
228_task1
Sentence: Amino acid sequence of porcine spleen cathepsin D. The amino acid sequence of porcine spleen cathepsin D heavy chain has been determined and, hence, the complete structure of this enzyme is now known. The sequence of heavy chain was constructed by aligning the structures of peptides generated by cyanogen bromide, trypsin, and endo-proteinase Lys C cleavages. The structure of the light chain has been published previously. The cathepsin D molecule contains 339 amino acid residues in two polypeptide chains: a 97-residue light chain and a 242-residue heavy chain, with a combined Mr of 36,779 (without carbohydrate). There are two carbohydrate units linked to asparagine residues 70 and 192. The disulfide bond arrangement in cathepsin D is probably similar to that of pepsin, because the positions of six half-cystine residues are conserved. The active site aspartyl residues, corresponding to aspartic acid-32 and -215 of pepsin, are located at residues 33 and 224 in the cathepsin D molecule. The amino acid sequence around these aspartyl residues is strongly conserved. Cathepsin D shows a strong homology with other acid proteases. When the sequence of cathepsin D, renin, and pepsin are aligned, 32.7% of the residues are identical. The homology is observed throughout the length of the molecules, indicating that three-dimensional structures of all three molecules are similar. Instructions: please typing these entity words according to sentence: cathepsin D, cathepsin D, asparagine residues 70, 192, cathepsin D, cathepsin D, Cathepsin D, cathepsin D Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Amino acid sequence of porcine spleen cathepsin D. The amino acid sequence of porcine spleen cathepsin D heavy chain has been determined and, hence, the complete structure of this enzyme is now known. The sequence of heavy chain was constructed by aligning the structures of peptides generated by cyanogen bromide, trypsin, and endo-proteinase Lys C cleavages. The structure of the light chain has been published previously. The cathepsin D molecule contains 339 amino acid residues in two polypeptide chains: a 97-residue light chain and a 242-residue heavy chain, with a combined Mr of 36,779 (without carbohydrate). There are two carbohydrate units linked to asparagine residues 70 and 192. The disulfide bond arrangement in cathepsin D is probably similar to that of pepsin, because the positions of six half-cystine residues are conserved. The active site aspartyl residues, corresponding to aspartic acid-32 and -215 of pepsin, are located at residues 33 and 224 in the cathepsin D molecule. The amino acid sequence around these aspartyl residues is strongly conserved. Cathepsin D shows a strong homology with other acid proteases. When the sequence of cathepsin D, renin, and pepsin are aligned, 32.7% of the residues are identical. The homology is observed throughout the length of the molecules, indicating that three-dimensional structures of all three molecules are similar.
[ "Amino", "acid", "sequence", "of", "porcine", "spleen", "cathepsin", "D.", "\n", "The", "amino", "acid", "sequence", "of", "porcine", "spleen", "cathepsin", "D", "heavy", "chain", "has", "been", "determined", "and", ",", "hence", ",", "the", "complete", "structure", "of", "this", "enzyme", "is", "now", "known", ".", "The", "sequence", "of", "heavy", "chain", "was", "constructed", "by", "aligning", "the", "structures", "of", "peptides", "generated", "by", "cyanogen", "bromide", ",", "trypsin", ",", "and", "endo", "-", "proteinase", "Lys", "C", "cleavages", ".", "The", "structure", "of", "the", "light", "chain", "has", "been", "published", "previously", ".", "The", "cathepsin", "D", "molecule", "contains", "339", "amino", "acid", "residues", "in", "two", "polypeptide", "chains", ":", "a", "97-residue", "light", "chain", "and", "a", "242-residue", "heavy", "chain", ",", "with", "a", "combined", "Mr", "of", "36,779", "(", "without", "carbohydrate", ")", ".", "There", "are", "two", "carbohydrate", "units", "linked", "to", "asparagine", "residues", "70", "and", "192", ".", "The", "disulfide", "bond", "arrangement", "in", "cathepsin", "D", "is", "probably", "similar", "to", "that", "of", "pepsin", ",", "because", "the", "positions", "of", "six", "half", "-", "cystine", "residues", "are", "conserved", ".", "The", "active", "site", "aspartyl", "residues", ",", "corresponding", "to", "aspartic", "acid-32", "and", "-215", "of", "pepsin", ",", "are", "located", "at", "residues", "33", "and", "224", "in", "the", "cathepsin", "D", "molecule", ".", "The", "amino", "acid", "sequence", "around", "these", "aspartyl", "residues", "is", "strongly", "conserved", ".", "Cathepsin", "D", "shows", "a", "strong", "homology", "with", "other", "acid", "proteases", ".", "When", "the", "sequence", "of", "cathepsin", "D", ",", "renin", ",", "and", "pepsin", "are", "aligned", ",", "32.7", "%", "of", "the", "residues", "are", "identical", ".", "The", "homology", "is", "observed", "throughout", "the", "length", "of", "the", "molecules", ",", "indicating", "that", "three", "-", "dimensional", "structures", "of", "all", "three", "molecules", "are", "similar", "." ]
[ "Entity", "Protein" ]
cathepsin D, cathepsin D, asparagine residues 70, 192, cathepsin D, cathepsin D, Cathepsin D, cathepsin D
228_task2
Sentence: Amino acid sequence of porcine spleen cathepsin D. The amino acid sequence of porcine spleen cathepsin D heavy chain has been determined and, hence, the complete structure of this enzyme is now known. The sequence of heavy chain was constructed by aligning the structures of peptides generated by cyanogen bromide, trypsin, and endo-proteinase Lys C cleavages. The structure of the light chain has been published previously. The cathepsin D molecule contains 339 amino acid residues in two polypeptide chains: a 97-residue light chain and a 242-residue heavy chain, with a combined Mr of 36,779 (without carbohydrate). There are two carbohydrate units linked to asparagine residues 70 and 192. The disulfide bond arrangement in cathepsin D is probably similar to that of pepsin, because the positions of six half-cystine residues are conserved. The active site aspartyl residues, corresponding to aspartic acid-32 and -215 of pepsin, are located at residues 33 and 224 in the cathepsin D molecule. The amino acid sequence around these aspartyl residues is strongly conserved. Cathepsin D shows a strong homology with other acid proteases. When the sequence of cathepsin D, renin, and pepsin are aligned, 32.7% of the residues are identical. The homology is observed throughout the length of the molecules, indicating that three-dimensional structures of all three molecules are similar. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Amino acid sequence of porcine spleen cathepsin D. The amino acid sequence of porcine spleen cathepsin D heavy chain has been determined and, hence, the complete structure of this enzyme is now known. The sequence of heavy chain was constructed by aligning the structures of peptides generated by cyanogen bromide, trypsin, and endo-proteinase Lys C cleavages. The structure of the light chain has been published previously. The cathepsin D molecule contains 339 amino acid residues in two polypeptide chains: a 97-residue light chain and a 242-residue heavy chain, with a combined Mr of 36,779 (without carbohydrate). There are two carbohydrate units linked to asparagine residues 70 and 192. The disulfide bond arrangement in cathepsin D is probably similar to that of pepsin, because the positions of six half-cystine residues are conserved. The active site aspartyl residues, corresponding to aspartic acid-32 and -215 of pepsin, are located at residues 33 and 224 in the cathepsin D molecule. The amino acid sequence around these aspartyl residues is strongly conserved. Cathepsin D shows a strong homology with other acid proteases. When the sequence of cathepsin D, renin, and pepsin are aligned, 32.7% of the residues are identical. The homology is observed throughout the length of the molecules, indicating that three-dimensional structures of all three molecules are similar.
[ "Amino", "acid", "sequence", "of", "porcine", "spleen", "cathepsin", "D.", "\n", "The", "amino", "acid", "sequence", "of", "porcine", "spleen", "cathepsin", "D", "heavy", "chain", "has", "been", "determined", "and", ",", "hence", ",", "the", "complete", "structure", "of", "this", "enzyme", "is", "now", "known", ".", "The", "sequence", "of", "heavy", "chain", "was", "constructed", "by", "aligning", "the", "structures", "of", "peptides", "generated", "by", "cyanogen", "bromide", ",", "trypsin", ",", "and", "endo", "-", "proteinase", "Lys", "C", "cleavages", ".", "The", "structure", "of", "the", "light", "chain", "has", "been", "published", "previously", ".", "The", "cathepsin", "D", "molecule", "contains", "339", "amino", "acid", "residues", "in", "two", "polypeptide", "chains", ":", "a", "97-residue", "light", "chain", "and", "a", "242-residue", "heavy", "chain", ",", "with", "a", "combined", "Mr", "of", "36,779", "(", "without", "carbohydrate", ")", ".", "There", "are", "two", "carbohydrate", "units", "linked", "to", "asparagine", "residues", "70", "and", "192", ".", "The", "disulfide", "bond", "arrangement", "in", "cathepsin", "D", "is", "probably", "similar", "to", "that", "of", "pepsin", ",", "because", "the", "positions", "of", "six", "half", "-", "cystine", "residues", "are", "conserved", ".", "The", "active", "site", "aspartyl", "residues", ",", "corresponding", "to", "aspartic", "acid-32", "and", "-215", "of", "pepsin", ",", "are", "located", "at", "residues", "33", "and", "224", "in", "the", "cathepsin", "D", "molecule", ".", "The", "amino", "acid", "sequence", "around", "these", "aspartyl", "residues", "is", "strongly", "conserved", ".", "Cathepsin", "D", "shows", "a", "strong", "homology", "with", "other", "acid", "proteases", ".", "When", "the", "sequence", "of", "cathepsin", "D", ",", "renin", ",", "and", "pepsin", "are", "aligned", ",", "32.7", "%", "of", "the", "residues", "are", "identical", ".", "The", "homology", "is", "observed", "throughout", "the", "length", "of", "the", "molecules", ",", "indicating", "that", "three", "-", "dimensional", "structures", "of", "all", "three", "molecules", "are", "similar", "." ]
[ "Entity", "Protein" ]
ischemia is an umlsterm, blood is an umlsterm, surgical is an umlsterm, emergency is an umlsterm, diagnosis is an umlsterm, awareness is an umlsterm, angiography is an umlsterm, therapy is an umlsterm, laparotomy is an umlsterm, embolectomy is an umlsterm, thrombectomy is an umlsterm, bowel is an umlsterm, diagnosis is an umlsterm, cause is an umlsterm, mortality is an umlsterm, ischemia is an umlsterm, thrombosis is an umlsterm, mesenteric veins is an umlsterm, survival is an umlsterm, ischemia is an umlsterm, identification is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, measures is an umlsterm, intra - arterial infusion is an umlsterm, papaverine is an umlsterm, catheter is an umlsterm, bowel is an umlsterm, assessment is an umlsterm, bowel is an umlsterm, viability is an umlsterm, judgement is an umlsterm, surgical is an umlsterm, ischemia is an umlsterm, grafting is an umlsterm, endarterectomy is an umlsterm, patients is an umlsterm, comorbidity is an umlsterm, diseases is an umlsterm, patients is an umlsterm, Prophylactic is an umlsterm, arteries is an umlsterm
DerChirurg.80690001.eng.abstr_task0
Sentence: Acute occlusive mesenteric ischemia is caused by a local impairment of splanchnic blood flow and poses a particular surgical challenge . Acute superior mesenteric occlusion is a medical/surgical emergency mandating prompt diagnosis ( clinical awareness , angiography ) and therapy ( exploratory laparotomy with possible arterial reconstruction ; embolectomy , thrombectomy ; and/or bowel resection ) . The difficulty of early diagnosis is probably the most important cause of the high mortality which varies from 70 % to 90 % in arterial and functional mesenteric ischemia and from 20 % to 70 % in an acute thrombosis of the mesenteric veins . Improved survival from nonocclusive mesenteric ischemia is dependent upon the identification of high-risk groups and on aggressive diagnostic and therapeutic measures ( intra-arterial infusion of papaverine through the angiographic catheter with or without bowel resection ) . For assessment of bowel viability , the clinical judgement during first- or second-look exploration is still the most reliable parameter . The surgical management of chronic mesenteric ischemia includes aortomesenteric grafting and transaortic endarterectomy in the majority of patients with comorbidity of cardiovascular arteriosclerotic diseases and results in a high rate of symptom-free patients . Prophylactic reconstruction of visceral arteries is indicated only in certain limited circumstances . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Acute occlusive mesenteric ischemia is caused by a local impairment of splanchnic blood flow and poses a particular surgical challenge . Acute superior mesenteric occlusion is a medical/surgical emergency mandating prompt diagnosis ( clinical awareness , angiography ) and therapy ( exploratory laparotomy with possible arterial reconstruction ; embolectomy , thrombectomy ; and/or bowel resection ) . The difficulty of early diagnosis is probably the most important cause of the high mortality which varies from 70 % to 90 % in arterial and functional mesenteric ischemia and from 20 % to 70 % in an acute thrombosis of the mesenteric veins . Improved survival from nonocclusive mesenteric ischemia is dependent upon the identification of high-risk groups and on aggressive diagnostic and therapeutic measures ( intra-arterial infusion of papaverine through the angiographic catheter with or without bowel resection ) . For assessment of bowel viability , the clinical judgement during first- or second-look exploration is still the most reliable parameter . The surgical management of chronic mesenteric ischemia includes aortomesenteric grafting and transaortic endarterectomy in the majority of patients with comorbidity of cardiovascular arteriosclerotic diseases and results in a high rate of symptom-free patients . Prophylactic reconstruction of visceral arteries is indicated only in certain limited circumstances .
[ "Acute", "occlusive", "mesenteric", "ischemia", "is", "caused", "by", "a", "local", "impairment", "of", "splanchnic", "blood", "flow", "and", "poses", "a", "particular", "surgical", "challenge", ".", "Acute", "superior", "mesenteric", "occlusion", "is", "a", "medical", "/", "surgical", "emergency", "mandating", "prompt", "diagnosis", "(", "clinical", "awareness", ",", "angiography", ")", "and", "therapy", "(", "exploratory", "laparotomy", "with", "possible", "arterial", "reconstruction", ";", "embolectomy", ",", "thrombectomy", ";", "and", "/", "or", "bowel", "resection", ")", ".", "The", "difficulty", "of", "early", "diagnosis", "is", "probably", "the", "most", "important", "cause", "of", "the", "high", "mortality", "which", "varies", "from", "70", "%", "to", "90", "%", "in", "arterial", "and", "functional", "mesenteric", "ischemia", "and", "from", "20", "%", "to", "70", "%", "in", "an", "acute", "thrombosis", "of", "the", "mesenteric", "veins", ".", "Improved", "survival", "from", "nonocclusive", "mesenteric", "ischemia", "is", "dependent", "upon", "the", "identification", "of", "high", "-", "risk", "groups", "and", "on", "aggressive", "diagnostic", "and", "therapeutic", "measures", "(", "intra", "-", "arterial", "infusion", "of", "papaverine", "through", "the", "angiographic", "catheter", "with", "or", "without", "bowel", "resection", ")", ".", "For", "assessment", "of", "bowel", "viability", ",", "the", "clinical", "judgement", "during", "first-", "or", "second", "-", "look", "exploration", "is", "still", "the", "most", "reliable", "parameter", ".", "The", "surgical", "management", "of", "chronic", "mesenteric", "ischemia", "includes", "aortomesenteric", "grafting", "and", "transaortic", "endarterectomy", "in", "the", "majority", "of", "patients", "with", "comorbidity", "of", "cardiovascular", "arteriosclerotic", "diseases", "and", "results", "in", "a", "high", "rate", "of", "symptom", "-", "free", "patients", ".", "Prophylactic", "reconstruction", "of", "visceral", "arteries", "is", "indicated", "only", "in", "certain", "limited", "circumstances", "." ]
[ "umlsterm" ]
ischemia is an umlsterm, blood is an umlsterm, surgical is an umlsterm, emergency is an umlsterm, diagnosis is an umlsterm, awareness is an umlsterm, angiography is an umlsterm, therapy is an umlsterm, laparotomy is an umlsterm, embolectomy is an umlsterm, thrombectomy is an umlsterm, bowel is an umlsterm, diagnosis is an umlsterm, cause is an umlsterm, mortality is an umlsterm, ischemia is an umlsterm, thrombosis is an umlsterm, mesenteric veins is an umlsterm, survival is an umlsterm, ischemia is an umlsterm, identification is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, measures is an umlsterm, intra - arterial infusion is an umlsterm, papaverine is an umlsterm, catheter is an umlsterm, bowel is an umlsterm, assessment is an umlsterm, bowel is an umlsterm, viability is an umlsterm, judgement is an umlsterm, surgical is an umlsterm, ischemia is an umlsterm, grafting is an umlsterm, endarterectomy is an umlsterm, patients is an umlsterm, comorbidity is an umlsterm, diseases is an umlsterm, patients is an umlsterm, Prophylactic is an umlsterm, arteries is an umlsterm
DerChirurg.80690001.eng.abstr_task1
Sentence: Acute occlusive mesenteric ischemia is caused by a local impairment of splanchnic blood flow and poses a particular surgical challenge . Acute superior mesenteric occlusion is a medical/surgical emergency mandating prompt diagnosis ( clinical awareness , angiography ) and therapy ( exploratory laparotomy with possible arterial reconstruction ; embolectomy , thrombectomy ; and/or bowel resection ) . The difficulty of early diagnosis is probably the most important cause of the high mortality which varies from 70 % to 90 % in arterial and functional mesenteric ischemia and from 20 % to 70 % in an acute thrombosis of the mesenteric veins . Improved survival from nonocclusive mesenteric ischemia is dependent upon the identification of high-risk groups and on aggressive diagnostic and therapeutic measures ( intra-arterial infusion of papaverine through the angiographic catheter with or without bowel resection ) . For assessment of bowel viability , the clinical judgement during first- or second-look exploration is still the most reliable parameter . The surgical management of chronic mesenteric ischemia includes aortomesenteric grafting and transaortic endarterectomy in the majority of patients with comorbidity of cardiovascular arteriosclerotic diseases and results in a high rate of symptom-free patients . Prophylactic reconstruction of visceral arteries is indicated only in certain limited circumstances . Instructions: please typing these entity words according to sentence: ischemia, blood, surgical, emergency, diagnosis, awareness, angiography, therapy, laparotomy, embolectomy, thrombectomy, bowel, diagnosis, cause, mortality, ischemia, thrombosis, mesenteric veins, survival, ischemia, identification, diagnostic, therapeutic, measures, intra - arterial infusion, papaverine, catheter, bowel, assessment, bowel, viability, judgement, surgical, ischemia, grafting, endarterectomy, patients, comorbidity, diseases, patients, Prophylactic, arteries Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Acute occlusive mesenteric ischemia is caused by a local impairment of splanchnic blood flow and poses a particular surgical challenge . Acute superior mesenteric occlusion is a medical/surgical emergency mandating prompt diagnosis ( clinical awareness , angiography ) and therapy ( exploratory laparotomy with possible arterial reconstruction ; embolectomy , thrombectomy ; and/or bowel resection ) . The difficulty of early diagnosis is probably the most important cause of the high mortality which varies from 70 % to 90 % in arterial and functional mesenteric ischemia and from 20 % to 70 % in an acute thrombosis of the mesenteric veins . Improved survival from nonocclusive mesenteric ischemia is dependent upon the identification of high-risk groups and on aggressive diagnostic and therapeutic measures ( intra-arterial infusion of papaverine through the angiographic catheter with or without bowel resection ) . For assessment of bowel viability , the clinical judgement during first- or second-look exploration is still the most reliable parameter . The surgical management of chronic mesenteric ischemia includes aortomesenteric grafting and transaortic endarterectomy in the majority of patients with comorbidity of cardiovascular arteriosclerotic diseases and results in a high rate of symptom-free patients . Prophylactic reconstruction of visceral arteries is indicated only in certain limited circumstances .
[ "Acute", "occlusive", "mesenteric", "ischemia", "is", "caused", "by", "a", "local", "impairment", "of", "splanchnic", "blood", "flow", "and", "poses", "a", "particular", "surgical", "challenge", ".", "Acute", "superior", "mesenteric", "occlusion", "is", "a", "medical", "/", "surgical", "emergency", "mandating", "prompt", "diagnosis", "(", "clinical", "awareness", ",", "angiography", ")", "and", "therapy", "(", "exploratory", "laparotomy", "with", "possible", "arterial", "reconstruction", ";", "embolectomy", ",", "thrombectomy", ";", "and", "/", "or", "bowel", "resection", ")", ".", "The", "difficulty", "of", "early", "diagnosis", "is", "probably", "the", "most", "important", "cause", "of", "the", "high", "mortality", "which", "varies", "from", "70", "%", "to", "90", "%", "in", "arterial", "and", "functional", "mesenteric", "ischemia", "and", "from", "20", "%", "to", "70", "%", "in", "an", "acute", "thrombosis", "of", "the", "mesenteric", "veins", ".", "Improved", "survival", "from", "nonocclusive", "mesenteric", "ischemia", "is", "dependent", "upon", "the", "identification", "of", "high", "-", "risk", "groups", "and", "on", "aggressive", "diagnostic", "and", "therapeutic", "measures", "(", "intra", "-", "arterial", "infusion", "of", "papaverine", "through", "the", "angiographic", "catheter", "with", "or", "without", "bowel", "resection", ")", ".", "For", "assessment", "of", "bowel", "viability", ",", "the", "clinical", "judgement", "during", "first-", "or", "second", "-", "look", "exploration", "is", "still", "the", "most", "reliable", "parameter", ".", "The", "surgical", "management", "of", "chronic", "mesenteric", "ischemia", "includes", "aortomesenteric", "grafting", "and", "transaortic", "endarterectomy", "in", "the", "majority", "of", "patients", "with", "comorbidity", "of", "cardiovascular", "arteriosclerotic", "diseases", "and", "results", "in", "a", "high", "rate", "of", "symptom", "-", "free", "patients", ".", "Prophylactic", "reconstruction", "of", "visceral", "arteries", "is", "indicated", "only", "in", "certain", "limited", "circumstances", "." ]
[ "umlsterm" ]
ischemia, blood, surgical, emergency, diagnosis, awareness, angiography, therapy, laparotomy, embolectomy, thrombectomy, bowel, diagnosis, cause, mortality, ischemia, thrombosis, mesenteric veins, survival, ischemia, identification, diagnostic, therapeutic, measures, intra - arterial infusion, papaverine, catheter, bowel, assessment, bowel, viability, judgement, surgical, ischemia, grafting, endarterectomy, patients, comorbidity, diseases, patients, Prophylactic, arteries
DerChirurg.80690001.eng.abstr_task2
Sentence: Acute occlusive mesenteric ischemia is caused by a local impairment of splanchnic blood flow and poses a particular surgical challenge . Acute superior mesenteric occlusion is a medical/surgical emergency mandating prompt diagnosis ( clinical awareness , angiography ) and therapy ( exploratory laparotomy with possible arterial reconstruction ; embolectomy , thrombectomy ; and/or bowel resection ) . The difficulty of early diagnosis is probably the most important cause of the high mortality which varies from 70 % to 90 % in arterial and functional mesenteric ischemia and from 20 % to 70 % in an acute thrombosis of the mesenteric veins . Improved survival from nonocclusive mesenteric ischemia is dependent upon the identification of high-risk groups and on aggressive diagnostic and therapeutic measures ( intra-arterial infusion of papaverine through the angiographic catheter with or without bowel resection ) . For assessment of bowel viability , the clinical judgement during first- or second-look exploration is still the most reliable parameter . The surgical management of chronic mesenteric ischemia includes aortomesenteric grafting and transaortic endarterectomy in the majority of patients with comorbidity of cardiovascular arteriosclerotic diseases and results in a high rate of symptom-free patients . Prophylactic reconstruction of visceral arteries is indicated only in certain limited circumstances . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Acute occlusive mesenteric ischemia is caused by a local impairment of splanchnic blood flow and poses a particular surgical challenge . Acute superior mesenteric occlusion is a medical/surgical emergency mandating prompt diagnosis ( clinical awareness , angiography ) and therapy ( exploratory laparotomy with possible arterial reconstruction ; embolectomy , thrombectomy ; and/or bowel resection ) . The difficulty of early diagnosis is probably the most important cause of the high mortality which varies from 70 % to 90 % in arterial and functional mesenteric ischemia and from 20 % to 70 % in an acute thrombosis of the mesenteric veins . Improved survival from nonocclusive mesenteric ischemia is dependent upon the identification of high-risk groups and on aggressive diagnostic and therapeutic measures ( intra-arterial infusion of papaverine through the angiographic catheter with or without bowel resection ) . For assessment of bowel viability , the clinical judgement during first- or second-look exploration is still the most reliable parameter . The surgical management of chronic mesenteric ischemia includes aortomesenteric grafting and transaortic endarterectomy in the majority of patients with comorbidity of cardiovascular arteriosclerotic diseases and results in a high rate of symptom-free patients . Prophylactic reconstruction of visceral arteries is indicated only in certain limited circumstances .
[ "Acute", "occlusive", "mesenteric", "ischemia", "is", "caused", "by", "a", "local", "impairment", "of", "splanchnic", "blood", "flow", "and", "poses", "a", "particular", "surgical", "challenge", ".", "Acute", "superior", "mesenteric", "occlusion", "is", "a", "medical", "/", "surgical", "emergency", "mandating", "prompt", "diagnosis", "(", "clinical", "awareness", ",", "angiography", ")", "and", "therapy", "(", "exploratory", "laparotomy", "with", "possible", "arterial", "reconstruction", ";", "embolectomy", ",", "thrombectomy", ";", "and", "/", "or", "bowel", "resection", ")", ".", "The", "difficulty", "of", "early", "diagnosis", "is", "probably", "the", "most", "important", "cause", "of", "the", "high", "mortality", "which", "varies", "from", "70", "%", "to", "90", "%", "in", "arterial", "and", "functional", "mesenteric", "ischemia", "and", "from", "20", "%", "to", "70", "%", "in", "an", "acute", "thrombosis", "of", "the", "mesenteric", "veins", ".", "Improved", "survival", "from", "nonocclusive", "mesenteric", "ischemia", "is", "dependent", "upon", "the", "identification", "of", "high", "-", "risk", "groups", "and", "on", "aggressive", "diagnostic", "and", "therapeutic", "measures", "(", "intra", "-", "arterial", "infusion", "of", "papaverine", "through", "the", "angiographic", "catheter", "with", "or", "without", "bowel", "resection", ")", ".", "For", "assessment", "of", "bowel", "viability", ",", "the", "clinical", "judgement", "during", "first-", "or", "second", "-", "look", "exploration", "is", "still", "the", "most", "reliable", "parameter", ".", "The", "surgical", "management", "of", "chronic", "mesenteric", "ischemia", "includes", "aortomesenteric", "grafting", "and", "transaortic", "endarterectomy", "in", "the", "majority", "of", "patients", "with", "comorbidity", "of", "cardiovascular", "arteriosclerotic", "diseases", "and", "results", "in", "a", "high", "rate", "of", "symptom", "-", "free", "patients", ".", "Prophylactic", "reconstruction", "of", "visceral", "arteries", "is", "indicated", "only", "in", "certain", "limited", "circumstances", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, Dermatitis is an umlsterm, Pityrosporum is an umlsterm, Antimykotika is an umlsterm, minimalen Hemmkonzentration is an umlsterm, Imidazolderivate is an umlsterm, Wachstum is an umlsterm, Pityrosporum is an umlsterm, in vitro is an umlsterm, Ketoconazol is an umlsterm, Itraconazol is an umlsterm, Azole is an umlsterm, Fluconazol is an umlsterm, Clotrimazol is an umlsterm, Natamycin is an umlsterm, Pityrosporum is an umlsterm, Pityrosporum is an umlsterm, Wachstumshemmung is an umlsterm, Pityrosporum is an umlsterm, Dithranol is an umlsterm, Steinkohlenteer is an umlsterm, Wirkstoffkonzentrationen is an umlsterm
DerHautarzt.40450464.ger.abstr_task0
Sentence: Zusammenfassung . Von Patienten mit seborrhoischer Dermatitis und Kopfschuppen wurden 30 Pityrosporum ovale-Staemme isoliert und deren In-vitro-Empfindlichkeit sowohl gegenueber verschiedenen klassischen Antimykotika , als auch gegen einige antiseborrhoische und antipsoriatische Wirkstoffe getestet . Fuer die Ermittlung der minimalen Hemmkonzentration ( MHK ) wurde ein Agardilutionstest eingesetzt . Wie zu erwarten war , hemmten die getesteten Imidazolderivate das Wachstum von Pityrosporum ovale in vitro gut . Den besten Hemmeffekt hatten Ketoconazol ( MHK 0,1 µg/ml) und Itraconazol ( MHK-Werte von 0,05 µg/ml fuer einige Staemme ) . Aber auch die MHK-Werte der anderen untersuchten Azole Fluconazol , Tioconazol und Clotrimazol sowie des Polyen-Antimykotikums Natamycin waren niedrig , was ebenfalls fuer eine gute Hemmwirkung gegenueber Pityrosporum spricht . Zink-Pyrithion wies eine sehr gute Wirksamkeit gegen Pityrosporum ovale auf MHK 0,78 - 1,56 ( µg/ml). Die MHK-Werte von Selendisulfid lagen im Bereich von 1,56 bis 3,13 µg/ml. Eine Wachstumshemmung von Pityrosporum konnte auch durch die Antipsoriatika Dithranol und Steinkohlenteer erzielt werden ; es waren dafuer jedoch hoehere Wirkstoffkonzentrationen erforderlich . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Von Patienten mit seborrhoischer Dermatitis und Kopfschuppen wurden 30 Pityrosporum ovale-Staemme isoliert und deren In-vitro-Empfindlichkeit sowohl gegenueber verschiedenen klassischen Antimykotika , als auch gegen einige antiseborrhoische und antipsoriatische Wirkstoffe getestet . Fuer die Ermittlung der minimalen Hemmkonzentration ( MHK ) wurde ein Agardilutionstest eingesetzt . Wie zu erwarten war , hemmten die getesteten Imidazolderivate das Wachstum von Pityrosporum ovale in vitro gut . Den besten Hemmeffekt hatten Ketoconazol ( MHK 0,1 µg/ml) und Itraconazol ( MHK-Werte von 0,05 µg/ml fuer einige Staemme ) . Aber auch die MHK-Werte der anderen untersuchten Azole Fluconazol , Tioconazol und Clotrimazol sowie des Polyen-Antimykotikums Natamycin waren niedrig , was ebenfalls fuer eine gute Hemmwirkung gegenueber Pityrosporum spricht . Zink-Pyrithion wies eine sehr gute Wirksamkeit gegen Pityrosporum ovale auf MHK 0,78 - 1,56 ( µg/ml). Die MHK-Werte von Selendisulfid lagen im Bereich von 1,56 bis 3,13 µg/ml. Eine Wachstumshemmung von Pityrosporum konnte auch durch die Antipsoriatika Dithranol und Steinkohlenteer erzielt werden ; es waren dafuer jedoch hoehere Wirkstoffkonzentrationen erforderlich .
[ "Zusammenfassung", ".", "Von", "Patienten", "mit", "seborrhoischer", "Dermatitis", "und", "Kopfschuppen", "wurden", "30", "Pityrosporum", "ovale", "-", "Staemme", "isoliert", "und", "deren", "In", "-", "vitro", "-", "Empfindlichkeit", "sowohl", "gegenueber", "verschiedenen", "klassischen", "Antimykotika", ",", "als", "auch", "gegen", "einige", "antiseborrhoische", "und", "antipsoriatische", "Wirkstoffe", "getestet", ".", "Fuer", "die", "Ermittlung", "der", "minimalen", "Hemmkonzentration", "(", "MHK", ")", "wurde", "ein", "Agardilutionstest", "eingesetzt", ".", "Wie", "zu", "erwarten", "war", ",", "hemmten", "die", "getesteten", "Imidazolderivate", "das", "Wachstum", "von", "Pityrosporum", "ovale", "in", "vitro", "gut", ".", "Den", "besten", "Hemmeffekt", "hatten", "Ketoconazol", "(", "MHK", "0,1", "µg", "/", "ml", ")", "und", "Itraconazol", "(", "MHK", "-", "Werte", "von", "0,05", "µg", "/", "ml", "fuer", "einige", "Staemme", ")", ".", "Aber", "auch", "die", "MHK", "-", "Werte", "der", "anderen", "untersuchten", "Azole", "Fluconazol", ",", "Tioconazol", "und", "Clotrimazol", "sowie", "des", "Polyen", "-", "Antimykotikums", "Natamycin", "waren", "niedrig", ",", "was", "ebenfalls", "fuer", "eine", "gute", "Hemmwirkung", "gegenueber", "Pityrosporum", "spricht", ".", "Zink", "-", "Pyrithion", "wies", "eine", "sehr", "gute", "Wirksamkeit", "gegen", "Pityrosporum", "ovale", "auf", "MHK", "0,78", "-", "1,56", "(", "µg", "/", "ml", ")", ".", "Die", "MHK", "-", "Werte", "von", "Selendisulfid", "lagen", "im", "Bereich", "von", "1,56", "bis", "3,13", "µg", "/", "ml", ".", "Eine", "Wachstumshemmung", "von", "Pityrosporum", "konnte", "auch", "durch", "die", "Antipsoriatika", "Dithranol", "und", "Steinkohlenteer", "erzielt", "werden", ";", "es", "waren", "dafuer", "jedoch", "hoehere", "Wirkstoffkonzentrationen", "erforderlich", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, Dermatitis is an umlsterm, Pityrosporum is an umlsterm, Antimykotika is an umlsterm, minimalen Hemmkonzentration is an umlsterm, Imidazolderivate is an umlsterm, Wachstum is an umlsterm, Pityrosporum is an umlsterm, in vitro is an umlsterm, Ketoconazol is an umlsterm, Itraconazol is an umlsterm, Azole is an umlsterm, Fluconazol is an umlsterm, Clotrimazol is an umlsterm, Natamycin is an umlsterm, Pityrosporum is an umlsterm, Pityrosporum is an umlsterm, Wachstumshemmung is an umlsterm, Pityrosporum is an umlsterm, Dithranol is an umlsterm, Steinkohlenteer is an umlsterm, Wirkstoffkonzentrationen is an umlsterm
DerHautarzt.40450464.ger.abstr_task1
Sentence: Zusammenfassung . Von Patienten mit seborrhoischer Dermatitis und Kopfschuppen wurden 30 Pityrosporum ovale-Staemme isoliert und deren In-vitro-Empfindlichkeit sowohl gegenueber verschiedenen klassischen Antimykotika , als auch gegen einige antiseborrhoische und antipsoriatische Wirkstoffe getestet . Fuer die Ermittlung der minimalen Hemmkonzentration ( MHK ) wurde ein Agardilutionstest eingesetzt . Wie zu erwarten war , hemmten die getesteten Imidazolderivate das Wachstum von Pityrosporum ovale in vitro gut . Den besten Hemmeffekt hatten Ketoconazol ( MHK 0,1 µg/ml) und Itraconazol ( MHK-Werte von 0,05 µg/ml fuer einige Staemme ) . Aber auch die MHK-Werte der anderen untersuchten Azole Fluconazol , Tioconazol und Clotrimazol sowie des Polyen-Antimykotikums Natamycin waren niedrig , was ebenfalls fuer eine gute Hemmwirkung gegenueber Pityrosporum spricht . Zink-Pyrithion wies eine sehr gute Wirksamkeit gegen Pityrosporum ovale auf MHK 0,78 - 1,56 ( µg/ml). Die MHK-Werte von Selendisulfid lagen im Bereich von 1,56 bis 3,13 µg/ml. Eine Wachstumshemmung von Pityrosporum konnte auch durch die Antipsoriatika Dithranol und Steinkohlenteer erzielt werden ; es waren dafuer jedoch hoehere Wirkstoffkonzentrationen erforderlich . Instructions: please typing these entity words according to sentence: Patienten, Dermatitis, Pityrosporum, Antimykotika, minimalen Hemmkonzentration, Imidazolderivate, Wachstum, Pityrosporum, in vitro, Ketoconazol, Itraconazol, Azole, Fluconazol, Clotrimazol, Natamycin, Pityrosporum, Pityrosporum, Wachstumshemmung, Pityrosporum, Dithranol, Steinkohlenteer, Wirkstoffkonzentrationen Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Von Patienten mit seborrhoischer Dermatitis und Kopfschuppen wurden 30 Pityrosporum ovale-Staemme isoliert und deren In-vitro-Empfindlichkeit sowohl gegenueber verschiedenen klassischen Antimykotika , als auch gegen einige antiseborrhoische und antipsoriatische Wirkstoffe getestet . Fuer die Ermittlung der minimalen Hemmkonzentration ( MHK ) wurde ein Agardilutionstest eingesetzt . Wie zu erwarten war , hemmten die getesteten Imidazolderivate das Wachstum von Pityrosporum ovale in vitro gut . Den besten Hemmeffekt hatten Ketoconazol ( MHK 0,1 µg/ml) und Itraconazol ( MHK-Werte von 0,05 µg/ml fuer einige Staemme ) . Aber auch die MHK-Werte der anderen untersuchten Azole Fluconazol , Tioconazol und Clotrimazol sowie des Polyen-Antimykotikums Natamycin waren niedrig , was ebenfalls fuer eine gute Hemmwirkung gegenueber Pityrosporum spricht . Zink-Pyrithion wies eine sehr gute Wirksamkeit gegen Pityrosporum ovale auf MHK 0,78 - 1,56 ( µg/ml). Die MHK-Werte von Selendisulfid lagen im Bereich von 1,56 bis 3,13 µg/ml. Eine Wachstumshemmung von Pityrosporum konnte auch durch die Antipsoriatika Dithranol und Steinkohlenteer erzielt werden ; es waren dafuer jedoch hoehere Wirkstoffkonzentrationen erforderlich .
[ "Zusammenfassung", ".", "Von", "Patienten", "mit", "seborrhoischer", "Dermatitis", "und", "Kopfschuppen", "wurden", "30", "Pityrosporum", "ovale", "-", "Staemme", "isoliert", "und", "deren", "In", "-", "vitro", "-", "Empfindlichkeit", "sowohl", "gegenueber", "verschiedenen", "klassischen", "Antimykotika", ",", "als", "auch", "gegen", "einige", "antiseborrhoische", "und", "antipsoriatische", "Wirkstoffe", "getestet", ".", "Fuer", "die", "Ermittlung", "der", "minimalen", "Hemmkonzentration", "(", "MHK", ")", "wurde", "ein", "Agardilutionstest", "eingesetzt", ".", "Wie", "zu", "erwarten", "war", ",", "hemmten", "die", "getesteten", "Imidazolderivate", "das", "Wachstum", "von", "Pityrosporum", "ovale", "in", "vitro", "gut", ".", "Den", "besten", "Hemmeffekt", "hatten", "Ketoconazol", "(", "MHK", "0,1", "µg", "/", "ml", ")", "und", "Itraconazol", "(", "MHK", "-", "Werte", "von", "0,05", "µg", "/", "ml", "fuer", "einige", "Staemme", ")", ".", "Aber", "auch", "die", "MHK", "-", "Werte", "der", "anderen", "untersuchten", "Azole", "Fluconazol", ",", "Tioconazol", "und", "Clotrimazol", "sowie", "des", "Polyen", "-", "Antimykotikums", "Natamycin", "waren", "niedrig", ",", "was", "ebenfalls", "fuer", "eine", "gute", "Hemmwirkung", "gegenueber", "Pityrosporum", "spricht", ".", "Zink", "-", "Pyrithion", "wies", "eine", "sehr", "gute", "Wirksamkeit", "gegen", "Pityrosporum", "ovale", "auf", "MHK", "0,78", "-", "1,56", "(", "µg", "/", "ml", ")", ".", "Die", "MHK", "-", "Werte", "von", "Selendisulfid", "lagen", "im", "Bereich", "von", "1,56", "bis", "3,13", "µg", "/", "ml", ".", "Eine", "Wachstumshemmung", "von", "Pityrosporum", "konnte", "auch", "durch", "die", "Antipsoriatika", "Dithranol", "und", "Steinkohlenteer", "erzielt", "werden", ";", "es", "waren", "dafuer", "jedoch", "hoehere", "Wirkstoffkonzentrationen", "erforderlich", "." ]
[ "umlsterm" ]
Patienten, Dermatitis, Pityrosporum, Antimykotika, minimalen Hemmkonzentration, Imidazolderivate, Wachstum, Pityrosporum, in vitro, Ketoconazol, Itraconazol, Azole, Fluconazol, Clotrimazol, Natamycin, Pityrosporum, Pityrosporum, Wachstumshemmung, Pityrosporum, Dithranol, Steinkohlenteer, Wirkstoffkonzentrationen
DerHautarzt.40450464.ger.abstr_task2
Sentence: Zusammenfassung . Von Patienten mit seborrhoischer Dermatitis und Kopfschuppen wurden 30 Pityrosporum ovale-Staemme isoliert und deren In-vitro-Empfindlichkeit sowohl gegenueber verschiedenen klassischen Antimykotika , als auch gegen einige antiseborrhoische und antipsoriatische Wirkstoffe getestet . Fuer die Ermittlung der minimalen Hemmkonzentration ( MHK ) wurde ein Agardilutionstest eingesetzt . Wie zu erwarten war , hemmten die getesteten Imidazolderivate das Wachstum von Pityrosporum ovale in vitro gut . Den besten Hemmeffekt hatten Ketoconazol ( MHK 0,1 µg/ml) und Itraconazol ( MHK-Werte von 0,05 µg/ml fuer einige Staemme ) . Aber auch die MHK-Werte der anderen untersuchten Azole Fluconazol , Tioconazol und Clotrimazol sowie des Polyen-Antimykotikums Natamycin waren niedrig , was ebenfalls fuer eine gute Hemmwirkung gegenueber Pityrosporum spricht . Zink-Pyrithion wies eine sehr gute Wirksamkeit gegen Pityrosporum ovale auf MHK 0,78 - 1,56 ( µg/ml). Die MHK-Werte von Selendisulfid lagen im Bereich von 1,56 bis 3,13 µg/ml. Eine Wachstumshemmung von Pityrosporum konnte auch durch die Antipsoriatika Dithranol und Steinkohlenteer erzielt werden ; es waren dafuer jedoch hoehere Wirkstoffkonzentrationen erforderlich . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Von Patienten mit seborrhoischer Dermatitis und Kopfschuppen wurden 30 Pityrosporum ovale-Staemme isoliert und deren In-vitro-Empfindlichkeit sowohl gegenueber verschiedenen klassischen Antimykotika , als auch gegen einige antiseborrhoische und antipsoriatische Wirkstoffe getestet . Fuer die Ermittlung der minimalen Hemmkonzentration ( MHK ) wurde ein Agardilutionstest eingesetzt . Wie zu erwarten war , hemmten die getesteten Imidazolderivate das Wachstum von Pityrosporum ovale in vitro gut . Den besten Hemmeffekt hatten Ketoconazol ( MHK 0,1 µg/ml) und Itraconazol ( MHK-Werte von 0,05 µg/ml fuer einige Staemme ) . Aber auch die MHK-Werte der anderen untersuchten Azole Fluconazol , Tioconazol und Clotrimazol sowie des Polyen-Antimykotikums Natamycin waren niedrig , was ebenfalls fuer eine gute Hemmwirkung gegenueber Pityrosporum spricht . Zink-Pyrithion wies eine sehr gute Wirksamkeit gegen Pityrosporum ovale auf MHK 0,78 - 1,56 ( µg/ml). Die MHK-Werte von Selendisulfid lagen im Bereich von 1,56 bis 3,13 µg/ml. Eine Wachstumshemmung von Pityrosporum konnte auch durch die Antipsoriatika Dithranol und Steinkohlenteer erzielt werden ; es waren dafuer jedoch hoehere Wirkstoffkonzentrationen erforderlich .
[ "Zusammenfassung", ".", "Von", "Patienten", "mit", "seborrhoischer", "Dermatitis", "und", "Kopfschuppen", "wurden", "30", "Pityrosporum", "ovale", "-", "Staemme", "isoliert", "und", "deren", "In", "-", "vitro", "-", "Empfindlichkeit", "sowohl", "gegenueber", "verschiedenen", "klassischen", "Antimykotika", ",", "als", "auch", "gegen", "einige", "antiseborrhoische", "und", "antipsoriatische", "Wirkstoffe", "getestet", ".", "Fuer", "die", "Ermittlung", "der", "minimalen", "Hemmkonzentration", "(", "MHK", ")", "wurde", "ein", "Agardilutionstest", "eingesetzt", ".", "Wie", "zu", "erwarten", "war", ",", "hemmten", "die", "getesteten", "Imidazolderivate", "das", "Wachstum", "von", "Pityrosporum", "ovale", "in", "vitro", "gut", ".", "Den", "besten", "Hemmeffekt", "hatten", "Ketoconazol", "(", "MHK", "0,1", "µg", "/", "ml", ")", "und", "Itraconazol", "(", "MHK", "-", "Werte", "von", "0,05", "µg", "/", "ml", "fuer", "einige", "Staemme", ")", ".", "Aber", "auch", "die", "MHK", "-", "Werte", "der", "anderen", "untersuchten", "Azole", "Fluconazol", ",", "Tioconazol", "und", "Clotrimazol", "sowie", "des", "Polyen", "-", "Antimykotikums", "Natamycin", "waren", "niedrig", ",", "was", "ebenfalls", "fuer", "eine", "gute", "Hemmwirkung", "gegenueber", "Pityrosporum", "spricht", ".", "Zink", "-", "Pyrithion", "wies", "eine", "sehr", "gute", "Wirksamkeit", "gegen", "Pityrosporum", "ovale", "auf", "MHK", "0,78", "-", "1,56", "(", "µg", "/", "ml", ")", ".", "Die", "MHK", "-", "Werte", "von", "Selendisulfid", "lagen", "im", "Bereich", "von", "1,56", "bis", "3,13", "µg", "/", "ml", ".", "Eine", "Wachstumshemmung", "von", "Pityrosporum", "konnte", "auch", "durch", "die", "Antipsoriatika", "Dithranol", "und", "Steinkohlenteer", "erzielt", "werden", ";", "es", "waren", "dafuer", "jedoch", "hoehere", "Wirkstoffkonzentrationen", "erforderlich", "." ]
[ "umlsterm" ]
Malignant lymphomas is an umlsterm, NK cells is an umlsterm, tumours is an umlsterm, Europe is an umlsterm, malignant lymphomas is an umlsterm, review is an umlsterm, NK cells is an umlsterm, cell is an umlsterm, lymphoma is an umlsterm, nose is an umlsterm, paranasal sinuses is an umlsterm, growth is an umlsterm, coagulation is an umlsterm, necrosis is an umlsterm, tumor is an umlsterm, cells is an umlsterm, CD2 is an umlsterm, Epstein - Barr virus is an umlsterm, T cell receptor is an umlsterm, gene rearrangements is an umlsterm, tumors is an umlsterm, NK cells is an umlsterm, Enteropathy - type is an umlsterm, T - cell lymphomas is an umlsterm, patients is an umlsterm, celiac disease is an umlsterm, prognosis is an umlsterm, tumour is an umlsterm, cells is an umlsterm, T cell is an umlsterm, antigens is an umlsterm, CD103 is an umlsterm, CD56 is an umlsterm, tumour is an umlsterm, celiac disease is an umlsterm, lymphocytes is an umlsterm, exhibit is an umlsterm, CD8 is an umlsterm, protein is an umlsterm, analysis is an umlsterm, patients is an umlsterm, sprue is an umlsterm, prognosis is an umlsterm, patients is an umlsterm, malnutrition is an umlsterm, T - cell lymphoma is an umlsterm, T - cell lymphoma is an umlsterm, morphological is an umlsterm, findings is an umlsterm, lymphoid cells is an umlsterm, pale is an umlsterm, cytoplasm is an umlsterm, venules is an umlsterm, symptoms is an umlsterm, signs is an umlsterm, Peripheral T - cell lymphomas is an umlsterm, classifications is an umlsterm, peripheral T - cell lymphomas is an umlsterm, morphological is an umlsterm, T - cell lymphomas is an umlsterm, cell sizes is an umlsterm, lymphoma is an umlsterm, lymphoma is an umlsterm
DerPathologe.00210137.eng.abstr_task0
Sentence: Malignant lymphomas , originating from peripheral T or NK cells , are rare tumours in Europe and account for less than 10% of all malignant lymphomas . In this review , the salient features of the more frequently occurring entities derived from T or NK cells will be presented . Nasal NK/T cell lymphoma is mainly found in the nose and paranasal sinuses and often , but not always , display an angiocentric growth pattern leading to coagulation necrosis . The tumor cells consistently express CD56, CD2 and the EBER molecules encoded by the Epstein-Barr virus . Clonal T cell receptor gene rearrangements are often absent indicating , in the majority of cases , a derivation of these tumors from NK cells . Enteropathy-type intestinal T-cell lymphomas often arise in patients with celiac disease and have a dismal prognosis . The tumour cells express T cell antigens , CD103 and cytotoxic molecules , but are negative for CD4. Approximately 20% of the cases display CD56 mostly in combination with CD8. Recently , an early purely intraepithelial form of this tumour was identified . Histologically these cases resemble celiac disease , however the intraepithelial lymphocytes often exhibit an abnormal immunophenotype with absent CD8 and T-cell-receptor protein expression , and , they are clonal by molecular analysis . Clinically , the patients suffer from refractory sprue or ulcerative jejunitis . The prognosis is bad with the patients often dying from malnutrition or an invasive tumour-forming T-cell lymphoma . Angioimmunoblastic T-cell lymphoma is defined by characteristic morphological findings ( atypical lymphoid cells in part with pale cytoplasm , arborizing high endothelial venules and large FDC-meshworks ) as well as clinical features ( systemic symptoms , signs of a dysregulated immune response ) . Peripheral T-cell lymphomas , that do not fit into a distinct entity , are classified in the REAL and the new WHO classifications as peripheral T-cell lymphomas unspecified . These display a broad morphological spectrum ( including the T-cell lymphomas of different cell sizes , Lennert's lymphoma and T-zone lymphoma of the Kiel-classification ) and in general are clinically aggressive . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Malignant lymphomas , originating from peripheral T or NK cells , are rare tumours in Europe and account for less than 10% of all malignant lymphomas . In this review , the salient features of the more frequently occurring entities derived from T or NK cells will be presented . Nasal NK/T cell lymphoma is mainly found in the nose and paranasal sinuses and often , but not always , display an angiocentric growth pattern leading to coagulation necrosis . The tumor cells consistently express CD56, CD2 and the EBER molecules encoded by the Epstein-Barr virus . Clonal T cell receptor gene rearrangements are often absent indicating , in the majority of cases , a derivation of these tumors from NK cells . Enteropathy-type intestinal T-cell lymphomas often arise in patients with celiac disease and have a dismal prognosis . The tumour cells express T cell antigens , CD103 and cytotoxic molecules , but are negative for CD4. Approximately 20% of the cases display CD56 mostly in combination with CD8. Recently , an early purely intraepithelial form of this tumour was identified . Histologically these cases resemble celiac disease , however the intraepithelial lymphocytes often exhibit an abnormal immunophenotype with absent CD8 and T-cell-receptor protein expression , and , they are clonal by molecular analysis . Clinically , the patients suffer from refractory sprue or ulcerative jejunitis . The prognosis is bad with the patients often dying from malnutrition or an invasive tumour-forming T-cell lymphoma . Angioimmunoblastic T-cell lymphoma is defined by characteristic morphological findings ( atypical lymphoid cells in part with pale cytoplasm , arborizing high endothelial venules and large FDC-meshworks ) as well as clinical features ( systemic symptoms , signs of a dysregulated immune response ) . Peripheral T-cell lymphomas , that do not fit into a distinct entity , are classified in the REAL and the new WHO classifications as peripheral T-cell lymphomas unspecified . These display a broad morphological spectrum ( including the T-cell lymphomas of different cell sizes , Lennert's lymphoma and T-zone lymphoma of the Kiel-classification ) and in general are clinically aggressive .
[ "Malignant", "lymphomas", ",", "originating", "from", "peripheral", "T", "or", "NK", "cells", ",", "are", "rare", "tumours", "in", "Europe", "and", "account", "for", "less", "than", "10", "%", "of", "all", "malignant", "lymphomas", ".", "In", "this", "review", ",", "the", "salient", "features", "of", "the", "more", "frequently", "occurring", "entities", "derived", "from", "T", "or", "NK", "cells", "will", "be", "presented", ".", "Nasal", "NK", "/", "T", "cell", "lymphoma", "is", "mainly", "found", "in", "the", "nose", "and", "paranasal", "sinuses", "and", "often", ",", "but", "not", "always", ",", "display", "an", "angiocentric", "growth", "pattern", "leading", "to", "coagulation", "necrosis", ".", "The", "tumor", "cells", "consistently", "express", "CD56", ",", "CD2", "and", "the", "EBER", "molecules", "encoded", "by", "the", "Epstein", "-", "Barr", "virus", ".", "Clonal", "T", "cell", "receptor", "gene", "rearrangements", "are", "often", "absent", "indicating", ",", "in", "the", "majority", "of", "cases", ",", "a", "derivation", "of", "these", "tumors", "from", "NK", "cells", ".", "Enteropathy", "-", "type", "intestinal", "T", "-", "cell", "lymphomas", "often", "arise", "in", "patients", "with", "celiac", "disease", "and", "have", "a", "dismal", "prognosis", ".", "The", "tumour", "cells", "express", "T", "cell", "antigens", ",", "CD103", "and", "cytotoxic", "molecules", ",", "but", "are", "negative", "for", "CD4", ".", "Approximately", "20", "%", "of", "the", "cases", "display", "CD56", "mostly", "in", "combination", "with", "CD8", ".", "Recently", ",", "an", "early", "purely", "intraepithelial", "form", "of", "this", "tumour", "was", "identified", ".", "Histologically", "these", "cases", "resemble", "celiac", "disease", ",", "however", "the", "intraepithelial", "lymphocytes", "often", "exhibit", "an", "abnormal", "immunophenotype", "with", "absent", "CD8", "and", "T", "-", "cell", "-", "receptor", "protein", "expression", ",", "and", ",", "they", "are", "clonal", "by", "molecular", "analysis", ".", "Clinically", ",", "the", "patients", "suffer", "from", "refractory", "sprue", "or", "ulcerative", "jejunitis", ".", "The", "prognosis", "is", "bad", "with", "the", "patients", "often", "dying", "from", "malnutrition", "or", "an", "invasive", "tumour", "-", "forming", "T", "-", "cell", "lymphoma", ".", "Angioimmunoblastic", "T", "-", "cell", "lymphoma", "is", "defined", "by", "characteristic", "morphological", "findings", "(", "atypical", "lymphoid", "cells", "in", "part", "with", "pale", "cytoplasm", ",", "arborizing", "high", "endothelial", "venules", "and", "large", "FDC", "-", "meshworks", ")", "as", "well", "as", "clinical", "features", "(", "systemic", "symptoms", ",", "signs", "of", "a", "dysregulated", "immune", "response", ")", ".", "Peripheral", "T", "-", "cell", "lymphomas", ",", "that", "do", "not", "fit", "into", "a", "distinct", "entity", ",", "are", "classified", "in", "the", "REAL", "and", "the", "new", "WHO", "classifications", "as", "peripheral", "T", "-", "cell", "lymphomas", "unspecified", ".", "These", "display", "a", "broad", "morphological", "spectrum", "(", "including", "the", "T", "-", "cell", "lymphomas", "of", "different", "cell", "sizes", ",", "Lennert", "'s", "lymphoma", "and", "T", "-", "zone", "lymphoma", "of", "the", "Kiel", "-", "classification", ")", "and", "in", "general", "are", "clinically", "aggressive", "." ]
[ "umlsterm" ]
Malignant lymphomas is an umlsterm, NK cells is an umlsterm, tumours is an umlsterm, Europe is an umlsterm, malignant lymphomas is an umlsterm, review is an umlsterm, NK cells is an umlsterm, cell is an umlsterm, lymphoma is an umlsterm, nose is an umlsterm, paranasal sinuses is an umlsterm, growth is an umlsterm, coagulation is an umlsterm, necrosis is an umlsterm, tumor is an umlsterm, cells is an umlsterm, CD2 is an umlsterm, Epstein - Barr virus is an umlsterm, T cell receptor is an umlsterm, gene rearrangements is an umlsterm, tumors is an umlsterm, NK cells is an umlsterm, Enteropathy - type is an umlsterm, T - cell lymphomas is an umlsterm, patients is an umlsterm, celiac disease is an umlsterm, prognosis is an umlsterm, tumour is an umlsterm, cells is an umlsterm, T cell is an umlsterm, antigens is an umlsterm, CD103 is an umlsterm, CD56 is an umlsterm, tumour is an umlsterm, celiac disease is an umlsterm, lymphocytes is an umlsterm, exhibit is an umlsterm, CD8 is an umlsterm, protein is an umlsterm, analysis is an umlsterm, patients is an umlsterm, sprue is an umlsterm, prognosis is an umlsterm, patients is an umlsterm, malnutrition is an umlsterm, T - cell lymphoma is an umlsterm, T - cell lymphoma is an umlsterm, morphological is an umlsterm, findings is an umlsterm, lymphoid cells is an umlsterm, pale is an umlsterm, cytoplasm is an umlsterm, venules is an umlsterm, symptoms is an umlsterm, signs is an umlsterm, Peripheral T - cell lymphomas is an umlsterm, classifications is an umlsterm, peripheral T - cell lymphomas is an umlsterm, morphological is an umlsterm, T - cell lymphomas is an umlsterm, cell sizes is an umlsterm, lymphoma is an umlsterm, lymphoma is an umlsterm
DerPathologe.00210137.eng.abstr_task1
Sentence: Malignant lymphomas , originating from peripheral T or NK cells , are rare tumours in Europe and account for less than 10% of all malignant lymphomas . In this review , the salient features of the more frequently occurring entities derived from T or NK cells will be presented . Nasal NK/T cell lymphoma is mainly found in the nose and paranasal sinuses and often , but not always , display an angiocentric growth pattern leading to coagulation necrosis . The tumor cells consistently express CD56, CD2 and the EBER molecules encoded by the Epstein-Barr virus . Clonal T cell receptor gene rearrangements are often absent indicating , in the majority of cases , a derivation of these tumors from NK cells . Enteropathy-type intestinal T-cell lymphomas often arise in patients with celiac disease and have a dismal prognosis . The tumour cells express T cell antigens , CD103 and cytotoxic molecules , but are negative for CD4. Approximately 20% of the cases display CD56 mostly in combination with CD8. Recently , an early purely intraepithelial form of this tumour was identified . Histologically these cases resemble celiac disease , however the intraepithelial lymphocytes often exhibit an abnormal immunophenotype with absent CD8 and T-cell-receptor protein expression , and , they are clonal by molecular analysis . Clinically , the patients suffer from refractory sprue or ulcerative jejunitis . The prognosis is bad with the patients often dying from malnutrition or an invasive tumour-forming T-cell lymphoma . Angioimmunoblastic T-cell lymphoma is defined by characteristic morphological findings ( atypical lymphoid cells in part with pale cytoplasm , arborizing high endothelial venules and large FDC-meshworks ) as well as clinical features ( systemic symptoms , signs of a dysregulated immune response ) . Peripheral T-cell lymphomas , that do not fit into a distinct entity , are classified in the REAL and the new WHO classifications as peripheral T-cell lymphomas unspecified . These display a broad morphological spectrum ( including the T-cell lymphomas of different cell sizes , Lennert's lymphoma and T-zone lymphoma of the Kiel-classification ) and in general are clinically aggressive . Instructions: please typing these entity words according to sentence: Malignant lymphomas, NK cells, tumours, Europe, malignant lymphomas, review, NK cells, cell, lymphoma, nose, paranasal sinuses, growth, coagulation, necrosis, tumor, cells, CD2, Epstein - Barr virus, T cell receptor, gene rearrangements, tumors, NK cells, Enteropathy - type, T - cell lymphomas, patients, celiac disease, prognosis, tumour, cells, T cell, antigens, CD103, CD56, tumour, celiac disease, lymphocytes, exhibit, CD8, protein, analysis, patients, sprue, prognosis, patients, malnutrition, T - cell lymphoma, T - cell lymphoma, morphological, findings, lymphoid cells, pale, cytoplasm, venules, symptoms, signs, Peripheral T - cell lymphomas, classifications, peripheral T - cell lymphomas, morphological, T - cell lymphomas, cell sizes, lymphoma, lymphoma Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Malignant lymphomas , originating from peripheral T or NK cells , are rare tumours in Europe and account for less than 10% of all malignant lymphomas . In this review , the salient features of the more frequently occurring entities derived from T or NK cells will be presented . Nasal NK/T cell lymphoma is mainly found in the nose and paranasal sinuses and often , but not always , display an angiocentric growth pattern leading to coagulation necrosis . The tumor cells consistently express CD56, CD2 and the EBER molecules encoded by the Epstein-Barr virus . Clonal T cell receptor gene rearrangements are often absent indicating , in the majority of cases , a derivation of these tumors from NK cells . Enteropathy-type intestinal T-cell lymphomas often arise in patients with celiac disease and have a dismal prognosis . The tumour cells express T cell antigens , CD103 and cytotoxic molecules , but are negative for CD4. Approximately 20% of the cases display CD56 mostly in combination with CD8. Recently , an early purely intraepithelial form of this tumour was identified . Histologically these cases resemble celiac disease , however the intraepithelial lymphocytes often exhibit an abnormal immunophenotype with absent CD8 and T-cell-receptor protein expression , and , they are clonal by molecular analysis . Clinically , the patients suffer from refractory sprue or ulcerative jejunitis . The prognosis is bad with the patients often dying from malnutrition or an invasive tumour-forming T-cell lymphoma . Angioimmunoblastic T-cell lymphoma is defined by characteristic morphological findings ( atypical lymphoid cells in part with pale cytoplasm , arborizing high endothelial venules and large FDC-meshworks ) as well as clinical features ( systemic symptoms , signs of a dysregulated immune response ) . Peripheral T-cell lymphomas , that do not fit into a distinct entity , are classified in the REAL and the new WHO classifications as peripheral T-cell lymphomas unspecified . These display a broad morphological spectrum ( including the T-cell lymphomas of different cell sizes , Lennert's lymphoma and T-zone lymphoma of the Kiel-classification ) and in general are clinically aggressive .
[ "Malignant", "lymphomas", ",", "originating", "from", "peripheral", "T", "or", "NK", "cells", ",", "are", "rare", "tumours", "in", "Europe", "and", "account", "for", "less", "than", "10", "%", "of", "all", "malignant", "lymphomas", ".", "In", "this", "review", ",", "the", "salient", "features", "of", "the", "more", "frequently", "occurring", "entities", "derived", "from", "T", "or", "NK", "cells", "will", "be", "presented", ".", "Nasal", "NK", "/", "T", "cell", "lymphoma", "is", "mainly", "found", "in", "the", "nose", "and", "paranasal", "sinuses", "and", "often", ",", "but", "not", "always", ",", "display", "an", "angiocentric", "growth", "pattern", "leading", "to", "coagulation", "necrosis", ".", "The", "tumor", "cells", "consistently", "express", "CD56", ",", "CD2", "and", "the", "EBER", "molecules", "encoded", "by", "the", "Epstein", "-", "Barr", "virus", ".", "Clonal", "T", "cell", "receptor", "gene", "rearrangements", "are", "often", "absent", "indicating", ",", "in", "the", "majority", "of", "cases", ",", "a", "derivation", "of", "these", "tumors", "from", "NK", "cells", ".", "Enteropathy", "-", "type", "intestinal", "T", "-", "cell", "lymphomas", "often", "arise", "in", "patients", "with", "celiac", "disease", "and", "have", "a", "dismal", "prognosis", ".", "The", "tumour", "cells", "express", "T", "cell", "antigens", ",", "CD103", "and", "cytotoxic", "molecules", ",", "but", "are", "negative", "for", "CD4", ".", "Approximately", "20", "%", "of", "the", "cases", "display", "CD56", "mostly", "in", "combination", "with", "CD8", ".", "Recently", ",", "an", "early", "purely", "intraepithelial", "form", "of", "this", "tumour", "was", "identified", ".", "Histologically", "these", "cases", "resemble", "celiac", "disease", ",", "however", "the", "intraepithelial", "lymphocytes", "often", "exhibit", "an", "abnormal", "immunophenotype", "with", "absent", "CD8", "and", "T", "-", "cell", "-", "receptor", "protein", "expression", ",", "and", ",", "they", "are", "clonal", "by", "molecular", "analysis", ".", "Clinically", ",", "the", "patients", "suffer", "from", "refractory", "sprue", "or", "ulcerative", "jejunitis", ".", "The", "prognosis", "is", "bad", "with", "the", "patients", "often", "dying", "from", "malnutrition", "or", "an", "invasive", "tumour", "-", "forming", "T", "-", "cell", "lymphoma", ".", "Angioimmunoblastic", "T", "-", "cell", "lymphoma", "is", "defined", "by", "characteristic", "morphological", "findings", "(", "atypical", "lymphoid", "cells", "in", "part", "with", "pale", "cytoplasm", ",", "arborizing", "high", "endothelial", "venules", "and", "large", "FDC", "-", "meshworks", ")", "as", "well", "as", "clinical", "features", "(", "systemic", "symptoms", ",", "signs", "of", "a", "dysregulated", "immune", "response", ")", ".", "Peripheral", "T", "-", "cell", "lymphomas", ",", "that", "do", "not", "fit", "into", "a", "distinct", "entity", ",", "are", "classified", "in", "the", "REAL", "and", "the", "new", "WHO", "classifications", "as", "peripheral", "T", "-", "cell", "lymphomas", "unspecified", ".", "These", "display", "a", "broad", "morphological", "spectrum", "(", "including", "the", "T", "-", "cell", "lymphomas", "of", "different", "cell", "sizes", ",", "Lennert", "'s", "lymphoma", "and", "T", "-", "zone", "lymphoma", "of", "the", "Kiel", "-", "classification", ")", "and", "in", "general", "are", "clinically", "aggressive", "." ]
[ "umlsterm" ]
Malignant lymphomas, NK cells, tumours, Europe, malignant lymphomas, review, NK cells, cell, lymphoma, nose, paranasal sinuses, growth, coagulation, necrosis, tumor, cells, CD2, Epstein - Barr virus, T cell receptor, gene rearrangements, tumors, NK cells, Enteropathy - type, T - cell lymphomas, patients, celiac disease, prognosis, tumour, cells, T cell, antigens, CD103, CD56, tumour, celiac disease, lymphocytes, exhibit, CD8, protein, analysis, patients, sprue, prognosis, patients, malnutrition, T - cell lymphoma, T - cell lymphoma, morphological, findings, lymphoid cells, pale, cytoplasm, venules, symptoms, signs, Peripheral T - cell lymphomas, classifications, peripheral T - cell lymphomas, morphological, T - cell lymphomas, cell sizes, lymphoma, lymphoma
DerPathologe.00210137.eng.abstr_task2
Sentence: Malignant lymphomas , originating from peripheral T or NK cells , are rare tumours in Europe and account for less than 10% of all malignant lymphomas . In this review , the salient features of the more frequently occurring entities derived from T or NK cells will be presented . Nasal NK/T cell lymphoma is mainly found in the nose and paranasal sinuses and often , but not always , display an angiocentric growth pattern leading to coagulation necrosis . The tumor cells consistently express CD56, CD2 and the EBER molecules encoded by the Epstein-Barr virus . Clonal T cell receptor gene rearrangements are often absent indicating , in the majority of cases , a derivation of these tumors from NK cells . Enteropathy-type intestinal T-cell lymphomas often arise in patients with celiac disease and have a dismal prognosis . The tumour cells express T cell antigens , CD103 and cytotoxic molecules , but are negative for CD4. Approximately 20% of the cases display CD56 mostly in combination with CD8. Recently , an early purely intraepithelial form of this tumour was identified . Histologically these cases resemble celiac disease , however the intraepithelial lymphocytes often exhibit an abnormal immunophenotype with absent CD8 and T-cell-receptor protein expression , and , they are clonal by molecular analysis . Clinically , the patients suffer from refractory sprue or ulcerative jejunitis . The prognosis is bad with the patients often dying from malnutrition or an invasive tumour-forming T-cell lymphoma . Angioimmunoblastic T-cell lymphoma is defined by characteristic morphological findings ( atypical lymphoid cells in part with pale cytoplasm , arborizing high endothelial venules and large FDC-meshworks ) as well as clinical features ( systemic symptoms , signs of a dysregulated immune response ) . Peripheral T-cell lymphomas , that do not fit into a distinct entity , are classified in the REAL and the new WHO classifications as peripheral T-cell lymphomas unspecified . These display a broad morphological spectrum ( including the T-cell lymphomas of different cell sizes , Lennert's lymphoma and T-zone lymphoma of the Kiel-classification ) and in general are clinically aggressive . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Malignant lymphomas , originating from peripheral T or NK cells , are rare tumours in Europe and account for less than 10% of all malignant lymphomas . In this review , the salient features of the more frequently occurring entities derived from T or NK cells will be presented . Nasal NK/T cell lymphoma is mainly found in the nose and paranasal sinuses and often , but not always , display an angiocentric growth pattern leading to coagulation necrosis . The tumor cells consistently express CD56, CD2 and the EBER molecules encoded by the Epstein-Barr virus . Clonal T cell receptor gene rearrangements are often absent indicating , in the majority of cases , a derivation of these tumors from NK cells . Enteropathy-type intestinal T-cell lymphomas often arise in patients with celiac disease and have a dismal prognosis . The tumour cells express T cell antigens , CD103 and cytotoxic molecules , but are negative for CD4. Approximately 20% of the cases display CD56 mostly in combination with CD8. Recently , an early purely intraepithelial form of this tumour was identified . Histologically these cases resemble celiac disease , however the intraepithelial lymphocytes often exhibit an abnormal immunophenotype with absent CD8 and T-cell-receptor protein expression , and , they are clonal by molecular analysis . Clinically , the patients suffer from refractory sprue or ulcerative jejunitis . The prognosis is bad with the patients often dying from malnutrition or an invasive tumour-forming T-cell lymphoma . Angioimmunoblastic T-cell lymphoma is defined by characteristic morphological findings ( atypical lymphoid cells in part with pale cytoplasm , arborizing high endothelial venules and large FDC-meshworks ) as well as clinical features ( systemic symptoms , signs of a dysregulated immune response ) . Peripheral T-cell lymphomas , that do not fit into a distinct entity , are classified in the REAL and the new WHO classifications as peripheral T-cell lymphomas unspecified . These display a broad morphological spectrum ( including the T-cell lymphomas of different cell sizes , Lennert's lymphoma and T-zone lymphoma of the Kiel-classification ) and in general are clinically aggressive .
[ "Malignant", "lymphomas", ",", "originating", "from", "peripheral", "T", "or", "NK", "cells", ",", "are", "rare", "tumours", "in", "Europe", "and", "account", "for", "less", "than", "10", "%", "of", "all", "malignant", "lymphomas", ".", "In", "this", "review", ",", "the", "salient", "features", "of", "the", "more", "frequently", "occurring", "entities", "derived", "from", "T", "or", "NK", "cells", "will", "be", "presented", ".", "Nasal", "NK", "/", "T", "cell", "lymphoma", "is", "mainly", "found", "in", "the", "nose", "and", "paranasal", "sinuses", "and", "often", ",", "but", "not", "always", ",", "display", "an", "angiocentric", "growth", "pattern", "leading", "to", "coagulation", "necrosis", ".", "The", "tumor", "cells", "consistently", "express", "CD56", ",", "CD2", "and", "the", "EBER", "molecules", "encoded", "by", "the", "Epstein", "-", "Barr", "virus", ".", "Clonal", "T", "cell", "receptor", "gene", "rearrangements", "are", "often", "absent", "indicating", ",", "in", "the", "majority", "of", "cases", ",", "a", "derivation", "of", "these", "tumors", "from", "NK", "cells", ".", "Enteropathy", "-", "type", "intestinal", "T", "-", "cell", "lymphomas", "often", "arise", "in", "patients", "with", "celiac", "disease", "and", "have", "a", "dismal", "prognosis", ".", "The", "tumour", "cells", "express", "T", "cell", "antigens", ",", "CD103", "and", "cytotoxic", "molecules", ",", "but", "are", "negative", "for", "CD4", ".", "Approximately", "20", "%", "of", "the", "cases", "display", "CD56", "mostly", "in", "combination", "with", "CD8", ".", "Recently", ",", "an", "early", "purely", "intraepithelial", "form", "of", "this", "tumour", "was", "identified", ".", "Histologically", "these", "cases", "resemble", "celiac", "disease", ",", "however", "the", "intraepithelial", "lymphocytes", "often", "exhibit", "an", "abnormal", "immunophenotype", "with", "absent", "CD8", "and", "T", "-", "cell", "-", "receptor", "protein", "expression", ",", "and", ",", "they", "are", "clonal", "by", "molecular", "analysis", ".", "Clinically", ",", "the", "patients", "suffer", "from", "refractory", "sprue", "or", "ulcerative", "jejunitis", ".", "The", "prognosis", "is", "bad", "with", "the", "patients", "often", "dying", "from", "malnutrition", "or", "an", "invasive", "tumour", "-", "forming", "T", "-", "cell", "lymphoma", ".", "Angioimmunoblastic", "T", "-", "cell", "lymphoma", "is", "defined", "by", "characteristic", "morphological", "findings", "(", "atypical", "lymphoid", "cells", "in", "part", "with", "pale", "cytoplasm", ",", "arborizing", "high", "endothelial", "venules", "and", "large", "FDC", "-", "meshworks", ")", "as", "well", "as", "clinical", "features", "(", "systemic", "symptoms", ",", "signs", "of", "a", "dysregulated", "immune", "response", ")", ".", "Peripheral", "T", "-", "cell", "lymphomas", ",", "that", "do", "not", "fit", "into", "a", "distinct", "entity", ",", "are", "classified", "in", "the", "REAL", "and", "the", "new", "WHO", "classifications", "as", "peripheral", "T", "-", "cell", "lymphomas", "unspecified", ".", "These", "display", "a", "broad", "morphological", "spectrum", "(", "including", "the", "T", "-", "cell", "lymphomas", "of", "different", "cell", "sizes", ",", "Lennert", "'s", "lymphoma", "and", "T", "-", "zone", "lymphoma", "of", "the", "Kiel", "-", "classification", ")", "and", "in", "general", "are", "clinically", "aggressive", "." ]
[ "umlsterm" ]
cyclophosphamide is an umlsterm, drug is an umlsterm, treatment is an umlsterm, rheumatoid arthritis is an umlsterm, drug is an umlsterm, cancer is an umlsterm, development is an umlsterm, open is an umlsterm, toxicity is an umlsterm, therapy is an umlsterm
ZfuerRheumatologie.80570101.eng.abstr_task0
Sentence: Although cyclophosphamide ( CYC ) is an effective drug in the treatment of refractory rheumatoid arthritis ( RA ) , the application of this drug in RA has largely been abandoned , due to potentially life-threatening adverse events such as myelosuppression and cancer development . However , the question remains open , whether it is possible to balance the toxicity and the efficacy of CYC with low-dose therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Although cyclophosphamide ( CYC ) is an effective drug in the treatment of refractory rheumatoid arthritis ( RA ) , the application of this drug in RA has largely been abandoned , due to potentially life-threatening adverse events such as myelosuppression and cancer development . However , the question remains open , whether it is possible to balance the toxicity and the efficacy of CYC with low-dose therapy .
[ "Although", "cyclophosphamide", "(", "CYC", ")", "is", "an", "effective", "drug", "in", "the", "treatment", "of", "refractory", "rheumatoid", "arthritis", "(", "RA", ")", ",", "the", "application", "of", "this", "drug", "in", "RA", "has", "largely", "been", "abandoned", ",", "due", "to", "potentially", "life", "-", "threatening", "adverse", "events", "such", "as", "myelosuppression", "and", "cancer", "development", ".", "However", ",", "the", "question", "remains", "open", ",", "whether", "it", "is", "possible", "to", "balance", "the", "toxicity", "and", "the", "efficacy", "of", "CYC", "with", "low", "-", "dose", "therapy", "." ]
[ "umlsterm" ]
cyclophosphamide is an umlsterm, drug is an umlsterm, treatment is an umlsterm, rheumatoid arthritis is an umlsterm, drug is an umlsterm, cancer is an umlsterm, development is an umlsterm, open is an umlsterm, toxicity is an umlsterm, therapy is an umlsterm
ZfuerRheumatologie.80570101.eng.abstr_task1
Sentence: Although cyclophosphamide ( CYC ) is an effective drug in the treatment of refractory rheumatoid arthritis ( RA ) , the application of this drug in RA has largely been abandoned , due to potentially life-threatening adverse events such as myelosuppression and cancer development . However , the question remains open , whether it is possible to balance the toxicity and the efficacy of CYC with low-dose therapy . Instructions: please typing these entity words according to sentence: cyclophosphamide, drug, treatment, rheumatoid arthritis, drug, cancer, development, open, toxicity, therapy Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Although cyclophosphamide ( CYC ) is an effective drug in the treatment of refractory rheumatoid arthritis ( RA ) , the application of this drug in RA has largely been abandoned , due to potentially life-threatening adverse events such as myelosuppression and cancer development . However , the question remains open , whether it is possible to balance the toxicity and the efficacy of CYC with low-dose therapy .
[ "Although", "cyclophosphamide", "(", "CYC", ")", "is", "an", "effective", "drug", "in", "the", "treatment", "of", "refractory", "rheumatoid", "arthritis", "(", "RA", ")", ",", "the", "application", "of", "this", "drug", "in", "RA", "has", "largely", "been", "abandoned", ",", "due", "to", "potentially", "life", "-", "threatening", "adverse", "events", "such", "as", "myelosuppression", "and", "cancer", "development", ".", "However", ",", "the", "question", "remains", "open", ",", "whether", "it", "is", "possible", "to", "balance", "the", "toxicity", "and", "the", "efficacy", "of", "CYC", "with", "low", "-", "dose", "therapy", "." ]
[ "umlsterm" ]
cyclophosphamide, drug, treatment, rheumatoid arthritis, drug, cancer, development, open, toxicity, therapy
ZfuerRheumatologie.80570101.eng.abstr_task2
Sentence: Although cyclophosphamide ( CYC ) is an effective drug in the treatment of refractory rheumatoid arthritis ( RA ) , the application of this drug in RA has largely been abandoned , due to potentially life-threatening adverse events such as myelosuppression and cancer development . However , the question remains open , whether it is possible to balance the toxicity and the efficacy of CYC with low-dose therapy . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Although cyclophosphamide ( CYC ) is an effective drug in the treatment of refractory rheumatoid arthritis ( RA ) , the application of this drug in RA has largely been abandoned , due to potentially life-threatening adverse events such as myelosuppression and cancer development . However , the question remains open , whether it is possible to balance the toxicity and the efficacy of CYC with low-dose therapy .
[ "Although", "cyclophosphamide", "(", "CYC", ")", "is", "an", "effective", "drug", "in", "the", "treatment", "of", "refractory", "rheumatoid", "arthritis", "(", "RA", ")", ",", "the", "application", "of", "this", "drug", "in", "RA", "has", "largely", "been", "abandoned", ",", "due", "to", "potentially", "life", "-", "threatening", "adverse", "events", "such", "as", "myelosuppression", "and", "cancer", "development", ".", "However", ",", "the", "question", "remains", "open", ",", "whether", "it", "is", "possible", "to", "balance", "the", "toxicity", "and", "the", "efficacy", "of", "CYC", "with", "low", "-", "dose", "therapy", "." ]
[ "umlsterm" ]
publications is an umlsterm, risk of is an umlsterm, amaurosis fugax is an umlsterm, sign is an umlsterm, cerebrovascular insufficiency is an umlsterm, risk of is an umlsterm, cerebral infarction is an umlsterm, patients is an umlsterm, symptom is an umlsterm, loss of vision is an umlsterm, patient is an umlsterm, vision is an umlsterm, vision is an umlsterm, causes is an umlsterm, embolism is an umlsterm, hemodynamics is an umlsterm, embolism is an umlsterm, carotid artery is an umlsterm, patients is an umlsterm, carotid stenosis is an umlsterm, symptom is an umlsterm, risk of is an umlsterm, stroke is an umlsterm, period is an umlsterm, stroke is an umlsterm, risk is an umlsterm, patients is an umlsterm, transient ischemic attack is an umlsterm, symptom is an umlsterm, risk of is an umlsterm, stroke is an umlsterm, risk of is an umlsterm, mortality is an umlsterm, older is an umlsterm, patients is an umlsterm, times is an umlsterm, controls is an umlsterm, myocardial infarction is an umlsterm, cause of death is an umlsterm, occurrence is an umlsterm, risk of is an umlsterm, cerebral stroke is an umlsterm, marker is an umlsterm, vascular disease is an umlsterm
Gefaesschirurgie.70020196.eng.abstr_task0
Sentence: This is an overview of publications concerning the risk of amaurosis fugax ( AF ) as a sign of cerebrovascular insufficiency and the risk of cerebral infarction in patients presenting with this symptom . AF is characterized by a sudden , painless , monocular loss of vision that typically lasts between 1 and 15 min . The patient frequently describes his vision as " dark " or " dim " and , generally , vision returns to normal immediatly after such an attack . The most common causes of AF are embolism , hemodynamics , or vasospasm . In 66% of cases the source of embolism was not detectable , in 27% it was likely to be caused by a carotid artery lesion , whereas a cardioembolic event was likely to be the source in only 2% . Most recent studies show that in patients with severe carotid stenosis ( 70% - 99% ) and AF as the first presenting symptom , there is a 16% risk of stroke within a period of 2 years . This stroke risk is lower than in patients with transient ischemic attack as the presenting symptom , who are at a risk of 43% of stroke within 2 years . The risk of early mortality in older patients with AF is three to five times higher than in age-matched controls , with myocardial infarction as the major cause of death . In conclusion , the occurrence of AF carries a considerable risk of cerebral stroke and AF is a marker of generalized vascular disease . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
This is an overview of publications concerning the risk of amaurosis fugax ( AF ) as a sign of cerebrovascular insufficiency and the risk of cerebral infarction in patients presenting with this symptom . AF is characterized by a sudden , painless , monocular loss of vision that typically lasts between 1 and 15 min . The patient frequently describes his vision as " dark " or " dim " and , generally , vision returns to normal immediatly after such an attack . The most common causes of AF are embolism , hemodynamics , or vasospasm . In 66% of cases the source of embolism was not detectable , in 27% it was likely to be caused by a carotid artery lesion , whereas a cardioembolic event was likely to be the source in only 2% . Most recent studies show that in patients with severe carotid stenosis ( 70% - 99% ) and AF as the first presenting symptom , there is a 16% risk of stroke within a period of 2 years . This stroke risk is lower than in patients with transient ischemic attack as the presenting symptom , who are at a risk of 43% of stroke within 2 years . The risk of early mortality in older patients with AF is three to five times higher than in age-matched controls , with myocardial infarction as the major cause of death . In conclusion , the occurrence of AF carries a considerable risk of cerebral stroke and AF is a marker of generalized vascular disease .
[ "This", "is", "an", "overview", "of", "publications", "concerning", "the", "risk", "of", "amaurosis", "fugax", "(", "AF", ")", "as", "a", "sign", "of", "cerebrovascular", "insufficiency", "and", "the", "risk", "of", "cerebral", "infarction", "in", "patients", "presenting", "with", "this", "symptom", ".", "AF", "is", "characterized", "by", "a", "sudden", ",", "painless", ",", "monocular", "loss", "of", "vision", "that", "typically", "lasts", "between", "1", "and", "15", "min", ".", "The", "patient", "frequently", "describes", "his", "vision", "as", "\"", "dark", "\"", "or", "\"", "dim", "\"", "and", ",", "generally", ",", "vision", "returns", "to", "normal", "immediatly", "after", "such", "an", "attack", ".", "The", "most", "common", "causes", "of", "AF", "are", "embolism", ",", "hemodynamics", ",", "or", "vasospasm", ".", "In", "66", "%", "of", "cases", "the", "source", "of", "embolism", "was", "not", "detectable", ",", "in", "27", "%", "it", "was", "likely", "to", "be", "caused", "by", "a", "carotid", "artery", "lesion", ",", "whereas", "a", "cardioembolic", "event", "was", "likely", "to", "be", "the", "source", "in", "only", "2", "%", ".", "Most", "recent", "studies", "show", "that", "in", "patients", "with", "severe", "carotid", "stenosis", "(", "70", "%", "-", "99", "%", ")", "and", "AF", "as", "the", "first", "presenting", "symptom", ",", "there", "is", "a", "16", "%", "risk", "of", "stroke", "within", "a", "period", "of", "2", "years", ".", "This", "stroke", "risk", "is", "lower", "than", "in", "patients", "with", "transient", "ischemic", "attack", "as", "the", "presenting", "symptom", ",", "who", "are", "at", "a", "risk", "of", "43", "%", "of", "stroke", "within", "2", "years", ".", "The", "risk", "of", "early", "mortality", "in", "older", "patients", "with", "AF", "is", "three", "to", "five", "times", "higher", "than", "in", "age", "-", "matched", "controls", ",", "with", "myocardial", "infarction", "as", "the", "major", "cause", "of", "death", ".", "In", "conclusion", ",", "the", "occurrence", "of", "AF", "carries", "a", "considerable", "risk", "of", "cerebral", "stroke", "and", "AF", "is", "a", "marker", "of", "generalized", "vascular", "disease", "." ]
[ "umlsterm" ]
publications is an umlsterm, risk of is an umlsterm, amaurosis fugax is an umlsterm, sign is an umlsterm, cerebrovascular insufficiency is an umlsterm, risk of is an umlsterm, cerebral infarction is an umlsterm, patients is an umlsterm, symptom is an umlsterm, loss of vision is an umlsterm, patient is an umlsterm, vision is an umlsterm, vision is an umlsterm, causes is an umlsterm, embolism is an umlsterm, hemodynamics is an umlsterm, embolism is an umlsterm, carotid artery is an umlsterm, patients is an umlsterm, carotid stenosis is an umlsterm, symptom is an umlsterm, risk of is an umlsterm, stroke is an umlsterm, period is an umlsterm, stroke is an umlsterm, risk is an umlsterm, patients is an umlsterm, transient ischemic attack is an umlsterm, symptom is an umlsterm, risk of is an umlsterm, stroke is an umlsterm, risk of is an umlsterm, mortality is an umlsterm, older is an umlsterm, patients is an umlsterm, times is an umlsterm, controls is an umlsterm, myocardial infarction is an umlsterm, cause of death is an umlsterm, occurrence is an umlsterm, risk of is an umlsterm, cerebral stroke is an umlsterm, marker is an umlsterm, vascular disease is an umlsterm
Gefaesschirurgie.70020196.eng.abstr_task1
Sentence: This is an overview of publications concerning the risk of amaurosis fugax ( AF ) as a sign of cerebrovascular insufficiency and the risk of cerebral infarction in patients presenting with this symptom . AF is characterized by a sudden , painless , monocular loss of vision that typically lasts between 1 and 15 min . The patient frequently describes his vision as " dark " or " dim " and , generally , vision returns to normal immediatly after such an attack . The most common causes of AF are embolism , hemodynamics , or vasospasm . In 66% of cases the source of embolism was not detectable , in 27% it was likely to be caused by a carotid artery lesion , whereas a cardioembolic event was likely to be the source in only 2% . Most recent studies show that in patients with severe carotid stenosis ( 70% - 99% ) and AF as the first presenting symptom , there is a 16% risk of stroke within a period of 2 years . This stroke risk is lower than in patients with transient ischemic attack as the presenting symptom , who are at a risk of 43% of stroke within 2 years . The risk of early mortality in older patients with AF is three to five times higher than in age-matched controls , with myocardial infarction as the major cause of death . In conclusion , the occurrence of AF carries a considerable risk of cerebral stroke and AF is a marker of generalized vascular disease . Instructions: please typing these entity words according to sentence: publications, risk of, amaurosis fugax, sign, cerebrovascular insufficiency, risk of, cerebral infarction, patients, symptom, loss of vision, patient, vision, vision, causes, embolism, hemodynamics, embolism, carotid artery, patients, carotid stenosis, symptom, risk of, stroke, period, stroke, risk, patients, transient ischemic attack, symptom, risk of, stroke, risk of, mortality, older, patients, times, controls, myocardial infarction, cause of death, occurrence, risk of, cerebral stroke, marker, vascular disease Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
This is an overview of publications concerning the risk of amaurosis fugax ( AF ) as a sign of cerebrovascular insufficiency and the risk of cerebral infarction in patients presenting with this symptom . AF is characterized by a sudden , painless , monocular loss of vision that typically lasts between 1 and 15 min . The patient frequently describes his vision as " dark " or " dim " and , generally , vision returns to normal immediatly after such an attack . The most common causes of AF are embolism , hemodynamics , or vasospasm . In 66% of cases the source of embolism was not detectable , in 27% it was likely to be caused by a carotid artery lesion , whereas a cardioembolic event was likely to be the source in only 2% . Most recent studies show that in patients with severe carotid stenosis ( 70% - 99% ) and AF as the first presenting symptom , there is a 16% risk of stroke within a period of 2 years . This stroke risk is lower than in patients with transient ischemic attack as the presenting symptom , who are at a risk of 43% of stroke within 2 years . The risk of early mortality in older patients with AF is three to five times higher than in age-matched controls , with myocardial infarction as the major cause of death . In conclusion , the occurrence of AF carries a considerable risk of cerebral stroke and AF is a marker of generalized vascular disease .
[ "This", "is", "an", "overview", "of", "publications", "concerning", "the", "risk", "of", "amaurosis", "fugax", "(", "AF", ")", "as", "a", "sign", "of", "cerebrovascular", "insufficiency", "and", "the", "risk", "of", "cerebral", "infarction", "in", "patients", "presenting", "with", "this", "symptom", ".", "AF", "is", "characterized", "by", "a", "sudden", ",", "painless", ",", "monocular", "loss", "of", "vision", "that", "typically", "lasts", "between", "1", "and", "15", "min", ".", "The", "patient", "frequently", "describes", "his", "vision", "as", "\"", "dark", "\"", "or", "\"", "dim", "\"", "and", ",", "generally", ",", "vision", "returns", "to", "normal", "immediatly", "after", "such", "an", "attack", ".", "The", "most", "common", "causes", "of", "AF", "are", "embolism", ",", "hemodynamics", ",", "or", "vasospasm", ".", "In", "66", "%", "of", "cases", "the", "source", "of", "embolism", "was", "not", "detectable", ",", "in", "27", "%", "it", "was", "likely", "to", "be", "caused", "by", "a", "carotid", "artery", "lesion", ",", "whereas", "a", "cardioembolic", "event", "was", "likely", "to", "be", "the", "source", "in", "only", "2", "%", ".", "Most", "recent", "studies", "show", "that", "in", "patients", "with", "severe", "carotid", "stenosis", "(", "70", "%", "-", "99", "%", ")", "and", "AF", "as", "the", "first", "presenting", "symptom", ",", "there", "is", "a", "16", "%", "risk", "of", "stroke", "within", "a", "period", "of", "2", "years", ".", "This", "stroke", "risk", "is", "lower", "than", "in", "patients", "with", "transient", "ischemic", "attack", "as", "the", "presenting", "symptom", ",", "who", "are", "at", "a", "risk", "of", "43", "%", "of", "stroke", "within", "2", "years", ".", "The", "risk", "of", "early", "mortality", "in", "older", "patients", "with", "AF", "is", "three", "to", "five", "times", "higher", "than", "in", "age", "-", "matched", "controls", ",", "with", "myocardial", "infarction", "as", "the", "major", "cause", "of", "death", ".", "In", "conclusion", ",", "the", "occurrence", "of", "AF", "carries", "a", "considerable", "risk", "of", "cerebral", "stroke", "and", "AF", "is", "a", "marker", "of", "generalized", "vascular", "disease", "." ]
[ "umlsterm" ]
publications, risk of, amaurosis fugax, sign, cerebrovascular insufficiency, risk of, cerebral infarction, patients, symptom, loss of vision, patient, vision, vision, causes, embolism, hemodynamics, embolism, carotid artery, patients, carotid stenosis, symptom, risk of, stroke, period, stroke, risk, patients, transient ischemic attack, symptom, risk of, stroke, risk of, mortality, older, patients, times, controls, myocardial infarction, cause of death, occurrence, risk of, cerebral stroke, marker, vascular disease
Gefaesschirurgie.70020196.eng.abstr_task2
Sentence: This is an overview of publications concerning the risk of amaurosis fugax ( AF ) as a sign of cerebrovascular insufficiency and the risk of cerebral infarction in patients presenting with this symptom . AF is characterized by a sudden , painless , monocular loss of vision that typically lasts between 1 and 15 min . The patient frequently describes his vision as " dark " or " dim " and , generally , vision returns to normal immediatly after such an attack . The most common causes of AF are embolism , hemodynamics , or vasospasm . In 66% of cases the source of embolism was not detectable , in 27% it was likely to be caused by a carotid artery lesion , whereas a cardioembolic event was likely to be the source in only 2% . Most recent studies show that in patients with severe carotid stenosis ( 70% - 99% ) and AF as the first presenting symptom , there is a 16% risk of stroke within a period of 2 years . This stroke risk is lower than in patients with transient ischemic attack as the presenting symptom , who are at a risk of 43% of stroke within 2 years . The risk of early mortality in older patients with AF is three to five times higher than in age-matched controls , with myocardial infarction as the major cause of death . In conclusion , the occurrence of AF carries a considerable risk of cerebral stroke and AF is a marker of generalized vascular disease . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
This is an overview of publications concerning the risk of amaurosis fugax ( AF ) as a sign of cerebrovascular insufficiency and the risk of cerebral infarction in patients presenting with this symptom . AF is characterized by a sudden , painless , monocular loss of vision that typically lasts between 1 and 15 min . The patient frequently describes his vision as " dark " or " dim " and , generally , vision returns to normal immediatly after such an attack . The most common causes of AF are embolism , hemodynamics , or vasospasm . In 66% of cases the source of embolism was not detectable , in 27% it was likely to be caused by a carotid artery lesion , whereas a cardioembolic event was likely to be the source in only 2% . Most recent studies show that in patients with severe carotid stenosis ( 70% - 99% ) and AF as the first presenting symptom , there is a 16% risk of stroke within a period of 2 years . This stroke risk is lower than in patients with transient ischemic attack as the presenting symptom , who are at a risk of 43% of stroke within 2 years . The risk of early mortality in older patients with AF is three to five times higher than in age-matched controls , with myocardial infarction as the major cause of death . In conclusion , the occurrence of AF carries a considerable risk of cerebral stroke and AF is a marker of generalized vascular disease .
[ "This", "is", "an", "overview", "of", "publications", "concerning", "the", "risk", "of", "amaurosis", "fugax", "(", "AF", ")", "as", "a", "sign", "of", "cerebrovascular", "insufficiency", "and", "the", "risk", "of", "cerebral", "infarction", "in", "patients", "presenting", "with", "this", "symptom", ".", "AF", "is", "characterized", "by", "a", "sudden", ",", "painless", ",", "monocular", "loss", "of", "vision", "that", "typically", "lasts", "between", "1", "and", "15", "min", ".", "The", "patient", "frequently", "describes", "his", "vision", "as", "\"", "dark", "\"", "or", "\"", "dim", "\"", "and", ",", "generally", ",", "vision", "returns", "to", "normal", "immediatly", "after", "such", "an", "attack", ".", "The", "most", "common", "causes", "of", "AF", "are", "embolism", ",", "hemodynamics", ",", "or", "vasospasm", ".", "In", "66", "%", "of", "cases", "the", "source", "of", "embolism", "was", "not", "detectable", ",", "in", "27", "%", "it", "was", "likely", "to", "be", "caused", "by", "a", "carotid", "artery", "lesion", ",", "whereas", "a", "cardioembolic", "event", "was", "likely", "to", "be", "the", "source", "in", "only", "2", "%", ".", "Most", "recent", "studies", "show", "that", "in", "patients", "with", "severe", "carotid", "stenosis", "(", "70", "%", "-", "99", "%", ")", "and", "AF", "as", "the", "first", "presenting", "symptom", ",", "there", "is", "a", "16", "%", "risk", "of", "stroke", "within", "a", "period", "of", "2", "years", ".", "This", "stroke", "risk", "is", "lower", "than", "in", "patients", "with", "transient", "ischemic", "attack", "as", "the", "presenting", "symptom", ",", "who", "are", "at", "a", "risk", "of", "43", "%", "of", "stroke", "within", "2", "years", ".", "The", "risk", "of", "early", "mortality", "in", "older", "patients", "with", "AF", "is", "three", "to", "five", "times", "higher", "than", "in", "age", "-", "matched", "controls", ",", "with", "myocardial", "infarction", "as", "the", "major", "cause", "of", "death", ".", "In", "conclusion", ",", "the", "occurrence", "of", "AF", "carries", "a", "considerable", "risk", "of", "cerebral", "stroke", "and", "AF", "is", "a", "marker", "of", "generalized", "vascular", "disease", "." ]
[ "umlsterm" ]
Diego is a NOMBRE_SUJETO_ASISTENCIA, Perez Mendieta is a NOMBRE_SUJETO_ASISTENCIA, 9734586 is a ID_SUJETO_ASISTENCIA, Madrid is a TERRITORIO, 49238 is a TERRITORIO, 15/08/1988 is a FECHAS, España is a PAIS, 29 años is a EDAD_SUJETO_ASISTENCIA, 27/07/2018 is a FECHAS, Jorge Planelles Gómez is a NOMBRE_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 29 años is a EDAD_SUJETO_ASISTENCIA, Diego is a NOMBRE_SUJETO_ASISTENCIA, Jorge Planelles Gómez is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitario Doctor Peset is a HOSPITAL, Gaspar Aguilar 90 is a CALLE, 46017 is a TERRITORIO, Valencia is a TERRITORIO, España is a PAIS, jorge_planelles@yahoo.es is a CORREO_ELECTRONICO
24_task0
Sentence: Datos del paciente. Nombre: Diego. Apellidos: Perez Mendieta. NHC: 9734586. Domicilio: Paseo de Juan Vidal, 13, 2A. Localidad/ Provincia: Madrid. CP: 49238. Datos asistenciales. Fecha de nacimiento: 15/08/1988. País: España. Edad: 29 años Sexo: H. Fecha de Ingreso: 27/07/2018. Servicio: Urologia. Médico: Jorge Planelles Gómez NºCol:49 49 38492. Informe clínico del paciente: Paciente varón de 29 años. Es remitido a nuestro servicio para completar estudio porque, tras cuadro de aparición de tumoración indolora en su testículo izquierdo de un mes de evolución, se le detecta en la ecografía un testículo izquierdo hipogénico y disminuido de tamaño, y un testículo derecho con parénquima heterogéneo sospechoso de neoplasia. Diego No presenta otra sintomatología urológica, no astenia, no pérdida de peso. Tampoco tiene antecedentes personales de interés. En la exploración física se palpa un teste izquierdo hipotrófico, y un teste derecho algo aumentado de tamaño. Ambos no dolorosos, de consistencia normales y de superficie regulares. Epidídimos y cordones sin hallazgos patológicos. En las determinaciones analíticas destaca una hemostasia, bioquímica y hemograma dentro de los parámetros correspondientes a la normalidad, y una alfa-feto proteína de 2.7ng/ml con una beta-hCG de 4.2mUI/ml. Durante el ingreso se realiza nueva ecografía con flujo Doppler y se aprecia: un teste derecho de 49mm x 36mm x 26mm con lesión hipoecoica, de bordes lobulados, heterogénea, que ocupa prácticamente todo el testículo, y que presenta aumento del flujo Doppler. Y un teste izquierdo de 32mm x 22mm x 20mm hetrogéneo con lesión focal ligeramente hipoecoica de aproximadamente 9mm con sutil flujo Doppler. Además, microlitiasis testiculares bilaterales. Se le realizó también una Radiografía de tórax, en la que no se apreció ningún hallazgo patológico, y un TAC toraco-abdomino-pélvico con contraste, donde no se identificaron adenopatías ni metástasis en ninguno de los territorios visualizados. Con el diagnóstico de tumor testicular bilateral, se le realizó una orquiectomía bilateral vía inguinal y se la pautó tratamiento hormonal sustitutivo. En la anatomía patológica informan de: testículo izquierdo atrófico con múltiples focos microscópicos de seminoma clásico asociado a amplias áreas de neoplasia intratubular de células germinales (NICG) con ausencia de infiltración tumoral en albugínea, rete testis, epidídimo o infiltración vascular. El testículo derecho presenta tumoración con características de seminoma clásico que ocupa prácticamente todo el parénquima, asociado a focos de neoplasia intratubular de células germinales (NICG) y focos de atrofia en el testículo restante. Túnica albugínea, rete testis, epidídimo y borde quirúrgico libres de tumor. El tratamiento se completó con dos ciclos de quimioterapia con carboplatino según protocolo del hospital. Actualmente lleva más de tres años en remisión completa de la enfermedad. Remitido por: Jorge Planelles Gómez Servicio de Urología Hospital Universitario Doctor Peset Gaspar Aguilar 90 46017 Valencia. (España). jorge_planelles@yahoo.es Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-PAIS", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Diego. Apellidos: Perez Mendieta. NHC: 9734586. Domicilio: Paseo de Juan Vidal, 13, 2A. Localidad/ Provincia: Madrid. CP: 49238. Datos asistenciales. Fecha de nacimiento: 15/08/1988. País: España. Edad: 29 años Sexo: H. Fecha de Ingreso: 27/07/2018. Servicio: Urologia. Médico: Jorge Planelles Gómez NºCol:49 49 38492. Informe clínico del paciente: Paciente varón de 29 años. Es remitido a nuestro servicio para completar estudio porque, tras cuadro de aparición de tumoración indolora en su testículo izquierdo de un mes de evolución, se le detecta en la ecografía un testículo izquierdo hipogénico y disminuido de tamaño, y un testículo derecho con parénquima heterogéneo sospechoso de neoplasia. Diego No presenta otra sintomatología urológica, no astenia, no pérdida de peso. Tampoco tiene antecedentes personales de interés. En la exploración física se palpa un teste izquierdo hipotrófico, y un teste derecho algo aumentado de tamaño. Ambos no dolorosos, de consistencia normales y de superficie regulares. Epidídimos y cordones sin hallazgos patológicos. En las determinaciones analíticas destaca una hemostasia, bioquímica y hemograma dentro de los parámetros correspondientes a la normalidad, y una alfa-feto proteína de 2.7ng/ml con una beta-hCG de 4.2mUI/ml. Durante el ingreso se realiza nueva ecografía con flujo Doppler y se aprecia: un teste derecho de 49mm x 36mm x 26mm con lesión hipoecoica, de bordes lobulados, heterogénea, que ocupa prácticamente todo el testículo, y que presenta aumento del flujo Doppler. Y un teste izquierdo de 32mm x 22mm x 20mm hetrogéneo con lesión focal ligeramente hipoecoica de aproximadamente 9mm con sutil flujo Doppler. Además, microlitiasis testiculares bilaterales. Se le realizó también una Radiografía de tórax, en la que no se apreció ningún hallazgo patológico, y un TAC toraco-abdomino-pélvico con contraste, donde no se identificaron adenopatías ni metástasis en ninguno de los territorios visualizados. Con el diagnóstico de tumor testicular bilateral, se le realizó una orquiectomía bilateral vía inguinal y se la pautó tratamiento hormonal sustitutivo. En la anatomía patológica informan de: testículo izquierdo atrófico con múltiples focos microscópicos de seminoma clásico asociado a amplias áreas de neoplasia intratubular de células germinales (NICG) con ausencia de infiltración tumoral en albugínea, rete testis, epidídimo o infiltración vascular. El testículo derecho presenta tumoración con características de seminoma clásico que ocupa prácticamente todo el parénquima, asociado a focos de neoplasia intratubular de células germinales (NICG) y focos de atrofia en el testículo restante. Túnica albugínea, rete testis, epidídimo y borde quirúrgico libres de tumor. El tratamiento se completó con dos ciclos de quimioterapia con carboplatino según protocolo del hospital. Actualmente lleva más de tres años en remisión completa de la enfermedad. Remitido por: Jorge Planelles Gómez Servicio de Urología Hospital Universitario Doctor Peset Gaspar Aguilar 90 46017 Valencia. (España). jorge_planelles@yahoo.es
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Diego", ".", "\n", "Apellidos", ":", "Perez", "Mendieta", ".", "\n", "NHC", ":", "9734586", ".", "\n", "Domicilio", ":", "Paseo", "de", "Juan", "Vidal", ",", "13", ",", "2A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "49238", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/08/1988", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "29", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "27/07/2018", ".", "\n", "Servicio", ":", "Urologia", ".", "\n", "Médico", ":", "Jorge", "Planelles", "Gómez", " ", "NºCol:49", "49", "38492", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "varón", "de", "29", "años", ".", "Es", "remitido", "a", "nuestro", "servicio", "para", "completar", "estudio", "porque", ",", "tras", "cuadro", "de", "aparición", "de", "tumoración", "indolora", "en", "su", "testículo", "izquierdo", "de", "un", "mes", "de", "evolución", ",", "se", "le", "detecta", "en", "la", "ecografía", "un", "testículo", "izquierdo", "hipogénico", "y", "disminuido", "de", "tamaño", ",", "y", "un", "testículo", "derecho", "con", "parénquima", "heterogéneo", "sospechoso", "de", "neoplasia", ".", "\n", "Diego", "No", "presenta", "otra", "sintomatología", "urológica", ",", "no", "astenia", ",", "no", "pérdida", "de", "peso", ".", "Tampoco", "tiene", "antecedentes", "personales", "de", "interés", ".", "\n", "En", "la", "exploración", "física", "se", "palpa", "un", "teste", "izquierdo", "hipotrófico", ",", "y", "un", "teste", "derecho", "algo", "aumentado", "de", "tamaño", ".", "Ambos", "no", "dolorosos", ",", "de", "consistencia", "normales", "y", "de", "superficie", "regulares", ".", "Epidídimos", "y", "cordones", "sin", "hallazgos", "patológicos", ".", "\n", "En", "las", "determinaciones", "analíticas", "destaca", "una", "hemostasia", ",", "bioquímica", "y", "hemograma", "dentro", "de", "los", "parámetros", "correspondientes", "a", "la", "normalidad", ",", "y", "una", "alfa", "-", "feto", "proteína", "de", "2.7ng", "/", "ml", "con", "una", "beta", "-", "hCG", "de", "4.2mUI", "/", "ml", ".", "\n", "Durante", "el", "ingreso", "se", "realiza", "nueva", "ecografía", "con", "flujo", "Doppler", "y", "se", "aprecia", ":", "un", "teste", "derecho", "de", "49", "mm", "x", "36", "mm", "x", "26", "mm", "con", "lesión", "hipoecoica", ",", "de", "bordes", "lobulados", ",", "heterogénea", ",", "que", "ocupa", "prácticamente", "todo", "el", "testículo", ",", "y", "que", "presenta", "aumento", "del", "flujo", "Doppler", ".", "Y", "un", "teste", "izquierdo", "de", "32", "mm", "x", "22", "mm", "x", "20", "mm", "hetrogéneo", "con", "lesión", "focal", "ligeramente", "hipoecoica", "de", "aproximadamente", "9", "mm", "con", "sutil", "flujo", "Doppler", ".", "Además", ",", "microlitiasis", "testiculares", "bilaterales", ".", "\n", "Se", "le", "realizó", "también", "una", "Radiografía", "de", "tórax", ",", "en", "la", "que", "no", "se", "apreció", "ningún", "hallazgo", "patológico", ",", "y", "un", "TAC", "toraco", "-", "abdomino", "-", "pélvico", "con", "contraste", ",", "donde", "no", "se", "identificaron", "adenopatías", "ni", "metástasis", "en", "ninguno", "de", "los", "territorios", "visualizados", ".", "\n", "Con", "el", "diagnóstico", "de", "tumor", "testicular", "bilateral", ",", "se", "le", "realizó", "una", "orquiectomía", "bilateral", "vía", "inguinal", "y", "se", "la", "pautó", "tratamiento", "hormonal", "sustitutivo", ".", "\n", "En", "la", "anatomía", "patológica", "informan", "de", ":", "testículo", "izquierdo", "atrófico", "con", "múltiples", "focos", "microscópicos", "de", "seminoma", "clásico", "asociado", "a", "amplias", "áreas", "de", "neoplasia", "intratubular", "de", "células", "germinales", "(", "NICG", ")", "con", "ausencia", "de", "infiltración", "tumoral", "en", "albugínea", ",", "rete", "testis", ",", "epidídimo", "o", "infiltración", "vascular", ".", "El", "testículo", "derecho", "presenta", "tumoración", "con", "características", "de", "seminoma", "clásico", "que", "ocupa", "prácticamente", "todo", "el", "parénquima", ",", "asociado", "a", "focos", "de", "neoplasia", "intratubular", "de", "células", "germinales", "(", "NICG", ")", "y", "focos", "de", "atrofia", "en", "el", "testículo", "restante", ".", "Túnica", "albugínea", ",", "rete", "testis", ",", "epidídimo", "y", "borde", "quirúrgico", "libres", "de", "tumor", ".", "\n", "El", "tratamiento", "se", "completó", "con", "dos", "ciclos", "de", "quimioterapia", "con", "carboplatino", "según", "protocolo", "del", "hospital", ".", "\n", "Actualmente", "lleva", "más", "de", "tres", "años", "en", "remisión", "completa", "de", "la", "enfermedad", ".", "\n", "Remitido", "por", ":", "Jorge", "Planelles", "Gómez", "Servicio", "de", "Urología", "Hospital", "Universitario", "Doctor", "Peset", "Gaspar", "Aguilar", "90", "46017", "Valencia", ".", "(", "España", ")", ".", "jorge_planelles@yahoo.es", "\n" ]
[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Diego is a NOMBRE_SUJETO_ASISTENCIA, Perez Mendieta is a NOMBRE_SUJETO_ASISTENCIA, 9734586 is a ID_SUJETO_ASISTENCIA, Madrid is a TERRITORIO, 49238 is a TERRITORIO, 15/08/1988 is a FECHAS, España is a PAIS, 29 años is a EDAD_SUJETO_ASISTENCIA, 27/07/2018 is a FECHAS, Jorge Planelles Gómez is a NOMBRE_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 29 años is a EDAD_SUJETO_ASISTENCIA, Diego is a NOMBRE_SUJETO_ASISTENCIA, Jorge Planelles Gómez is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitario Doctor Peset is a HOSPITAL, Gaspar Aguilar 90 is a CALLE, 46017 is a TERRITORIO, Valencia is a TERRITORIO, España is a PAIS, jorge_planelles@yahoo.es is a CORREO_ELECTRONICO
24_task1
Sentence: Datos del paciente. Nombre: Diego. Apellidos: Perez Mendieta. NHC: 9734586. Domicilio: Paseo de Juan Vidal, 13, 2A. Localidad/ Provincia: Madrid. CP: 49238. Datos asistenciales. Fecha de nacimiento: 15/08/1988. País: España. Edad: 29 años Sexo: H. Fecha de Ingreso: 27/07/2018. Servicio: Urologia. Médico: Jorge Planelles Gómez NºCol:49 49 38492. Informe clínico del paciente: Paciente varón de 29 años. Es remitido a nuestro servicio para completar estudio porque, tras cuadro de aparición de tumoración indolora en su testículo izquierdo de un mes de evolución, se le detecta en la ecografía un testículo izquierdo hipogénico y disminuido de tamaño, y un testículo derecho con parénquima heterogéneo sospechoso de neoplasia. Diego No presenta otra sintomatología urológica, no astenia, no pérdida de peso. Tampoco tiene antecedentes personales de interés. En la exploración física se palpa un teste izquierdo hipotrófico, y un teste derecho algo aumentado de tamaño. Ambos no dolorosos, de consistencia normales y de superficie regulares. Epidídimos y cordones sin hallazgos patológicos. En las determinaciones analíticas destaca una hemostasia, bioquímica y hemograma dentro de los parámetros correspondientes a la normalidad, y una alfa-feto proteína de 2.7ng/ml con una beta-hCG de 4.2mUI/ml. Durante el ingreso se realiza nueva ecografía con flujo Doppler y se aprecia: un teste derecho de 49mm x 36mm x 26mm con lesión hipoecoica, de bordes lobulados, heterogénea, que ocupa prácticamente todo el testículo, y que presenta aumento del flujo Doppler. Y un teste izquierdo de 32mm x 22mm x 20mm hetrogéneo con lesión focal ligeramente hipoecoica de aproximadamente 9mm con sutil flujo Doppler. Además, microlitiasis testiculares bilaterales. Se le realizó también una Radiografía de tórax, en la que no se apreció ningún hallazgo patológico, y un TAC toraco-abdomino-pélvico con contraste, donde no se identificaron adenopatías ni metástasis en ninguno de los territorios visualizados. Con el diagnóstico de tumor testicular bilateral, se le realizó una orquiectomía bilateral vía inguinal y se la pautó tratamiento hormonal sustitutivo. En la anatomía patológica informan de: testículo izquierdo atrófico con múltiples focos microscópicos de seminoma clásico asociado a amplias áreas de neoplasia intratubular de células germinales (NICG) con ausencia de infiltración tumoral en albugínea, rete testis, epidídimo o infiltración vascular. El testículo derecho presenta tumoración con características de seminoma clásico que ocupa prácticamente todo el parénquima, asociado a focos de neoplasia intratubular de células germinales (NICG) y focos de atrofia en el testículo restante. Túnica albugínea, rete testis, epidídimo y borde quirúrgico libres de tumor. El tratamiento se completó con dos ciclos de quimioterapia con carboplatino según protocolo del hospital. Actualmente lleva más de tres años en remisión completa de la enfermedad. Remitido por: Jorge Planelles Gómez Servicio de Urología Hospital Universitario Doctor Peset Gaspar Aguilar 90 46017 Valencia. (España). jorge_planelles@yahoo.es Instructions: please typing these entity words according to sentence: Diego, Perez Mendieta, 9734586, Madrid, 49238, 15/08/1988, España, 29 años, 27/07/2018, Jorge Planelles Gómez, varón, 29 años, Diego, Jorge Planelles Gómez, Hospital Universitario Doctor Peset, Gaspar Aguilar 90, 46017, Valencia, España, jorge_planelles@yahoo.es Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-PAIS", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Diego. Apellidos: Perez Mendieta. NHC: 9734586. Domicilio: Paseo de Juan Vidal, 13, 2A. Localidad/ Provincia: Madrid. CP: 49238. Datos asistenciales. Fecha de nacimiento: 15/08/1988. País: España. Edad: 29 años Sexo: H. Fecha de Ingreso: 27/07/2018. Servicio: Urologia. Médico: Jorge Planelles Gómez NºCol:49 49 38492. Informe clínico del paciente: Paciente varón de 29 años. Es remitido a nuestro servicio para completar estudio porque, tras cuadro de aparición de tumoración indolora en su testículo izquierdo de un mes de evolución, se le detecta en la ecografía un testículo izquierdo hipogénico y disminuido de tamaño, y un testículo derecho con parénquima heterogéneo sospechoso de neoplasia. Diego No presenta otra sintomatología urológica, no astenia, no pérdida de peso. Tampoco tiene antecedentes personales de interés. En la exploración física se palpa un teste izquierdo hipotrófico, y un teste derecho algo aumentado de tamaño. Ambos no dolorosos, de consistencia normales y de superficie regulares. Epidídimos y cordones sin hallazgos patológicos. En las determinaciones analíticas destaca una hemostasia, bioquímica y hemograma dentro de los parámetros correspondientes a la normalidad, y una alfa-feto proteína de 2.7ng/ml con una beta-hCG de 4.2mUI/ml. Durante el ingreso se realiza nueva ecografía con flujo Doppler y se aprecia: un teste derecho de 49mm x 36mm x 26mm con lesión hipoecoica, de bordes lobulados, heterogénea, que ocupa prácticamente todo el testículo, y que presenta aumento del flujo Doppler. Y un teste izquierdo de 32mm x 22mm x 20mm hetrogéneo con lesión focal ligeramente hipoecoica de aproximadamente 9mm con sutil flujo Doppler. Además, microlitiasis testiculares bilaterales. Se le realizó también una Radiografía de tórax, en la que no se apreció ningún hallazgo patológico, y un TAC toraco-abdomino-pélvico con contraste, donde no se identificaron adenopatías ni metástasis en ninguno de los territorios visualizados. Con el diagnóstico de tumor testicular bilateral, se le realizó una orquiectomía bilateral vía inguinal y se la pautó tratamiento hormonal sustitutivo. En la anatomía patológica informan de: testículo izquierdo atrófico con múltiples focos microscópicos de seminoma clásico asociado a amplias áreas de neoplasia intratubular de células germinales (NICG) con ausencia de infiltración tumoral en albugínea, rete testis, epidídimo o infiltración vascular. El testículo derecho presenta tumoración con características de seminoma clásico que ocupa prácticamente todo el parénquima, asociado a focos de neoplasia intratubular de células germinales (NICG) y focos de atrofia en el testículo restante. Túnica albugínea, rete testis, epidídimo y borde quirúrgico libres de tumor. El tratamiento se completó con dos ciclos de quimioterapia con carboplatino según protocolo del hospital. Actualmente lleva más de tres años en remisión completa de la enfermedad. Remitido por: Jorge Planelles Gómez Servicio de Urología Hospital Universitario Doctor Peset Gaspar Aguilar 90 46017 Valencia. (España). jorge_planelles@yahoo.es
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Diego", ".", "\n", "Apellidos", ":", "Perez", "Mendieta", ".", "\n", "NHC", ":", "9734586", ".", "\n", "Domicilio", ":", "Paseo", "de", "Juan", "Vidal", ",", "13", ",", "2A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "49238", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/08/1988", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "29", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "27/07/2018", ".", "\n", "Servicio", ":", "Urologia", ".", "\n", "Médico", ":", "Jorge", "Planelles", "Gómez", " ", "NºCol:49", "49", "38492", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "varón", "de", "29", "años", ".", "Es", "remitido", "a", "nuestro", "servicio", "para", "completar", "estudio", "porque", ",", "tras", "cuadro", "de", "aparición", "de", "tumoración", "indolora", "en", "su", "testículo", "izquierdo", "de", "un", "mes", "de", "evolución", ",", "se", "le", "detecta", "en", "la", "ecografía", "un", "testículo", "izquierdo", "hipogénico", "y", "disminuido", "de", "tamaño", ",", "y", "un", "testículo", "derecho", "con", "parénquima", "heterogéneo", "sospechoso", "de", "neoplasia", ".", "\n", "Diego", "No", "presenta", "otra", "sintomatología", "urológica", ",", "no", "astenia", ",", "no", "pérdida", "de", "peso", ".", "Tampoco", "tiene", "antecedentes", "personales", "de", "interés", ".", "\n", "En", "la", "exploración", "física", "se", "palpa", "un", "teste", "izquierdo", "hipotrófico", ",", "y", "un", "teste", "derecho", "algo", "aumentado", "de", "tamaño", ".", "Ambos", "no", "dolorosos", ",", "de", "consistencia", "normales", "y", "de", "superficie", "regulares", ".", "Epidídimos", "y", "cordones", "sin", "hallazgos", "patológicos", ".", "\n", "En", "las", "determinaciones", "analíticas", "destaca", "una", "hemostasia", ",", "bioquímica", "y", "hemograma", "dentro", "de", "los", "parámetros", "correspondientes", "a", "la", "normalidad", ",", "y", "una", "alfa", "-", "feto", "proteína", "de", "2.7ng", "/", "ml", "con", "una", "beta", "-", "hCG", "de", "4.2mUI", "/", "ml", ".", "\n", "Durante", "el", "ingreso", "se", "realiza", "nueva", "ecografía", "con", "flujo", "Doppler", "y", "se", "aprecia", ":", "un", "teste", "derecho", "de", "49", "mm", "x", "36", "mm", "x", "26", "mm", "con", "lesión", "hipoecoica", ",", "de", "bordes", "lobulados", ",", "heterogénea", ",", "que", "ocupa", "prácticamente", "todo", "el", "testículo", ",", "y", "que", "presenta", "aumento", "del", "flujo", "Doppler", ".", "Y", "un", "teste", "izquierdo", "de", "32", "mm", "x", "22", "mm", "x", "20", "mm", "hetrogéneo", "con", "lesión", "focal", "ligeramente", "hipoecoica", "de", "aproximadamente", "9", "mm", "con", "sutil", "flujo", "Doppler", ".", "Además", ",", "microlitiasis", "testiculares", "bilaterales", ".", "\n", "Se", "le", "realizó", "también", "una", "Radiografía", "de", "tórax", ",", "en", "la", "que", "no", "se", "apreció", "ningún", "hallazgo", "patológico", ",", "y", "un", "TAC", "toraco", "-", "abdomino", "-", "pélvico", "con", "contraste", ",", "donde", "no", "se", "identificaron", "adenopatías", "ni", "metástasis", "en", "ninguno", "de", "los", "territorios", "visualizados", ".", "\n", "Con", "el", "diagnóstico", "de", "tumor", "testicular", "bilateral", ",", "se", "le", "realizó", "una", "orquiectomía", "bilateral", "vía", "inguinal", "y", "se", "la", "pautó", "tratamiento", "hormonal", "sustitutivo", ".", "\n", "En", "la", "anatomía", "patológica", "informan", "de", ":", "testículo", "izquierdo", "atrófico", "con", "múltiples", "focos", "microscópicos", "de", "seminoma", "clásico", "asociado", "a", "amplias", "áreas", "de", "neoplasia", "intratubular", "de", "células", "germinales", "(", "NICG", ")", "con", "ausencia", "de", "infiltración", "tumoral", "en", "albugínea", ",", "rete", "testis", ",", "epidídimo", "o", "infiltración", "vascular", ".", "El", "testículo", "derecho", "presenta", "tumoración", "con", "características", "de", "seminoma", "clásico", "que", "ocupa", "prácticamente", "todo", "el", "parénquima", ",", "asociado", "a", "focos", "de", "neoplasia", "intratubular", "de", "células", "germinales", "(", "NICG", ")", "y", "focos", "de", "atrofia", "en", "el", "testículo", "restante", ".", "Túnica", "albugínea", ",", "rete", "testis", ",", "epidídimo", "y", "borde", "quirúrgico", "libres", "de", "tumor", ".", "\n", "El", "tratamiento", "se", "completó", "con", "dos", "ciclos", "de", "quimioterapia", "con", "carboplatino", "según", "protocolo", "del", "hospital", ".", "\n", "Actualmente", "lleva", "más", "de", "tres", "años", "en", "remisión", "completa", "de", "la", "enfermedad", ".", "\n", "Remitido", "por", ":", "Jorge", "Planelles", "Gómez", "Servicio", "de", "Urología", "Hospital", "Universitario", "Doctor", "Peset", "Gaspar", "Aguilar", "90", "46017", "Valencia", ".", "(", "España", ")", ".", "jorge_planelles@yahoo.es", "\n" ]
[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Diego, Perez Mendieta, 9734586, Madrid, 49238, 15/08/1988, España, 29 años, 27/07/2018, Jorge Planelles Gómez, varón, 29 años, Diego, Jorge Planelles Gómez, Hospital Universitario Doctor Peset, Gaspar Aguilar 90, 46017, Valencia, España, jorge_planelles@yahoo.es
24_task2
Sentence: Datos del paciente. Nombre: Diego. Apellidos: Perez Mendieta. NHC: 9734586. Domicilio: Paseo de Juan Vidal, 13, 2A. Localidad/ Provincia: Madrid. CP: 49238. Datos asistenciales. Fecha de nacimiento: 15/08/1988. País: España. Edad: 29 años Sexo: H. Fecha de Ingreso: 27/07/2018. Servicio: Urologia. Médico: Jorge Planelles Gómez NºCol:49 49 38492. Informe clínico del paciente: Paciente varón de 29 años. Es remitido a nuestro servicio para completar estudio porque, tras cuadro de aparición de tumoración indolora en su testículo izquierdo de un mes de evolución, se le detecta en la ecografía un testículo izquierdo hipogénico y disminuido de tamaño, y un testículo derecho con parénquima heterogéneo sospechoso de neoplasia. Diego No presenta otra sintomatología urológica, no astenia, no pérdida de peso. Tampoco tiene antecedentes personales de interés. En la exploración física se palpa un teste izquierdo hipotrófico, y un teste derecho algo aumentado de tamaño. Ambos no dolorosos, de consistencia normales y de superficie regulares. Epidídimos y cordones sin hallazgos patológicos. En las determinaciones analíticas destaca una hemostasia, bioquímica y hemograma dentro de los parámetros correspondientes a la normalidad, y una alfa-feto proteína de 2.7ng/ml con una beta-hCG de 4.2mUI/ml. Durante el ingreso se realiza nueva ecografía con flujo Doppler y se aprecia: un teste derecho de 49mm x 36mm x 26mm con lesión hipoecoica, de bordes lobulados, heterogénea, que ocupa prácticamente todo el testículo, y que presenta aumento del flujo Doppler. Y un teste izquierdo de 32mm x 22mm x 20mm hetrogéneo con lesión focal ligeramente hipoecoica de aproximadamente 9mm con sutil flujo Doppler. Además, microlitiasis testiculares bilaterales. Se le realizó también una Radiografía de tórax, en la que no se apreció ningún hallazgo patológico, y un TAC toraco-abdomino-pélvico con contraste, donde no se identificaron adenopatías ni metástasis en ninguno de los territorios visualizados. Con el diagnóstico de tumor testicular bilateral, se le realizó una orquiectomía bilateral vía inguinal y se la pautó tratamiento hormonal sustitutivo. En la anatomía patológica informan de: testículo izquierdo atrófico con múltiples focos microscópicos de seminoma clásico asociado a amplias áreas de neoplasia intratubular de células germinales (NICG) con ausencia de infiltración tumoral en albugínea, rete testis, epidídimo o infiltración vascular. El testículo derecho presenta tumoración con características de seminoma clásico que ocupa prácticamente todo el parénquima, asociado a focos de neoplasia intratubular de células germinales (NICG) y focos de atrofia en el testículo restante. Túnica albugínea, rete testis, epidídimo y borde quirúrgico libres de tumor. El tratamiento se completó con dos ciclos de quimioterapia con carboplatino según protocolo del hospital. Actualmente lleva más de tres años en remisión completa de la enfermedad. Remitido por: Jorge Planelles Gómez Servicio de Urología Hospital Universitario Doctor Peset Gaspar Aguilar 90 46017 Valencia. (España). jorge_planelles@yahoo.es Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-PAIS", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Diego. Apellidos: Perez Mendieta. NHC: 9734586. Domicilio: Paseo de Juan Vidal, 13, 2A. Localidad/ Provincia: Madrid. CP: 49238. Datos asistenciales. Fecha de nacimiento: 15/08/1988. País: España. Edad: 29 años Sexo: H. Fecha de Ingreso: 27/07/2018. Servicio: Urologia. Médico: Jorge Planelles Gómez NºCol:49 49 38492. Informe clínico del paciente: Paciente varón de 29 años. Es remitido a nuestro servicio para completar estudio porque, tras cuadro de aparición de tumoración indolora en su testículo izquierdo de un mes de evolución, se le detecta en la ecografía un testículo izquierdo hipogénico y disminuido de tamaño, y un testículo derecho con parénquima heterogéneo sospechoso de neoplasia. Diego No presenta otra sintomatología urológica, no astenia, no pérdida de peso. Tampoco tiene antecedentes personales de interés. En la exploración física se palpa un teste izquierdo hipotrófico, y un teste derecho algo aumentado de tamaño. Ambos no dolorosos, de consistencia normales y de superficie regulares. Epidídimos y cordones sin hallazgos patológicos. En las determinaciones analíticas destaca una hemostasia, bioquímica y hemograma dentro de los parámetros correspondientes a la normalidad, y una alfa-feto proteína de 2.7ng/ml con una beta-hCG de 4.2mUI/ml. Durante el ingreso se realiza nueva ecografía con flujo Doppler y se aprecia: un teste derecho de 49mm x 36mm x 26mm con lesión hipoecoica, de bordes lobulados, heterogénea, que ocupa prácticamente todo el testículo, y que presenta aumento del flujo Doppler. Y un teste izquierdo de 32mm x 22mm x 20mm hetrogéneo con lesión focal ligeramente hipoecoica de aproximadamente 9mm con sutil flujo Doppler. Además, microlitiasis testiculares bilaterales. Se le realizó también una Radiografía de tórax, en la que no se apreció ningún hallazgo patológico, y un TAC toraco-abdomino-pélvico con contraste, donde no se identificaron adenopatías ni metástasis en ninguno de los territorios visualizados. Con el diagnóstico de tumor testicular bilateral, se le realizó una orquiectomía bilateral vía inguinal y se la pautó tratamiento hormonal sustitutivo. En la anatomía patológica informan de: testículo izquierdo atrófico con múltiples focos microscópicos de seminoma clásico asociado a amplias áreas de neoplasia intratubular de células germinales (NICG) con ausencia de infiltración tumoral en albugínea, rete testis, epidídimo o infiltración vascular. El testículo derecho presenta tumoración con características de seminoma clásico que ocupa prácticamente todo el parénquima, asociado a focos de neoplasia intratubular de células germinales (NICG) y focos de atrofia en el testículo restante. Túnica albugínea, rete testis, epidídimo y borde quirúrgico libres de tumor. El tratamiento se completó con dos ciclos de quimioterapia con carboplatino según protocolo del hospital. Actualmente lleva más de tres años en remisión completa de la enfermedad. Remitido por: Jorge Planelles Gómez Servicio de Urología Hospital Universitario Doctor Peset Gaspar Aguilar 90 46017 Valencia. (España). jorge_planelles@yahoo.es
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Diego", ".", "\n", "Apellidos", ":", "Perez", "Mendieta", ".", "\n", "NHC", ":", "9734586", ".", "\n", "Domicilio", ":", "Paseo", "de", "Juan", "Vidal", ",", "13", ",", "2A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "49238", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/08/1988", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "29", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "27/07/2018", ".", "\n", "Servicio", ":", "Urologia", ".", "\n", "Médico", ":", "Jorge", "Planelles", "Gómez", " ", "NºCol:49", "49", "38492", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "varón", "de", "29", "años", ".", "Es", "remitido", "a", "nuestro", "servicio", "para", "completar", "estudio", "porque", ",", "tras", "cuadro", "de", "aparición", "de", "tumoración", "indolora", "en", "su", "testículo", "izquierdo", "de", "un", "mes", "de", "evolución", ",", "se", "le", "detecta", "en", "la", "ecografía", "un", "testículo", "izquierdo", "hipogénico", "y", "disminuido", "de", "tamaño", ",", "y", "un", "testículo", "derecho", "con", "parénquima", "heterogéneo", "sospechoso", "de", "neoplasia", ".", "\n", "Diego", "No", "presenta", "otra", "sintomatología", "urológica", ",", "no", "astenia", ",", "no", "pérdida", "de", "peso", ".", "Tampoco", "tiene", "antecedentes", "personales", "de", "interés", ".", "\n", "En", "la", "exploración", "física", "se", "palpa", "un", "teste", "izquierdo", "hipotrófico", ",", "y", "un", "teste", "derecho", "algo", "aumentado", "de", "tamaño", ".", "Ambos", "no", "dolorosos", ",", "de", "consistencia", "normales", "y", "de", "superficie", "regulares", ".", "Epidídimos", "y", "cordones", "sin", "hallazgos", "patológicos", ".", "\n", "En", "las", "determinaciones", "analíticas", "destaca", "una", "hemostasia", ",", "bioquímica", "y", "hemograma", "dentro", "de", "los", "parámetros", "correspondientes", "a", "la", "normalidad", ",", "y", "una", "alfa", "-", "feto", "proteína", "de", "2.7ng", "/", "ml", "con", "una", "beta", "-", "hCG", "de", "4.2mUI", "/", "ml", ".", "\n", "Durante", "el", "ingreso", "se", "realiza", "nueva", "ecografía", "con", "flujo", "Doppler", "y", "se", "aprecia", ":", "un", "teste", "derecho", "de", "49", "mm", "x", "36", "mm", "x", "26", "mm", "con", "lesión", "hipoecoica", ",", "de", "bordes", "lobulados", ",", "heterogénea", ",", "que", "ocupa", "prácticamente", "todo", "el", "testículo", ",", "y", "que", "presenta", "aumento", "del", "flujo", "Doppler", ".", "Y", "un", "teste", "izquierdo", "de", "32", "mm", "x", "22", "mm", "x", "20", "mm", "hetrogéneo", "con", "lesión", "focal", "ligeramente", "hipoecoica", "de", "aproximadamente", "9", "mm", "con", "sutil", "flujo", "Doppler", ".", "Además", ",", "microlitiasis", "testiculares", "bilaterales", ".", "\n", "Se", "le", "realizó", "también", "una", "Radiografía", "de", "tórax", ",", "en", "la", "que", "no", "se", "apreció", "ningún", "hallazgo", "patológico", ",", "y", "un", "TAC", "toraco", "-", "abdomino", "-", "pélvico", "con", "contraste", ",", "donde", "no", "se", "identificaron", "adenopatías", "ni", "metástasis", "en", "ninguno", "de", "los", "territorios", "visualizados", ".", "\n", "Con", "el", "diagnóstico", "de", "tumor", "testicular", "bilateral", ",", "se", "le", "realizó", "una", "orquiectomía", "bilateral", "vía", "inguinal", "y", "se", "la", "pautó", "tratamiento", "hormonal", "sustitutivo", ".", "\n", "En", "la", "anatomía", "patológica", "informan", "de", ":", "testículo", "izquierdo", "atrófico", "con", "múltiples", "focos", "microscópicos", "de", "seminoma", "clásico", "asociado", "a", "amplias", "áreas", "de", "neoplasia", "intratubular", "de", "células", "germinales", "(", "NICG", ")", "con", "ausencia", "de", "infiltración", "tumoral", "en", "albugínea", ",", "rete", "testis", ",", "epidídimo", "o", "infiltración", "vascular", ".", "El", "testículo", "derecho", "presenta", "tumoración", "con", "características", "de", "seminoma", "clásico", "que", "ocupa", "prácticamente", "todo", "el", "parénquima", ",", "asociado", "a", "focos", "de", "neoplasia", "intratubular", "de", "células", "germinales", "(", "NICG", ")", "y", "focos", "de", "atrofia", "en", "el", "testículo", "restante", ".", "Túnica", "albugínea", ",", "rete", "testis", ",", "epidídimo", "y", "borde", "quirúrgico", "libres", "de", "tumor", ".", "\n", "El", "tratamiento", "se", "completó", "con", "dos", "ciclos", "de", "quimioterapia", "con", "carboplatino", "según", "protocolo", "del", "hospital", ".", "\n", "Actualmente", "lleva", "más", "de", "tres", "años", "en", "remisión", "completa", "de", "la", "enfermedad", ".", "\n", "Remitido", "por", ":", "Jorge", "Planelles", "Gómez", "Servicio", "de", "Urología", "Hospital", "Universitario", "Doctor", "Peset", "Gaspar", "Aguilar", "90", "46017", "Valencia", ".", "(", "España", ")", ".", "jorge_planelles@yahoo.es", "\n" ]
[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Kehlkopfkrebszellen is an umlsterm, Krebsgewebe is an umlsterm, Larynxkarzinompatienten is an umlsterm, Behandlung is an umlsterm, Radiotherapie is an umlsterm, kombinierte Therapie is an umlsterm, Krankheit is an umlsterm, Enzym is an umlsterm, Faerbung is an umlsterm, Faerbung is an umlsterm, Zellkerne is an umlsterm, PCNA is an umlsterm, DNA is an umlsterm, Charakter is an umlsterm, Tumoren is an umlsterm, Faerbung is an umlsterm, Zellkerne is an umlsterm, PCNA is an umlsterm, Aneuploidie is an umlsterm, Krebsgewebes is an umlsterm
HNO.80460233.ger.abstr_task0
Sentence: Dieser Beitrag setzt sich um Ziel , die Profilierungsaktivitaet der Kehlkopfkrebszellen in bezug auf klinische Befunde zu bestimmen . Im Mittelpunkt unserer Untersuchungen stand das Krebsgewebe von 120 Larynxkarzinompatienten , bei denen eine chirurgische Behandlung , Radiotherapie bzw. kombinierte Therapie vorgenommen wurde . Das klinische Fortschreiten der Krankheit stuften wir bei 39 Kranken als Grad III und bei 31 Faellen als Grad IV ein . Immunhistochemische Untersuchungen fuehrten wir mit der " Avidin-biothin-Methode " durch , wobei Peroxydase als Enzym und Diaminobezidin als Chromogen angewandt wurden . Fuer die Bestimmung der immunohistochemischen Faerbung der Krebszellen benutzten wir eine 5stufige Skala . Eine positive Faerbung der Zellkerne des Laynxkrebses mit p53 wurde in 70% , mit Ki67 in 57% und mit PCNA in 80% der Faelle festgestellt . Wir fanden in 38% der Faelle aneuploidale und in 62% diploidale DNA . Mit den ultrastrukturellen Untersuchungen ermittelten wir den individuellen Charakter des Plasmas und der Kerne . Alle aneuploidalen Tumoren zeigten eine starke Faerbung der Zellkerne der p53- und Ki67-Gene. Bei der PCNA wurden keine Reaktionen beobachtet . Dabei wurde eine statistisch hoch signifikante Korrelation ( p 0,001 ) zwischen der Aneuploidie und dem T und N nachgewiesen . Man kann behaupten , dass der angewandte Komplex von Untersuchungstechniken des Krebsgewebes zu einer praeziseren Einschaetzung seiner biologischen Aktivitaet beitragen kann . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Dieser Beitrag setzt sich um Ziel , die Profilierungsaktivitaet der Kehlkopfkrebszellen in bezug auf klinische Befunde zu bestimmen . Im Mittelpunkt unserer Untersuchungen stand das Krebsgewebe von 120 Larynxkarzinompatienten , bei denen eine chirurgische Behandlung , Radiotherapie bzw. kombinierte Therapie vorgenommen wurde . Das klinische Fortschreiten der Krankheit stuften wir bei 39 Kranken als Grad III und bei 31 Faellen als Grad IV ein . Immunhistochemische Untersuchungen fuehrten wir mit der " Avidin-biothin-Methode " durch , wobei Peroxydase als Enzym und Diaminobezidin als Chromogen angewandt wurden . Fuer die Bestimmung der immunohistochemischen Faerbung der Krebszellen benutzten wir eine 5stufige Skala . Eine positive Faerbung der Zellkerne des Laynxkrebses mit p53 wurde in 70% , mit Ki67 in 57% und mit PCNA in 80% der Faelle festgestellt . Wir fanden in 38% der Faelle aneuploidale und in 62% diploidale DNA . Mit den ultrastrukturellen Untersuchungen ermittelten wir den individuellen Charakter des Plasmas und der Kerne . Alle aneuploidalen Tumoren zeigten eine starke Faerbung der Zellkerne der p53- und Ki67-Gene. Bei der PCNA wurden keine Reaktionen beobachtet . Dabei wurde eine statistisch hoch signifikante Korrelation ( p 0,001 ) zwischen der Aneuploidie und dem T und N nachgewiesen . Man kann behaupten , dass der angewandte Komplex von Untersuchungstechniken des Krebsgewebes zu einer praeziseren Einschaetzung seiner biologischen Aktivitaet beitragen kann .
[ "Dieser", "Beitrag", "setzt", "sich", "um", "Ziel", ",", "die", "Profilierungsaktivitaet", "der", "Kehlkopfkrebszellen", "in", "bezug", "auf", "klinische", "Befunde", "zu", "bestimmen", ".", "Im", "Mittelpunkt", "unserer", "Untersuchungen", "stand", "das", "Krebsgewebe", "von", "120", "Larynxkarzinompatienten", ",", "bei", "denen", "eine", "chirurgische", "Behandlung", ",", "Radiotherapie", "bzw", ".", "kombinierte", "Therapie", "vorgenommen", "wurde", ".", "Das", "klinische", "Fortschreiten", "der", "Krankheit", "stuften", "wir", "bei", "39", "Kranken", "als", "Grad", "III", "und", "bei", "31", "Faellen", "als", "Grad", "IV", "ein", ".", "Immunhistochemische", "Untersuchungen", "fuehrten", "wir", "mit", "der", "\"", "Avidin", "-", "biothin", "-", "Methode", "\"", "durch", ",", "wobei", "Peroxydase", "als", "Enzym", "und", "Diaminobezidin", "als", "Chromogen", "angewandt", "wurden", ".", "Fuer", "die", "Bestimmung", "der", "immunohistochemischen", "Faerbung", "der", "Krebszellen", "benutzten", "wir", "eine", "5stufige", "Skala", ".", "Eine", "positive", "Faerbung", "der", "Zellkerne", "des", "Laynxkrebses", "mit", "p53", "wurde", "in", "70", "%", ",", "mit", "Ki67", "in", "57", "%", "und", "mit", "PCNA", "in", "80", "%", "der", "Faelle", "festgestellt", ".", "Wir", "fanden", "in", "38", "%", "der", "Faelle", "aneuploidale", "und", "in", "62", "%", "diploidale", "DNA", ".", "Mit", "den", "ultrastrukturellen", "Untersuchungen", "ermittelten", "wir", "den", "individuellen", "Charakter", "des", "Plasmas", "und", "der", "Kerne", ".", "Alle", "aneuploidalen", "Tumoren", "zeigten", "eine", "starke", "Faerbung", "der", "Zellkerne", "der", "p53-", "und", "Ki67-Gene", ".", "Bei", "der", "PCNA", "wurden", "keine", "Reaktionen", "beobachtet", ".", "Dabei", "wurde", "eine", "statistisch", "hoch", "signifikante", "Korrelation", "(", "p", "0,001", ")", "zwischen", "der", "Aneuploidie", "und", "dem", "T", "und", "N", "nachgewiesen", ".", "Man", "kann", "behaupten", ",", "dass", "der", "angewandte", "Komplex", "von", "Untersuchungstechniken", "des", "Krebsgewebes", "zu", "einer", "praeziseren", "Einschaetzung", "seiner", "biologischen", "Aktivitaet", "beitragen", "kann", "." ]
[ "umlsterm" ]
Kehlkopfkrebszellen is an umlsterm, Krebsgewebe is an umlsterm, Larynxkarzinompatienten is an umlsterm, Behandlung is an umlsterm, Radiotherapie is an umlsterm, kombinierte Therapie is an umlsterm, Krankheit is an umlsterm, Enzym is an umlsterm, Faerbung is an umlsterm, Faerbung is an umlsterm, Zellkerne is an umlsterm, PCNA is an umlsterm, DNA is an umlsterm, Charakter is an umlsterm, Tumoren is an umlsterm, Faerbung is an umlsterm, Zellkerne is an umlsterm, PCNA is an umlsterm, Aneuploidie is an umlsterm, Krebsgewebes is an umlsterm
HNO.80460233.ger.abstr_task1
Sentence: Dieser Beitrag setzt sich um Ziel , die Profilierungsaktivitaet der Kehlkopfkrebszellen in bezug auf klinische Befunde zu bestimmen . Im Mittelpunkt unserer Untersuchungen stand das Krebsgewebe von 120 Larynxkarzinompatienten , bei denen eine chirurgische Behandlung , Radiotherapie bzw. kombinierte Therapie vorgenommen wurde . Das klinische Fortschreiten der Krankheit stuften wir bei 39 Kranken als Grad III und bei 31 Faellen als Grad IV ein . Immunhistochemische Untersuchungen fuehrten wir mit der " Avidin-biothin-Methode " durch , wobei Peroxydase als Enzym und Diaminobezidin als Chromogen angewandt wurden . Fuer die Bestimmung der immunohistochemischen Faerbung der Krebszellen benutzten wir eine 5stufige Skala . Eine positive Faerbung der Zellkerne des Laynxkrebses mit p53 wurde in 70% , mit Ki67 in 57% und mit PCNA in 80% der Faelle festgestellt . Wir fanden in 38% der Faelle aneuploidale und in 62% diploidale DNA . Mit den ultrastrukturellen Untersuchungen ermittelten wir den individuellen Charakter des Plasmas und der Kerne . Alle aneuploidalen Tumoren zeigten eine starke Faerbung der Zellkerne der p53- und Ki67-Gene. Bei der PCNA wurden keine Reaktionen beobachtet . Dabei wurde eine statistisch hoch signifikante Korrelation ( p 0,001 ) zwischen der Aneuploidie und dem T und N nachgewiesen . Man kann behaupten , dass der angewandte Komplex von Untersuchungstechniken des Krebsgewebes zu einer praeziseren Einschaetzung seiner biologischen Aktivitaet beitragen kann . Instructions: please typing these entity words according to sentence: Kehlkopfkrebszellen, Krebsgewebe, Larynxkarzinompatienten, Behandlung, Radiotherapie, kombinierte Therapie, Krankheit, Enzym, Faerbung, Faerbung, Zellkerne, PCNA, DNA, Charakter, Tumoren, Faerbung, Zellkerne, PCNA, Aneuploidie, Krebsgewebes Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Dieser Beitrag setzt sich um Ziel , die Profilierungsaktivitaet der Kehlkopfkrebszellen in bezug auf klinische Befunde zu bestimmen . Im Mittelpunkt unserer Untersuchungen stand das Krebsgewebe von 120 Larynxkarzinompatienten , bei denen eine chirurgische Behandlung , Radiotherapie bzw. kombinierte Therapie vorgenommen wurde . Das klinische Fortschreiten der Krankheit stuften wir bei 39 Kranken als Grad III und bei 31 Faellen als Grad IV ein . Immunhistochemische Untersuchungen fuehrten wir mit der " Avidin-biothin-Methode " durch , wobei Peroxydase als Enzym und Diaminobezidin als Chromogen angewandt wurden . Fuer die Bestimmung der immunohistochemischen Faerbung der Krebszellen benutzten wir eine 5stufige Skala . Eine positive Faerbung der Zellkerne des Laynxkrebses mit p53 wurde in 70% , mit Ki67 in 57% und mit PCNA in 80% der Faelle festgestellt . Wir fanden in 38% der Faelle aneuploidale und in 62% diploidale DNA . Mit den ultrastrukturellen Untersuchungen ermittelten wir den individuellen Charakter des Plasmas und der Kerne . Alle aneuploidalen Tumoren zeigten eine starke Faerbung der Zellkerne der p53- und Ki67-Gene. Bei der PCNA wurden keine Reaktionen beobachtet . Dabei wurde eine statistisch hoch signifikante Korrelation ( p 0,001 ) zwischen der Aneuploidie und dem T und N nachgewiesen . Man kann behaupten , dass der angewandte Komplex von Untersuchungstechniken des Krebsgewebes zu einer praeziseren Einschaetzung seiner biologischen Aktivitaet beitragen kann .
[ "Dieser", "Beitrag", "setzt", "sich", "um", "Ziel", ",", "die", "Profilierungsaktivitaet", "der", "Kehlkopfkrebszellen", "in", "bezug", "auf", "klinische", "Befunde", "zu", "bestimmen", ".", "Im", "Mittelpunkt", "unserer", "Untersuchungen", "stand", "das", "Krebsgewebe", "von", "120", "Larynxkarzinompatienten", ",", "bei", "denen", "eine", "chirurgische", "Behandlung", ",", "Radiotherapie", "bzw", ".", "kombinierte", "Therapie", "vorgenommen", "wurde", ".", "Das", "klinische", "Fortschreiten", "der", "Krankheit", "stuften", "wir", "bei", "39", "Kranken", "als", "Grad", "III", "und", "bei", "31", "Faellen", "als", "Grad", "IV", "ein", ".", "Immunhistochemische", "Untersuchungen", "fuehrten", "wir", "mit", "der", "\"", "Avidin", "-", "biothin", "-", "Methode", "\"", "durch", ",", "wobei", "Peroxydase", "als", "Enzym", "und", "Diaminobezidin", "als", "Chromogen", "angewandt", "wurden", ".", "Fuer", "die", "Bestimmung", "der", "immunohistochemischen", "Faerbung", "der", "Krebszellen", "benutzten", "wir", "eine", "5stufige", "Skala", ".", "Eine", "positive", "Faerbung", "der", "Zellkerne", "des", "Laynxkrebses", "mit", "p53", "wurde", "in", "70", "%", ",", "mit", "Ki67", "in", "57", "%", "und", "mit", "PCNA", "in", "80", "%", "der", "Faelle", "festgestellt", ".", "Wir", "fanden", "in", "38", "%", "der", "Faelle", "aneuploidale", "und", "in", "62", "%", "diploidale", "DNA", ".", "Mit", "den", "ultrastrukturellen", "Untersuchungen", "ermittelten", "wir", "den", "individuellen", "Charakter", "des", "Plasmas", "und", "der", "Kerne", ".", "Alle", "aneuploidalen", "Tumoren", "zeigten", "eine", "starke", "Faerbung", "der", "Zellkerne", "der", "p53-", "und", "Ki67-Gene", ".", "Bei", "der", "PCNA", "wurden", "keine", "Reaktionen", "beobachtet", ".", "Dabei", "wurde", "eine", "statistisch", "hoch", "signifikante", "Korrelation", "(", "p", "0,001", ")", "zwischen", "der", "Aneuploidie", "und", "dem", "T", "und", "N", "nachgewiesen", ".", "Man", "kann", "behaupten", ",", "dass", "der", "angewandte", "Komplex", "von", "Untersuchungstechniken", "des", "Krebsgewebes", "zu", "einer", "praeziseren", "Einschaetzung", "seiner", "biologischen", "Aktivitaet", "beitragen", "kann", "." ]
[ "umlsterm" ]
Kehlkopfkrebszellen, Krebsgewebe, Larynxkarzinompatienten, Behandlung, Radiotherapie, kombinierte Therapie, Krankheit, Enzym, Faerbung, Faerbung, Zellkerne, PCNA, DNA, Charakter, Tumoren, Faerbung, Zellkerne, PCNA, Aneuploidie, Krebsgewebes
HNO.80460233.ger.abstr_task2
Sentence: Dieser Beitrag setzt sich um Ziel , die Profilierungsaktivitaet der Kehlkopfkrebszellen in bezug auf klinische Befunde zu bestimmen . Im Mittelpunkt unserer Untersuchungen stand das Krebsgewebe von 120 Larynxkarzinompatienten , bei denen eine chirurgische Behandlung , Radiotherapie bzw. kombinierte Therapie vorgenommen wurde . Das klinische Fortschreiten der Krankheit stuften wir bei 39 Kranken als Grad III und bei 31 Faellen als Grad IV ein . Immunhistochemische Untersuchungen fuehrten wir mit der " Avidin-biothin-Methode " durch , wobei Peroxydase als Enzym und Diaminobezidin als Chromogen angewandt wurden . Fuer die Bestimmung der immunohistochemischen Faerbung der Krebszellen benutzten wir eine 5stufige Skala . Eine positive Faerbung der Zellkerne des Laynxkrebses mit p53 wurde in 70% , mit Ki67 in 57% und mit PCNA in 80% der Faelle festgestellt . Wir fanden in 38% der Faelle aneuploidale und in 62% diploidale DNA . Mit den ultrastrukturellen Untersuchungen ermittelten wir den individuellen Charakter des Plasmas und der Kerne . Alle aneuploidalen Tumoren zeigten eine starke Faerbung der Zellkerne der p53- und Ki67-Gene. Bei der PCNA wurden keine Reaktionen beobachtet . Dabei wurde eine statistisch hoch signifikante Korrelation ( p 0,001 ) zwischen der Aneuploidie und dem T und N nachgewiesen . Man kann behaupten , dass der angewandte Komplex von Untersuchungstechniken des Krebsgewebes zu einer praeziseren Einschaetzung seiner biologischen Aktivitaet beitragen kann . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Dieser Beitrag setzt sich um Ziel , die Profilierungsaktivitaet der Kehlkopfkrebszellen in bezug auf klinische Befunde zu bestimmen . Im Mittelpunkt unserer Untersuchungen stand das Krebsgewebe von 120 Larynxkarzinompatienten , bei denen eine chirurgische Behandlung , Radiotherapie bzw. kombinierte Therapie vorgenommen wurde . Das klinische Fortschreiten der Krankheit stuften wir bei 39 Kranken als Grad III und bei 31 Faellen als Grad IV ein . Immunhistochemische Untersuchungen fuehrten wir mit der " Avidin-biothin-Methode " durch , wobei Peroxydase als Enzym und Diaminobezidin als Chromogen angewandt wurden . Fuer die Bestimmung der immunohistochemischen Faerbung der Krebszellen benutzten wir eine 5stufige Skala . Eine positive Faerbung der Zellkerne des Laynxkrebses mit p53 wurde in 70% , mit Ki67 in 57% und mit PCNA in 80% der Faelle festgestellt . Wir fanden in 38% der Faelle aneuploidale und in 62% diploidale DNA . Mit den ultrastrukturellen Untersuchungen ermittelten wir den individuellen Charakter des Plasmas und der Kerne . Alle aneuploidalen Tumoren zeigten eine starke Faerbung der Zellkerne der p53- und Ki67-Gene. Bei der PCNA wurden keine Reaktionen beobachtet . Dabei wurde eine statistisch hoch signifikante Korrelation ( p 0,001 ) zwischen der Aneuploidie und dem T und N nachgewiesen . Man kann behaupten , dass der angewandte Komplex von Untersuchungstechniken des Krebsgewebes zu einer praeziseren Einschaetzung seiner biologischen Aktivitaet beitragen kann .
[ "Dieser", "Beitrag", "setzt", "sich", "um", "Ziel", ",", "die", "Profilierungsaktivitaet", "der", "Kehlkopfkrebszellen", "in", "bezug", "auf", "klinische", "Befunde", "zu", "bestimmen", ".", "Im", "Mittelpunkt", "unserer", "Untersuchungen", "stand", "das", "Krebsgewebe", "von", "120", "Larynxkarzinompatienten", ",", "bei", "denen", "eine", "chirurgische", "Behandlung", ",", "Radiotherapie", "bzw", ".", "kombinierte", "Therapie", "vorgenommen", "wurde", ".", "Das", "klinische", "Fortschreiten", "der", "Krankheit", "stuften", "wir", "bei", "39", "Kranken", "als", "Grad", "III", "und", "bei", "31", "Faellen", "als", "Grad", "IV", "ein", ".", "Immunhistochemische", "Untersuchungen", "fuehrten", "wir", "mit", "der", "\"", "Avidin", "-", "biothin", "-", "Methode", "\"", "durch", ",", "wobei", "Peroxydase", "als", "Enzym", "und", "Diaminobezidin", "als", "Chromogen", "angewandt", "wurden", ".", "Fuer", "die", "Bestimmung", "der", "immunohistochemischen", "Faerbung", "der", "Krebszellen", "benutzten", "wir", "eine", "5stufige", "Skala", ".", "Eine", "positive", "Faerbung", "der", "Zellkerne", "des", "Laynxkrebses", "mit", "p53", "wurde", "in", "70", "%", ",", "mit", "Ki67", "in", "57", "%", "und", "mit", "PCNA", "in", "80", "%", "der", "Faelle", "festgestellt", ".", "Wir", "fanden", "in", "38", "%", "der", "Faelle", "aneuploidale", "und", "in", "62", "%", "diploidale", "DNA", ".", "Mit", "den", "ultrastrukturellen", "Untersuchungen", "ermittelten", "wir", "den", "individuellen", "Charakter", "des", "Plasmas", "und", "der", "Kerne", ".", "Alle", "aneuploidalen", "Tumoren", "zeigten", "eine", "starke", "Faerbung", "der", "Zellkerne", "der", "p53-", "und", "Ki67-Gene", ".", "Bei", "der", "PCNA", "wurden", "keine", "Reaktionen", "beobachtet", ".", "Dabei", "wurde", "eine", "statistisch", "hoch", "signifikante", "Korrelation", "(", "p", "0,001", ")", "zwischen", "der", "Aneuploidie", "und", "dem", "T", "und", "N", "nachgewiesen", ".", "Man", "kann", "behaupten", ",", "dass", "der", "angewandte", "Komplex", "von", "Untersuchungstechniken", "des", "Krebsgewebes", "zu", "einer", "praeziseren", "Einschaetzung", "seiner", "biologischen", "Aktivitaet", "beitragen", "kann", "." ]
[ "umlsterm" ]
cadaver is an umlsterm, dissections is an umlsterm, anatomy is an umlsterm, iliac artery is an umlsterm, epigastric artery is an umlsterm, donor is an umlsterm, vessels is an umlsterm, transfer is an umlsterm, groin is an umlsterm, flaps is an umlsterm, bone is an umlsterm, injection is an umlsterm, ink is an umlsterm, capillary is an umlsterm, vessels is an umlsterm, crest is an umlsterm, bone is an umlsterm, muscle is an umlsterm, skin is an umlsterm, groin is an umlsterm, thigh is an umlsterm, iliac artery is an umlsterm, supply is an umlsterm, vessels is an umlsterm, groin is an umlsterm, thigh is an umlsterm, drainage is an umlsterm, iliac veins is an umlsterm, iliac artery is an umlsterm, skin is an umlsterm, donor is an umlsterm, vessel is an umlsterm, skin is an umlsterm, tissue transplants is an umlsterm, iliac artery is an umlsterm, pelvic bone is an umlsterm, muscle is an umlsterm, skin is an umlsterm, crest is an umlsterm, Bone is an umlsterm, muscle is an umlsterm, bone is an umlsterm, muscle is an umlsterm, skin is an umlsterm, transplants is an umlsterm, donor is an umlsterm, vessel is an umlsterm, enlargement is an umlsterm, skin is an umlsterm, transplant is an umlsterm, vessel is an umlsterm, iliac artery is an umlsterm, iliac artery is an umlsterm, vessels is an umlsterm, transplantation is an umlsterm, tissues is an umlsterm, muscle is an umlsterm, bone is an umlsterm, skin is an umlsterm, defects is an umlsterm
HNO.70450967.eng.abstr_task0
Sentence: We performed 25 fresh cadaver dissections to describe the anatomy of the superficial and deep circumflex iliac artery and the superficial inferior epigastric artery to determine how they could least to used as donor vessels for the free transfer of groin flaps and living iliac bone . With injection of ink the capillary region of these vessels was stained in ( iliac crest ) bone , the internal oblique muscle and skin of the groin and thigh . The superficial and deep circumflex iliac artery were shown to be the main supply vessels of the groin and thigh and could be found in 96%-100% of cases . The venous drainage of this region followed from a superficial system ( superficial circumflex iliac veins ) and a deep venous system ( Vv . comitantes accompaning arterial branches ) . Both venous systems could always be found . The superficial circumflex iliac artery was shown to only supply the skin and was the main donor vessel to the skin and soft tissue transplants . The deep circumflex iliac artery supplied the pelvic bone , the internal oblique muscle and a small constant area of skin above the iliac crest . Bone , muscle and bone , muscle and skin transplants could be obtained with this donor vessel , with enlargement of the skin area possible by combining two arterial branches combined in one transplant . With an average vessel diameter of 1.5 mm ( superficial circumflex iliac artery ) and 3 mm ( deep circumflex iliac artery ) both vessels could be used satisfactorily for microvascular transplantation . Different tissues including muscle , bone and skin could be obtained in adequate amounts to replace composite defects in the upper aerodigestive tract . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
We performed 25 fresh cadaver dissections to describe the anatomy of the superficial and deep circumflex iliac artery and the superficial inferior epigastric artery to determine how they could least to used as donor vessels for the free transfer of groin flaps and living iliac bone . With injection of ink the capillary region of these vessels was stained in ( iliac crest ) bone , the internal oblique muscle and skin of the groin and thigh . The superficial and deep circumflex iliac artery were shown to be the main supply vessels of the groin and thigh and could be found in 96%-100% of cases . The venous drainage of this region followed from a superficial system ( superficial circumflex iliac veins ) and a deep venous system ( Vv . comitantes accompaning arterial branches ) . Both venous systems could always be found . The superficial circumflex iliac artery was shown to only supply the skin and was the main donor vessel to the skin and soft tissue transplants . The deep circumflex iliac artery supplied the pelvic bone , the internal oblique muscle and a small constant area of skin above the iliac crest . Bone , muscle and bone , muscle and skin transplants could be obtained with this donor vessel , with enlargement of the skin area possible by combining two arterial branches combined in one transplant . With an average vessel diameter of 1.5 mm ( superficial circumflex iliac artery ) and 3 mm ( deep circumflex iliac artery ) both vessels could be used satisfactorily for microvascular transplantation . Different tissues including muscle , bone and skin could be obtained in adequate amounts to replace composite defects in the upper aerodigestive tract .
[ "We", "performed", "25", "fresh", "cadaver", "dissections", "to", "describe", "the", "anatomy", "of", "the", "superficial", "and", "deep", "circumflex", "iliac", "artery", "and", "the", "superficial", "inferior", "epigastric", "artery", "to", "determine", "how", "they", "could", "least", "to", "used", "as", "donor", "vessels", "for", "the", "free", "transfer", "of", "groin", "flaps", "and", "living", "iliac", "bone", ".", "With", "injection", "of", "ink", "the", "capillary", "region", "of", "these", "vessels", "was", "stained", "in", "(", "iliac", "crest", ")", "bone", ",", "the", "internal", "oblique", "muscle", "and", "skin", "of", "the", "groin", "and", "thigh", ".", "The", "superficial", "and", "deep", "circumflex", "iliac", "artery", "were", "shown", "to", "be", "the", "main", "supply", "vessels", "of", "the", "groin", "and", "thigh", "and", "could", "be", "found", "in", "96%-100", "%", "of", "cases", ".", "The", "venous", "drainage", "of", "this", "region", "followed", "from", "a", "superficial", "system", "(", "superficial", "circumflex", "iliac", "veins", ")", "and", "a", "deep", "venous", "system", "(", "Vv", ".", "comitantes", "accompaning", "arterial", "branches", ")", ".", "Both", "venous", "systems", "could", "always", "be", "found", ".", "The", "superficial", "circumflex", "iliac", "artery", "was", "shown", "to", "only", "supply", "the", "skin", "and", "was", "the", "main", "donor", "vessel", "to", "the", "skin", "and", "soft", "tissue", "transplants", ".", "The", "deep", "circumflex", "iliac", "artery", "supplied", "the", "pelvic", "bone", ",", "the", "internal", "oblique", "muscle", "and", "a", "small", "constant", "area", "of", "skin", "above", "the", "iliac", "crest", ".", "Bone", ",", "muscle", "and", "bone", ",", "muscle", "and", "skin", "transplants", "could", "be", "obtained", "with", "this", "donor", "vessel", ",", "with", "enlargement", "of", "the", "skin", "area", "possible", "by", "combining", "two", "arterial", "branches", "combined", "in", "one", "transplant", ".", "With", "an", "average", "vessel", "diameter", "of", "1.5", "mm", "(", "superficial", "circumflex", "iliac", "artery", ")", "and", "3", "mm", "(", "deep", "circumflex", "iliac", "artery", ")", "both", "vessels", "could", "be", "used", "satisfactorily", "for", "microvascular", "transplantation", ".", "Different", "tissues", "including", "muscle", ",", "bone", "and", "skin", "could", "be", "obtained", "in", "adequate", "amounts", "to", "replace", "composite", "defects", "in", "the", "upper", "aerodigestive", "tract", "." ]
[ "umlsterm" ]
cadaver is an umlsterm, dissections is an umlsterm, anatomy is an umlsterm, iliac artery is an umlsterm, epigastric artery is an umlsterm, donor is an umlsterm, vessels is an umlsterm, transfer is an umlsterm, groin is an umlsterm, flaps is an umlsterm, bone is an umlsterm, injection is an umlsterm, ink is an umlsterm, capillary is an umlsterm, vessels is an umlsterm, crest is an umlsterm, bone is an umlsterm, muscle is an umlsterm, skin is an umlsterm, groin is an umlsterm, thigh is an umlsterm, iliac artery is an umlsterm, supply is an umlsterm, vessels is an umlsterm, groin is an umlsterm, thigh is an umlsterm, drainage is an umlsterm, iliac veins is an umlsterm, iliac artery is an umlsterm, skin is an umlsterm, donor is an umlsterm, vessel is an umlsterm, skin is an umlsterm, tissue transplants is an umlsterm, iliac artery is an umlsterm, pelvic bone is an umlsterm, muscle is an umlsterm, skin is an umlsterm, crest is an umlsterm, Bone is an umlsterm, muscle is an umlsterm, bone is an umlsterm, muscle is an umlsterm, skin is an umlsterm, transplants is an umlsterm, donor is an umlsterm, vessel is an umlsterm, enlargement is an umlsterm, skin is an umlsterm, transplant is an umlsterm, vessel is an umlsterm, iliac artery is an umlsterm, iliac artery is an umlsterm, vessels is an umlsterm, transplantation is an umlsterm, tissues is an umlsterm, muscle is an umlsterm, bone is an umlsterm, skin is an umlsterm, defects is an umlsterm
HNO.70450967.eng.abstr_task1
Sentence: We performed 25 fresh cadaver dissections to describe the anatomy of the superficial and deep circumflex iliac artery and the superficial inferior epigastric artery to determine how they could least to used as donor vessels for the free transfer of groin flaps and living iliac bone . With injection of ink the capillary region of these vessels was stained in ( iliac crest ) bone , the internal oblique muscle and skin of the groin and thigh . The superficial and deep circumflex iliac artery were shown to be the main supply vessels of the groin and thigh and could be found in 96%-100% of cases . The venous drainage of this region followed from a superficial system ( superficial circumflex iliac veins ) and a deep venous system ( Vv . comitantes accompaning arterial branches ) . Both venous systems could always be found . The superficial circumflex iliac artery was shown to only supply the skin and was the main donor vessel to the skin and soft tissue transplants . The deep circumflex iliac artery supplied the pelvic bone , the internal oblique muscle and a small constant area of skin above the iliac crest . Bone , muscle and bone , muscle and skin transplants could be obtained with this donor vessel , with enlargement of the skin area possible by combining two arterial branches combined in one transplant . With an average vessel diameter of 1.5 mm ( superficial circumflex iliac artery ) and 3 mm ( deep circumflex iliac artery ) both vessels could be used satisfactorily for microvascular transplantation . Different tissues including muscle , bone and skin could be obtained in adequate amounts to replace composite defects in the upper aerodigestive tract . Instructions: please typing these entity words according to sentence: cadaver, dissections, anatomy, iliac artery, epigastric artery, donor, vessels, transfer, groin, flaps, bone, injection, ink, capillary, vessels, crest, bone, muscle, skin, groin, thigh, iliac artery, supply, vessels, groin, thigh, drainage, iliac veins, iliac artery, skin, donor, vessel, skin, tissue transplants, iliac artery, pelvic bone, muscle, skin, crest, Bone, muscle, bone, muscle, skin, transplants, donor, vessel, enlargement, skin, transplant, vessel, iliac artery, iliac artery, vessels, transplantation, tissues, muscle, bone, skin, defects Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
We performed 25 fresh cadaver dissections to describe the anatomy of the superficial and deep circumflex iliac artery and the superficial inferior epigastric artery to determine how they could least to used as donor vessels for the free transfer of groin flaps and living iliac bone . With injection of ink the capillary region of these vessels was stained in ( iliac crest ) bone , the internal oblique muscle and skin of the groin and thigh . The superficial and deep circumflex iliac artery were shown to be the main supply vessels of the groin and thigh and could be found in 96%-100% of cases . The venous drainage of this region followed from a superficial system ( superficial circumflex iliac veins ) and a deep venous system ( Vv . comitantes accompaning arterial branches ) . Both venous systems could always be found . The superficial circumflex iliac artery was shown to only supply the skin and was the main donor vessel to the skin and soft tissue transplants . The deep circumflex iliac artery supplied the pelvic bone , the internal oblique muscle and a small constant area of skin above the iliac crest . Bone , muscle and bone , muscle and skin transplants could be obtained with this donor vessel , with enlargement of the skin area possible by combining two arterial branches combined in one transplant . With an average vessel diameter of 1.5 mm ( superficial circumflex iliac artery ) and 3 mm ( deep circumflex iliac artery ) both vessels could be used satisfactorily for microvascular transplantation . Different tissues including muscle , bone and skin could be obtained in adequate amounts to replace composite defects in the upper aerodigestive tract .
[ "We", "performed", "25", "fresh", "cadaver", "dissections", "to", "describe", "the", "anatomy", "of", "the", "superficial", "and", "deep", "circumflex", "iliac", "artery", "and", "the", "superficial", "inferior", "epigastric", "artery", "to", "determine", "how", "they", "could", "least", "to", "used", "as", "donor", "vessels", "for", "the", "free", "transfer", "of", "groin", "flaps", "and", "living", "iliac", "bone", ".", "With", "injection", "of", "ink", "the", "capillary", "region", "of", "these", "vessels", "was", "stained", "in", "(", "iliac", "crest", ")", "bone", ",", "the", "internal", "oblique", "muscle", "and", "skin", "of", "the", "groin", "and", "thigh", ".", "The", "superficial", "and", "deep", "circumflex", "iliac", "artery", "were", "shown", "to", "be", "the", "main", "supply", "vessels", "of", "the", "groin", "and", "thigh", "and", "could", "be", "found", "in", "96%-100", "%", "of", "cases", ".", "The", "venous", "drainage", "of", "this", "region", "followed", "from", "a", "superficial", "system", "(", "superficial", "circumflex", "iliac", "veins", ")", "and", "a", "deep", "venous", "system", "(", "Vv", ".", "comitantes", "accompaning", "arterial", "branches", ")", ".", "Both", "venous", "systems", "could", "always", "be", "found", ".", "The", "superficial", "circumflex", "iliac", "artery", "was", "shown", "to", "only", "supply", "the", "skin", "and", "was", "the", "main", "donor", "vessel", "to", "the", "skin", "and", "soft", "tissue", "transplants", ".", "The", "deep", "circumflex", "iliac", "artery", "supplied", "the", "pelvic", "bone", ",", "the", "internal", "oblique", "muscle", "and", "a", "small", "constant", "area", "of", "skin", "above", "the", "iliac", "crest", ".", "Bone", ",", "muscle", "and", "bone", ",", "muscle", "and", "skin", "transplants", "could", "be", "obtained", "with", "this", "donor", "vessel", ",", "with", "enlargement", "of", "the", "skin", "area", "possible", "by", "combining", "two", "arterial", "branches", "combined", "in", "one", "transplant", ".", "With", "an", "average", "vessel", "diameter", "of", "1.5", "mm", "(", "superficial", "circumflex", "iliac", "artery", ")", "and", "3", "mm", "(", "deep", "circumflex", "iliac", "artery", ")", "both", "vessels", "could", "be", "used", "satisfactorily", "for", "microvascular", "transplantation", ".", "Different", "tissues", "including", "muscle", ",", "bone", "and", "skin", "could", "be", "obtained", "in", "adequate", "amounts", "to", "replace", "composite", "defects", "in", "the", "upper", "aerodigestive", "tract", "." ]
[ "umlsterm" ]
cadaver, dissections, anatomy, iliac artery, epigastric artery, donor, vessels, transfer, groin, flaps, bone, injection, ink, capillary, vessels, crest, bone, muscle, skin, groin, thigh, iliac artery, supply, vessels, groin, thigh, drainage, iliac veins, iliac artery, skin, donor, vessel, skin, tissue transplants, iliac artery, pelvic bone, muscle, skin, crest, Bone, muscle, bone, muscle, skin, transplants, donor, vessel, enlargement, skin, transplant, vessel, iliac artery, iliac artery, vessels, transplantation, tissues, muscle, bone, skin, defects
HNO.70450967.eng.abstr_task2
Sentence: We performed 25 fresh cadaver dissections to describe the anatomy of the superficial and deep circumflex iliac artery and the superficial inferior epigastric artery to determine how they could least to used as donor vessels for the free transfer of groin flaps and living iliac bone . With injection of ink the capillary region of these vessels was stained in ( iliac crest ) bone , the internal oblique muscle and skin of the groin and thigh . The superficial and deep circumflex iliac artery were shown to be the main supply vessels of the groin and thigh and could be found in 96%-100% of cases . The venous drainage of this region followed from a superficial system ( superficial circumflex iliac veins ) and a deep venous system ( Vv . comitantes accompaning arterial branches ) . Both venous systems could always be found . The superficial circumflex iliac artery was shown to only supply the skin and was the main donor vessel to the skin and soft tissue transplants . The deep circumflex iliac artery supplied the pelvic bone , the internal oblique muscle and a small constant area of skin above the iliac crest . Bone , muscle and bone , muscle and skin transplants could be obtained with this donor vessel , with enlargement of the skin area possible by combining two arterial branches combined in one transplant . With an average vessel diameter of 1.5 mm ( superficial circumflex iliac artery ) and 3 mm ( deep circumflex iliac artery ) both vessels could be used satisfactorily for microvascular transplantation . Different tissues including muscle , bone and skin could be obtained in adequate amounts to replace composite defects in the upper aerodigestive tract . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
We performed 25 fresh cadaver dissections to describe the anatomy of the superficial and deep circumflex iliac artery and the superficial inferior epigastric artery to determine how they could least to used as donor vessels for the free transfer of groin flaps and living iliac bone . With injection of ink the capillary region of these vessels was stained in ( iliac crest ) bone , the internal oblique muscle and skin of the groin and thigh . The superficial and deep circumflex iliac artery were shown to be the main supply vessels of the groin and thigh and could be found in 96%-100% of cases . The venous drainage of this region followed from a superficial system ( superficial circumflex iliac veins ) and a deep venous system ( Vv . comitantes accompaning arterial branches ) . Both venous systems could always be found . The superficial circumflex iliac artery was shown to only supply the skin and was the main donor vessel to the skin and soft tissue transplants . The deep circumflex iliac artery supplied the pelvic bone , the internal oblique muscle and a small constant area of skin above the iliac crest . Bone , muscle and bone , muscle and skin transplants could be obtained with this donor vessel , with enlargement of the skin area possible by combining two arterial branches combined in one transplant . With an average vessel diameter of 1.5 mm ( superficial circumflex iliac artery ) and 3 mm ( deep circumflex iliac artery ) both vessels could be used satisfactorily for microvascular transplantation . Different tissues including muscle , bone and skin could be obtained in adequate amounts to replace composite defects in the upper aerodigestive tract .
[ "We", "performed", "25", "fresh", "cadaver", "dissections", "to", "describe", "the", "anatomy", "of", "the", "superficial", "and", "deep", "circumflex", "iliac", "artery", "and", "the", "superficial", "inferior", "epigastric", "artery", "to", "determine", "how", "they", "could", "least", "to", "used", "as", "donor", "vessels", "for", "the", "free", "transfer", "of", "groin", "flaps", "and", "living", "iliac", "bone", ".", "With", "injection", "of", "ink", "the", "capillary", "region", "of", "these", "vessels", "was", "stained", "in", "(", "iliac", "crest", ")", "bone", ",", "the", "internal", "oblique", "muscle", "and", "skin", "of", "the", "groin", "and", "thigh", ".", "The", "superficial", "and", "deep", "circumflex", "iliac", "artery", "were", "shown", "to", "be", "the", "main", "supply", "vessels", "of", "the", "groin", "and", "thigh", "and", "could", "be", "found", "in", "96%-100", "%", "of", "cases", ".", "The", "venous", "drainage", "of", "this", "region", "followed", "from", "a", "superficial", "system", "(", "superficial", "circumflex", "iliac", "veins", ")", "and", "a", "deep", "venous", "system", "(", "Vv", ".", "comitantes", "accompaning", "arterial", "branches", ")", ".", "Both", "venous", "systems", "could", "always", "be", "found", ".", "The", "superficial", "circumflex", "iliac", "artery", "was", "shown", "to", "only", "supply", "the", "skin", "and", "was", "the", "main", "donor", "vessel", "to", "the", "skin", "and", "soft", "tissue", "transplants", ".", "The", "deep", "circumflex", "iliac", "artery", "supplied", "the", "pelvic", "bone", ",", "the", "internal", "oblique", "muscle", "and", "a", "small", "constant", "area", "of", "skin", "above", "the", "iliac", "crest", ".", "Bone", ",", "muscle", "and", "bone", ",", "muscle", "and", "skin", "transplants", "could", "be", "obtained", "with", "this", "donor", "vessel", ",", "with", "enlargement", "of", "the", "skin", "area", "possible", "by", "combining", "two", "arterial", "branches", "combined", "in", "one", "transplant", ".", "With", "an", "average", "vessel", "diameter", "of", "1.5", "mm", "(", "superficial", "circumflex", "iliac", "artery", ")", "and", "3", "mm", "(", "deep", "circumflex", "iliac", "artery", ")", "both", "vessels", "could", "be", "used", "satisfactorily", "for", "microvascular", "transplantation", ".", "Different", "tissues", "including", "muscle", ",", "bone", "and", "skin", "could", "be", "obtained", "in", "adequate", "amounts", "to", "replace", "composite", "defects", "in", "the", "upper", "aerodigestive", "tract", "." ]
[ "umlsterm" ]
insulin is a GENE-Y, Insulin is a GENE-Y, insulin is a GENE-Y, glutaraldehyde is a CHEMICAL, insulin is a GENE-Y, Bacitracin is a CHEMICAL, sodium taurocholate is a CHEMICAL, insulin is a GENE-Y, phosphate is a CHEMICAL, HCl is a CHEMICAL, trypsin is a GENE-N, bacitracin is a CHEMICAL, bacitracin is a CHEMICAL, insulin is a GENE-Y, Insulin is a GENE-Y, insulin is a GENE-Y
32576_task0
Sentence: Predictive modeling of insulin release profile from cross-linked chitosan microspheres. Insulin-loaded microspheres composed of chitosan 3% (w/v), and loading 120 IU insulin were produced by emulsion cross-linking method. Cross-linking time was 5 h and glutaraldehyde 3.5% (v/v) was used as cross-linker. Swelling ratio studies were evaluated to predict release of insulin from chitosan microspheres. Bacitracin and sodium taurocholate were incorporated in the formulations as proteolytic enzyme inhibitor and absorption enhancer, respectively. In vitro insulin release studies were performed in phosphate buffer pH 7.4 and also in HCl pH 2 with and without trypsin. Activity of bacitracin was also evaluated. In vitro release showed a controlled profile up to 12 h and the formulation containing 0.15% (w/v) of bacitracin revealed a maximum biological activity of about 49.1 ± 4.1%. Mathematical modeling using Higuchi and Korsmeyer-Peppas suggested a non-Fickian diffusion as the mechanism of insulin release. Insulin-loaded chitosan microspheres for oral delivery showed to be an innovative and reliable delivery system to overcome conventional insulin therapy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL
[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]
Predictive modeling of insulin release profile from cross-linked chitosan microspheres. Insulin-loaded microspheres composed of chitosan 3% (w/v), and loading 120 IU insulin were produced by emulsion cross-linking method. Cross-linking time was 5 h and glutaraldehyde 3.5% (v/v) was used as cross-linker. Swelling ratio studies were evaluated to predict release of insulin from chitosan microspheres. Bacitracin and sodium taurocholate were incorporated in the formulations as proteolytic enzyme inhibitor and absorption enhancer, respectively. In vitro insulin release studies were performed in phosphate buffer pH 7.4 and also in HCl pH 2 with and without trypsin. Activity of bacitracin was also evaluated. In vitro release showed a controlled profile up to 12 h and the formulation containing 0.15% (w/v) of bacitracin revealed a maximum biological activity of about 49.1 ± 4.1%. Mathematical modeling using Higuchi and Korsmeyer-Peppas suggested a non-Fickian diffusion as the mechanism of insulin release. Insulin-loaded chitosan microspheres for oral delivery showed to be an innovative and reliable delivery system to overcome conventional insulin therapy.
[ "Predictive", "modeling", "of", "insulin", "release", "profile", "from", "cross", "-", "linked", "chitosan", "microspheres", ".", "\n", "Insulin", "-", "loaded", "microspheres", "composed", "of", "chitosan", "3", "%", "(", "w", "/", "v", ")", ",", "and", "loading", "120", "IU", "insulin", "were", "produced", "by", "emulsion", "cross", "-", "linking", "method", ".", "Cross", "-", "linking", "time", "was", "5", "h", "and", "glutaraldehyde", "3.5", "%", "(", "v", "/", "v", ")", "was", "used", "as", "cross", "-", "linker", ".", "Swelling", "ratio", "studies", "were", "evaluated", "to", "predict", "release", "of", "insulin", "from", "chitosan", "microspheres", ".", "Bacitracin", "and", "sodium", "taurocholate", "were", "incorporated", "in", "the", "formulations", "as", "proteolytic", "enzyme", "inhibitor", "and", "absorption", "enhancer", ",", "respectively", ".", "In", "vitro", "insulin", "release", "studies", "were", "performed", "in", "phosphate", "buffer", "pH", "7.4", "and", "also", "in", "HCl", "pH", "2", "with", "and", "without", "trypsin", ".", "Activity", "of", "bacitracin", "was", "also", "evaluated", ".", "In", "vitro", "release", "showed", "a", "controlled", "profile", "up", "to", "12", "h", "and", "the", "formulation", "containing", "0.15", "%", "(", "w", "/", "v", ")", "of", "bacitracin", "revealed", "a", "maximum", "biological", "activity", "of", "about", "49.1", "±", "4.1", "%", ".", "Mathematical", "modeling", "using", "Higuchi", "and", "Korsmeyer", "-", "Peppas", "suggested", "a", "non", "-", "Fickian", "diffusion", "as", "the", "mechanism", "of", "insulin", "release", ".", "Insulin", "-", "loaded", "chitosan", "microspheres", "for", "oral", "delivery", "showed", "to", "be", "an", "innovative", "and", "reliable", "delivery", "system", "to", "overcome", "conventional", "insulin", "therapy", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
insulin is a GENE-Y, Insulin is a GENE-Y, insulin is a GENE-Y, glutaraldehyde is a CHEMICAL, insulin is a GENE-Y, Bacitracin is a CHEMICAL, sodium taurocholate is a CHEMICAL, insulin is a GENE-Y, phosphate is a CHEMICAL, HCl is a CHEMICAL, trypsin is a GENE-N, bacitracin is a CHEMICAL, bacitracin is a CHEMICAL, insulin is a GENE-Y, Insulin is a GENE-Y, insulin is a GENE-Y
32576_task1
Sentence: Predictive modeling of insulin release profile from cross-linked chitosan microspheres. Insulin-loaded microspheres composed of chitosan 3% (w/v), and loading 120 IU insulin were produced by emulsion cross-linking method. Cross-linking time was 5 h and glutaraldehyde 3.5% (v/v) was used as cross-linker. Swelling ratio studies were evaluated to predict release of insulin from chitosan microspheres. Bacitracin and sodium taurocholate were incorporated in the formulations as proteolytic enzyme inhibitor and absorption enhancer, respectively. In vitro insulin release studies were performed in phosphate buffer pH 7.4 and also in HCl pH 2 with and without trypsin. Activity of bacitracin was also evaluated. In vitro release showed a controlled profile up to 12 h and the formulation containing 0.15% (w/v) of bacitracin revealed a maximum biological activity of about 49.1 ± 4.1%. Mathematical modeling using Higuchi and Korsmeyer-Peppas suggested a non-Fickian diffusion as the mechanism of insulin release. Insulin-loaded chitosan microspheres for oral delivery showed to be an innovative and reliable delivery system to overcome conventional insulin therapy. Instructions: please typing these entity words according to sentence: insulin, Insulin, insulin, glutaraldehyde, insulin, Bacitracin, sodium taurocholate, insulin, phosphate, HCl, trypsin, bacitracin, bacitracin, insulin, Insulin, insulin Options: GENE-N, GENE-Y, CHEMICAL
[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]
Predictive modeling of insulin release profile from cross-linked chitosan microspheres. Insulin-loaded microspheres composed of chitosan 3% (w/v), and loading 120 IU insulin were produced by emulsion cross-linking method. Cross-linking time was 5 h and glutaraldehyde 3.5% (v/v) was used as cross-linker. Swelling ratio studies were evaluated to predict release of insulin from chitosan microspheres. Bacitracin and sodium taurocholate were incorporated in the formulations as proteolytic enzyme inhibitor and absorption enhancer, respectively. In vitro insulin release studies were performed in phosphate buffer pH 7.4 and also in HCl pH 2 with and without trypsin. Activity of bacitracin was also evaluated. In vitro release showed a controlled profile up to 12 h and the formulation containing 0.15% (w/v) of bacitracin revealed a maximum biological activity of about 49.1 ± 4.1%. Mathematical modeling using Higuchi and Korsmeyer-Peppas suggested a non-Fickian diffusion as the mechanism of insulin release. Insulin-loaded chitosan microspheres for oral delivery showed to be an innovative and reliable delivery system to overcome conventional insulin therapy.
[ "Predictive", "modeling", "of", "insulin", "release", "profile", "from", "cross", "-", "linked", "chitosan", "microspheres", ".", "\n", "Insulin", "-", "loaded", "microspheres", "composed", "of", "chitosan", "3", "%", "(", "w", "/", "v", ")", ",", "and", "loading", "120", "IU", "insulin", "were", "produced", "by", "emulsion", "cross", "-", "linking", "method", ".", "Cross", "-", "linking", "time", "was", "5", "h", "and", "glutaraldehyde", "3.5", "%", "(", "v", "/", "v", ")", "was", "used", "as", "cross", "-", "linker", ".", "Swelling", "ratio", "studies", "were", "evaluated", "to", "predict", "release", "of", "insulin", "from", "chitosan", "microspheres", ".", "Bacitracin", "and", "sodium", "taurocholate", "were", "incorporated", "in", "the", "formulations", "as", "proteolytic", "enzyme", "inhibitor", "and", "absorption", "enhancer", ",", "respectively", ".", "In", "vitro", "insulin", "release", "studies", "were", "performed", "in", "phosphate", "buffer", "pH", "7.4", "and", "also", "in", "HCl", "pH", "2", "with", "and", "without", "trypsin", ".", "Activity", "of", "bacitracin", "was", "also", "evaluated", ".", "In", "vitro", "release", "showed", "a", "controlled", "profile", "up", "to", "12", "h", "and", "the", "formulation", "containing", "0.15", "%", "(", "w", "/", "v", ")", "of", "bacitracin", "revealed", "a", "maximum", "biological", "activity", "of", "about", "49.1", "±", "4.1", "%", ".", "Mathematical", "modeling", "using", "Higuchi", "and", "Korsmeyer", "-", "Peppas", "suggested", "a", "non", "-", "Fickian", "diffusion", "as", "the", "mechanism", "of", "insulin", "release", ".", "Insulin", "-", "loaded", "chitosan", "microspheres", "for", "oral", "delivery", "showed", "to", "be", "an", "innovative", "and", "reliable", "delivery", "system", "to", "overcome", "conventional", "insulin", "therapy", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
insulin, Insulin, insulin, glutaraldehyde, insulin, Bacitracin, sodium taurocholate, insulin, phosphate, HCl, trypsin, bacitracin, bacitracin, insulin, Insulin, insulin
32576_task2
Sentence: Predictive modeling of insulin release profile from cross-linked chitosan microspheres. Insulin-loaded microspheres composed of chitosan 3% (w/v), and loading 120 IU insulin were produced by emulsion cross-linking method. Cross-linking time was 5 h and glutaraldehyde 3.5% (v/v) was used as cross-linker. Swelling ratio studies were evaluated to predict release of insulin from chitosan microspheres. Bacitracin and sodium taurocholate were incorporated in the formulations as proteolytic enzyme inhibitor and absorption enhancer, respectively. In vitro insulin release studies were performed in phosphate buffer pH 7.4 and also in HCl pH 2 with and without trypsin. Activity of bacitracin was also evaluated. In vitro release showed a controlled profile up to 12 h and the formulation containing 0.15% (w/v) of bacitracin revealed a maximum biological activity of about 49.1 ± 4.1%. Mathematical modeling using Higuchi and Korsmeyer-Peppas suggested a non-Fickian diffusion as the mechanism of insulin release. Insulin-loaded chitosan microspheres for oral delivery showed to be an innovative and reliable delivery system to overcome conventional insulin therapy. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]
Predictive modeling of insulin release profile from cross-linked chitosan microspheres. Insulin-loaded microspheres composed of chitosan 3% (w/v), and loading 120 IU insulin were produced by emulsion cross-linking method. Cross-linking time was 5 h and glutaraldehyde 3.5% (v/v) was used as cross-linker. Swelling ratio studies were evaluated to predict release of insulin from chitosan microspheres. Bacitracin and sodium taurocholate were incorporated in the formulations as proteolytic enzyme inhibitor and absorption enhancer, respectively. In vitro insulin release studies were performed in phosphate buffer pH 7.4 and also in HCl pH 2 with and without trypsin. Activity of bacitracin was also evaluated. In vitro release showed a controlled profile up to 12 h and the formulation containing 0.15% (w/v) of bacitracin revealed a maximum biological activity of about 49.1 ± 4.1%. Mathematical modeling using Higuchi and Korsmeyer-Peppas suggested a non-Fickian diffusion as the mechanism of insulin release. Insulin-loaded chitosan microspheres for oral delivery showed to be an innovative and reliable delivery system to overcome conventional insulin therapy.
[ "Predictive", "modeling", "of", "insulin", "release", "profile", "from", "cross", "-", "linked", "chitosan", "microspheres", ".", "\n", "Insulin", "-", "loaded", "microspheres", "composed", "of", "chitosan", "3", "%", "(", "w", "/", "v", ")", ",", "and", "loading", "120", "IU", "insulin", "were", "produced", "by", "emulsion", "cross", "-", "linking", "method", ".", "Cross", "-", "linking", "time", "was", "5", "h", "and", "glutaraldehyde", "3.5", "%", "(", "v", "/", "v", ")", "was", "used", "as", "cross", "-", "linker", ".", "Swelling", "ratio", "studies", "were", "evaluated", "to", "predict", "release", "of", "insulin", "from", "chitosan", "microspheres", ".", "Bacitracin", "and", "sodium", "taurocholate", "were", "incorporated", "in", "the", "formulations", "as", "proteolytic", "enzyme", "inhibitor", "and", "absorption", "enhancer", ",", "respectively", ".", "In", "vitro", "insulin", "release", "studies", "were", "performed", "in", "phosphate", "buffer", "pH", "7.4", "and", "also", "in", "HCl", "pH", "2", "with", "and", "without", "trypsin", ".", "Activity", "of", "bacitracin", "was", "also", "evaluated", ".", "In", "vitro", "release", "showed", "a", "controlled", "profile", "up", "to", "12", "h", "and", "the", "formulation", "containing", "0.15", "%", "(", "w", "/", "v", ")", "of", "bacitracin", "revealed", "a", "maximum", "biological", "activity", "of", "about", "49.1", "±", "4.1", "%", ".", "Mathematical", "modeling", "using", "Higuchi", "and", "Korsmeyer", "-", "Peppas", "suggested", "a", "non", "-", "Fickian", "diffusion", "as", "the", "mechanism", "of", "insulin", "release", ".", "Insulin", "-", "loaded", "chitosan", "microspheres", "for", "oral", "delivery", "showed", "to", "be", "an", "innovative", "and", "reliable", "delivery", "system", "to", "overcome", "conventional", "insulin", "therapy", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Munc18 - 2 is a Gene/protein/RNA, syntaxin 3 is a Gene/protein/RNA
81_task0
Sentence: This implies that Munc18-2 function in apical membrane trafficking involves aspects independent of the syntaxin 3 interaction. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA
[ "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O" ]
This implies that Munc18-2 function in apical membrane trafficking involves aspects independent of the syntaxin 3 interaction.
[ "This", "implies", "that", "Munc18", "-", "2", "function", "in", "apical", "membrane", "trafficking", "involves", "aspects", "independent", "of", "the", "syntaxin", "3", "interaction", "." ]
[ "Gene/protein/RNA" ]
Munc18 - 2 is a Gene/protein/RNA, syntaxin 3 is a Gene/protein/RNA
81_task1
Sentence: This implies that Munc18-2 function in apical membrane trafficking involves aspects independent of the syntaxin 3 interaction. Instructions: please typing these entity words according to sentence: Munc18 - 2, syntaxin 3 Options: Gene/protein/RNA
[ "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O" ]
This implies that Munc18-2 function in apical membrane trafficking involves aspects independent of the syntaxin 3 interaction.
[ "This", "implies", "that", "Munc18", "-", "2", "function", "in", "apical", "membrane", "trafficking", "involves", "aspects", "independent", "of", "the", "syntaxin", "3", "interaction", "." ]
[ "Gene/protein/RNA" ]
Munc18 - 2, syntaxin 3
81_task2
Sentence: This implies that Munc18-2 function in apical membrane trafficking involves aspects independent of the syntaxin 3 interaction. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O" ]
This implies that Munc18-2 function in apical membrane trafficking involves aspects independent of the syntaxin 3 interaction.
[ "This", "implies", "that", "Munc18", "-", "2", "function", "in", "apical", "membrane", "trafficking", "involves", "aspects", "independent", "of", "the", "syntaxin", "3", "interaction", "." ]
[ "Gene/protein/RNA" ]
placebo - controlled is a Intervention_Control, olanzapine is a Intervention_Pharmacological, childhood / adolescent is a Participant_Age, pervasive developmental disorder is a Participant_Condition, disruptive and repetitive behaviors is a Outcome_Mental, side effects is a Outcome_Adverse-effects, Eleven is a Participant_Sample-size, autism is a Participant_Condition, Asperger ' s syndrome is a Participant_Condition, PDD - NOS is a Participant_Condition, 6 - 14 years is a Participant_Age, Clinical Global Impressions- Improvement ( CGI - I ) is a Outcome_Mental, significant weight gain is a Outcome_Physical, global functioning of PDDs is a Outcome_Mental
28462_task0
Sentence: A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder . Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders ( PDDs ) , but they require assessment of potential side effects . This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD . Eleven patients with a diagnosis of either autism , Asperger 's syndrome , or PDD not otherwise specified ( PDD-NOS ) and aged 6-14 years were randomized into an 8-week double-blind , placebo-controlled , parallel treatment study with olanzapine . There was a significant linear trend x group interaction on the Clinical Global Impressions- Improvement ( CGI-I ) and 50 % on olanzapine versus 20 % on placebo were responders . Olanzapine was associated with significant weight gain ( 7.5 +/- 4.8 lbs vs. 1.5 +/- 1.5 lbs on placebo ) . Olanzapine may be a promising treatment for improving global functioning of PDDs , but the risk of significant weight gain remains a concern . Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder . Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders ( PDDs ) , but they require assessment of potential side effects . This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD . Eleven patients with a diagnosis of either autism , Asperger 's syndrome , or PDD not otherwise specified ( PDD-NOS ) and aged 6-14 years were randomized into an 8-week double-blind , placebo-controlled , parallel treatment study with olanzapine . There was a significant linear trend x group interaction on the Clinical Global Impressions- Improvement ( CGI-I ) and 50 % on olanzapine versus 20 % on placebo were responders . Olanzapine was associated with significant weight gain ( 7.5 +/- 4.8 lbs vs. 1.5 +/- 1.5 lbs on placebo ) . Olanzapine may be a promising treatment for improving global functioning of PDDs , but the risk of significant weight gain remains a concern . Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD .
[ "A", "double", "-", "blind", "placebo", "-", "controlled", "pilot", "study", "of", "olanzapine", "in", "childhood", "/", "adolescent", "pervasive", "developmental", "disorder", ".", "Atypical", "antipsychotics", "have", "been", "shown", "to", "improve", "disruptive", "and", "repetitive", "behaviors", "in", "pervasive", "developmental", "disorders", "(", "PDDs", ")", ",", "but", "they", "require", "assessment", "of", "potential", "side", "effects", ".", "This", "is", "the", "first", "placebo", "-", "controlled", "trial", "of", "olanzapine", "in", "the", "treatment", "of", "children", "and", "adolescents", "with", "PDD", ".", "Eleven", "patients", "with", "a", "diagnosis", "of", "either", "autism", ",", "Asperger", "'", "s", "syndrome", ",", "or", "PDD", "not", "otherwise", "specified", "(", "PDD", "-", "NOS", ")", "and", "aged", "6", "-", "14", "years", "were", "randomized", "into", "an", "8-week", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "treatment", "study", "with", "olanzapine", ".", "There", "was", "a", "significant", "linear", "trend", "x", "group", "interaction", "on", "the", "Clinical", "Global", "Impressions-", "Improvement", "(", "CGI", "-", "I", ")", "and", "50", "%", "on", "olanzapine", "versus", "20", "%", "on", "placebo", "were", "responders", ".", "Olanzapine", "was", "associated", "with", "significant", "weight", "gain", "(", "7.5", "+", "/-", "4.8", "lbs", "vs", ".", "1.5", "+", "/-", "1.5", "lbs", "on", "placebo", ")", ".", "Olanzapine", "may", "be", "a", "promising", "treatment", "for", "improving", "global", "functioning", "of", "PDDs", ",", "but", "the", "risk", "of", "significant", "weight", "gain", "remains", "a", "concern", ".", "Additional", "studies", "are", "needed", "to", "determine", "the", "efficacy", "and", "safety", "of", "olanzapine", "in", "the", "treatment", "of", "children", "with", "PDD", "." ]
[ "Outcome_Mental", "Participant_Condition", "Outcome_Physical", "Participant_Age", "Intervention_Control", "Outcome_Adverse-effects", "Intervention_Pharmacological", "Participant_Sample-size" ]
placebo - controlled is a Intervention_Control, olanzapine is a Intervention_Pharmacological, childhood / adolescent is a Participant_Age, pervasive developmental disorder is a Participant_Condition, disruptive and repetitive behaviors is a Outcome_Mental, side effects is a Outcome_Adverse-effects, Eleven is a Participant_Sample-size, autism is a Participant_Condition, Asperger ' s syndrome is a Participant_Condition, PDD - NOS is a Participant_Condition, 6 - 14 years is a Participant_Age, Clinical Global Impressions- Improvement ( CGI - I ) is a Outcome_Mental, significant weight gain is a Outcome_Physical, global functioning of PDDs is a Outcome_Mental
28462_task1
Sentence: A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder . Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders ( PDDs ) , but they require assessment of potential side effects . This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD . Eleven patients with a diagnosis of either autism , Asperger 's syndrome , or PDD not otherwise specified ( PDD-NOS ) and aged 6-14 years were randomized into an 8-week double-blind , placebo-controlled , parallel treatment study with olanzapine . There was a significant linear trend x group interaction on the Clinical Global Impressions- Improvement ( CGI-I ) and 50 % on olanzapine versus 20 % on placebo were responders . Olanzapine was associated with significant weight gain ( 7.5 +/- 4.8 lbs vs. 1.5 +/- 1.5 lbs on placebo ) . Olanzapine may be a promising treatment for improving global functioning of PDDs , but the risk of significant weight gain remains a concern . Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD . Instructions: please typing these entity words according to sentence: placebo - controlled, olanzapine, childhood / adolescent, pervasive developmental disorder, disruptive and repetitive behaviors, side effects, Eleven, autism, Asperger ' s syndrome, PDD - NOS, 6 - 14 years, Clinical Global Impressions- Improvement ( CGI - I ), significant weight gain, global functioning of PDDs Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder . Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders ( PDDs ) , but they require assessment of potential side effects . This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD . Eleven patients with a diagnosis of either autism , Asperger 's syndrome , or PDD not otherwise specified ( PDD-NOS ) and aged 6-14 years were randomized into an 8-week double-blind , placebo-controlled , parallel treatment study with olanzapine . There was a significant linear trend x group interaction on the Clinical Global Impressions- Improvement ( CGI-I ) and 50 % on olanzapine versus 20 % on placebo were responders . Olanzapine was associated with significant weight gain ( 7.5 +/- 4.8 lbs vs. 1.5 +/- 1.5 lbs on placebo ) . Olanzapine may be a promising treatment for improving global functioning of PDDs , but the risk of significant weight gain remains a concern . Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD .
[ "A", "double", "-", "blind", "placebo", "-", "controlled", "pilot", "study", "of", "olanzapine", "in", "childhood", "/", "adolescent", "pervasive", "developmental", "disorder", ".", "Atypical", "antipsychotics", "have", "been", "shown", "to", "improve", "disruptive", "and", "repetitive", "behaviors", "in", "pervasive", "developmental", "disorders", "(", "PDDs", ")", ",", "but", "they", "require", "assessment", "of", "potential", "side", "effects", ".", "This", "is", "the", "first", "placebo", "-", "controlled", "trial", "of", "olanzapine", "in", "the", "treatment", "of", "children", "and", "adolescents", "with", "PDD", ".", "Eleven", "patients", "with", "a", "diagnosis", "of", "either", "autism", ",", "Asperger", "'", "s", "syndrome", ",", "or", "PDD", "not", "otherwise", "specified", "(", "PDD", "-", "NOS", ")", "and", "aged", "6", "-", "14", "years", "were", "randomized", "into", "an", "8-week", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "treatment", "study", "with", "olanzapine", ".", "There", "was", "a", "significant", "linear", "trend", "x", "group", "interaction", "on", "the", "Clinical", "Global", "Impressions-", "Improvement", "(", "CGI", "-", "I", ")", "and", "50", "%", "on", "olanzapine", "versus", "20", "%", "on", "placebo", "were", "responders", ".", "Olanzapine", "was", "associated", "with", "significant", "weight", "gain", "(", "7.5", "+", "/-", "4.8", "lbs", "vs", ".", "1.5", "+", "/-", "1.5", "lbs", "on", "placebo", ")", ".", "Olanzapine", "may", "be", "a", "promising", "treatment", "for", "improving", "global", "functioning", "of", "PDDs", ",", "but", "the", "risk", "of", "significant", "weight", "gain", "remains", "a", "concern", ".", "Additional", "studies", "are", "needed", "to", "determine", "the", "efficacy", "and", "safety", "of", "olanzapine", "in", "the", "treatment", "of", "children", "with", "PDD", "." ]
[ "Outcome_Mental", "Participant_Condition", "Outcome_Physical", "Participant_Age", "Intervention_Control", "Outcome_Adverse-effects", "Intervention_Pharmacological", "Participant_Sample-size" ]
placebo - controlled, olanzapine, childhood / adolescent, pervasive developmental disorder, disruptive and repetitive behaviors, side effects, Eleven, autism, Asperger ' s syndrome, PDD - NOS, 6 - 14 years, Clinical Global Impressions- Improvement ( CGI - I ), significant weight gain, global functioning of PDDs
28462_task2
Sentence: A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder . Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders ( PDDs ) , but they require assessment of potential side effects . This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD . Eleven patients with a diagnosis of either autism , Asperger 's syndrome , or PDD not otherwise specified ( PDD-NOS ) and aged 6-14 years were randomized into an 8-week double-blind , placebo-controlled , parallel treatment study with olanzapine . There was a significant linear trend x group interaction on the Clinical Global Impressions- Improvement ( CGI-I ) and 50 % on olanzapine versus 20 % on placebo were responders . Olanzapine was associated with significant weight gain ( 7.5 +/- 4.8 lbs vs. 1.5 +/- 1.5 lbs on placebo ) . Olanzapine may be a promising treatment for improving global functioning of PDDs , but the risk of significant weight gain remains a concern . Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder . Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders ( PDDs ) , but they require assessment of potential side effects . This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD . Eleven patients with a diagnosis of either autism , Asperger 's syndrome , or PDD not otherwise specified ( PDD-NOS ) and aged 6-14 years were randomized into an 8-week double-blind , placebo-controlled , parallel treatment study with olanzapine . There was a significant linear trend x group interaction on the Clinical Global Impressions- Improvement ( CGI-I ) and 50 % on olanzapine versus 20 % on placebo were responders . Olanzapine was associated with significant weight gain ( 7.5 +/- 4.8 lbs vs. 1.5 +/- 1.5 lbs on placebo ) . Olanzapine may be a promising treatment for improving global functioning of PDDs , but the risk of significant weight gain remains a concern . Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD .
[ "A", "double", "-", "blind", "placebo", "-", "controlled", "pilot", "study", "of", "olanzapine", "in", "childhood", "/", "adolescent", "pervasive", "developmental", "disorder", ".", "Atypical", "antipsychotics", "have", "been", "shown", "to", "improve", "disruptive", "and", "repetitive", "behaviors", "in", "pervasive", "developmental", "disorders", "(", "PDDs", ")", ",", "but", "they", "require", "assessment", "of", "potential", "side", "effects", ".", "This", "is", "the", "first", "placebo", "-", "controlled", "trial", "of", "olanzapine", "in", "the", "treatment", "of", "children", "and", "adolescents", "with", "PDD", ".", "Eleven", "patients", "with", "a", "diagnosis", "of", "either", "autism", ",", "Asperger", "'", "s", "syndrome", ",", "or", "PDD", "not", "otherwise", "specified", "(", "PDD", "-", "NOS", ")", "and", "aged", "6", "-", "14", "years", "were", "randomized", "into", "an", "8-week", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "treatment", "study", "with", "olanzapine", ".", "There", "was", "a", "significant", "linear", "trend", "x", "group", "interaction", "on", "the", "Clinical", "Global", "Impressions-", "Improvement", "(", "CGI", "-", "I", ")", "and", "50", "%", "on", "olanzapine", "versus", "20", "%", "on", "placebo", "were", "responders", ".", "Olanzapine", "was", "associated", "with", "significant", "weight", "gain", "(", "7.5", "+", "/-", "4.8", "lbs", "vs", ".", "1.5", "+", "/-", "1.5", "lbs", "on", "placebo", ")", ".", "Olanzapine", "may", "be", "a", "promising", "treatment", "for", "improving", "global", "functioning", "of", "PDDs", ",", "but", "the", "risk", "of", "significant", "weight", "gain", "remains", "a", "concern", ".", "Additional", "studies", "are", "needed", "to", "determine", "the", "efficacy", "and", "safety", "of", "olanzapine", "in", "the", "treatment", "of", "children", "with", "PDD", "." ]
[ "Outcome_Mental", "Participant_Condition", "Outcome_Physical", "Participant_Age", "Intervention_Control", "Outcome_Adverse-effects", "Intervention_Pharmacological", "Participant_Sample-size" ]
Blood purification is a Intervention_Physical, blood purifying technologies is a Intervention_Physical, critically ill patients , especially those with severe sepsis . is a Participant_Condition, polymyxin B immobilized fiber is a Intervention_Pharmacological, charcoal hemoperfusion is a Intervention_Pharmacological, plasma or whole blood exchange is a Intervention_Physical, efficacy is a Outcome_Other, indications is a Outcome_Other
815_task0
Sentence: Blood purification for critical care medicine : endotoxin adsorption . Many kinds of blood purifying technologies have been applied to the treatment of critically ill patients since 1979 when plasma exchange with hollow-fiber membranes was developed . These technologies have been applied not only to the removal of toxic substances , but also to the treatment of objective diseases and the removal of the factors relating to the associated inflammation . This article summarizes these methods and their efficacies for critically ill patients , especially those with severe sepsis . Attempts have been made to remove endotoxin , the main cause of sepsis , from the circulation using polymyxin B immobilized fiber , charcoal hemoperfusion , and plasma or whole blood exchange . Attempts have also been made to remove proinflammatory cytokines , eicosanoides , and coagulative factors from the circulation in the human body . Continuous hemofiltration or hemodiafiltration is the representative technology . The efficacy of these methods has been established , but several issues remain unresolved . All methods of the treatment of severe sepsis are discussed with reference to treatment indications , efficacy , and outcome parameters . In particular , the clinical results of endotoxin removal with polymyxin B immobilized fiber are summarized in this article . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Other, Intervention_Pharmacological, Participant_Condition
[ "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Blood purification for critical care medicine : endotoxin adsorption . Many kinds of blood purifying technologies have been applied to the treatment of critically ill patients since 1979 when plasma exchange with hollow-fiber membranes was developed . These technologies have been applied not only to the removal of toxic substances , but also to the treatment of objective diseases and the removal of the factors relating to the associated inflammation . This article summarizes these methods and their efficacies for critically ill patients , especially those with severe sepsis . Attempts have been made to remove endotoxin , the main cause of sepsis , from the circulation using polymyxin B immobilized fiber , charcoal hemoperfusion , and plasma or whole blood exchange . Attempts have also been made to remove proinflammatory cytokines , eicosanoides , and coagulative factors from the circulation in the human body . Continuous hemofiltration or hemodiafiltration is the representative technology . The efficacy of these methods has been established , but several issues remain unresolved . All methods of the treatment of severe sepsis are discussed with reference to treatment indications , efficacy , and outcome parameters . In particular , the clinical results of endotoxin removal with polymyxin B immobilized fiber are summarized in this article .
[ "Blood", "purification", "for", "critical", "care", "medicine", ":", "endotoxin", "adsorption", ".", "Many", "kinds", "of", "blood", "purifying", "technologies", "have", "been", "applied", "to", "the", "treatment", "of", "critically", "ill", "patients", "since", "1979", "when", "plasma", "exchange", "with", "hollow", "-", "fiber", "membranes", "was", "developed", ".", "These", "technologies", "have", "been", "applied", "not", "only", "to", "the", "removal", "of", "toxic", "substances", ",", "but", "also", "to", "the", "treatment", "of", "objective", "diseases", "and", "the", "removal", "of", "the", "factors", "relating", "to", "the", "associated", "inflammation", ".", "This", "article", "summarizes", "these", "methods", "and", "their", "efficacies", "for", "critically", "ill", "patients", ",", "especially", "those", "with", "severe", "sepsis", ".", "Attempts", "have", "been", "made", "to", "remove", "endotoxin", ",", "the", "main", "cause", "of", "sepsis", ",", "from", "the", "circulation", "using", "polymyxin", "B", "immobilized", "fiber", ",", "charcoal", "hemoperfusion", ",", "and", "plasma", "or", "whole", "blood", "exchange", ".", "Attempts", "have", "also", "been", "made", "to", "remove", "proinflammatory", "cytokines", ",", "eicosanoides", ",", "and", "coagulative", "factors", "from", "the", "circulation", "in", "the", "human", "body", ".", "Continuous", "hemofiltration", "or", "hemodiafiltration", "is", "the", "representative", "technology", ".", "The", "efficacy", "of", "these", "methods", "has", "been", "established", ",", "but", "several", "issues", "remain", "unresolved", ".", "All", "methods", "of", "the", "treatment", "of", "severe", "sepsis", "are", "discussed", "with", "reference", "to", "treatment", "indications", ",", "efficacy", ",", "and", "outcome", "parameters", ".", "In", "particular", ",", "the", "clinical", "results", "of", "endotoxin", "removal", "with", "polymyxin", "B", "immobilized", "fiber", "are", "summarized", "in", "this", "article", "." ]
[ "Participant_Condition", "Intervention_Physical", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other" ]
Blood purification is a Intervention_Physical, blood purifying technologies is a Intervention_Physical, critically ill patients , especially those with severe sepsis . is a Participant_Condition, polymyxin B immobilized fiber is a Intervention_Pharmacological, charcoal hemoperfusion is a Intervention_Pharmacological, plasma or whole blood exchange is a Intervention_Physical, efficacy is a Outcome_Other, indications is a Outcome_Other
815_task1
Sentence: Blood purification for critical care medicine : endotoxin adsorption . Many kinds of blood purifying technologies have been applied to the treatment of critically ill patients since 1979 when plasma exchange with hollow-fiber membranes was developed . These technologies have been applied not only to the removal of toxic substances , but also to the treatment of objective diseases and the removal of the factors relating to the associated inflammation . This article summarizes these methods and their efficacies for critically ill patients , especially those with severe sepsis . Attempts have been made to remove endotoxin , the main cause of sepsis , from the circulation using polymyxin B immobilized fiber , charcoal hemoperfusion , and plasma or whole blood exchange . Attempts have also been made to remove proinflammatory cytokines , eicosanoides , and coagulative factors from the circulation in the human body . Continuous hemofiltration or hemodiafiltration is the representative technology . The efficacy of these methods has been established , but several issues remain unresolved . All methods of the treatment of severe sepsis are discussed with reference to treatment indications , efficacy , and outcome parameters . In particular , the clinical results of endotoxin removal with polymyxin B immobilized fiber are summarized in this article . Instructions: please typing these entity words according to sentence: Blood purification, blood purifying technologies, critically ill patients , especially those with severe sepsis ., polymyxin B immobilized fiber, charcoal hemoperfusion, plasma or whole blood exchange, efficacy, indications Options: Intervention_Physical, Outcome_Other, Intervention_Pharmacological, Participant_Condition
[ "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Blood purification for critical care medicine : endotoxin adsorption . Many kinds of blood purifying technologies have been applied to the treatment of critically ill patients since 1979 when plasma exchange with hollow-fiber membranes was developed . These technologies have been applied not only to the removal of toxic substances , but also to the treatment of objective diseases and the removal of the factors relating to the associated inflammation . This article summarizes these methods and their efficacies for critically ill patients , especially those with severe sepsis . Attempts have been made to remove endotoxin , the main cause of sepsis , from the circulation using polymyxin B immobilized fiber , charcoal hemoperfusion , and plasma or whole blood exchange . Attempts have also been made to remove proinflammatory cytokines , eicosanoides , and coagulative factors from the circulation in the human body . Continuous hemofiltration or hemodiafiltration is the representative technology . The efficacy of these methods has been established , but several issues remain unresolved . All methods of the treatment of severe sepsis are discussed with reference to treatment indications , efficacy , and outcome parameters . In particular , the clinical results of endotoxin removal with polymyxin B immobilized fiber are summarized in this article .
[ "Blood", "purification", "for", "critical", "care", "medicine", ":", "endotoxin", "adsorption", ".", "Many", "kinds", "of", "blood", "purifying", "technologies", "have", "been", "applied", "to", "the", "treatment", "of", "critically", "ill", "patients", "since", "1979", "when", "plasma", "exchange", "with", "hollow", "-", "fiber", "membranes", "was", "developed", ".", "These", "technologies", "have", "been", "applied", "not", "only", "to", "the", "removal", "of", "toxic", "substances", ",", "but", "also", "to", "the", "treatment", "of", "objective", "diseases", "and", "the", "removal", "of", "the", "factors", "relating", "to", "the", "associated", "inflammation", ".", "This", "article", "summarizes", "these", "methods", "and", "their", "efficacies", "for", "critically", "ill", "patients", ",", "especially", "those", "with", "severe", "sepsis", ".", "Attempts", "have", "been", "made", "to", "remove", "endotoxin", ",", "the", "main", "cause", "of", "sepsis", ",", "from", "the", "circulation", "using", "polymyxin", "B", "immobilized", "fiber", ",", "charcoal", "hemoperfusion", ",", "and", "plasma", "or", "whole", "blood", "exchange", ".", "Attempts", "have", "also", "been", "made", "to", "remove", "proinflammatory", "cytokines", ",", "eicosanoides", ",", "and", "coagulative", "factors", "from", "the", "circulation", "in", "the", "human", "body", ".", "Continuous", "hemofiltration", "or", "hemodiafiltration", "is", "the", "representative", "technology", ".", "The", "efficacy", "of", "these", "methods", "has", "been", "established", ",", "but", "several", "issues", "remain", "unresolved", ".", "All", "methods", "of", "the", "treatment", "of", "severe", "sepsis", "are", "discussed", "with", "reference", "to", "treatment", "indications", ",", "efficacy", ",", "and", "outcome", "parameters", ".", "In", "particular", ",", "the", "clinical", "results", "of", "endotoxin", "removal", "with", "polymyxin", "B", "immobilized", "fiber", "are", "summarized", "in", "this", "article", "." ]
[ "Participant_Condition", "Intervention_Physical", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other" ]
Blood purification, blood purifying technologies, critically ill patients , especially those with severe sepsis ., polymyxin B immobilized fiber, charcoal hemoperfusion, plasma or whole blood exchange, efficacy, indications
815_task2
Sentence: Blood purification for critical care medicine : endotoxin adsorption . Many kinds of blood purifying technologies have been applied to the treatment of critically ill patients since 1979 when plasma exchange with hollow-fiber membranes was developed . These technologies have been applied not only to the removal of toxic substances , but also to the treatment of objective diseases and the removal of the factors relating to the associated inflammation . This article summarizes these methods and their efficacies for critically ill patients , especially those with severe sepsis . Attempts have been made to remove endotoxin , the main cause of sepsis , from the circulation using polymyxin B immobilized fiber , charcoal hemoperfusion , and plasma or whole blood exchange . Attempts have also been made to remove proinflammatory cytokines , eicosanoides , and coagulative factors from the circulation in the human body . Continuous hemofiltration or hemodiafiltration is the representative technology . The efficacy of these methods has been established , but several issues remain unresolved . All methods of the treatment of severe sepsis are discussed with reference to treatment indications , efficacy , and outcome parameters . In particular , the clinical results of endotoxin removal with polymyxin B immobilized fiber are summarized in this article . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Blood purification for critical care medicine : endotoxin adsorption . Many kinds of blood purifying technologies have been applied to the treatment of critically ill patients since 1979 when plasma exchange with hollow-fiber membranes was developed . These technologies have been applied not only to the removal of toxic substances , but also to the treatment of objective diseases and the removal of the factors relating to the associated inflammation . This article summarizes these methods and their efficacies for critically ill patients , especially those with severe sepsis . Attempts have been made to remove endotoxin , the main cause of sepsis , from the circulation using polymyxin B immobilized fiber , charcoal hemoperfusion , and plasma or whole blood exchange . Attempts have also been made to remove proinflammatory cytokines , eicosanoides , and coagulative factors from the circulation in the human body . Continuous hemofiltration or hemodiafiltration is the representative technology . The efficacy of these methods has been established , but several issues remain unresolved . All methods of the treatment of severe sepsis are discussed with reference to treatment indications , efficacy , and outcome parameters . In particular , the clinical results of endotoxin removal with polymyxin B immobilized fiber are summarized in this article .
[ "Blood", "purification", "for", "critical", "care", "medicine", ":", "endotoxin", "adsorption", ".", "Many", "kinds", "of", "blood", "purifying", "technologies", "have", "been", "applied", "to", "the", "treatment", "of", "critically", "ill", "patients", "since", "1979", "when", "plasma", "exchange", "with", "hollow", "-", "fiber", "membranes", "was", "developed", ".", "These", "technologies", "have", "been", "applied", "not", "only", "to", "the", "removal", "of", "toxic", "substances", ",", "but", "also", "to", "the", "treatment", "of", "objective", "diseases", "and", "the", "removal", "of", "the", "factors", "relating", "to", "the", "associated", "inflammation", ".", "This", "article", "summarizes", "these", "methods", "and", "their", "efficacies", "for", "critically", "ill", "patients", ",", "especially", "those", "with", "severe", "sepsis", ".", "Attempts", "have", "been", "made", "to", "remove", "endotoxin", ",", "the", "main", "cause", "of", "sepsis", ",", "from", "the", "circulation", "using", "polymyxin", "B", "immobilized", "fiber", ",", "charcoal", "hemoperfusion", ",", "and", "plasma", "or", "whole", "blood", "exchange", ".", "Attempts", "have", "also", "been", "made", "to", "remove", "proinflammatory", "cytokines", ",", "eicosanoides", ",", "and", "coagulative", "factors", "from", "the", "circulation", "in", "the", "human", "body", ".", "Continuous", "hemofiltration", "or", "hemodiafiltration", "is", "the", "representative", "technology", ".", "The", "efficacy", "of", "these", "methods", "has", "been", "established", ",", "but", "several", "issues", "remain", "unresolved", ".", "All", "methods", "of", "the", "treatment", "of", "severe", "sepsis", "are", "discussed", "with", "reference", "to", "treatment", "indications", ",", "efficacy", ",", "and", "outcome", "parameters", ".", "In", "particular", ",", "the", "clinical", "results", "of", "endotoxin", "removal", "with", "polymyxin", "B", "immobilized", "fiber", "are", "summarized", "in", "this", "article", "." ]
[ "Participant_Condition", "Intervention_Physical", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Other" ]
Uvulopalatopharyngoplasty is a Intervention_Surgical, laser assisted uvulopalatoplasty is a Intervention_Physical, snoring is a Participant_Condition, conventional uvulopalatopharyngoplasty ( UPPP ) is a Intervention_Surgical, laser assisted uvulopalatoplasty ( LAUP ) is a Intervention_Surgical, Forty - seven is a Participant_Sample-size, snoring loudness is a Outcome_Physical, duration in the home is a Outcome_Other, mean postoperative Snore Index ( SI ) is a Outcome_Physical, effectiveness of snoring surgery is a Outcome_Other
4259_task0
Sentence: Uvulopalatopharyngoplasty versus laser assisted uvulopalatoplasty for the treatment of snoring : an objective randomised clinical trial . This study was designed to evaluate objectively the clinical effectiveness of surgery for snoring and to compare the results of conventional uvulopalatopharyngoplasty ( UPPP ) and laser assisted uvulopalatoplasty ( LAUP ) in the treatment of snoring . Patients who had been referred for investigation and treatment of their snoring were randomly allocated to receive either UPPP or LAUP . Forty-seven patients with confirmed palatal flutter had surgery and all of them had a preoperative and postoperative objective assessment of their snoring loudness and duration in the home . The recording device ( Snore Box ) is simple for the patient to operate , portable with a built in microphone , and able to produce objective results , which can be automatically analysed . Of the 38 patients , who had technically valid recordings , 22 underwent LAUP and 16 UPPP . Overall the mean postoperative Snore Index ( SI ) was less than the preoperative SI ( P < 0.0001 ) , the average difference being 78.2 snores/h . There was no significant difference between the LAUP and UPPP regarding the fall in the SI . This study is the first objective comparative study to demonstrate the effectiveness of snoring surgery . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Intervention_Surgical
[ "B-Intervention_Surgical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]
Uvulopalatopharyngoplasty versus laser assisted uvulopalatoplasty for the treatment of snoring : an objective randomised clinical trial . This study was designed to evaluate objectively the clinical effectiveness of surgery for snoring and to compare the results of conventional uvulopalatopharyngoplasty ( UPPP ) and laser assisted uvulopalatoplasty ( LAUP ) in the treatment of snoring . Patients who had been referred for investigation and treatment of their snoring were randomly allocated to receive either UPPP or LAUP . Forty-seven patients with confirmed palatal flutter had surgery and all of them had a preoperative and postoperative objective assessment of their snoring loudness and duration in the home . The recording device ( Snore Box ) is simple for the patient to operate , portable with a built in microphone , and able to produce objective results , which can be automatically analysed . Of the 38 patients , who had technically valid recordings , 22 underwent LAUP and 16 UPPP . Overall the mean postoperative Snore Index ( SI ) was less than the preoperative SI ( P < 0.0001 ) , the average difference being 78.2 snores/h . There was no significant difference between the LAUP and UPPP regarding the fall in the SI . This study is the first objective comparative study to demonstrate the effectiveness of snoring surgery .
[ "Uvulopalatopharyngoplasty", "versus", "laser", "assisted", "uvulopalatoplasty", "for", "the", "treatment", "of", "snoring", ":", "an", "objective", "randomised", "clinical", "trial", ".", "This", "study", "was", "designed", "to", "evaluate", "objectively", "the", "clinical", "effectiveness", "of", "surgery", "for", "snoring", "and", "to", "compare", "the", "results", "of", "conventional", "uvulopalatopharyngoplasty", "(", "UPPP", ")", "and", "laser", "assisted", "uvulopalatoplasty", "(", "LAUP", ")", "in", "the", "treatment", "of", "snoring", ".", "Patients", "who", "had", "been", "referred", "for", "investigation", "and", "treatment", "of", "their", "snoring", "were", "randomly", "allocated", "to", "receive", "either", "UPPP", "or", "LAUP", ".", "Forty", "-", "seven", "patients", "with", "confirmed", "palatal", "flutter", "had", "surgery", "and", "all", "of", "them", "had", "a", "preoperative", "and", "postoperative", "objective", "assessment", "of", "their", "snoring", "loudness", "and", "duration", "in", "the", "home", ".", "The", "recording", "device", "(", "Snore", "Box", ")", "is", "simple", "for", "the", "patient", "to", "operate", ",", "portable", "with", "a", "built", "in", "microphone", ",", "and", "able", "to", "produce", "objective", "results", ",", "which", "can", "be", "automatically", "analysed", ".", "Of", "the", "38", "patients", ",", "who", "had", "technically", "valid", "recordings", ",", "22", "underwent", "LAUP", "and", "16", "UPPP", ".", "Overall", "the", "mean", "postoperative", "Snore", "Index", "(", "SI", ")", "was", "less", "than", "the", "preoperative", "SI", "(", "P", "<", "0.0001", ")", ",", "the", "average", "difference", "being", "78.2", "snores", "/", "h", ".", "There", "was", "no", "significant", "difference", "between", "the", "LAUP", "and", "UPPP", "regarding", "the", "fall", "in", "the", "SI", ".", "This", "study", "is", "the", "first", "objective", "comparative", "study", "to", "demonstrate", "the", "effectiveness", "of", "snoring", "surgery", "." ]
[ "Intervention_Surgical", "Outcome_Physical", "Intervention_Physical", "Outcome_Other", "Participant_Sample-size", "Participant_Condition" ]
Uvulopalatopharyngoplasty is a Intervention_Surgical, laser assisted uvulopalatoplasty is a Intervention_Physical, snoring is a Participant_Condition, conventional uvulopalatopharyngoplasty ( UPPP ) is a Intervention_Surgical, laser assisted uvulopalatoplasty ( LAUP ) is a Intervention_Surgical, Forty - seven is a Participant_Sample-size, snoring loudness is a Outcome_Physical, duration in the home is a Outcome_Other, mean postoperative Snore Index ( SI ) is a Outcome_Physical, effectiveness of snoring surgery is a Outcome_Other
4259_task1
Sentence: Uvulopalatopharyngoplasty versus laser assisted uvulopalatoplasty for the treatment of snoring : an objective randomised clinical trial . This study was designed to evaluate objectively the clinical effectiveness of surgery for snoring and to compare the results of conventional uvulopalatopharyngoplasty ( UPPP ) and laser assisted uvulopalatoplasty ( LAUP ) in the treatment of snoring . Patients who had been referred for investigation and treatment of their snoring were randomly allocated to receive either UPPP or LAUP . Forty-seven patients with confirmed palatal flutter had surgery and all of them had a preoperative and postoperative objective assessment of their snoring loudness and duration in the home . The recording device ( Snore Box ) is simple for the patient to operate , portable with a built in microphone , and able to produce objective results , which can be automatically analysed . Of the 38 patients , who had technically valid recordings , 22 underwent LAUP and 16 UPPP . Overall the mean postoperative Snore Index ( SI ) was less than the preoperative SI ( P < 0.0001 ) , the average difference being 78.2 snores/h . There was no significant difference between the LAUP and UPPP regarding the fall in the SI . This study is the first objective comparative study to demonstrate the effectiveness of snoring surgery . Instructions: please typing these entity words according to sentence: Uvulopalatopharyngoplasty, laser assisted uvulopalatoplasty, snoring, conventional uvulopalatopharyngoplasty ( UPPP ), laser assisted uvulopalatoplasty ( LAUP ), Forty - seven, snoring loudness, duration in the home, mean postoperative Snore Index ( SI ), effectiveness of snoring surgery Options: Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Intervention_Surgical
[ "B-Intervention_Surgical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]
Uvulopalatopharyngoplasty versus laser assisted uvulopalatoplasty for the treatment of snoring : an objective randomised clinical trial . This study was designed to evaluate objectively the clinical effectiveness of surgery for snoring and to compare the results of conventional uvulopalatopharyngoplasty ( UPPP ) and laser assisted uvulopalatoplasty ( LAUP ) in the treatment of snoring . Patients who had been referred for investigation and treatment of their snoring were randomly allocated to receive either UPPP or LAUP . Forty-seven patients with confirmed palatal flutter had surgery and all of them had a preoperative and postoperative objective assessment of their snoring loudness and duration in the home . The recording device ( Snore Box ) is simple for the patient to operate , portable with a built in microphone , and able to produce objective results , which can be automatically analysed . Of the 38 patients , who had technically valid recordings , 22 underwent LAUP and 16 UPPP . Overall the mean postoperative Snore Index ( SI ) was less than the preoperative SI ( P < 0.0001 ) , the average difference being 78.2 snores/h . There was no significant difference between the LAUP and UPPP regarding the fall in the SI . This study is the first objective comparative study to demonstrate the effectiveness of snoring surgery .
[ "Uvulopalatopharyngoplasty", "versus", "laser", "assisted", "uvulopalatoplasty", "for", "the", "treatment", "of", "snoring", ":", "an", "objective", "randomised", "clinical", "trial", ".", "This", "study", "was", "designed", "to", "evaluate", "objectively", "the", "clinical", "effectiveness", "of", "surgery", "for", "snoring", "and", "to", "compare", "the", "results", "of", "conventional", "uvulopalatopharyngoplasty", "(", "UPPP", ")", "and", "laser", "assisted", "uvulopalatoplasty", "(", "LAUP", ")", "in", "the", "treatment", "of", "snoring", ".", "Patients", "who", "had", "been", "referred", "for", "investigation", "and", "treatment", "of", "their", "snoring", "were", "randomly", "allocated", "to", "receive", "either", "UPPP", "or", "LAUP", ".", "Forty", "-", "seven", "patients", "with", "confirmed", "palatal", "flutter", "had", "surgery", "and", "all", "of", "them", "had", "a", "preoperative", "and", "postoperative", "objective", "assessment", "of", "their", "snoring", "loudness", "and", "duration", "in", "the", "home", ".", "The", "recording", "device", "(", "Snore", "Box", ")", "is", "simple", "for", "the", "patient", "to", "operate", ",", "portable", "with", "a", "built", "in", "microphone", ",", "and", "able", "to", "produce", "objective", "results", ",", "which", "can", "be", "automatically", "analysed", ".", "Of", "the", "38", "patients", ",", "who", "had", "technically", "valid", "recordings", ",", "22", "underwent", "LAUP", "and", "16", "UPPP", ".", "Overall", "the", "mean", "postoperative", "Snore", "Index", "(", "SI", ")", "was", "less", "than", "the", "preoperative", "SI", "(", "P", "<", "0.0001", ")", ",", "the", "average", "difference", "being", "78.2", "snores", "/", "h", ".", "There", "was", "no", "significant", "difference", "between", "the", "LAUP", "and", "UPPP", "regarding", "the", "fall", "in", "the", "SI", ".", "This", "study", "is", "the", "first", "objective", "comparative", "study", "to", "demonstrate", "the", "effectiveness", "of", "snoring", "surgery", "." ]
[ "Intervention_Surgical", "Outcome_Physical", "Intervention_Physical", "Outcome_Other", "Participant_Sample-size", "Participant_Condition" ]
Uvulopalatopharyngoplasty, laser assisted uvulopalatoplasty, snoring, conventional uvulopalatopharyngoplasty ( UPPP ), laser assisted uvulopalatoplasty ( LAUP ), Forty - seven, snoring loudness, duration in the home, mean postoperative Snore Index ( SI ), effectiveness of snoring surgery
4259_task2
Sentence: Uvulopalatopharyngoplasty versus laser assisted uvulopalatoplasty for the treatment of snoring : an objective randomised clinical trial . This study was designed to evaluate objectively the clinical effectiveness of surgery for snoring and to compare the results of conventional uvulopalatopharyngoplasty ( UPPP ) and laser assisted uvulopalatoplasty ( LAUP ) in the treatment of snoring . Patients who had been referred for investigation and treatment of their snoring were randomly allocated to receive either UPPP or LAUP . Forty-seven patients with confirmed palatal flutter had surgery and all of them had a preoperative and postoperative objective assessment of their snoring loudness and duration in the home . The recording device ( Snore Box ) is simple for the patient to operate , portable with a built in microphone , and able to produce objective results , which can be automatically analysed . Of the 38 patients , who had technically valid recordings , 22 underwent LAUP and 16 UPPP . Overall the mean postoperative Snore Index ( SI ) was less than the preoperative SI ( P < 0.0001 ) , the average difference being 78.2 snores/h . There was no significant difference between the LAUP and UPPP regarding the fall in the SI . This study is the first objective comparative study to demonstrate the effectiveness of snoring surgery . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Surgical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]
Uvulopalatopharyngoplasty versus laser assisted uvulopalatoplasty for the treatment of snoring : an objective randomised clinical trial . This study was designed to evaluate objectively the clinical effectiveness of surgery for snoring and to compare the results of conventional uvulopalatopharyngoplasty ( UPPP ) and laser assisted uvulopalatoplasty ( LAUP ) in the treatment of snoring . Patients who had been referred for investigation and treatment of their snoring were randomly allocated to receive either UPPP or LAUP . Forty-seven patients with confirmed palatal flutter had surgery and all of them had a preoperative and postoperative objective assessment of their snoring loudness and duration in the home . The recording device ( Snore Box ) is simple for the patient to operate , portable with a built in microphone , and able to produce objective results , which can be automatically analysed . Of the 38 patients , who had technically valid recordings , 22 underwent LAUP and 16 UPPP . Overall the mean postoperative Snore Index ( SI ) was less than the preoperative SI ( P < 0.0001 ) , the average difference being 78.2 snores/h . There was no significant difference between the LAUP and UPPP regarding the fall in the SI . This study is the first objective comparative study to demonstrate the effectiveness of snoring surgery .
[ "Uvulopalatopharyngoplasty", "versus", "laser", "assisted", "uvulopalatoplasty", "for", "the", "treatment", "of", "snoring", ":", "an", "objective", "randomised", "clinical", "trial", ".", "This", "study", "was", "designed", "to", "evaluate", "objectively", "the", "clinical", "effectiveness", "of", "surgery", "for", "snoring", "and", "to", "compare", "the", "results", "of", "conventional", "uvulopalatopharyngoplasty", "(", "UPPP", ")", "and", "laser", "assisted", "uvulopalatoplasty", "(", "LAUP", ")", "in", "the", "treatment", "of", "snoring", ".", "Patients", "who", "had", "been", "referred", "for", "investigation", "and", "treatment", "of", "their", "snoring", "were", "randomly", "allocated", "to", "receive", "either", "UPPP", "or", "LAUP", ".", "Forty", "-", "seven", "patients", "with", "confirmed", "palatal", "flutter", "had", "surgery", "and", "all", "of", "them", "had", "a", "preoperative", "and", "postoperative", "objective", "assessment", "of", "their", "snoring", "loudness", "and", "duration", "in", "the", "home", ".", "The", "recording", "device", "(", "Snore", "Box", ")", "is", "simple", "for", "the", "patient", "to", "operate", ",", "portable", "with", "a", "built", "in", "microphone", ",", "and", "able", "to", "produce", "objective", "results", ",", "which", "can", "be", "automatically", "analysed", ".", "Of", "the", "38", "patients", ",", "who", "had", "technically", "valid", "recordings", ",", "22", "underwent", "LAUP", "and", "16", "UPPP", ".", "Overall", "the", "mean", "postoperative", "Snore", "Index", "(", "SI", ")", "was", "less", "than", "the", "preoperative", "SI", "(", "P", "<", "0.0001", ")", ",", "the", "average", "difference", "being", "78.2", "snores", "/", "h", ".", "There", "was", "no", "significant", "difference", "between", "the", "LAUP", "and", "UPPP", "regarding", "the", "fall", "in", "the", "SI", ".", "This", "study", "is", "the", "first", "objective", "comparative", "study", "to", "demonstrate", "the", "effectiveness", "of", "snoring", "surgery", "." ]
[ "Intervention_Surgical", "Outcome_Physical", "Intervention_Physical", "Outcome_Other", "Participant_Sample-size", "Participant_Condition" ]
GLP-1 receptor is a GENE-Y
23427056_task0
Sentence: Exendin-4, a GLP-1 receptor agonist, prevents osteopnia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y
[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Exendin-4, a GLP-1 receptor agonist, prevents osteopnia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats.
[ "Exendin-4", ",", "a", "GLP-1", "receptor", "agonist", ",", "prevents", "osteopnia", "by", "promoting", "bone", "formation", "and", "suppressing", "bone", "resorption", "in", "aged", "ovariectomized", "rats", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
GLP-1 receptor is a GENE-Y
23427056_task1
Sentence: Exendin-4, a GLP-1 receptor agonist, prevents osteopnia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. Instructions: please typing these entity words according to sentence: GLP-1 receptor Options: GENE-Y
[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Exendin-4, a GLP-1 receptor agonist, prevents osteopnia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats.
[ "Exendin-4", ",", "a", "GLP-1", "receptor", "agonist", ",", "prevents", "osteopnia", "by", "promoting", "bone", "formation", "and", "suppressing", "bone", "resorption", "in", "aged", "ovariectomized", "rats", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
GLP-1 receptor
23427056_task2
Sentence: Exendin-4, a GLP-1 receptor agonist, prevents osteopnia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Exendin-4, a GLP-1 receptor agonist, prevents osteopnia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats.
[ "Exendin-4", ",", "a", "GLP-1", "receptor", "agonist", ",", "prevents", "osteopnia", "by", "promoting", "bone", "formation", "and", "suppressing", "bone", "resorption", "in", "aged", "ovariectomized", "rats", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
anagrelide is a DRUG, digoxin is a DRUG, warfarin is a DRUG, anagrelide is a DRUG, anagrelide is a DRUG, digoxin is a DRUG, warfarin is a DRUG, anagrelide is a DRUG, aspirin is a BRAND, acetaminophen is a DRUG, furosemide is a DRUG, iron is a DRUG, ranitidine is a DRUG, hydroxyurea is a DRUG, allopurinol is a DRUG, anagrelide is a DRUG, anagrelide is a DRUG, aspirin is a BRAND, anagrelide is a DRUG, acetylsalicylic acid is a DRUG, aspirin is a BRAND, Anagrelide is a DRUG, aspirin is a BRAND, Anagrelide is a DRUG, fluvoxamine is a DRUG, anagrelide is a DRUG, Anagrelide is a DRUG, Anagrelide is a DRUG, theophylline is a DRUG, Anagrelide is a DRUG, milrinone is a DRUG, enoximone is a DRUG, amrinone is a DRUG, olprinone is a DRUG_N, cilostazol is a DRUG, anagrelide is a DRUG, sucralfate is a DRUG, anagrelide is a DRUG, anagrelide is a DRUG
Anagrelide_ddi_task0
Sentence: Limited PK and/or PD studies investigating possible interactions between anagrelide and other medicinal products have been conducted. In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin. Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol. There is no clinical evidence to suggest that anagrelide interacts with any of these compounds. An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated. There was no effect on bleeding time, PT or aPTT. No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed. In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo. Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin. Anagrelide is metabolized at least in part by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline. Anagrelide is an inhibitor of cyclic AMP PDE III. The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide. There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption. Food has no clinically significant effect on the bioavailability of anagrelide. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG_N, BRAND, DRUG
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]
Limited PK and/or PD studies investigating possible interactions between anagrelide and other medicinal products have been conducted. In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin. Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol. There is no clinical evidence to suggest that anagrelide interacts with any of these compounds. An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated. There was no effect on bleeding time, PT or aPTT. No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed. In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo. Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin. Anagrelide is metabolized at least in part by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline. Anagrelide is an inhibitor of cyclic AMP PDE III. The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide. There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption. Food has no clinically significant effect on the bioavailability of anagrelide.
[ "Limited", "PK", "and", "/", "or", "PD", "studies", "investigating", "possible", "interactions", "between", "anagrelide", "and", "other", "medicinal", "products", "have", "been", "conducted", ".", "In", "vivo", "interaction", "studies", "in", "humans", "have", "demonstrated", "that", "digoxin", "and", "warfarin", "do", "not", "affect", "the", "PK", "properties", "of", "anagrelide", ",", "nor", "does", "anagrelide", "affect", "the", "PK", "properties", "of", "digoxin", "or", "warfarin", ".", "Although", "additional", "drug", "interaction", "studies", "have", "not", "been", "conducted", ",", "the", "most", "common", "medications", "used", "concomitantly", "with", "anagrelide", "in", "clinical", "trials", "were", "aspirin", ",", "acetaminophen", ",", "furosemide", ",", "iron", ",", "ranitidine", ",", "hydroxyurea", ",", "and", "allopurinol", ".", "There", "is", "no", "clinical", "evidence", "to", "suggest", "that", "anagrelide", "interacts", "with", "any", "of", "these", "compounds", ".", "An", "in", "vivo", "interaction", "study", "in", "humans", "demonstrated", "that", "a", "single", "1", "mg", "dose", "of", "anagrelide", "administered", "concomitantly", "with", "a", "single", "900", "mg", "dose", "of", "aspirin", "was", "generally", "well", "tolerated", ".", "There", "was", "no", "effect", "on", "bleeding", "time", ",", "PT", "or", "aPTT", ".", "No", "clinically", "relevant", "pharmacokinetic", "interactions", "between", "anagrelide", "and", "acetylsalicylic", "acid", "were", "observed", ".", "In", "that", "same", "study", ",", "aspirin", "alone", "produced", "a", "marked", "inhibition", "in", "platelet", "aggregation", "ex", "vivo", ".", "Anagrelide", "alone", "had", "no", "effect", "on", "platelet", "aggregation", ",", "but", "did", "slightly", "enhance", "the", "inhibition", "of", "platelet", "aggregation", "by", "aspirin", ".", "Anagrelide", "is", "metabolized", "at", "least", "in", "part", "by", "CYP1A2", ".", "It", "is", "known", "that", "CYP1A2", "is", "inhibited", "by", "several", "medicinal", "products", ",", "including", "fluvoxamine", ",", "and", "such", "medicinal", "products", "could", "theoretically", "adversely", "influence", "the", "clearance", "of", "anagrelide", ".", "Anagrelide", "demonstrates", "some", "limited", "inhibitory", "activity", "towards", "CYP1A2", "which", "may", "present", "a", "theoretical", "potential", "for", "interaction", "with", "other", "coadministered", "medicinal", "products", "sharing", "that", "clearance", "mechanism", "e.g", ".", "Anagrelide", "demonstrates", "some", "limited", "inhibitory", "activity", "towards", "CYP1A2", "which", "may", "present", "a", "theoretical", "potential", "for", "interaction", "with", "other", "coadministered", "medicinal", "products", "sharing", "that", "clearance", "mechanism", "e.g", ".", "theophylline", ".", "Anagrelide", "is", "an", "inhibitor", "of", "cyclic", "AMP", "PDE", "III", ".", "The", "effects", "of", "medicinal", "products", "with", "similar", "properties", "such", "as", "inotropes", "milrinone", ",", "enoximone", ",", "amrinone", ",", "olprinone", "and", "cilostazol", "may", "be", "exacerbated", "by", "anagrelide", ".", "There", "is", "a", "single", "case", "report", ",", "which", "suggests", "that", "sucralfate", "may", "interfere", "with", "anagrelide", "absorption", ".", "Food", "has", "no", "clinically", "significant", "effect", "on", "the", "bioavailability", "of", "anagrelide", "." ]
[ "DRUG", "DRUG_N", "BRAND" ]
anagrelide is a DRUG, digoxin is a DRUG, warfarin is a DRUG, anagrelide is a DRUG, anagrelide is a DRUG, digoxin is a DRUG, warfarin is a DRUG, anagrelide is a DRUG, aspirin is a BRAND, acetaminophen is a DRUG, furosemide is a DRUG, iron is a DRUG, ranitidine is a DRUG, hydroxyurea is a DRUG, allopurinol is a DRUG, anagrelide is a DRUG, anagrelide is a DRUG, aspirin is a BRAND, anagrelide is a DRUG, acetylsalicylic acid is a DRUG, aspirin is a BRAND, Anagrelide is a DRUG, aspirin is a BRAND, Anagrelide is a DRUG, fluvoxamine is a DRUG, anagrelide is a DRUG, Anagrelide is a DRUG, Anagrelide is a DRUG, theophylline is a DRUG, Anagrelide is a DRUG, milrinone is a DRUG, enoximone is a DRUG, amrinone is a DRUG, olprinone is a DRUG_N, cilostazol is a DRUG, anagrelide is a DRUG, sucralfate is a DRUG, anagrelide is a DRUG, anagrelide is a DRUG
Anagrelide_ddi_task1
Sentence: Limited PK and/or PD studies investigating possible interactions between anagrelide and other medicinal products have been conducted. In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin. Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol. There is no clinical evidence to suggest that anagrelide interacts with any of these compounds. An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated. There was no effect on bleeding time, PT or aPTT. No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed. In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo. Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin. Anagrelide is metabolized at least in part by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline. Anagrelide is an inhibitor of cyclic AMP PDE III. The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide. There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption. Food has no clinically significant effect on the bioavailability of anagrelide. Instructions: please typing these entity words according to sentence: anagrelide, digoxin, warfarin, anagrelide, anagrelide, digoxin, warfarin, anagrelide, aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, allopurinol, anagrelide, anagrelide, aspirin, anagrelide, acetylsalicylic acid, aspirin, Anagrelide, aspirin, Anagrelide, fluvoxamine, anagrelide, Anagrelide, Anagrelide, theophylline, Anagrelide, milrinone, enoximone, amrinone, olprinone, cilostazol, anagrelide, sucralfate, anagrelide, anagrelide Options: DRUG_N, BRAND, DRUG
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]
Limited PK and/or PD studies investigating possible interactions between anagrelide and other medicinal products have been conducted. In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin. Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol. There is no clinical evidence to suggest that anagrelide interacts with any of these compounds. An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated. There was no effect on bleeding time, PT or aPTT. No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed. In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo. Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin. Anagrelide is metabolized at least in part by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline. Anagrelide is an inhibitor of cyclic AMP PDE III. The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide. There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption. Food has no clinically significant effect on the bioavailability of anagrelide.
[ "Limited", "PK", "and", "/", "or", "PD", "studies", "investigating", "possible", "interactions", "between", "anagrelide", "and", "other", "medicinal", "products", "have", "been", "conducted", ".", "In", "vivo", "interaction", "studies", "in", "humans", "have", "demonstrated", "that", "digoxin", "and", "warfarin", "do", "not", "affect", "the", "PK", "properties", "of", "anagrelide", ",", "nor", "does", "anagrelide", "affect", "the", "PK", "properties", "of", "digoxin", "or", "warfarin", ".", "Although", "additional", "drug", "interaction", "studies", "have", "not", "been", "conducted", ",", "the", "most", "common", "medications", "used", "concomitantly", "with", "anagrelide", "in", "clinical", "trials", "were", "aspirin", ",", "acetaminophen", ",", "furosemide", ",", "iron", ",", "ranitidine", ",", "hydroxyurea", ",", "and", "allopurinol", ".", "There", "is", "no", "clinical", "evidence", "to", "suggest", "that", "anagrelide", "interacts", "with", "any", "of", "these", "compounds", ".", "An", "in", "vivo", "interaction", "study", "in", "humans", "demonstrated", "that", "a", "single", "1", "mg", "dose", "of", "anagrelide", "administered", "concomitantly", "with", "a", "single", "900", "mg", "dose", "of", "aspirin", "was", "generally", "well", "tolerated", ".", "There", "was", "no", "effect", "on", "bleeding", "time", ",", "PT", "or", "aPTT", ".", "No", "clinically", "relevant", "pharmacokinetic", "interactions", "between", "anagrelide", "and", "acetylsalicylic", "acid", "were", "observed", ".", "In", "that", "same", "study", ",", "aspirin", "alone", "produced", "a", "marked", "inhibition", "in", "platelet", "aggregation", "ex", "vivo", ".", "Anagrelide", "alone", "had", "no", "effect", "on", "platelet", "aggregation", ",", "but", "did", "slightly", "enhance", "the", "inhibition", "of", "platelet", "aggregation", "by", "aspirin", ".", "Anagrelide", "is", "metabolized", "at", "least", "in", "part", "by", "CYP1A2", ".", "It", "is", "known", "that", "CYP1A2", "is", "inhibited", "by", "several", "medicinal", "products", ",", "including", "fluvoxamine", ",", "and", "such", "medicinal", "products", "could", "theoretically", "adversely", "influence", "the", "clearance", "of", "anagrelide", ".", "Anagrelide", "demonstrates", "some", "limited", "inhibitory", "activity", "towards", "CYP1A2", "which", "may", "present", "a", "theoretical", "potential", "for", "interaction", "with", "other", "coadministered", "medicinal", "products", "sharing", "that", "clearance", "mechanism", "e.g", ".", "Anagrelide", "demonstrates", "some", "limited", "inhibitory", "activity", "towards", "CYP1A2", "which", "may", "present", "a", "theoretical", "potential", "for", "interaction", "with", "other", "coadministered", "medicinal", "products", "sharing", "that", "clearance", "mechanism", "e.g", ".", "theophylline", ".", "Anagrelide", "is", "an", "inhibitor", "of", "cyclic", "AMP", "PDE", "III", ".", "The", "effects", "of", "medicinal", "products", "with", "similar", "properties", "such", "as", "inotropes", "milrinone", ",", "enoximone", ",", "amrinone", ",", "olprinone", "and", "cilostazol", "may", "be", "exacerbated", "by", "anagrelide", ".", "There", "is", "a", "single", "case", "report", ",", "which", "suggests", "that", "sucralfate", "may", "interfere", "with", "anagrelide", "absorption", ".", "Food", "has", "no", "clinically", "significant", "effect", "on", "the", "bioavailability", "of", "anagrelide", "." ]
[ "DRUG", "DRUG_N", "BRAND" ]
anagrelide, digoxin, warfarin, anagrelide, anagrelide, digoxin, warfarin, anagrelide, aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, allopurinol, anagrelide, anagrelide, aspirin, anagrelide, acetylsalicylic acid, aspirin, Anagrelide, aspirin, Anagrelide, fluvoxamine, anagrelide, Anagrelide, Anagrelide, theophylline, Anagrelide, milrinone, enoximone, amrinone, olprinone, cilostazol, anagrelide, sucralfate, anagrelide, anagrelide
Anagrelide_ddi_task2
Sentence: Limited PK and/or PD studies investigating possible interactions between anagrelide and other medicinal products have been conducted. In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin. Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol. There is no clinical evidence to suggest that anagrelide interacts with any of these compounds. An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated. There was no effect on bleeding time, PT or aPTT. No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed. In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo. Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin. Anagrelide is metabolized at least in part by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline. Anagrelide is an inhibitor of cyclic AMP PDE III. The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide. There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption. Food has no clinically significant effect on the bioavailability of anagrelide. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]
Limited PK and/or PD studies investigating possible interactions between anagrelide and other medicinal products have been conducted. In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin. Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol. There is no clinical evidence to suggest that anagrelide interacts with any of these compounds. An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated. There was no effect on bleeding time, PT or aPTT. No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed. In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo. Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin. Anagrelide is metabolized at least in part by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline. Anagrelide is an inhibitor of cyclic AMP PDE III. The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide. There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption. Food has no clinically significant effect on the bioavailability of anagrelide.
[ "Limited", "PK", "and", "/", "or", "PD", "studies", "investigating", "possible", "interactions", "between", "anagrelide", "and", "other", "medicinal", "products", "have", "been", "conducted", ".", "In", "vivo", "interaction", "studies", "in", "humans", "have", "demonstrated", "that", "digoxin", "and", "warfarin", "do", "not", "affect", "the", "PK", "properties", "of", "anagrelide", ",", "nor", "does", "anagrelide", "affect", "the", "PK", "properties", "of", "digoxin", "or", "warfarin", ".", "Although", "additional", "drug", "interaction", "studies", "have", "not", "been", "conducted", ",", "the", "most", "common", "medications", "used", "concomitantly", "with", "anagrelide", "in", "clinical", "trials", "were", "aspirin", ",", "acetaminophen", ",", "furosemide", ",", "iron", ",", "ranitidine", ",", "hydroxyurea", ",", "and", "allopurinol", ".", "There", "is", "no", "clinical", "evidence", "to", "suggest", "that", "anagrelide", "interacts", "with", "any", "of", "these", "compounds", ".", "An", "in", "vivo", "interaction", "study", "in", "humans", "demonstrated", "that", "a", "single", "1", "mg", "dose", "of", "anagrelide", "administered", "concomitantly", "with", "a", "single", "900", "mg", "dose", "of", "aspirin", "was", "generally", "well", "tolerated", ".", "There", "was", "no", "effect", "on", "bleeding", "time", ",", "PT", "or", "aPTT", ".", "No", "clinically", "relevant", "pharmacokinetic", "interactions", "between", "anagrelide", "and", "acetylsalicylic", "acid", "were", "observed", ".", "In", "that", "same", "study", ",", "aspirin", "alone", "produced", "a", "marked", "inhibition", "in", "platelet", "aggregation", "ex", "vivo", ".", "Anagrelide", "alone", "had", "no", "effect", "on", "platelet", "aggregation", ",", "but", "did", "slightly", "enhance", "the", "inhibition", "of", "platelet", "aggregation", "by", "aspirin", ".", "Anagrelide", "is", "metabolized", "at", "least", "in", "part", "by", "CYP1A2", ".", "It", "is", "known", "that", "CYP1A2", "is", "inhibited", "by", "several", "medicinal", "products", ",", "including", "fluvoxamine", ",", "and", "such", "medicinal", "products", "could", "theoretically", "adversely", "influence", "the", "clearance", "of", "anagrelide", ".", "Anagrelide", "demonstrates", "some", "limited", "inhibitory", "activity", "towards", "CYP1A2", "which", "may", "present", "a", "theoretical", "potential", "for", "interaction", "with", "other", "coadministered", "medicinal", "products", "sharing", "that", "clearance", "mechanism", "e.g", ".", "Anagrelide", "demonstrates", "some", "limited", "inhibitory", "activity", "towards", "CYP1A2", "which", "may", "present", "a", "theoretical", "potential", "for", "interaction", "with", "other", "coadministered", "medicinal", "products", "sharing", "that", "clearance", "mechanism", "e.g", ".", "theophylline", ".", "Anagrelide", "is", "an", "inhibitor", "of", "cyclic", "AMP", "PDE", "III", ".", "The", "effects", "of", "medicinal", "products", "with", "similar", "properties", "such", "as", "inotropes", "milrinone", ",", "enoximone", ",", "amrinone", ",", "olprinone", "and", "cilostazol", "may", "be", "exacerbated", "by", "anagrelide", ".", "There", "is", "a", "single", "case", "report", ",", "which", "suggests", "that", "sucralfate", "may", "interfere", "with", "anagrelide", "absorption", ".", "Food", "has", "no", "clinically", "significant", "effect", "on", "the", "bioavailability", "of", "anagrelide", "." ]
[ "DRUG", "DRUG_N", "BRAND" ]
Knochenperfusion is an umlsterm, Belastung is an umlsterm, Abwehrleistung is an umlsterm, Operationstechniken is an umlsterm, Knochenbruchheilung is an umlsterm
DerUnfallchirurg.81010115.ger.abstr_task0
Sentence: Erhaltung der Knochenperfusion , Schutz des Weichteilmantels und Verminderung der systemischen Belastung durch Staerkung der Abwehrleistung sind wesentliche allgemeine Aspekte der biologischen Osteosynthese . Die minimal-invasiven Operationstechniken schaffen unter Einsatz technischer Hilfen und Tricks die notwendigen Voraussetzungen fuer eine erfolgreiche und komplikationsarme Knochenbruchheilung . Fuer die sog . perkutane perkutane Plattenosteosynthese werden Voraussetzungen und technische Durchfuehrung unter Einsatz einer Gleitkufe und eines Manipulationshandgriffes dargestellt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Erhaltung der Knochenperfusion , Schutz des Weichteilmantels und Verminderung der systemischen Belastung durch Staerkung der Abwehrleistung sind wesentliche allgemeine Aspekte der biologischen Osteosynthese . Die minimal-invasiven Operationstechniken schaffen unter Einsatz technischer Hilfen und Tricks die notwendigen Voraussetzungen fuer eine erfolgreiche und komplikationsarme Knochenbruchheilung . Fuer die sog . perkutane perkutane Plattenosteosynthese werden Voraussetzungen und technische Durchfuehrung unter Einsatz einer Gleitkufe und eines Manipulationshandgriffes dargestellt .
[ "Erhaltung", "der", "Knochenperfusion", ",", "Schutz", "des", "Weichteilmantels", "und", "Verminderung", "der", "systemischen", "Belastung", "durch", "Staerkung", "der", "Abwehrleistung", "sind", "wesentliche", "allgemeine", "Aspekte", "der", "biologischen", "Osteosynthese", ".", "Die", "minimal", "-", "invasiven", "Operationstechniken", "schaffen", "unter", "Einsatz", "technischer", "Hilfen", "und", "Tricks", "die", "notwendigen", "Voraussetzungen", "fuer", "eine", "erfolgreiche", "und", "komplikationsarme", "Knochenbruchheilung", ".", "Fuer", "die", "sog", ".", "perkutane", "perkutane", "Plattenosteosynthese", "werden", "Voraussetzungen", "und", "technische", "Durchfuehrung", "unter", "Einsatz", "einer", "Gleitkufe", "und", "eines", "Manipulationshandgriffes", "dargestellt", "." ]
[ "umlsterm" ]
Knochenperfusion is an umlsterm, Belastung is an umlsterm, Abwehrleistung is an umlsterm, Operationstechniken is an umlsterm, Knochenbruchheilung is an umlsterm
DerUnfallchirurg.81010115.ger.abstr_task1
Sentence: Erhaltung der Knochenperfusion , Schutz des Weichteilmantels und Verminderung der systemischen Belastung durch Staerkung der Abwehrleistung sind wesentliche allgemeine Aspekte der biologischen Osteosynthese . Die minimal-invasiven Operationstechniken schaffen unter Einsatz technischer Hilfen und Tricks die notwendigen Voraussetzungen fuer eine erfolgreiche und komplikationsarme Knochenbruchheilung . Fuer die sog . perkutane perkutane Plattenosteosynthese werden Voraussetzungen und technische Durchfuehrung unter Einsatz einer Gleitkufe und eines Manipulationshandgriffes dargestellt . Instructions: please typing these entity words according to sentence: Knochenperfusion, Belastung, Abwehrleistung, Operationstechniken, Knochenbruchheilung Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Erhaltung der Knochenperfusion , Schutz des Weichteilmantels und Verminderung der systemischen Belastung durch Staerkung der Abwehrleistung sind wesentliche allgemeine Aspekte der biologischen Osteosynthese . Die minimal-invasiven Operationstechniken schaffen unter Einsatz technischer Hilfen und Tricks die notwendigen Voraussetzungen fuer eine erfolgreiche und komplikationsarme Knochenbruchheilung . Fuer die sog . perkutane perkutane Plattenosteosynthese werden Voraussetzungen und technische Durchfuehrung unter Einsatz einer Gleitkufe und eines Manipulationshandgriffes dargestellt .
[ "Erhaltung", "der", "Knochenperfusion", ",", "Schutz", "des", "Weichteilmantels", "und", "Verminderung", "der", "systemischen", "Belastung", "durch", "Staerkung", "der", "Abwehrleistung", "sind", "wesentliche", "allgemeine", "Aspekte", "der", "biologischen", "Osteosynthese", ".", "Die", "minimal", "-", "invasiven", "Operationstechniken", "schaffen", "unter", "Einsatz", "technischer", "Hilfen", "und", "Tricks", "die", "notwendigen", "Voraussetzungen", "fuer", "eine", "erfolgreiche", "und", "komplikationsarme", "Knochenbruchheilung", ".", "Fuer", "die", "sog", ".", "perkutane", "perkutane", "Plattenosteosynthese", "werden", "Voraussetzungen", "und", "technische", "Durchfuehrung", "unter", "Einsatz", "einer", "Gleitkufe", "und", "eines", "Manipulationshandgriffes", "dargestellt", "." ]
[ "umlsterm" ]
Knochenperfusion, Belastung, Abwehrleistung, Operationstechniken, Knochenbruchheilung
DerUnfallchirurg.81010115.ger.abstr_task2
Sentence: Erhaltung der Knochenperfusion , Schutz des Weichteilmantels und Verminderung der systemischen Belastung durch Staerkung der Abwehrleistung sind wesentliche allgemeine Aspekte der biologischen Osteosynthese . Die minimal-invasiven Operationstechniken schaffen unter Einsatz technischer Hilfen und Tricks die notwendigen Voraussetzungen fuer eine erfolgreiche und komplikationsarme Knochenbruchheilung . Fuer die sog . perkutane perkutane Plattenosteosynthese werden Voraussetzungen und technische Durchfuehrung unter Einsatz einer Gleitkufe und eines Manipulationshandgriffes dargestellt . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Erhaltung der Knochenperfusion , Schutz des Weichteilmantels und Verminderung der systemischen Belastung durch Staerkung der Abwehrleistung sind wesentliche allgemeine Aspekte der biologischen Osteosynthese . Die minimal-invasiven Operationstechniken schaffen unter Einsatz technischer Hilfen und Tricks die notwendigen Voraussetzungen fuer eine erfolgreiche und komplikationsarme Knochenbruchheilung . Fuer die sog . perkutane perkutane Plattenosteosynthese werden Voraussetzungen und technische Durchfuehrung unter Einsatz einer Gleitkufe und eines Manipulationshandgriffes dargestellt .
[ "Erhaltung", "der", "Knochenperfusion", ",", "Schutz", "des", "Weichteilmantels", "und", "Verminderung", "der", "systemischen", "Belastung", "durch", "Staerkung", "der", "Abwehrleistung", "sind", "wesentliche", "allgemeine", "Aspekte", "der", "biologischen", "Osteosynthese", ".", "Die", "minimal", "-", "invasiven", "Operationstechniken", "schaffen", "unter", "Einsatz", "technischer", "Hilfen", "und", "Tricks", "die", "notwendigen", "Voraussetzungen", "fuer", "eine", "erfolgreiche", "und", "komplikationsarme", "Knochenbruchheilung", ".", "Fuer", "die", "sog", ".", "perkutane", "perkutane", "Plattenosteosynthese", "werden", "Voraussetzungen", "und", "technische", "Durchfuehrung", "unter", "Einsatz", "einer", "Gleitkufe", "und", "eines", "Manipulationshandgriffes", "dargestellt", "." ]
[ "umlsterm" ]
Schmerztherapie is an umlsterm, Arzt is an umlsterm, Betaeubungsmittel is an umlsterm, Schmerztherapie is an umlsterm, Sicherheit is an umlsterm, Betaeubungsmitteln is an umlsterm, Apotheke is an umlsterm, Betaeubungsmittels is an umlsterm, Betaeubungsmittelgesetzes is an umlsterm, Nachweisfuehrung is an umlsterm, handhabbare is an umlsterm, Praxis is an umlsterm
DerSchmerz.60100299.ger.abstr_task0
Sentence: Die derzeit gueltige Betaeubungsmittel-Verschreibungsverordnung ist nach wie vor wegen ihrer ueberzogenen Regelungsdichte ein Hemmnis fuer eine adaequate Schmerztherapie . Derjenige Arzt , der Betaeubungsmittel verordnen muss , hat u. a. Verschreibungshoechstmengen , den Verschreibungszeitraum , zahlreiche Quer- und Rueckverweise sowie sonstige Spezialregelungen zu beachten und muss befuerchten , gegen Formerfordernisse zu verstossen . Dies fuehrt dazu , dass unter Umstaenden eine notwendige Schmerztherapie unterbleibt ! Ohne die Sicherheit im Verkehr mit Betaeubungsmitteln zu gefaehrden , reicht es nach Ansicht des Autors aus , wenn ein Betaeubungsmittel-Sonderrezeptformular wie jedes andere uebliche Rezept ausgefertigt und von der Apotheke beliefert wird . Entscheidend ist , dass die Anwendung des Betaeubungsmittels im Sinne des § 13 Abs. 1 des Betaeubungsmittelgesetzes begruendet und vom Verordner entsprechend verantwortet wird sowie Verstoesse geahndet werden koennen . Das dreiteilige Sonderrezeptformular gewaehrleistet eine ausreichende Nachweisfuehrung . Der Gesetzgeber wird aufgefordert , die nur schwer les- und handhabbare Betaeubungsmittel-Verschreibungsverordnung durch eine an der Praxis orientierte Verordnung zu ersetzen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Die derzeit gueltige Betaeubungsmittel-Verschreibungsverordnung ist nach wie vor wegen ihrer ueberzogenen Regelungsdichte ein Hemmnis fuer eine adaequate Schmerztherapie . Derjenige Arzt , der Betaeubungsmittel verordnen muss , hat u. a. Verschreibungshoechstmengen , den Verschreibungszeitraum , zahlreiche Quer- und Rueckverweise sowie sonstige Spezialregelungen zu beachten und muss befuerchten , gegen Formerfordernisse zu verstossen . Dies fuehrt dazu , dass unter Umstaenden eine notwendige Schmerztherapie unterbleibt ! Ohne die Sicherheit im Verkehr mit Betaeubungsmitteln zu gefaehrden , reicht es nach Ansicht des Autors aus , wenn ein Betaeubungsmittel-Sonderrezeptformular wie jedes andere uebliche Rezept ausgefertigt und von der Apotheke beliefert wird . Entscheidend ist , dass die Anwendung des Betaeubungsmittels im Sinne des § 13 Abs. 1 des Betaeubungsmittelgesetzes begruendet und vom Verordner entsprechend verantwortet wird sowie Verstoesse geahndet werden koennen . Das dreiteilige Sonderrezeptformular gewaehrleistet eine ausreichende Nachweisfuehrung . Der Gesetzgeber wird aufgefordert , die nur schwer les- und handhabbare Betaeubungsmittel-Verschreibungsverordnung durch eine an der Praxis orientierte Verordnung zu ersetzen .
[ "Die", "derzeit", "gueltige", "Betaeubungsmittel", "-", "Verschreibungsverordnung", "ist", "nach", "wie", "vor", "wegen", "ihrer", "ueberzogenen", "Regelungsdichte", "ein", "Hemmnis", "fuer", "eine", "adaequate", "Schmerztherapie", ".", "Derjenige", "Arzt", ",", "der", "Betaeubungsmittel", "verordnen", "muss", ",", "hat", "u.", "a.", "Verschreibungshoechstmengen", ",", "den", "Verschreibungszeitraum", ",", "zahlreiche", "Quer-", "und", "Rueckverweise", "sowie", "sonstige", "Spezialregelungen", "zu", "beachten", "und", "muss", "befuerchten", ",", "gegen", "Formerfordernisse", "zu", "verstossen", ".", "Dies", "fuehrt", "dazu", ",", "dass", "unter", "Umstaenden", "eine", "notwendige", "Schmerztherapie", "unterbleibt", "!", "Ohne", "die", "Sicherheit", "im", "Verkehr", "mit", "Betaeubungsmitteln", "zu", "gefaehrden", ",", "reicht", "es", "nach", "Ansicht", "des", "Autors", "aus", ",", "wenn", "ein", "Betaeubungsmittel", "-", "Sonderrezeptformular", "wie", "jedes", "andere", "uebliche", "Rezept", "ausgefertigt", "und", "von", "der", "Apotheke", "beliefert", "wird", ".", "Entscheidend", "ist", ",", "dass", "die", "Anwendung", "des", "Betaeubungsmittels", "im", "Sinne", "des", "§", "13", "Abs", ".", "1", "des", "Betaeubungsmittelgesetzes", "begruendet", "und", "vom", "Verordner", "entsprechend", "verantwortet", "wird", "sowie", "Verstoesse", "geahndet", "werden", "koennen", ".", "Das", "dreiteilige", "Sonderrezeptformular", "gewaehrleistet", "eine", "ausreichende", "Nachweisfuehrung", ".", "Der", "Gesetzgeber", "wird", "aufgefordert", ",", "die", "nur", "schwer", "les-", "und", "handhabbare", "Betaeubungsmittel", "-", "Verschreibungsverordnung", "durch", "eine", "an", "der", "Praxis", "orientierte", "Verordnung", "zu", "ersetzen", "." ]
[ "umlsterm" ]
Schmerztherapie is an umlsterm, Arzt is an umlsterm, Betaeubungsmittel is an umlsterm, Schmerztherapie is an umlsterm, Sicherheit is an umlsterm, Betaeubungsmitteln is an umlsterm, Apotheke is an umlsterm, Betaeubungsmittels is an umlsterm, Betaeubungsmittelgesetzes is an umlsterm, Nachweisfuehrung is an umlsterm, handhabbare is an umlsterm, Praxis is an umlsterm
DerSchmerz.60100299.ger.abstr_task1
Sentence: Die derzeit gueltige Betaeubungsmittel-Verschreibungsverordnung ist nach wie vor wegen ihrer ueberzogenen Regelungsdichte ein Hemmnis fuer eine adaequate Schmerztherapie . Derjenige Arzt , der Betaeubungsmittel verordnen muss , hat u. a. Verschreibungshoechstmengen , den Verschreibungszeitraum , zahlreiche Quer- und Rueckverweise sowie sonstige Spezialregelungen zu beachten und muss befuerchten , gegen Formerfordernisse zu verstossen . Dies fuehrt dazu , dass unter Umstaenden eine notwendige Schmerztherapie unterbleibt ! Ohne die Sicherheit im Verkehr mit Betaeubungsmitteln zu gefaehrden , reicht es nach Ansicht des Autors aus , wenn ein Betaeubungsmittel-Sonderrezeptformular wie jedes andere uebliche Rezept ausgefertigt und von der Apotheke beliefert wird . Entscheidend ist , dass die Anwendung des Betaeubungsmittels im Sinne des § 13 Abs. 1 des Betaeubungsmittelgesetzes begruendet und vom Verordner entsprechend verantwortet wird sowie Verstoesse geahndet werden koennen . Das dreiteilige Sonderrezeptformular gewaehrleistet eine ausreichende Nachweisfuehrung . Der Gesetzgeber wird aufgefordert , die nur schwer les- und handhabbare Betaeubungsmittel-Verschreibungsverordnung durch eine an der Praxis orientierte Verordnung zu ersetzen . Instructions: please typing these entity words according to sentence: Schmerztherapie, Arzt, Betaeubungsmittel, Schmerztherapie, Sicherheit, Betaeubungsmitteln, Apotheke, Betaeubungsmittels, Betaeubungsmittelgesetzes, Nachweisfuehrung, handhabbare, Praxis Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Die derzeit gueltige Betaeubungsmittel-Verschreibungsverordnung ist nach wie vor wegen ihrer ueberzogenen Regelungsdichte ein Hemmnis fuer eine adaequate Schmerztherapie . Derjenige Arzt , der Betaeubungsmittel verordnen muss , hat u. a. Verschreibungshoechstmengen , den Verschreibungszeitraum , zahlreiche Quer- und Rueckverweise sowie sonstige Spezialregelungen zu beachten und muss befuerchten , gegen Formerfordernisse zu verstossen . Dies fuehrt dazu , dass unter Umstaenden eine notwendige Schmerztherapie unterbleibt ! Ohne die Sicherheit im Verkehr mit Betaeubungsmitteln zu gefaehrden , reicht es nach Ansicht des Autors aus , wenn ein Betaeubungsmittel-Sonderrezeptformular wie jedes andere uebliche Rezept ausgefertigt und von der Apotheke beliefert wird . Entscheidend ist , dass die Anwendung des Betaeubungsmittels im Sinne des § 13 Abs. 1 des Betaeubungsmittelgesetzes begruendet und vom Verordner entsprechend verantwortet wird sowie Verstoesse geahndet werden koennen . Das dreiteilige Sonderrezeptformular gewaehrleistet eine ausreichende Nachweisfuehrung . Der Gesetzgeber wird aufgefordert , die nur schwer les- und handhabbare Betaeubungsmittel-Verschreibungsverordnung durch eine an der Praxis orientierte Verordnung zu ersetzen .
[ "Die", "derzeit", "gueltige", "Betaeubungsmittel", "-", "Verschreibungsverordnung", "ist", "nach", "wie", "vor", "wegen", "ihrer", "ueberzogenen", "Regelungsdichte", "ein", "Hemmnis", "fuer", "eine", "adaequate", "Schmerztherapie", ".", "Derjenige", "Arzt", ",", "der", "Betaeubungsmittel", "verordnen", "muss", ",", "hat", "u.", "a.", "Verschreibungshoechstmengen", ",", "den", "Verschreibungszeitraum", ",", "zahlreiche", "Quer-", "und", "Rueckverweise", "sowie", "sonstige", "Spezialregelungen", "zu", "beachten", "und", "muss", "befuerchten", ",", "gegen", "Formerfordernisse", "zu", "verstossen", ".", "Dies", "fuehrt", "dazu", ",", "dass", "unter", "Umstaenden", "eine", "notwendige", "Schmerztherapie", "unterbleibt", "!", "Ohne", "die", "Sicherheit", "im", "Verkehr", "mit", "Betaeubungsmitteln", "zu", "gefaehrden", ",", "reicht", "es", "nach", "Ansicht", "des", "Autors", "aus", ",", "wenn", "ein", "Betaeubungsmittel", "-", "Sonderrezeptformular", "wie", "jedes", "andere", "uebliche", "Rezept", "ausgefertigt", "und", "von", "der", "Apotheke", "beliefert", "wird", ".", "Entscheidend", "ist", ",", "dass", "die", "Anwendung", "des", "Betaeubungsmittels", "im", "Sinne", "des", "§", "13", "Abs", ".", "1", "des", "Betaeubungsmittelgesetzes", "begruendet", "und", "vom", "Verordner", "entsprechend", "verantwortet", "wird", "sowie", "Verstoesse", "geahndet", "werden", "koennen", ".", "Das", "dreiteilige", "Sonderrezeptformular", "gewaehrleistet", "eine", "ausreichende", "Nachweisfuehrung", ".", "Der", "Gesetzgeber", "wird", "aufgefordert", ",", "die", "nur", "schwer", "les-", "und", "handhabbare", "Betaeubungsmittel", "-", "Verschreibungsverordnung", "durch", "eine", "an", "der", "Praxis", "orientierte", "Verordnung", "zu", "ersetzen", "." ]
[ "umlsterm" ]
Schmerztherapie, Arzt, Betaeubungsmittel, Schmerztherapie, Sicherheit, Betaeubungsmitteln, Apotheke, Betaeubungsmittels, Betaeubungsmittelgesetzes, Nachweisfuehrung, handhabbare, Praxis
DerSchmerz.60100299.ger.abstr_task2
Sentence: Die derzeit gueltige Betaeubungsmittel-Verschreibungsverordnung ist nach wie vor wegen ihrer ueberzogenen Regelungsdichte ein Hemmnis fuer eine adaequate Schmerztherapie . Derjenige Arzt , der Betaeubungsmittel verordnen muss , hat u. a. Verschreibungshoechstmengen , den Verschreibungszeitraum , zahlreiche Quer- und Rueckverweise sowie sonstige Spezialregelungen zu beachten und muss befuerchten , gegen Formerfordernisse zu verstossen . Dies fuehrt dazu , dass unter Umstaenden eine notwendige Schmerztherapie unterbleibt ! Ohne die Sicherheit im Verkehr mit Betaeubungsmitteln zu gefaehrden , reicht es nach Ansicht des Autors aus , wenn ein Betaeubungsmittel-Sonderrezeptformular wie jedes andere uebliche Rezept ausgefertigt und von der Apotheke beliefert wird . Entscheidend ist , dass die Anwendung des Betaeubungsmittels im Sinne des § 13 Abs. 1 des Betaeubungsmittelgesetzes begruendet und vom Verordner entsprechend verantwortet wird sowie Verstoesse geahndet werden koennen . Das dreiteilige Sonderrezeptformular gewaehrleistet eine ausreichende Nachweisfuehrung . Der Gesetzgeber wird aufgefordert , die nur schwer les- und handhabbare Betaeubungsmittel-Verschreibungsverordnung durch eine an der Praxis orientierte Verordnung zu ersetzen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Die derzeit gueltige Betaeubungsmittel-Verschreibungsverordnung ist nach wie vor wegen ihrer ueberzogenen Regelungsdichte ein Hemmnis fuer eine adaequate Schmerztherapie . Derjenige Arzt , der Betaeubungsmittel verordnen muss , hat u. a. Verschreibungshoechstmengen , den Verschreibungszeitraum , zahlreiche Quer- und Rueckverweise sowie sonstige Spezialregelungen zu beachten und muss befuerchten , gegen Formerfordernisse zu verstossen . Dies fuehrt dazu , dass unter Umstaenden eine notwendige Schmerztherapie unterbleibt ! Ohne die Sicherheit im Verkehr mit Betaeubungsmitteln zu gefaehrden , reicht es nach Ansicht des Autors aus , wenn ein Betaeubungsmittel-Sonderrezeptformular wie jedes andere uebliche Rezept ausgefertigt und von der Apotheke beliefert wird . Entscheidend ist , dass die Anwendung des Betaeubungsmittels im Sinne des § 13 Abs. 1 des Betaeubungsmittelgesetzes begruendet und vom Verordner entsprechend verantwortet wird sowie Verstoesse geahndet werden koennen . Das dreiteilige Sonderrezeptformular gewaehrleistet eine ausreichende Nachweisfuehrung . Der Gesetzgeber wird aufgefordert , die nur schwer les- und handhabbare Betaeubungsmittel-Verschreibungsverordnung durch eine an der Praxis orientierte Verordnung zu ersetzen .
[ "Die", "derzeit", "gueltige", "Betaeubungsmittel", "-", "Verschreibungsverordnung", "ist", "nach", "wie", "vor", "wegen", "ihrer", "ueberzogenen", "Regelungsdichte", "ein", "Hemmnis", "fuer", "eine", "adaequate", "Schmerztherapie", ".", "Derjenige", "Arzt", ",", "der", "Betaeubungsmittel", "verordnen", "muss", ",", "hat", "u.", "a.", "Verschreibungshoechstmengen", ",", "den", "Verschreibungszeitraum", ",", "zahlreiche", "Quer-", "und", "Rueckverweise", "sowie", "sonstige", "Spezialregelungen", "zu", "beachten", "und", "muss", "befuerchten", ",", "gegen", "Formerfordernisse", "zu", "verstossen", ".", "Dies", "fuehrt", "dazu", ",", "dass", "unter", "Umstaenden", "eine", "notwendige", "Schmerztherapie", "unterbleibt", "!", "Ohne", "die", "Sicherheit", "im", "Verkehr", "mit", "Betaeubungsmitteln", "zu", "gefaehrden", ",", "reicht", "es", "nach", "Ansicht", "des", "Autors", "aus", ",", "wenn", "ein", "Betaeubungsmittel", "-", "Sonderrezeptformular", "wie", "jedes", "andere", "uebliche", "Rezept", "ausgefertigt", "und", "von", "der", "Apotheke", "beliefert", "wird", ".", "Entscheidend", "ist", ",", "dass", "die", "Anwendung", "des", "Betaeubungsmittels", "im", "Sinne", "des", "§", "13", "Abs", ".", "1", "des", "Betaeubungsmittelgesetzes", "begruendet", "und", "vom", "Verordner", "entsprechend", "verantwortet", "wird", "sowie", "Verstoesse", "geahndet", "werden", "koennen", ".", "Das", "dreiteilige", "Sonderrezeptformular", "gewaehrleistet", "eine", "ausreichende", "Nachweisfuehrung", ".", "Der", "Gesetzgeber", "wird", "aufgefordert", ",", "die", "nur", "schwer", "les-", "und", "handhabbare", "Betaeubungsmittel", "-", "Verschreibungsverordnung", "durch", "eine", "an", "der", "Praxis", "orientierte", "Verordnung", "zu", "ersetzen", "." ]
[ "umlsterm" ]
Mechanorezeptoren is an umlsterm, Schultergelenk is an umlsterm, Immunfluoreszenz is an umlsterm, Schultergelenkkapsel is an umlsterm, Rotatorenmanschette is an umlsterm, Leichen is an umlsterm, Todeseintritt is an umlsterm, Fluoreszinantikoerpern is an umlsterm, Nervenfaserendigungen is an umlsterm
DerOrthopaede.80270510.ger.abstr_task0
Sentence: Das Ziel dieser Studie bestand darin , die Verteilung und Morphologie von Mechanorezeptoren im Schultergelenk mittels spezifischer Immunfluoreszenz zu untersuchen . Die komplette Schultergelenkkapsel , Rotatorenmanschette und das Lig . coracoacromiale von 3 Leichen wurden innerhalb von 12 h nach Todeseintritt entnommen , Serienkryoschnitte angefertigt und diese entweder mit Neurofilament- , Laminin- oder Myelinantiserum und anschliessend mit Fluoreszinantikoerpern inkubiert . Die Nervenfaserendigungen wurden fotographiert und computerunterstuetzt dreidimensional ( 3D-) rekonstruiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Das Ziel dieser Studie bestand darin , die Verteilung und Morphologie von Mechanorezeptoren im Schultergelenk mittels spezifischer Immunfluoreszenz zu untersuchen . Die komplette Schultergelenkkapsel , Rotatorenmanschette und das Lig . coracoacromiale von 3 Leichen wurden innerhalb von 12 h nach Todeseintritt entnommen , Serienkryoschnitte angefertigt und diese entweder mit Neurofilament- , Laminin- oder Myelinantiserum und anschliessend mit Fluoreszinantikoerpern inkubiert . Die Nervenfaserendigungen wurden fotographiert und computerunterstuetzt dreidimensional ( 3D-) rekonstruiert .
[ "Das", "Ziel", "dieser", "Studie", "bestand", "darin", ",", "die", "Verteilung", "und", "Morphologie", "von", "Mechanorezeptoren", "im", "Schultergelenk", "mittels", "spezifischer", "Immunfluoreszenz", "zu", "untersuchen", ".", "Die", "komplette", "Schultergelenkkapsel", ",", "Rotatorenmanschette", "und", "das", "Lig", ".", "coracoacromiale", "von", "3", "Leichen", "wurden", "innerhalb", "von", "12", "h", "nach", "Todeseintritt", "entnommen", ",", "Serienkryoschnitte", "angefertigt", "und", "diese", "entweder", "mit", "Neurofilament-", ",", "Laminin-", "oder", "Myelinantiserum", "und", "anschliessend", "mit", "Fluoreszinantikoerpern", "inkubiert", ".", "Die", "Nervenfaserendigungen", "wurden", "fotographiert", "und", "computerunterstuetzt", "dreidimensional", "(", "3D-", ")", "rekonstruiert", "." ]
[ "umlsterm" ]
Mechanorezeptoren is an umlsterm, Schultergelenk is an umlsterm, Immunfluoreszenz is an umlsterm, Schultergelenkkapsel is an umlsterm, Rotatorenmanschette is an umlsterm, Leichen is an umlsterm, Todeseintritt is an umlsterm, Fluoreszinantikoerpern is an umlsterm, Nervenfaserendigungen is an umlsterm
DerOrthopaede.80270510.ger.abstr_task1
Sentence: Das Ziel dieser Studie bestand darin , die Verteilung und Morphologie von Mechanorezeptoren im Schultergelenk mittels spezifischer Immunfluoreszenz zu untersuchen . Die komplette Schultergelenkkapsel , Rotatorenmanschette und das Lig . coracoacromiale von 3 Leichen wurden innerhalb von 12 h nach Todeseintritt entnommen , Serienkryoschnitte angefertigt und diese entweder mit Neurofilament- , Laminin- oder Myelinantiserum und anschliessend mit Fluoreszinantikoerpern inkubiert . Die Nervenfaserendigungen wurden fotographiert und computerunterstuetzt dreidimensional ( 3D-) rekonstruiert . Instructions: please typing these entity words according to sentence: Mechanorezeptoren, Schultergelenk, Immunfluoreszenz, Schultergelenkkapsel, Rotatorenmanschette, Leichen, Todeseintritt, Fluoreszinantikoerpern, Nervenfaserendigungen Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Das Ziel dieser Studie bestand darin , die Verteilung und Morphologie von Mechanorezeptoren im Schultergelenk mittels spezifischer Immunfluoreszenz zu untersuchen . Die komplette Schultergelenkkapsel , Rotatorenmanschette und das Lig . coracoacromiale von 3 Leichen wurden innerhalb von 12 h nach Todeseintritt entnommen , Serienkryoschnitte angefertigt und diese entweder mit Neurofilament- , Laminin- oder Myelinantiserum und anschliessend mit Fluoreszinantikoerpern inkubiert . Die Nervenfaserendigungen wurden fotographiert und computerunterstuetzt dreidimensional ( 3D-) rekonstruiert .
[ "Das", "Ziel", "dieser", "Studie", "bestand", "darin", ",", "die", "Verteilung", "und", "Morphologie", "von", "Mechanorezeptoren", "im", "Schultergelenk", "mittels", "spezifischer", "Immunfluoreszenz", "zu", "untersuchen", ".", "Die", "komplette", "Schultergelenkkapsel", ",", "Rotatorenmanschette", "und", "das", "Lig", ".", "coracoacromiale", "von", "3", "Leichen", "wurden", "innerhalb", "von", "12", "h", "nach", "Todeseintritt", "entnommen", ",", "Serienkryoschnitte", "angefertigt", "und", "diese", "entweder", "mit", "Neurofilament-", ",", "Laminin-", "oder", "Myelinantiserum", "und", "anschliessend", "mit", "Fluoreszinantikoerpern", "inkubiert", ".", "Die", "Nervenfaserendigungen", "wurden", "fotographiert", "und", "computerunterstuetzt", "dreidimensional", "(", "3D-", ")", "rekonstruiert", "." ]
[ "umlsterm" ]
Mechanorezeptoren, Schultergelenk, Immunfluoreszenz, Schultergelenkkapsel, Rotatorenmanschette, Leichen, Todeseintritt, Fluoreszinantikoerpern, Nervenfaserendigungen
DerOrthopaede.80270510.ger.abstr_task2
Sentence: Das Ziel dieser Studie bestand darin , die Verteilung und Morphologie von Mechanorezeptoren im Schultergelenk mittels spezifischer Immunfluoreszenz zu untersuchen . Die komplette Schultergelenkkapsel , Rotatorenmanschette und das Lig . coracoacromiale von 3 Leichen wurden innerhalb von 12 h nach Todeseintritt entnommen , Serienkryoschnitte angefertigt und diese entweder mit Neurofilament- , Laminin- oder Myelinantiserum und anschliessend mit Fluoreszinantikoerpern inkubiert . Die Nervenfaserendigungen wurden fotographiert und computerunterstuetzt dreidimensional ( 3D-) rekonstruiert . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Das Ziel dieser Studie bestand darin , die Verteilung und Morphologie von Mechanorezeptoren im Schultergelenk mittels spezifischer Immunfluoreszenz zu untersuchen . Die komplette Schultergelenkkapsel , Rotatorenmanschette und das Lig . coracoacromiale von 3 Leichen wurden innerhalb von 12 h nach Todeseintritt entnommen , Serienkryoschnitte angefertigt und diese entweder mit Neurofilament- , Laminin- oder Myelinantiserum und anschliessend mit Fluoreszinantikoerpern inkubiert . Die Nervenfaserendigungen wurden fotographiert und computerunterstuetzt dreidimensional ( 3D-) rekonstruiert .
[ "Das", "Ziel", "dieser", "Studie", "bestand", "darin", ",", "die", "Verteilung", "und", "Morphologie", "von", "Mechanorezeptoren", "im", "Schultergelenk", "mittels", "spezifischer", "Immunfluoreszenz", "zu", "untersuchen", ".", "Die", "komplette", "Schultergelenkkapsel", ",", "Rotatorenmanschette", "und", "das", "Lig", ".", "coracoacromiale", "von", "3", "Leichen", "wurden", "innerhalb", "von", "12", "h", "nach", "Todeseintritt", "entnommen", ",", "Serienkryoschnitte", "angefertigt", "und", "diese", "entweder", "mit", "Neurofilament-", ",", "Laminin-", "oder", "Myelinantiserum", "und", "anschliessend", "mit", "Fluoreszinantikoerpern", "inkubiert", ".", "Die", "Nervenfaserendigungen", "wurden", "fotographiert", "und", "computerunterstuetzt", "dreidimensional", "(", "3D-", ")", "rekonstruiert", "." ]
[ "umlsterm" ]
patient is an umlsterm, discoid lupus is an umlsterm, erythematosus is an umlsterm, argon - laser is an umlsterm, patient is an umlsterm, drugs is an umlsterm, argon - laser is an umlsterm, skin is an umlsterm, skin is an umlsterm, disease is an umlsterm, biopsies is an umlsterm, skin is an umlsterm, role is an umlsterm, generation is an umlsterm, maintenance is an umlsterm, lupus is an umlsterm, erythematosus is an umlsterm, treatment is an umlsterm, skin is an umlsterm, lupus is an umlsterm, erythematosus is an umlsterm, patient is an umlsterm, argon - laser is an umlsterm
DerHautarzt.60470767.eng.abstr_task0
Sentence: We report on a patient with chronic discoid lupus erythematosus who was treated with argon-laser . The patient suffered from long-standing lesions and had been pretreated with various drugs , with no or slight improvement . After a few argon-laser applications , the treated skin lesions improved dramatically while the untreated lesional skin showed continuous disease activity . Histological and immunohistological investigations of biopsies from treated and untreated lesional skin suggest that endothelial mechanisms play a role in the generation and maintenance of discoid lesions in lupus erythematosus . This is the first reported case of successful treatment of chronic discoid skin lesions of a lupus erythematosus patient with argon-laser . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]
We report on a patient with chronic discoid lupus erythematosus who was treated with argon-laser . The patient suffered from long-standing lesions and had been pretreated with various drugs , with no or slight improvement . After a few argon-laser applications , the treated skin lesions improved dramatically while the untreated lesional skin showed continuous disease activity . Histological and immunohistological investigations of biopsies from treated and untreated lesional skin suggest that endothelial mechanisms play a role in the generation and maintenance of discoid lesions in lupus erythematosus . This is the first reported case of successful treatment of chronic discoid skin lesions of a lupus erythematosus patient with argon-laser .
[ "We", "report", "on", "a", "patient", "with", "chronic", "discoid", "lupus", "erythematosus", "who", "was", "treated", "with", "argon", "-", "laser", ".", "The", "patient", "suffered", "from", "long", "-", "standing", "lesions", "and", "had", "been", "pretreated", "with", "various", "drugs", ",", "with", "no", "or", "slight", "improvement", ".", "After", "a", "few", "argon", "-", "laser", "applications", ",", "the", "treated", "skin", "lesions", "improved", "dramatically", "while", "the", "untreated", "lesional", "skin", "showed", "continuous", "disease", "activity", ".", "Histological", "and", "immunohistological", "investigations", "of", "biopsies", "from", "treated", "and", "untreated", "lesional", "skin", "suggest", "that", "endothelial", "mechanisms", "play", "a", "role", "in", "the", "generation", "and", "maintenance", "of", "discoid", "lesions", "in", "lupus", "erythematosus", ".", "This", "is", "the", "first", "reported", "case", "of", "successful", "treatment", "of", "chronic", "discoid", "skin", "lesions", "of", "a", "lupus", "erythematosus", "patient", "with", "argon", "-", "laser", "." ]
[ "umlsterm" ]
patient is an umlsterm, discoid lupus is an umlsterm, erythematosus is an umlsterm, argon - laser is an umlsterm, patient is an umlsterm, drugs is an umlsterm, argon - laser is an umlsterm, skin is an umlsterm, skin is an umlsterm, disease is an umlsterm, biopsies is an umlsterm, skin is an umlsterm, role is an umlsterm, generation is an umlsterm, maintenance is an umlsterm, lupus is an umlsterm, erythematosus is an umlsterm, treatment is an umlsterm, skin is an umlsterm, lupus is an umlsterm, erythematosus is an umlsterm, patient is an umlsterm, argon - laser is an umlsterm
DerHautarzt.60470767.eng.abstr_task1
Sentence: We report on a patient with chronic discoid lupus erythematosus who was treated with argon-laser . The patient suffered from long-standing lesions and had been pretreated with various drugs , with no or slight improvement . After a few argon-laser applications , the treated skin lesions improved dramatically while the untreated lesional skin showed continuous disease activity . Histological and immunohistological investigations of biopsies from treated and untreated lesional skin suggest that endothelial mechanisms play a role in the generation and maintenance of discoid lesions in lupus erythematosus . This is the first reported case of successful treatment of chronic discoid skin lesions of a lupus erythematosus patient with argon-laser . Instructions: please typing these entity words according to sentence: patient, discoid lupus, erythematosus, argon - laser, patient, drugs, argon - laser, skin, skin, disease, biopsies, skin, role, generation, maintenance, lupus, erythematosus, treatment, skin, lupus, erythematosus, patient, argon - laser Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]
We report on a patient with chronic discoid lupus erythematosus who was treated with argon-laser . The patient suffered from long-standing lesions and had been pretreated with various drugs , with no or slight improvement . After a few argon-laser applications , the treated skin lesions improved dramatically while the untreated lesional skin showed continuous disease activity . Histological and immunohistological investigations of biopsies from treated and untreated lesional skin suggest that endothelial mechanisms play a role in the generation and maintenance of discoid lesions in lupus erythematosus . This is the first reported case of successful treatment of chronic discoid skin lesions of a lupus erythematosus patient with argon-laser .
[ "We", "report", "on", "a", "patient", "with", "chronic", "discoid", "lupus", "erythematosus", "who", "was", "treated", "with", "argon", "-", "laser", ".", "The", "patient", "suffered", "from", "long", "-", "standing", "lesions", "and", "had", "been", "pretreated", "with", "various", "drugs", ",", "with", "no", "or", "slight", "improvement", ".", "After", "a", "few", "argon", "-", "laser", "applications", ",", "the", "treated", "skin", "lesions", "improved", "dramatically", "while", "the", "untreated", "lesional", "skin", "showed", "continuous", "disease", "activity", ".", "Histological", "and", "immunohistological", "investigations", "of", "biopsies", "from", "treated", "and", "untreated", "lesional", "skin", "suggest", "that", "endothelial", "mechanisms", "play", "a", "role", "in", "the", "generation", "and", "maintenance", "of", "discoid", "lesions", "in", "lupus", "erythematosus", ".", "This", "is", "the", "first", "reported", "case", "of", "successful", "treatment", "of", "chronic", "discoid", "skin", "lesions", "of", "a", "lupus", "erythematosus", "patient", "with", "argon", "-", "laser", "." ]
[ "umlsterm" ]
patient, discoid lupus, erythematosus, argon - laser, patient, drugs, argon - laser, skin, skin, disease, biopsies, skin, role, generation, maintenance, lupus, erythematosus, treatment, skin, lupus, erythematosus, patient, argon - laser
DerHautarzt.60470767.eng.abstr_task2
Sentence: We report on a patient with chronic discoid lupus erythematosus who was treated with argon-laser . The patient suffered from long-standing lesions and had been pretreated with various drugs , with no or slight improvement . After a few argon-laser applications , the treated skin lesions improved dramatically while the untreated lesional skin showed continuous disease activity . Histological and immunohistological investigations of biopsies from treated and untreated lesional skin suggest that endothelial mechanisms play a role in the generation and maintenance of discoid lesions in lupus erythematosus . This is the first reported case of successful treatment of chronic discoid skin lesions of a lupus erythematosus patient with argon-laser . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]
We report on a patient with chronic discoid lupus erythematosus who was treated with argon-laser . The patient suffered from long-standing lesions and had been pretreated with various drugs , with no or slight improvement . After a few argon-laser applications , the treated skin lesions improved dramatically while the untreated lesional skin showed continuous disease activity . Histological and immunohistological investigations of biopsies from treated and untreated lesional skin suggest that endothelial mechanisms play a role in the generation and maintenance of discoid lesions in lupus erythematosus . This is the first reported case of successful treatment of chronic discoid skin lesions of a lupus erythematosus patient with argon-laser .
[ "We", "report", "on", "a", "patient", "with", "chronic", "discoid", "lupus", "erythematosus", "who", "was", "treated", "with", "argon", "-", "laser", ".", "The", "patient", "suffered", "from", "long", "-", "standing", "lesions", "and", "had", "been", "pretreated", "with", "various", "drugs", ",", "with", "no", "or", "slight", "improvement", ".", "After", "a", "few", "argon", "-", "laser", "applications", ",", "the", "treated", "skin", "lesions", "improved", "dramatically", "while", "the", "untreated", "lesional", "skin", "showed", "continuous", "disease", "activity", ".", "Histological", "and", "immunohistological", "investigations", "of", "biopsies", "from", "treated", "and", "untreated", "lesional", "skin", "suggest", "that", "endothelial", "mechanisms", "play", "a", "role", "in", "the", "generation", "and", "maintenance", "of", "discoid", "lesions", "in", "lupus", "erythematosus", ".", "This", "is", "the", "first", "reported", "case", "of", "successful", "treatment", "of", "chronic", "discoid", "skin", "lesions", "of", "a", "lupus", "erythematosus", "patient", "with", "argon", "-", "laser", "." ]
[ "umlsterm" ]
dependent and nondependent harmful drinkers . is a Participant_Condition, receive or not to receive diagnostic information and counseling directives on is a Intervention_Educational, binary logistic regression is a Intervention_Educational, Physician prompting is a Outcome_Mental, dependent drinking is a Outcome_Mental, recent disorder activity is a Outcome_Mental, physician counseling and improvements is a Intervention_Educational
85206_task0
Sentence: A program of screening and prompting improves short-term physician counseling of dependent and nondependent harmful drinkers . BACKGROUND Physicians in the general medical setting commonly encounter but rarely counsel patients with dependent or harmful drinking behaviors . We tested whether providing physicians with their patients ' results on the alcohol module of the Diagnostic Interview Schedule and counseling directives would prompt them to counsel these patients . METHODS We randomly assigned 83 first- , second- , and third-year medical residents to receive or not to receive diagnostic information and counseling directives on 214 patients who reported at least one symptom of alcohol impairment as defined in the Diagnostic and Statistical Manual of Mental Disorders , Third Edition . Using binary logistic regression , we examined the effect of specific covariables on rates of physician counseling . These variables included physician information status , patient gender , and drinking disorder severity and recency . We also examined the effect of physician prompting on counseling of female patients , patients with inactive disorders , and nondependent but harmful drinkers . We determined counseling by post-visit patient interviews . RESULTS Physician prompting , dependent drinking , and recent disorder activity were significant correlates of physician counseling ( P < .05 ) , while male gender was a marginally significant correlate ( P = .08 ) . Informed physicians counseled female patients , harmful but nondependent drinkers , and patients with inactive disorders more often than their uninformed colleagues , although only the last variable achieved statistical significance . CONCLUSIONS Providing physicians with the results of the Diagnostic Interview Schedule and counseling directives resulted in short-term improvement in their rates of counseling patients with a history of dependent or nondependent but harmful drinking . Further research is necessary to determine long-term gains in rates of physician counseling and improvements in the course of these patients . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Educational, Participant_Condition, Outcome_Mental
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O" ]
A program of screening and prompting improves short-term physician counseling of dependent and nondependent harmful drinkers . BACKGROUND Physicians in the general medical setting commonly encounter but rarely counsel patients with dependent or harmful drinking behaviors . We tested whether providing physicians with their patients ' results on the alcohol module of the Diagnostic Interview Schedule and counseling directives would prompt them to counsel these patients . METHODS We randomly assigned 83 first- , second- , and third-year medical residents to receive or not to receive diagnostic information and counseling directives on 214 patients who reported at least one symptom of alcohol impairment as defined in the Diagnostic and Statistical Manual of Mental Disorders , Third Edition . Using binary logistic regression , we examined the effect of specific covariables on rates of physician counseling . These variables included physician information status , patient gender , and drinking disorder severity and recency . We also examined the effect of physician prompting on counseling of female patients , patients with inactive disorders , and nondependent but harmful drinkers . We determined counseling by post-visit patient interviews . RESULTS Physician prompting , dependent drinking , and recent disorder activity were significant correlates of physician counseling ( P < .05 ) , while male gender was a marginally significant correlate ( P = .08 ) . Informed physicians counseled female patients , harmful but nondependent drinkers , and patients with inactive disorders more often than their uninformed colleagues , although only the last variable achieved statistical significance . CONCLUSIONS Providing physicians with the results of the Diagnostic Interview Schedule and counseling directives resulted in short-term improvement in their rates of counseling patients with a history of dependent or nondependent but harmful drinking . Further research is necessary to determine long-term gains in rates of physician counseling and improvements in the course of these patients .
[ "A", "program", "of", "screening", "and", "prompting", "improves", "short", "-", "term", "physician", "counseling", "of", "dependent", "and", "nondependent", "harmful", "drinkers", ".", "BACKGROUND", "Physicians", "in", "the", "general", "medical", "setting", "commonly", "encounter", "but", "rarely", "counsel", "patients", "with", "dependent", "or", "harmful", "drinking", "behaviors", ".", "We", "tested", "whether", "providing", "physicians", "with", "their", "patients", "'", "results", "on", "the", "alcohol", "module", "of", "the", "Diagnostic", "Interview", "Schedule", "and", "counseling", "directives", "would", "prompt", "them", "to", "counsel", "these", "patients", ".", "METHODS", "We", "randomly", "assigned", "83", "first-", ",", "second-", ",", "and", "third", "-", "year", "medical", "residents", "to", "receive", "or", "not", "to", "receive", "diagnostic", "information", "and", "counseling", "directives", "on", "214", "patients", "who", "reported", "at", "least", "one", "symptom", "of", "alcohol", "impairment", "as", "defined", "in", "the", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", ",", "Third", "Edition", ".", "Using", "binary", "logistic", "regression", ",", "we", "examined", "the", "effect", "of", "specific", "covariables", "on", "rates", "of", "physician", "counseling", ".", "These", "variables", "included", "physician", "information", "status", ",", "patient", "gender", ",", "and", "drinking", "disorder", "severity", "and", "recency", ".", "We", "also", "examined", "the", "effect", "of", "physician", "prompting", "on", "counseling", "of", "female", "patients", ",", "patients", "with", "inactive", "disorders", ",", "and", "nondependent", "but", "harmful", "drinkers", ".", "We", "determined", "counseling", "by", "post", "-", "visit", "patient", "interviews", ".", "RESULTS", "Physician", "prompting", ",", "dependent", "drinking", ",", "and", "recent", "disorder", "activity", "were", "significant", "correlates", "of", "physician", "counseling", "(", "P", "<", ".05", ")", ",", "while", "male", "gender", "was", "a", "marginally", "significant", "correlate", "(", "P", "=", ".08", ")", ".", "Informed", "physicians", "counseled", "female", "patients", ",", "harmful", "but", "nondependent", "drinkers", ",", "and", "patients", "with", "inactive", "disorders", "more", "often", "than", "their", "uninformed", "colleagues", ",", "although", "only", "the", "last", "variable", "achieved", "statistical", "significance", ".", "CONCLUSIONS", "Providing", "physicians", "with", "the", "results", "of", "the", "Diagnostic", "Interview", "Schedule", "and", "counseling", "directives", "resulted", "in", "short", "-", "term", "improvement", "in", "their", "rates", "of", "counseling", "patients", "with", "a", "history", "of", "dependent", "or", "nondependent", "but", "harmful", "drinking", ".", "Further", "research", "is", "necessary", "to", "determine", "long", "-", "term", "gains", "in", "rates", "of", "physician", "counseling", "and", "improvements", "in", "the", "course", "of", "these", "patients", "." ]
[ "Intervention_Educational", "Participant_Condition", "Outcome_Mental" ]
dependent and nondependent harmful drinkers . is a Participant_Condition, receive or not to receive diagnostic information and counseling directives on is a Intervention_Educational, binary logistic regression is a Intervention_Educational, Physician prompting is a Outcome_Mental, dependent drinking is a Outcome_Mental, recent disorder activity is a Outcome_Mental, physician counseling and improvements is a Intervention_Educational
85206_task1
Sentence: A program of screening and prompting improves short-term physician counseling of dependent and nondependent harmful drinkers . BACKGROUND Physicians in the general medical setting commonly encounter but rarely counsel patients with dependent or harmful drinking behaviors . We tested whether providing physicians with their patients ' results on the alcohol module of the Diagnostic Interview Schedule and counseling directives would prompt them to counsel these patients . METHODS We randomly assigned 83 first- , second- , and third-year medical residents to receive or not to receive diagnostic information and counseling directives on 214 patients who reported at least one symptom of alcohol impairment as defined in the Diagnostic and Statistical Manual of Mental Disorders , Third Edition . Using binary logistic regression , we examined the effect of specific covariables on rates of physician counseling . These variables included physician information status , patient gender , and drinking disorder severity and recency . We also examined the effect of physician prompting on counseling of female patients , patients with inactive disorders , and nondependent but harmful drinkers . We determined counseling by post-visit patient interviews . RESULTS Physician prompting , dependent drinking , and recent disorder activity were significant correlates of physician counseling ( P < .05 ) , while male gender was a marginally significant correlate ( P = .08 ) . Informed physicians counseled female patients , harmful but nondependent drinkers , and patients with inactive disorders more often than their uninformed colleagues , although only the last variable achieved statistical significance . CONCLUSIONS Providing physicians with the results of the Diagnostic Interview Schedule and counseling directives resulted in short-term improvement in their rates of counseling patients with a history of dependent or nondependent but harmful drinking . Further research is necessary to determine long-term gains in rates of physician counseling and improvements in the course of these patients . Instructions: please typing these entity words according to sentence: dependent and nondependent harmful drinkers ., receive or not to receive diagnostic information and counseling directives on, binary logistic regression, Physician prompting, dependent drinking, recent disorder activity, physician counseling and improvements Options: Intervention_Educational, Participant_Condition, Outcome_Mental
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O" ]
A program of screening and prompting improves short-term physician counseling of dependent and nondependent harmful drinkers . BACKGROUND Physicians in the general medical setting commonly encounter but rarely counsel patients with dependent or harmful drinking behaviors . We tested whether providing physicians with their patients ' results on the alcohol module of the Diagnostic Interview Schedule and counseling directives would prompt them to counsel these patients . METHODS We randomly assigned 83 first- , second- , and third-year medical residents to receive or not to receive diagnostic information and counseling directives on 214 patients who reported at least one symptom of alcohol impairment as defined in the Diagnostic and Statistical Manual of Mental Disorders , Third Edition . Using binary logistic regression , we examined the effect of specific covariables on rates of physician counseling . These variables included physician information status , patient gender , and drinking disorder severity and recency . We also examined the effect of physician prompting on counseling of female patients , patients with inactive disorders , and nondependent but harmful drinkers . We determined counseling by post-visit patient interviews . RESULTS Physician prompting , dependent drinking , and recent disorder activity were significant correlates of physician counseling ( P < .05 ) , while male gender was a marginally significant correlate ( P = .08 ) . Informed physicians counseled female patients , harmful but nondependent drinkers , and patients with inactive disorders more often than their uninformed colleagues , although only the last variable achieved statistical significance . CONCLUSIONS Providing physicians with the results of the Diagnostic Interview Schedule and counseling directives resulted in short-term improvement in their rates of counseling patients with a history of dependent or nondependent but harmful drinking . Further research is necessary to determine long-term gains in rates of physician counseling and improvements in the course of these patients .
[ "A", "program", "of", "screening", "and", "prompting", "improves", "short", "-", "term", "physician", "counseling", "of", "dependent", "and", "nondependent", "harmful", "drinkers", ".", "BACKGROUND", "Physicians", "in", "the", "general", "medical", "setting", "commonly", "encounter", "but", "rarely", "counsel", "patients", "with", "dependent", "or", "harmful", "drinking", "behaviors", ".", "We", "tested", "whether", "providing", "physicians", "with", "their", "patients", "'", "results", "on", "the", "alcohol", "module", "of", "the", "Diagnostic", "Interview", "Schedule", "and", "counseling", "directives", "would", "prompt", "them", "to", "counsel", "these", "patients", ".", "METHODS", "We", "randomly", "assigned", "83", "first-", ",", "second-", ",", "and", "third", "-", "year", "medical", "residents", "to", "receive", "or", "not", "to", "receive", "diagnostic", "information", "and", "counseling", "directives", "on", "214", "patients", "who", "reported", "at", "least", "one", "symptom", "of", "alcohol", "impairment", "as", "defined", "in", "the", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", ",", "Third", "Edition", ".", "Using", "binary", "logistic", "regression", ",", "we", "examined", "the", "effect", "of", "specific", "covariables", "on", "rates", "of", "physician", "counseling", ".", "These", "variables", "included", "physician", "information", "status", ",", "patient", "gender", ",", "and", "drinking", "disorder", "severity", "and", "recency", ".", "We", "also", "examined", "the", "effect", "of", "physician", "prompting", "on", "counseling", "of", "female", "patients", ",", "patients", "with", "inactive", "disorders", ",", "and", "nondependent", "but", "harmful", "drinkers", ".", "We", "determined", "counseling", "by", "post", "-", "visit", "patient", "interviews", ".", "RESULTS", "Physician", "prompting", ",", "dependent", "drinking", ",", "and", "recent", "disorder", "activity", "were", "significant", "correlates", "of", "physician", "counseling", "(", "P", "<", ".05", ")", ",", "while", "male", "gender", "was", "a", "marginally", "significant", "correlate", "(", "P", "=", ".08", ")", ".", "Informed", "physicians", "counseled", "female", "patients", ",", "harmful", "but", "nondependent", "drinkers", ",", "and", "patients", "with", "inactive", "disorders", "more", "often", "than", "their", "uninformed", "colleagues", ",", "although", "only", "the", "last", "variable", "achieved", "statistical", "significance", ".", "CONCLUSIONS", "Providing", "physicians", "with", "the", "results", "of", "the", "Diagnostic", "Interview", "Schedule", "and", "counseling", "directives", "resulted", "in", "short", "-", "term", "improvement", "in", "their", "rates", "of", "counseling", "patients", "with", "a", "history", "of", "dependent", "or", "nondependent", "but", "harmful", "drinking", ".", "Further", "research", "is", "necessary", "to", "determine", "long", "-", "term", "gains", "in", "rates", "of", "physician", "counseling", "and", "improvements", "in", "the", "course", "of", "these", "patients", "." ]
[ "Intervention_Educational", "Participant_Condition", "Outcome_Mental" ]